{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 2574, 'offsetInEndSection': 2784, 'text': \"INTERPRETATION: 12 months of treatment with losartan was well tolerated but was not effective in reducing the rate of brain atrophy in individuals with clinically diagnosed mild-to-moderate Alzheimer's disease.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34687634'}]\n\n\n             'Can losartan reduce brain atrophy in Alzheimer's disease?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "No. 12 months of treatment with losartan was well tolerated but was not effective in reducing the rate of brain atrophy in individuals with clinically diagnosed mild-to-moderate Alzheimer's disease."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 452, 'offsetInEndSection': 569, 'text': 'CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35633976'}, {'offsetInBeginSection': 1208, 'offsetInEndSection': 1359, 'text': 'We will extract data based on the Checklist for\\xa0Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS), ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35321760'}, {'offsetInBeginSection': 688, 'offsetInEndSection': 807, 'text': 'Checklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS-PF).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35196337'}, {'offsetInBeginSection': 892, 'offsetInEndSection': 993, 'text': 'Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS)', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35493941'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 267, 'text': 'The CHARMS (critical appraisal and data extraction for systematic reviews of prediction modelling studies) checklist was created to provide methodological appraisals of predictive models, based on the best available scientific evidence and through systematic reviews.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32583899'}, {'offsetInBeginSection': 53, 'offsetInEndSection': 298, 'text': 'However, these models should be developed appropriately (CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modeling Studies [CHARMS] and Prediction model Risk Of Bias ASsessment Tool [PROBAST] statements).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31762119'}, {'offsetInBeginSection': 621, 'offsetInEndSection': 842, 'text': 'tudies with model updating. Data was extracted following the Checklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS) checklist.PRIMARY AND SECONDARY OUTCOME MEA', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31439598'}, {'offsetInBeginSection': 693, 'offsetInEndSection': 931, 'text': 'Data collection was guided by the checklist for critical appraisal and data extraction for systematic reviews (CHARMS) and applicability and methodological quality assessment by the prediction model risk of bias assessment tool (PROBAST).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32453803'}, {'offsetInBeginSection': 351, 'offsetInEndSection': 509, 'text': 'Studies were assessed using the checklist for critical appraisal and data extraction for systematic reviews of prediction modeling studies (CHARMS) checklist.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31090660'}, {'offsetInBeginSection': 321, 'offsetInEndSection': 688, 'text': 'methods in oncology. We used the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) statement, Prediction model Risk Of Bias ASsessment Tool (PROBAST) and CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS) to assess the methodological conduct of i', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35395724'}, {'offsetInBeginSection': 372, 'offsetInEndSection': 591, 'text': 'inclusion criteria). We followed the CHARMS recommendations (Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies), extracting the information from its 11 domains (Source of data', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33492724'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 116, 'text': 'Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25314315'}, {'offsetInBeginSection': 678, 'offsetInEndSection': 847, 'text': 'The CHARMS (Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies) checklist was used for data extraction and quality assessment.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28284255'}, {'offsetInBeginSection': 190, 'offsetInEndSection': 1256, 'text': 'ion making. Systematic reviews of prognostic model studies can help identify prognostic models that need to further be validated or are ready to be implemented in healthcare.OBJECTIVES: To provide a step-by-step guidance on how to conduct and read a systematic review of prognostic model studies and to provide an overview of methodology and guidance available for every step of the review progress.SOURCES: Published, peer-reviewed guidance articles.CONTENT: We describe the following steps for conducting a systematic review of prognosis studies: 1) Developing the review question using the Population, Index model, Comparator model, Outcome(s), Timing, Setting format, 2) Searching and selection of articles, 3) Data extraction using the Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies (CHARMS) checklist, 4) Quality and risk of bias assessment using the Prediction model Risk Of Bias ASsessment (PROBAST) tool, 5) Analysing data and undertaking quantitative meta-analysis, and 6) Presenting summary of findings, inte', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35934199'}, {'offsetInBeginSection': 1028, 'offsetInEndSection': 1211, 'text': 'te, or status of the publication. To carry out the systematic review, the CHARMS (Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies) guidel', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33407048'}, {'offsetInBeginSection': 1042, 'offsetInEndSection': 1457, 'text': 'The authors did not put any restrictions on the models included in their study regarding the model setting, prediction horizon or outcomes.Data extraction and synthesis Checklists of critical appraisal and data extraction for systematic reviews of prediction modelling studies (CHARMS) and prediction model risk of bias assessment tool (PROBAST) were used to guide developing of a standardised data extraction form.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32978532'}, {'offsetInBeginSection': 764, 'offsetInEndSection': 1015, 'text': 'We critically appraised these models by means of criteria derived from the CHARMS (CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modeling Studies) and PROBAST (Prediction model Risk Of Bias ASsessment Tool).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34413828'}, {'offsetInBeginSection': 116, 'offsetInEndSection': 266, 'text': 'ist for critical Appraisal and data extraction for systematic Reviews of prediction Modeling Studies [CHARMS] and Prediction model Risk Of Bias ASsess', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31762119'}, {'offsetInBeginSection': 690, 'offsetInEndSection': 840, 'text': 't for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS) checklist.PRIMARY AND SECONDARY OUTCOME M', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31439598'}, {'offsetInBeginSection': 405, 'offsetInEndSection': 555, 'text': 'the CHARMS recommendations (Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies), extracting the information', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33492724'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'The CHARMS (critical appraisal and data extraction for systematic reviews of prediction modelling studies) checklist was created to provide methodolog', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32583899'}, {'offsetInBeginSection': 389, 'offsetInEndSection': 539, 'text': 'ist for critical appraisal and data extraction for systematic reviews of prediction modeling studies (CHARMS) checklist. In total 89,959 citations wer', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31090660'}, {'offsetInBeginSection': 864, 'offsetInEndSection': 1014, 'text': 'acted the data. We used the Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS) checklist for the ri', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35493941'}, {'offsetInBeginSection': 517, 'offsetInEndSection': 667, 'text': 'ical appraisal and data extraction for systematic reviews of prediction modeling studies (CHARMS) and the prediction model risk of bias assessment too', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33364802'}, {'offsetInBeginSection': 461, 'offsetInEndSection': 611, 'text': 'nalysed (domains of CHARMS, Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies) the following: source of da', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31441567'}, {'offsetInBeginSection': 690, 'offsetInEndSection': 850, 'text': 't for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS) checklist.PRIMARY AND SECONDARY OUTCOME MEASURES: P', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31439598'}, {'offsetInBeginSection': 405, 'offsetInEndSection': 624, 'text': 'the CHARMS recommendations (Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies), extracting the information from its 11 domains (Source of data, Participants, etc). We determin', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33492724'}, {'offsetInBeginSection': 864, 'offsetInEndSection': 1020, 'text': 'acted the data. We used the Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS) checklist for the risk of ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35493941'}, {'offsetInBeginSection': 517, 'offsetInEndSection': 764, 'text': 'ical appraisal and data extraction for systematic reviews of prediction modeling studies (CHARMS) and the prediction model risk of bias assessment tool (PROBAST) were used for the data extraction process and critical appraisal.RESULTS: From the 29', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33364802'}, {'offsetInBeginSection': 461, 'offsetInEndSection': 821, 'text': 'nalysed (domains of CHARMS, Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies) the following: source of data, participants, outcome to be predicted, candidate predictors, sample size, missing data, model development, model performance, model evaluation, results and interpretation and discussion.RESULTS: We found tw', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31441567'}]\n\n\n             'What is CHARMS with respect to medical review of predictive modeling?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "CHARMS stands for CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS)."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 745, 'offsetInEndSection': 917, 'text': 'Our work suggests that an intricate interplay of programs controlling gene expression levels and AS is fundamental to organ development, especially for the brain and heart.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33941934'}, {'offsetInBeginSection': 1266, 'offsetInEndSection': 1452, 'text': 'Bioinformatical analysis pointed to the tissue-specific splicing factors Srrm4 and Nova1 as likely upstream regulators of the observed splicing changes in the PLN-R14del cardiomyocytes. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36375644'}]\n\n\n             'Which splicing factors have been associated with alternative splicing in PLN R14del hearts?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Bioinformatical analysis pointed to the tissue-specific splicing factors Srrm4 and Nova1 as likely upstream regulators of the observed splicing changes in the PLN-R14del cardiomyocytes."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 620, 'offsetInEndSection': 678, 'text': ' 64% deletions, 18% duplications and 18% point mutations. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31381525'}, {'offsetInBeginSection': 926, 'offsetInEndSection': 1241, 'text': 'Of these, 406 (70.5%) were exonic deletions, 64 (11.1%) were exonic duplications, and one was a deletion/duplication complex rearrangement (0.2%). Small mutations were identified in 105 cases (18.2%), most being nonsense/frameshift types (75.2%). Mutations in splice sites, however, were relatively frequent (20%). ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26284620'}, {'offsetInBeginSection': 440, 'offsetInEndSection': 524, 'text': 'gene deletion rate was 54.3% (391/720), and gene duplication rate was 10.6% (76/720)', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21402533'}, {'offsetInBeginSection': 526, 'offsetInEndSection': 737, 'text': 'The rate of deletion mutant occurred in Exon 45-54 was 71.9% (281/391) in all gene deletion patients; meanwhile, the rate of gene duplication occurred in Exon 1-40 was 82.9% (63/76) in all gene duplication ones.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21402533'}, {'offsetInBeginSection': 738, 'offsetInEndSection': 862, 'text': 'In all the patients with gene deletion and duplication, the rate of DMD and IMD was 90.6% (423/467), and BMD, 9.4% (44/467).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21402533'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 243, 'text': 'The Duchenne Muscular dystrophy (DMD) is the most frequent muscle disorder in childhood caused by mutations in the Xlinked dystrophin gene (about 65% deletions, about 7% duplications, about 26% point mutations and about 2% unknown mutations). ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23620649'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 242, 'text': 'The Duchenne Muscular dystrophy (DMD) is the most frequent muscle disorder in childhood caused by mutations in the Xlinked dystrophin gene (about 65% deletions, about 7% duplications, about 26% point mutations and about 2% unknown mutations).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23620649'}, {'offsetInBeginSection': 419, 'offsetInEndSection': 703, 'text': 'While in earlier studies equal mutation rates in males and females had been reported, a breakdown by mutation types can better explain the sex ratio of mutations: Point mutations and duplications arise preferentially during spermatogenesis whereas deletions mostly arise in oogenesis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23620649'}, {'offsetInBeginSection': 388, 'offsetInEndSection': 1129, 'text': 'l spectrum. This information is extremely beneficial for basic scientific research, genetic diagnosis, trial planning, clinical care, and gene therapy.METHODS: We collected data from 1400 patients (1042 patients with confirmed unrelated Duchenne muscular dystrophy [DMD] or Becker muscular dystrophy [BMD]) registered in the Chinese Genetic Disease Registry from March 2012 to August 2017 and analyzed the genetic mutational characteristics of these patients.RESULTS: Large deletions were the most frequent type of mutation (72.2%), followed by nonsense mutations (11.9%), exon duplications (8.8%), small deletions (3.0%), splice-site mutations (2.1%), small insertions (1.3%), missense mutations (0.6%), and a combination mutation of a dele', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29973226'}, {'offsetInBeginSection': 706, 'offsetInEndSection': 831, 'text': 'Deletions were the most common mutation type (256, 79%), followed by point mutations (45, 13.9%) and duplications (23, 7.1%).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35064276'}]\n\n\n             'What are the most common mutation types in Duchenne muscular Dystrophy?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "The most common mutation types are deletions, duplications, point mutations, deletion/duplication complex rearrangement,nonsense/frameshift mutations, mutations in splice sites."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 75, 'text': 'Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35939578'}, {'offsetInBeginSection': 193, 'offsetInEndSection': 406, 'text': 'Whether treatment with litifilimab, a humanized monoclonal antibody against BDCA2, would be efficacious in reducing disease activity in patients with cutaneous lupus erythematosus has not been extensively studied.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35939578'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 74, 'text': 'Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36069871'}, {'offsetInBeginSection': 258, 'offsetInEndSection': 420, 'text': ' The safety and efficacy of subcutaneous litifilimab, a humanized monoclonal antibody that binds to BDCA2, in patients with SLE have not been extensively studied.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36069871'}]\n\n\n             'What is the target of Litifilimab?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Litifilimab is a humanized monoclonal antibody against BDCA2 that is being developed for treatment of cutaneous lupus erythematosus."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 847, 'offsetInEndSection': 915, 'text': '. The area under the receiver operator characteristics curve (AUROC)', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35610482'}, {'offsetInBeginSection': 1513, 'offsetInEndSection': 1556, 'text': 'area under receiver operator curve [AUROC] ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35426141'}, {'offsetInBeginSection': 819, 'offsetInEndSection': 927, 'text': 'The model performance was evaluated using the area under the receiver operating characteristic curve (AUROC)', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35438215'}, {'offsetInBeginSection': 478, 'offsetInEndSection': 672, 'text': 'Our models predict GDM with high accuracy even at pregnancy initiation (area under the receiver operating curve (auROC)\\u2009=\\u20090.85), substantially outperforming a baseline risk score (auROC\\u2009=\\u20090.68).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31932807'}, {'offsetInBeginSection': 858, 'offsetInEndSection': 1147, 'text': ' prediction of pancreatic cancer. Two popular models were evaluated: logistic regression and a recurrent neural network.RESULTS: For logistic regression, using UMLS delivered the optimal area under the receiver operating characteristics (AUROC) results in both dengue hemorrhagic fever (81', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32930711'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 102, 'text': 'Area under the receiver operating characteristics (AUROC) curve is often used to evaluate risk models.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21958955'}, {'offsetInBeginSection': 117, 'offsetInEndSection': 271, 'text': 'stic tests. Rather, researchers use the area under the receiver operating characteristic (AUROC) as the key metric to gauge and report predictive performa', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31093546'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 175, 'text': 'Area under a receiver-operating-characteristic (AUROC) curve is widely used in medicine to summarize the ability of a continuous predictive marker to predict a binary outcome.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28860560'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 258, 'text': 'The c statistic, or area under the receiver operating characteristic (ROC) curve, achieved popularity in diagnostic testing, in which the test characteristics of sensitivity and specificity are relevant to discriminating diseased versus nondiseased patients.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17309939'}, {'offsetInBeginSection': 1598, 'offsetInEndSection': 1949, 'text': '-day mortality, respectively. When using only baseline variables to predict mortality, all algorithms except SVM (area under the receiver operator characteristic curve [AUROC], 0.83 [95% confidence interval {CI}, 0.69-0.97]) had AUROC >0.9: GBM (AUROC, 0.96 [0.94-1.0]), RF (AUROC, 0.96 [0.92-1.0]), CNN (AUROC, 0.96 [0.92-0.99]), and logistic regress', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34908548'}, {'offsetInBeginSection': 99, 'offsetInEndSection': 361, 'text': 'We assessed model performance using two metrics, the area under the receiver operating characteristic curve (AUROC) and the area under the precision-recall curve (AUPRC), to illustrate the differences in information they convey in the setting of class imbalance.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31437918'}, {'offsetInBeginSection': 777, 'offsetInEndSection': 958, 'text': 'The two approaches were explored and validated within the context of mRNA expression level prediction and have the area under the ROC curve (auROC) values ranging from 0.75 to 0.94.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30842277'}, {'offsetInBeginSection': 862, 'offsetInEndSection': 1132, 'text': '.4%) and validation (47.4%) cohorts. The FibroGENE-DT yielded the area under the receiver operating characteristic curve (AUROCs) of 0.87, 0.85 and 0.804 for the prediction of fast fibrosis progression, cirrhosis and significant fibrosis risk, respectively, with compara', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26592354'}, {'offsetInBeginSection': 1711, 'offsetInEndSection': 1952, 'text': 'ement (oral or IV) was 41.1%. Independent predictors using history alone were female sex, decreasing age, surgical history, and non-Caucasian ethnicity (model area under the receiver operating characteristic curve [AUROC], 0.59 [95% confiden', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31094792'}, {'offsetInBeginSection': 808, 'offsetInEndSection': 1084, 'text': ' reduction of at least I\u00b0 MR. One-year mortality was 28.2%.In Kaplan-Meier analysis, one- year mortality was significantly higher in RVD-pts (34.8% vs 2.8%, p\\xa0=\\xa00.009).Area under the Receiver Operating Characteristic (AUROC) for SHFM and MAGGIC were comparable for both scores', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33088899'}, {'offsetInBeginSection': 1371, 'offsetInEndSection': 1584, 'text': 'Using a standard multivariate approach to combine predictors, the PPIN model achieved an AUROC (area under the receiver operating characteristic curve) of 0.81 with a sensitivity of 48% given a specificity of 90%.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23620757'}, {'offsetInBeginSection': 360, 'offsetInEndSection': 510, 'text': 'cognitive impairment was evaluated using area under the receiver operating characteristic curve (AUROC), and multivariate logistic regression was appl', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35879562'}, {'offsetInBeginSection': 1005, 'offsetInEndSection': 1155, 'text': 'ssion, using UMLS delivered the optimal area under the receiver operating characteristics (AUROC) results in both dengue hemorrhagic fever (81.15%) an', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32930711'}, {'offsetInBeginSection': 1325, 'offsetInEndSection': 1475, 'text': 's). Sensitivity, specificity, predictive values and area under receiving operating curves (AUROC) of RBUS for VCUG abnormalities were determined.RESUL', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25958031'}, {'offsetInBeginSection': 598, 'offsetInEndSection': 748, 'text': 'ys). Model performance was assessed using area under the receiver operator characteristic curve (AUROC). Pre-N8-GP prophylaxis models learned from dat', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34865209'}, {'offsetInBeginSection': 536, 'offsetInEndSection': 686, 'text': 'agnostic threshold were evaluated using area under the receiver operating characteristic curve (AUROC). Stratification analysis by age and MP-IgM tite', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34154565'}, {'offsetInBeginSection': 543, 'offsetInEndSection': 693, 'text': ' learning algorithms was assessed by the area under the receiver operating characteristic curve (AUROC). The conventional scoring models had various p', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35505048'}, {'offsetInBeginSection': 471, 'offsetInEndSection': 621, 'text': 'sing PubMed, MEDLINE, and Scopus databases. Papers with area under the receiver operating curve (AUROC) scores reported were included in the analysis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33203588'}, {'offsetInBeginSection': 837, 'offsetInEndSection': 987, 'text': 'nstruct the prediction model. Finally, the area under the receiver operating characteristic (AUROC) curve was used to compare the model performance.RE', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36329470'}, {'offsetInBeginSection': 1029, 'offsetInEndSection': 1179, 'text': 'cy for tasks such as predicting: in-hospital mortality (area under the receiver operator curve [AUROC] across sites 0.93-0.94), 30-day unplanned readm', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31304302'}, {'offsetInBeginSection': 112, 'offsetInEndSection': 262, 'text': 'rognostic tests. Rather, researchers use the area under the receiver operating characteristic (AUROC) as the key metric to gauge and report predictive', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31093546'}, {'offsetInBeginSection': 1005, 'offsetInEndSection': 1216, 'text': 'ssion, using UMLS delivered the optimal area under the receiver operating characteristics (AUROC) results in both dengue hemorrhagic fever (81.15%) and pancreatic cancer (80.53%) tasks. For recurrent neural netw', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32930711'}, {'offsetInBeginSection': 1325, 'offsetInEndSection': 1466, 'text': 's). Sensitivity, specificity, predictive values and area under receiving operating curves (AUROC) of RBUS for VCUG abnormalities were determi', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25958031'}, {'offsetInBeginSection': 471, 'offsetInEndSection': 577, 'text': 'sing PubMed, MEDLINE, and Scopus databases. Papers with area under the receiver operating curve (AUROC) sc', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33203588'}, {'offsetInBeginSection': 837, 'offsetInEndSection': 955, 'text': 'nstruct the prediction model. Finally, the area under the receiver operating characteristic (AUROC) curve was used to ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36329470'}, {'offsetInBeginSection': 112, 'offsetInEndSection': 266, 'text': 'rognostic tests. Rather, researchers use the area under the receiver operating characteristic (AUROC) as the key metric to gauge and report predictive per', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31093546'}, {'offsetInBeginSection': 360, 'offsetInEndSection': 706, 'text': 'cognitive impairment was evaluated using area under the receiver operating characteristic curve (AUROC), and multivariate logistic regression was applied to evaluate predictive accuracy of biomarkers on cognitive impairment; 178 subjects (41 PD, 31 VaD and 106 normal controls) were included. In multiple linear regression analysis of PD patients', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35879562'}, {'offsetInBeginSection': 652, 'offsetInEndSection': 945, 'text': 'of outcome (AC), sensitivity (SN), specificity (SP), and area under receiver-operating curve (AUROC) were compared between 3 models: KCC (INR, creatinine, coma grade, pH), CART analysis using only KCC variables (KCC-CART) and a CART model using new variables (NEW-CART).RESULTS: Traditional KC', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25885260'}, {'offsetInBeginSection': 652, 'offsetInEndSection': 941, 'text': 'models of the EGFR mutation status (Model 1: area under the receiver operating characteristic curve [AUROC]\\u2009=\\u20090.910, 95% CI 0.861-0.945; Model 2: AUROC\\u2009=\\u20090.859, 95% CI 0.803-0.904; Model 3: AUROC\\u2009=\\u20090.711, 95% CI 0.643-0.773). A testing set (n\\u2009=\\u200950) and temporal validation data set (n\\u2009=\\u200970', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31807867'}, {'offsetInBeginSection': 1029, 'offsetInEndSection': 1371, 'text': \"cy for tasks such as predicting: in-hospital mortality (area under the receiver operator curve [AUROC] across sites 0.93-0.94), 30-day unplanned readmission (AUROC 0.75-0.76), prolonged length of stay (AUROC 0.85-0.86), and all of a patient's final discharge diagnoses (frequency-weighted AUROC 0.90). These models outperformed traditional, c\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31304302'}, {'offsetInBeginSection': 838, 'offsetInEndSection': 1056, 'text': ' matrix, accuracy, precision, recall, F1 score, and Area under the\\xa0Receiver Operating Characteristics (AUROC) were used to evaluate the performance of predictive models.RESULTS: Ability of prediction was between 68.6% ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35509018'}, {'offsetInBeginSection': 846, 'offsetInEndSection': 1064, 'text': ' accuracy, precision, recall, F1 score, and Area under the\\xa0Receiver Operating Characteristics (AUROC) were used to evaluate the performance of predictive models.RESULTS: Ability of prediction was between 68.6% and 61.5', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35509018'}, {'offsetInBeginSection': 1023, 'offsetInEndSection': 1173, 'text': 's), positive predictive values (PPVs), and area under the receiver operating characteristic curve (AUROC), of machine learning models when predicting ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31509205'}, {'offsetInBeginSection': 645, 'offsetInEndSection': 838, 'text': 'ance of prediction, accuracy of discrimination (area under the receiver operating characteristic curve [AUROC]), calibration, and validity of the two predictive models were investigated. The co', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28323524'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 734, 'text': 'The area under the receiver operating characteristic (ROC) curve (AUC) is commonly used for assessing the discriminative ability of prediction models even though the measure is criticized for being clinically irrelevant and lacking an intuitive interpretation. Every tutorial explains how the coordinates of the ROC curve are obtained from the risk distributions of diseased and non-diseased individuals, but it has not become common sense that therewith the ROC plot is just another way of presenting these risk distributions. We show how the ROC curve is an alternative way to present risk distributions of diseased and non-diseased individuals and how the shape of the ROC curve informs about the overlap of the risk distributions.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31967640'}]\n\n\n             'What is AUROC in context of predictive modeling?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": ". AUROC stands for the area under the receiver operator characteristics curve (AUROC)"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 1011, 'offsetInEndSection': 1095, 'text': 'PRP-40 regulation of neuronal microexons is therefore a widely conserved phenomenon.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34348142'}]\n\n\n             'Is PRP-40 regulation of microexons a conserved phenomenon?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Yes, PRP-40 regulation of neuronal microexons is a widely conserved phenomenon."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 568, 'offsetInEndSection': 761, 'text': 'Casimersen received its first approval on 25\\xa0February 2021, in the USA, for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon\\xa045 skipping. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33861387'}, {'offsetInBeginSection': 762, 'offsetInEndSection': 943, 'text': 'he approval, granted under the US FDA Accelerated Approval Program, was based on an observed increase in dystrophin production in skeletal muscle in patients treated with casimersen', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33861387'}]\n\n\n             'Is casimersen effective for the treatment of Duchenne muscular dystrophy?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Yes, casimersen is considered to be effective for the treatment of Duchenne muscular dystrophy."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 110, 'text': 'Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35651477'}, {'offsetInBeginSection': 102, 'offsetInEndSection': 277, 'text': 'he efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35658024'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 144, 'text': 'Tirzepatide - a dual GIP/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35593668'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 400, 'text': 'The incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are responsible for up to 65% of postprandial insulin secretion. Tirzepatide, developed by Eli Lilly, is a dual GIP/GLP-1 receptor agonist in the form of a synthetic linear peptide; its acylation technology allows it to bind to albumin, thus making it possible to dose the drug once a week. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35593668'}]\n\n\n             'Which are the targets of Tirzepatide?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Tirzepatide is a dual incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)  receptor agonist in the form of a synthetic linear peptide."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 187, 'offsetInEndSection': 315, 'text': 'hydrotherapy,\" \"balneotherapy,\" \"spa therapy,\" \"spa treatment,\" \"creno-balneotherapy,\" \"water treatments,\" and \"aqua therapy,\" o', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35779167'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 554, 'text': 'Spa therapy is an integral part of the treatment of burn scars. The objective of this systematic review is to provide an overview of the spa therapy used in the treatment of burn scars and analyze its effects reported in clinical studies. We used the PRISMA checklist and queried 8 scientific databases from August 2019 to July 2020 for articles referenced with the specific key words: (burn) AND ((spa) OR (crenotherap*) OR (sulfur bath) OR (balneo*) OR (hydrotherap*) OR (mineral water) OR (thermal water) OR (spring water) OR (health resort medicine))', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32875343'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 249, 'text': 'Soon after qualification, Fortescue Fox (1858-1940) began practice in a Scottish spa where he acquired a lifelong interest in chronic disorders, especially arthritis. He worked to improve the status of spa medicine, recasting it as medical hydrology', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32568298'}, {'offsetInBeginSection': 167, 'offsetInEndSection': 250, 'text': 'He worked to improve the status of spa medicine, recasting it as medical hydrology.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32568298'}, {'offsetInBeginSection': 166, 'offsetInEndSection': 250, 'text': ' He worked to improve the status of spa medicine, recasting it as medical hydrology.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32568298'}]\n\n\n             'Is medical hydrology the same as Spa therapy?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Medical Hydrology is defined as the therapeutic use of bathing and water and would include therapeutic spa therapy"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 204, 'text': 'CYP1A2 polymorphisms modify the association of habitual coffee consumption with appetite, macronutrient intake, and body mass index: results from an observational cohort and a cross-over randomized study.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34564706'}, {'offsetInBeginSection': 1340, 'offsetInEndSection': 1952, 'text': 'High coffee consumption was more prevalent in rapid compared to slow metabolizers (P\\u2009=\\u20090.008 after adjustment for age, sex, and BMI) and was associated with lower appetite perception and lower BMI only in rapid metabolizers (P for interaction of rs762551 genotype*coffee consumption\\u2009=\\u20090.002 and 0.048, respectively). This differential association of rs762551 genotype and coffee consumption with BMI was more evident in individuals at higher genetic risk of obesity (mean adjusted difference in BMI\\u2009=\\u2009-5.82\\u2009kg/m2 for rapid versus slow/intermediate metabolizers who consumed more than 14 cups of coffee per week).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34564706'}, {'offsetInBeginSection': 1965, 'offsetInEndSection': 2256, 'text': 'CYP1A2 rs762551 polymorphism modifies the association of habitual coffee consumption with BMI, in part by influencing appetite, energy intake and circulating levels of the orexigenic hormone asprosin. This association is more evident in subjects with high genetic predisposition to obesity. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34564706'}]\n\n\n             'How does CYP1A2 relate to coffee consumption and apetite?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "CYP1A2 rs762551 polymorphism modifies the association of habitual coffee consumption with BMI, in part by influencing appetite, energy intake and circulating levels of the orexigenic hormone asprosin. In specific, high coffee consumption was more prevalent in rapid compared to slow metabolizers (P\u2009=\u20090.008 after adjustment for age, sex, and BMI) and was associated with lower appetite perception and lower BMI only in rapid metabolizers (P for interaction of rs762551 genotype*coffee consumption\u2009=\u20090.002 and 0.048, respectively)"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 1347, 'offsetInEndSection': 1641, 'text': 'Eteplirsen-treated patients experienced a statistically significant longer median time to LOA by 2.09 years (5.09 vs. 3.00 years, p\\u200a<\\u200a0.01) and significantly attenuated rates of pulmonary decline vs. natural history patients (FVC%p change: -3.3 vs. -6.0 percentage points annually, p\\u200a<\\u200a0.0001).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34420980'}, {'offsetInBeginSection': 967, 'offsetInEndSection': 1200, 'text': 'At Years 3 and 4, eteplirsen-treated patients demonstrated markedly greater mean 6MWT than controls (difference in change from baseline of 132 m [95%CI (29, 235), p\\u200a=\\u200a0.015] at Year 3 and 159\\u200am [95%CI (66, 253), p\\u200a=\\u200a0.002] at Year 4)', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33523015'}, {'offsetInBeginSection': 1202, 'offsetInEndSection': 1341, 'text': 'At Year 4, a significantly greater proportion of eteplirsen-treated patients were still ambulant versus controls (10/12 vs 3/11; p\\u200a=\\u200a0.020)', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33523015'}, {'offsetInBeginSection': 1606, 'offsetInEndSection': 1803, 'text': ' In this retrospective matched control study, eteplirsen treatment resulted in attenuation of ambulatory decline over a 4-year observation period, supporting long-term benefit in patients with DMD.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33523015'}]\n\n\n             'Is eteplirsen effective for the treatment of Duchenne muscular dystrophy?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Yes, eteplirsen is effective for the treatment of Duchenne muscular dystrophy."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 1482, 'offsetInEndSection': 1648, 'text': 'CONCLUSIONS: All three ARAT agents are efficacious options for the treatment of nmCRPC, whereas darolutamide appears to have the most favorable tolerability profile. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34308608'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 335, 'text': 'BACKGROUND: For nonmetastatic castration-resistant prostate cancer (nmCRPC), 3 drugs under patent protection-apalutamide, enzalutamide, and darolutamide-were approved based on randomized, placebo-controlled trials; 1 drug with generic availability, abiraterone acetate, showed efficacy in a single-arm trial and is commonly prescribed.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33830214'}, {'offsetInBeginSection': 1701, 'offsetInEndSection': 1920, 'text': 'CONCLUSIONS: For nmCRPC, darolutamide offered optimal efficacy and safety among approved drugs, and abiraterone acetate may offer comparable metastasis-free survival benefit with cost savings from generic availability. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33830214'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 160, 'text': 'Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35656777'}, {'offsetInBeginSection': 687, 'offsetInEndSection': 846, 'text': 'Darolutamide is an approved treatment for a different type of prostate cancer called non-metastatic, castration-resistant prostate cancer (also called nmCRPC).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35656777'}]\n\n\n             'What is the use of darolutamide?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Darolutamide is an approved treatment of non-metastatic, castration-resistant prostate cancer (also called nmCRPC)."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 155, 'offsetInEndSection': 272, 'text': ' Selective SFN (without large fiber affection) manifests with pain, sensory disturbances, or autonomic dysfunction. T', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35130356'}, {'offsetInBeginSection': 14, 'offsetInEndSection': 236, 'text': 'Neuropathic pain (NP) is a main feature of Fabry disease (FD) as consequence of small fiber neuropathy. Restless legs syndrome (RLS) in FD was not described, but it is an important feature in other small fiber neuropathies', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17948213'}, {'offsetInBeginSection': 13, 'offsetInEndSection': 184, 'text': 'mall fiber neuropathy (SFN) can be associated with autoantibodies, including those of IgM class with specificity for the trisulfated heparan disaccharide (TS-HDS) antigen.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34698404'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 234, 'text': 'Up to 50% of small fiber neuropathy (SFN) cases are idiopathic, but novel antibodies to Trisulfated Heparin Disaccharide (TS-HDS) and fibroblast growth factor receptor 3 (FGFR-3) have been implicated in half of these cases', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36005471'}, {'offsetInBeginSection': 683, 'offsetInEndSection': 961, 'text': 'an the patients without SFN. Restless leg syndrome was also more frequently observed in patients with SFN, who had pain aggravated at rest that improved by moving.CONCLUSIONS: These findings are in favor of the sensitization of relatively spared large A\u03b2-fibers and second-order', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30247738'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 218, 'text': 'Small fiber neuropathies (SFN) comprise a clinical syndrome typically associated with acral burning pain, where the pathophysiological processes affect the thinly myelinated A-delta and the unmyelinated C nerve fibers.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30125923'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 210, 'text': 'Small fibre neuropathy (SFN), a condition dominated by neuropathic pain, is frequently encountered in clinical practise either as prevalent manifestation of more diffuse neuropathy or distinct nosologic entity.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18524793'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 171, 'text': 'Neuropathic pain is a characteristic feature of small fiber neuropathy (SFN), which in 18% of the cases is caused by genetic variants in voltage-gated sodium ion channels.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36430572'}, {'offsetInBeginSection': 240, 'offsetInEndSection': 466, 'text': 'SFN was defined by the presence of suggestive sensory painful symptoms with normal nerve conduction studies and abnormal neurophysiologic tests for small nerve fibers or a low intraepidermal nerve fiber density at skin biopsy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23982054'}, {'offsetInBeginSection': 94, 'offsetInEndSection': 222, 'text': 'SFN is clinically dominated by neuropathic pain and autonomic complaints, leading to a significant reduction in quality of life.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30569495'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 222, 'text': 'Small-fiber neuropathy (SFN) is a disorder of thinly myelinated A\u03b4 and unmyelinated C fibers. SFN is clinically dominated by neuropathic pain and autonomic complaints, leading to a significant reduction in quality of life.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30569495'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 336, 'text': 'INTRODUCTION: Small fiber neuropathy (SFN) is a heterogeneous group of disorders affecting thin myelinated A\u03b4 and unmyelinated C fibers. Common symptoms include neuropathic pain and autonomic disturbances, and the typical clinical presentation is that of a length-dependent polyneuropathy, although other distributions could be present.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32654574'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 452, 'text': 'Small fiber neuropathy (SFN) is a peripheral nervous system disease due to affection of A-delta or C-fibers in a proximal, distal, or diffuse distribution. Selective SFN (without large fiber affection) manifests with pain, sensory disturbances, or autonomic dysfunction. Though uniform diagnostic criteria are unavailable, most of them request typical clinical features and reduced intra-epidermal nerve fiber density on proximal or distal skin biopsy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35130356'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 480, 'text': 'Small fibre neuropathies are a heterogeneous group of disorders affecting thinly myelinated A\u03b4-fibres and unmyelinated C-fibres. Although multiple causes of small nerve fibre degeneration have been reported, including via genetic mutations, the cause of small fibre neuropathy remains unknown in up to 50% of cases. The typical clinical presentation of small fibre neuropathy is that of a symmetrical, length-dependent polyneuropathy associated with sensory or autonomic symptoms.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29029847'}]\n\n\n             'What are the main clinical features of small-fiber neuropathy (SFN)?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Small fiber neuropathy manifests with pain, sensory disturbances, or autonomic dysfunction."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 713, 'text': 'On October 24, 2016, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda; Merck & Co., Inc., https://www.merck.com) for treatment of patients with metastatic non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1) as determined by an FDA-approved test, as follows: (a) first-line treatment of patients with mNSCLC whose tumors have high PD-L1 expression (tumor proportion score [TPS] \u226550%), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations, and (b) treatment of patients with mNSCLC whose tumors express PD-L1 (TPS \u22651%), with disease progression on or after platinum-containing chemotherapy. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28835513'}]\n\n\n             'When was Keytruda approved by the FDA for the treatment of metastatic non-small cell lung cancer?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "On October 24, 2016, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for treatment of metastatic non-small cell lung cancer."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 706, 'offsetInEndSection': 1045, 'text': ' In relation to clinical trials, in the last ten years, has experienced great advances in the field of therapeutic options, divided into two major therapeutic targets: 1) the area of gene therapies and 2) trying to reverse or block the pathophysiological processes of the disease, such as inflammation, fibrosis, muscle regeneration, etc. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31603849'}, {'offsetInBeginSection': 646, 'offsetInEndSection': 788, 'text': 'Several promising gene therapies are currently under investigation. These include gene replacement, exon skipping, suppression of stop codons.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29351004'}, {'offsetInBeginSection': 789, 'offsetInEndSection': 947, 'text': 'More recently, a promising gene editing tool referred to as CRISPR/Cas9 offers exciting perspectives for restoring dystrophin expression in patients with DMD.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29351004'}, {'offsetInBeginSection': 271, 'offsetInEndSection': 561, 'text': 'Adeno-associated virus-vectorized gene therapies to restore dystrophin protein expression using gene replacement or antisense oligonucleotide-mediated pre-mRNA splicing modulation have emerged, making great strides in uncovering barriers to gene therapies for DMD and other genetic diseases', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34175043'}, {'offsetInBeginSection': 522, 'offsetInEndSection': 742, 'text': 'We recently showed that antisense oligoribonucleotide-mediated skipping of exon 46 efficiently induced dystrophin synthesis in cultured muscle cells from Duchenne muscular dystrophy patients carrying an exon 45 deletion.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12206800'}, {'offsetInBeginSection': 1125, 'offsetInEndSection': 1429, 'text': 'The success of induced exon skipping has spawned a number of \"fusion therapies\", including vector-mediated dystrophin exon skipping and ex vivo viral delivery of splice-switching antisense molecules into myogenic stem cells, followed by implantation, which may address long term oligomer delivery issues.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20041827'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 273, 'text': 'Several clinical trials have recently demonstrated that oligonucleotide-based drugs induced targeted exon skipping in dystrophin pre-mRNA in Duchenne muscular dystrophy patients, resulting in novel expression of a truncated but functional isoform of the dystrophin protein.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22846203'}, {'offsetInBeginSection': 516, 'offsetInEndSection': 715, 'text': 'These strategies include gene replacement with adeno-associated virus, exon skipping with antisense oligonucleotides, and mutation suppression with compounds that \"read through\" stop codon mutations.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23328943'}, {'offsetInBeginSection': 150, 'offsetInEndSection': 398, 'text': 'There are several promising genetic approaches, including viral delivery of the missing dystrophin gene, read-through of translation stop codons, exon skipping to restore the reading frame and increased expression of the compensatory utrophin gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23609411'}, {'offsetInBeginSection': 133, 'offsetInEndSection': 418, 'text': 'So far, there is no effective treatment but new gene-based therapies are currently being developed with particular noted advances in using conventional gene replacement strategies, RNA-based approaches, or cell-based gene therapy with a main focus on Duchenne muscular dystrophy (DMD).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19527108'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 104, 'text': 'Myodys, a full-length dystrophin plasmid vector for Duchenne and Becker muscular dystrophy gene therapy.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18228186'}, {'offsetInBeginSection': 450, 'offsetInEndSection': 762, 'text': \"The first viral-mediated gene transfer for any muscle disease was carried out at Columbus Children's Research Institute and Ohio State University for limb girdle muscular dystrophy type 2D, and the first viral-mediated trial of gene transfer for Duchenne muscular dystrophy is under way at the same institutions.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17846262'}, {'offsetInBeginSection': 271, 'offsetInEndSection': 562, 'text': 'Adeno-associated virus-vectorized gene therapies to restore dystrophin protein expression using gene replacement or antisense oligonucleotide-mediated pre-mRNA splicing modulation have emerged, making great strides in uncovering barriers to gene therapies for DMD and other genetic diseases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34175043'}, {'offsetInBeginSection': 742, 'offsetInEndSection': 1174, 'text': \"Of all novel molecular interventions currently being investigated for Duchenne muscular dystrophy, perhaps the most promising method aiming to restore dystrophin expression to diseased cells is known as 'exon skipping' or splice-modulation, whereby antisense oligonucleotides eliminate the deleterious effects of DMD mutations by modulating dystrophin pre-messenger RNA splicing, such that functional dystrophin protein is produced.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20150322'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 94, 'text': 'Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12206800'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 114, 'text': 'Several new approaches to gene therapy for the muscular dystrophies involve oligonucleotides as targeting vectors.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12206797'}, {'offsetInBeginSection': 146, 'offsetInEndSection': 448, 'text': 'gene therapy, an approach that demonstrates promise for treating Duchenne muscular dystrophy. Gene therapy is not limited to replacement of defective genes but also includes strategies using surrogate genes with alternative but effective means of improving cellular function or repairing gene mutations', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17846262'}, {'offsetInBeginSection': 107, 'offsetInEndSection': 257, 'text': 'rophy gene which abort dystrophin synthesis. We have explored a gene correction therapy aimed at restoration of the reading frame in Duchenne muscular', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12206800'}, {'offsetInBeginSection': 359, 'offsetInEndSection': 579, 'text': 'on gene replacement and gene/expression repair, including exon-skipping, vector-mediated gene therapy and cell therapy. Therapeutic strategies for different forms of muscular dystrophy are discussed, with an emphasis on ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23387802'}]\n\n\n             'Which gene therapies are under investigation for Duchenne muscular dystrophy?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "The following gene therapies are under investigation for Duchenne muscular dystrophy: adeno-associated virus-vectorized gene therapies to restore dystrophin protein expression using gene replacement and exon skipping, suppression of stop codons and the use CRISPR/Cas9 system."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 65, 'text': 'Germline Mutations in CIDEB and Protection against Liver Disease.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35939579'}, {'offsetInBeginSection': 897, 'offsetInEndSection': 1028, 'text': 'We also found that variants in CIDEB, which encodes a structural protein found in hepatic lipid droplets, had a protective effect. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35939579'}, {'offsetInBeginSection': 2119, 'offsetInEndSection': 2217, 'text': 'CONCLUSIONS: Rare germline mutations in CIDEB conferred substantial protection from liver disease.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35939579'}]\n\n\n             'Does CIDEB mutation protect from liver disease?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Yes. CIDEB mutation protects from liver disease."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 238, 'text': 'Cdk9 is a member of the Cdc2-like family of kinases. Its cyclin partners are members of the family of cyclin T (T1, T2a and T2b) and cyclin K. The Cdk9/cyclin T complexes appear to be involved in regulating several physiological processes', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12432243'}, {'offsetInBeginSection': 120, 'offsetInEndSection': 236, 'text': 'We previously cloned a cdc2-related kinase, cdk9/PITALRE, that is able to phosphorylate the retinoblastoma protein i', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9766517'}, {'offsetInBeginSection': 924, 'offsetInEndSection': 1057, 'text': 'hese results suggest that, among other roles, cdk9/PITALRE plays a role not unlike cdk5 in the differentiation of certain cell types.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9766517'}, {'offsetInBeginSection': 10, 'offsetInEndSection': 143, 'text': ' CDK9/Cyclin T1 kinase is a protein kinase, indirectly involved in the cell cycle progression in the form of transcription elongation', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31603123'}, {'offsetInBeginSection': 152, 'offsetInEndSection': 302, 'text': 'Among various clinically validated kinases, the cyclin-dependent kinases (CDK) are one of the extensively studied drug targets for clinical developmen', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34605036'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 246, 'text': 'Cyclin-dependent kinases (CDKs) are a broad family of proteins involved in the cell cycle and transcriptional regulation. In this article, we explore the antitumoral activity of a novel proteolysis-targeting chimera (PROTAC) compound against CDK9', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35628286'}, {'offsetInBeginSection': 240, 'offsetInEndSection': 427, 'text': 'Cdk9/cyclin T1 belongs to the P-TEFb complex, and is responsible for the phosphorylation of the carboxyl-terminal domain (CTD) of the RNA Polymerase II, thus promoting general elongation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12432243'}, {'offsetInBeginSection': 93, 'offsetInEndSection': 403, 'text': 'Cdk9 function depends on its kinase activity and also on its regulatory units: the T-family cyclins and cyclin K. Recently, several studies confirmed the role of cdk9 in different cellular processes such as signal transduction, basal transcription, HIV-Tat- and MyoD-mediated transcription and differentiation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11532614'}, {'offsetInBeginSection': 930, 'offsetInEndSection': 1146, 'text': 'This data suggests the involvement of Cdk9 in several physiological processes in the cell, the deregulation of which may be related to the genesis of transforming events, that may in turn lead to the onset of cancer.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12432243'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 197, 'text': 'CDK9 is a prominent member of the transcriptional CDKs subfamily, a group of kinases whose function is to control the primary steps of mRNA synthesis and processing by eukaryotic RNA polymerase II.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27833949'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 293, 'text': 'Cyclin-dependent kinase 9 (CDK9), with its cyclin T regulatory subunit, is a component of the positive transcription elongation factor b (P-TEFb) complex, which stimulates transcription elongation and also functions in co-transcriptional histone modification, mRNA processing, and mRNA export.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21200140'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 481, 'text': 'Cyclin Dependent Kinase 9 (CDK9) is one of the most important transcription regulatory members of the CDK family. In conjunction with its main cyclin partner-Cyclin T1, it forms the Positive Transcription Elongation Factor b (P-TEFb) whose primary function in eukaryotic cells is to mediate the positive transcription elongation of nascent mRNA strands, by phosphorylating the S2 residues of the YSPTSPS tandem repeats at the C-terminus domain (CTD) of RNA Polymerase II (RNAP II).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34062779'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 367, 'text': 'CDK9 is a prominent member of the transcriptional CDKs subfamily, a group of kinases whose function is to control the primary steps of mRNA synthesis and processing by eukaryotic RNA polymerase II. As a cyclin-dependent kinase, CDK9 activation in vivo depends upon its association with T-type cyclins to assemble the positive transcription elongation factor (P-TEFb).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27833949'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 201, 'text': 'Cyclin-dependent kinase 9 (CDK9), the kinase component of positive transcription elongation factor b (P-TEFb), is essential for transcription of most protein-coding genes by RNA polymerase II (RNAPII).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34146121'}]\n\n\n             'Can you summarize the function of CDK9?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Cyclin-dependent kinase 9 (CDK9) is critical for RNA Polymerase II (Pol II) transcription initiation, elongation, and termination in several key biological processes including development, differentiation, and cell fate responses."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 1178, 'offsetInEndSection': 1350, 'text': 'Thus, our data suggest that RBM24 is a critical regulator of CaMKII\u03b4 to control the cardiac QT interval, highlighting the key role of splicing regulation in cardiac rhythm.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36454480'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 60, 'text': 'RBM24 controls cardiac QT interval through CaMKII\u03b4 splicing.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36454480'}]\n\n\n             'How does RBM24 control QT interval?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "RBM24 controls cardiac QT interval through CaMKII\u03b4 splicing."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 1854, 'offsetInEndSection': 1990, 'text': 'The results showed a significant difference in the NSAA score between the deletion and nonsense groups at the age of 3 years (P\\u2009=\\u20090.04).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35501714'}, {'offsetInBeginSection': 583, 'offsetInEndSection': 1202, 'text': 'The boys were evaluated with standardized assessments at the screening and baseline visits at 32 sites in 5 countries (US, UK, Canada, Italy, Germany). Assessments included timed rise from floor, timed 10\\u202fm walk/run, six-minute walk distance, North Star Ambulatory Assessment (NSAA) and forced vital capacity (FVC). Mean age at baseline was 5.9 years (range 4.1-8.1 years). Test-retest reliability was high for functional assessments, regardless of time lag between assessments (up to 90 days) and for the majority of age groups. Correlations were strong among the functional measures and timed tests, less so with FVC.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35618576'}, {'offsetInBeginSection': 11, 'offsetInEndSection': 190, 'text': 'The North Star Ambulatory Assessment (NSAA) is a validated 17-item functional rating scale and widely used to assess motor function in boys with Duchenne muscular dystrophy (DMD).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35626905'}, {'offsetInBeginSection': 1319, 'offsetInEndSection': 1645, 'text': 'hese exploratory analyses reveal additional approaches to interpreting the NSAA data beyond just change in NSAA total score. These observations also highlight the importance of reporting items as \"not obtainable\" for a patient with a temporary/transient physical disability that impacts their ability to perform the NSAA test.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35998119'}, {'offsetInBeginSection': 836, 'offsetInEndSection': 1119, 'text': 'measurement. All analyses were performed using the Rasch Unidimensional Measurement Model.RESULTS: Overall, Rasch analysis supported the NSAA as being a reliable (high Person Separation Index of 0.91) and valid (good targeting, little misfit, no reversed thresholds) measure of ambul', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21410696'}, {'offsetInBeginSection': 144, 'offsetInEndSection': 344, 'text': 'We hypothesised that boys with DMD could be clustered into groups sharing similar trajectories of ambulatory function over time, as measured by the North Star Ambulatory Assessment (NSAA) total score.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31479456'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 152, 'text': 'INTRODUCTION: The North Star Ambulatory Assessment (NSAA) tool is a key instrument for measuring clinical outcomes in patients with Duchenne muscular dy', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35998119'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 145, 'text': 'The North Star Ambulatory Assessment is a functional scale specifically designed for ambulant boys affected by Duchenne muscular dystrophy (DMD).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20634072'}, {'offsetInBeginSection': 1416, 'offsetInEndSection': 1581, 'text': ' North Star Ambulatory Assessment in Brazilian Portuguese is a reliable and valid instrument to measure functional capacity in boys with Duchenne muscular dystrophy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28648683'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 344, 'text': 'Functional variability among boys with Duchenne muscular dystrophy (DMD) is well recognised and complicates interpretation of clinical studies. We hypothesised that boys with DMD could be clustered into groups sharing similar trajectories of ambulatory function over time, as measured by the North Star Ambulatory Assessment (NSAA) total score.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31479456'}]\n\n\n             'Is North Star Ambulatory Assessment score a reliable clinical outcome for disease progression assessment in Duchenne Muscular Dystrophy?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Yes, North Star Ambulatory Assessment score is a reliable clinical outcome and widely used for disease progression assessment in Duchenne Muscular Dystrophy."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 262, 'text': 'This study aimed to define the clinically relevant supratherapeutic dose of rilzabrutinib, an oral Bruton tyrosine kinase (BTK) inhibitor, and evaluate potential effects of therapeutic and supratherapeutic exposures on cardiac repolarization in healthy subjects.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35301810'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 104, 'text': \"Discovery of Reversible Covalent Bruton's Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib).\", 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35302767'}, {'offsetInBeginSection': 303, 'offsetInEndSection': 440, 'text': 'Herein, we describe the design of covalent reversible BTK inhibitors and the discoveries of PRN473 (11) and rilzabrutinib (PRN1008, 12). ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35302767'}, {'offsetInBeginSection': 813, 'offsetInEndSection': 1016, 'text': 'Ongoing trials include new B-cell/plasma-cell targeting agents such as the Bruton tyrosine kinase inhibitors ibrutinib and rilzabrutinib, and the anti-CD38 MoAbs daratumumab and its analogue isatuximab. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36182620'}]\n\n\n             'What is the mechanism of action of rilzabrutinib?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Rilzabrutinib is oral Bruton tyrosine kinase (BTK) inhibitor."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 237, 'offsetInEndSection': 435, 'text': ' Adult-type diffuse gliomas are genetically defined and include astrocytoma, isocitrate dehydrogenase (IDH)-mutant, oligodendroglioma, IDH-mutant and 1p/19q codeleted, and glioblastoma, IDH-wildtype', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35562130'}, {'offsetInBeginSection': 456, 'offsetInEndSection': 769, 'text': ' According to the 2021 World Health Organization classification, the three risk types included (1) low-risk, expecting oligodendroglioma, isocitrate dehydrogenase (IDH)-mutant, and 1p/19q-codeleted; (2) intermediate-risk, expecting astrocytoma, IDH-mutant; and (3) high-risk, expecting glioblastoma, IDH-wildtype.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35587830'}, {'offsetInBeginSection': 238, 'offsetInEndSection': 436, 'text': 'Adult-type diffuse gliomas are genetically defined and include astrocytoma, isocitrate dehydrogenase (IDH)-mutant, oligodendroglioma, IDH-mutant and 1p/19q codeleted, and glioblastoma, IDH-wildtype.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35562130'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 175, 'text': 'A review of adult-type diffuse gliomas in the WHO CNS5 classification with special reference to Astrocytoma, IDH-mutant and Oligodendroglioma, IDH-mutant and 1p/19q codeleted.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35562130'}, {'offsetInBeginSection': 1213, 'offsetInEndSection': 1456, 'text': 'thogenesis and prognosis. Furthermore, the previous broad category of adult-type diffuse gliomas has been consolidated into 3 types: astrocytoma, isocitrate dehydrogenase (IDH) mutant; oligodendroglioma, IDH mutant and 1p/19q codeleted; and gl', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36006639'}, {'offsetInBeginSection': 437, 'offsetInEndSection': 666, 'text': 'This review briefly discusses two tumor types: astrocytoma, IDH-mutant, and oligodendroglioma, IDH-mutant and 1p/19q codeleted, with emphasis on relevant changes in their classification and defining molecular genetic alterations.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35562130'}, {'offsetInBeginSection': 201, 'offsetInEndSection': 490, 'text': 'Since brainstem biopsies are rarely performed, these tumours are commonly classified according to their MR imaging characteristics into 4 subgroups: (a) diffuse intrinsic low-grade gliomas, (b) enhancing malignant gliomas, (c) focal tectal gliomas and (d) exophytic gliomas/other subtypes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25641008'}, {'offsetInBeginSection': 1566, 'offsetInEndSection': 2019, 'text': 'C\\u2009>\\u20090.5, k\\u2009>\\u20090.6, p\\u2009<\\u20090.001). IBGS type-I, type-II, and type-III gliomas had good specificity in identifying IDHmut 1p19q-codel oligodendroglioma (training - 97%, validation - 85%); IDHmut 1p19q non-codel astrocytoma (training - 80%, validation - 85.9%); and IDHwt glioblastoma (training - 76.5%, validation- 87.3%) respectively (p-value\\u2009<\\u20090.01).CONCLUSIONS: Imaging-based stratification of adult diffuse gliomas predicted patient survival and correlate', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35876874'}, {'offsetInBeginSection': 119, 'offsetInEndSection': 340, 'text': 'In the new WHO classification 2021, adult-type diffuse astrocytic gliomas subdivide into isocitrate dehydrogenase (IDH)-mutant astrocytoma, IDH-mutant and 1p/19q-codeleted oligodendroglioma, and IDH-wildtype glioblastoma.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36299937'}, {'offsetInBeginSection': 415, 'offsetInEndSection': 776, 'text': 'Recent genetic studies have revealed that the major categories of gliomas, such as circumscribe astrocytomas, infiltrating astrocytomas/oligodendrogliomas, and glioblastoma, roughly correspond to major genetic alterations, including isocitrate dehydrogenases (IDHs) 1/2 mutations, TP53 mutations, co-deletion of chromosome arms 1p/19q, and BRAF mutation/fusion.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25744348'}, {'offsetInBeginSection': 151, 'offsetInEndSection': 590, 'text': \"This improves diagnostic accuracy and prognostication: oligo-astrocytoma no longer exists as a clinical entity; isocitrate dehydrogenase (IDH) mutant and 1p/19q co-deleted oligodendroglioma is a smaller category with better prognosis; IDH wild-type 'low-grade' glioma has a much poorer prognosis; and glioblastoma is divided into IDH mutant (with an better prognosis than pre-2016 glioblastoma) and IDH wild type (with a poorer prognosis).\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31175262'}, {'offsetInBeginSection': 203, 'offsetInEndSection': 414, 'text': 'A four-tiered WHO grading scheme has been successfully applied to a spectrum of diffusely infiltrative astrocytomas, but it is not fully applicable to other gliomas, including oligodendrogliomas and ependymomas.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25744348'}, {'offsetInBeginSection': 262, 'offsetInEndSection': 435, 'text': 'This has resulted in a major revision of the WHO classification, which is now for adult diffuse glioma centered around isocitrate dehydrogenase (IDH) and 1p/19q diagnostics.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28339700'}, {'offsetInBeginSection': 247, 'offsetInEndSection': 370, 'text': 'The major representatives in this subgroup are the diffuse astrocytic, oligodendroglial, and mixed oligo-astrocytic tumors.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16700618'}, {'offsetInBeginSection': 246, 'offsetInEndSection': 370, 'text': ' The major representatives in this subgroup are the diffuse astrocytic, oligodendroglial, and mixed oligo-astrocytic tumors.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16700618'}, {'offsetInBeginSection': 609, 'offsetInEndSection': 759, 'text': 'ssion, and 1p/19q co-deletion detection in adult diffuse gliomas (Grade II, III, and IV) and to correlate them with clinicopathological and histopatho', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34729052'}, {'offsetInBeginSection': 198, 'offsetInEndSection': 348, 'text': 'vide into isocitrate dehydrogenase (IDH)-mutant astrocytoma, IDH-mutant and 1p/19q-codeleted oligodendroglioma, and IDH-wildtype glioblastoma. The T2-', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36299937'}, {'offsetInBeginSection': 293, 'offsetInEndSection': 443, 'text': 'include astrocytoma, isocitrate dehydrogenase (IDH)-mutant, oligodendroglioma, IDH-mutant and 1p/19q codeleted, and glioblastoma, IDH-wildtype. This r', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35562130'}, {'offsetInBeginSection': 494, 'offsetInEndSection': 644, 'text': 'hese changes has been the division of adult astrocytomas into IDH-wildtype and IDH-mutant categories in addition to histologic grade as part of the ma', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32640746'}, {'offsetInBeginSection': 148, 'offsetInEndSection': 363, 'text': 'O classification, five main molecular subgroups of adult diffuse gliomas can be distinguished based on the 1p/19q codeletion, isocitrate dehydrogenase (IDH), and histone H3.3 mutation status. In the future, this cla', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30148717'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 467, 'text': 'Adult gliomas are most often infiltrative. The World Health Organization (WHO) has classed them into three major groups according to the presomptive cell of origin: astrocytoma, oligodendroglioma and mixed oligoastrocytoma. Depending on the presence or absence of a small number of signs of anaplasia (mitosis, nuclear atypia, cell density, microvascular proliferation and necrosis) the WHO distinguishes grade II (LGG), III (anaplastic), and IV (glioblastomas, GBM).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21889777'}]\n\n\n             'What are the  types/categories of adult diffuse gliomas.'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Adult-type diffuse gliomas are genetically defined and include astrocytoma, isocitrate dehydrogenase (IDH)-mutant, oligodendroglioma, IDH-mutant and 1p/19q codeleted, and glioblastoma, IDH-wildtype"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 345, 'offsetInEndSection': 592, 'text': 'Engineered T cells have achieved success in the treatment of blood cancers, with four chimeric antigen receptor (CAR)-T cell therapies now approved for the treatment of B cell malignancies based on their unprecedented efficacy in clinical trials. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33833444'}]\n\n\n             'Have chimeric antigen receptor (CAR)-T cell therapies been approved for the treatment of B cell malignancies?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Yes, four chimeric antigen receptor (CAR)-T cell therapies now approved for the treatment of B cell malignancies."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 783, 'offsetInEndSection': 902, 'text': 'Golodirsen is a provisionally approved PMO-based drug for approx. 8% of all DMD patients amenable to exon 53 skipping. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33025945'}, {'offsetInBeginSection': 599, 'offsetInEndSection': 710, 'text': 'This article summarizes the milestones in the development of golodirsen leading to this first approval for DMD.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32026421'}, {'offsetInBeginSection': 252, 'offsetInEndSection': 513, 'text': 'n December 2019, intravenous golodirsen received its first global approval in the USA for the treatment of DMD in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping, based on positive results from a phase I/II clinical trial', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32026421'}, {'offsetInBeginSection': 334, 'offsetInEndSection': 486, 'text': 'To date, four PMOs, including eteplirsen, casimersen, viltolarsen, and golodirsen, have been conditionally approved by the FDA for the treatment of DMD.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36401026'}, {'offsetInBeginSection': 965, 'offsetInEndSection': 1069, 'text': 'Golodirsen increased dystrophin protein (16.0-fold; P\\u2009<\\u20090.001) and exon skipping (28.9-fold; P\\u2009<\\u20090.001).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34788571'}, {'offsetInBeginSection': 1381, 'offsetInEndSection': 1552, 'text': 'This study provides evidence for golodirsen biologic activity and long-term safety in a declining DMD population and suggests functional benefit versus external controls. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34788571'}]\n\n\n             'Is golodirsen effective for the treatment of Duchenne muscular dystrophy?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Yes, golodirsen can be considered effective for the treatment of Duchenne muscular dystrophy."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 345, 'offsetInEndSection': 617, 'text': 'Thus far, it has been approved for the treatment of rheumatoid arthritis (RA); however, an increasing number of studies have suggested that baricitinib can be used to treat dermatological diseases, such as atopic dermatitis (AD), psoriasis, vitiligo, and alopecia areata. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35330989'}, {'offsetInBeginSection': 744, 'offsetInEndSection': 979, 'text': 'We reviewed the application, efficacy, side effects, precautions, limitations and prospect of baricitinib in atopic dermatitis, psoriasis, vitiligo and alopecia areata (AA) in recent 5 years including clinical trials and case reports. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35330989'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 54, 'text': 'Two Phase 3 Trials of Baricitinib for Alopecia Areata.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35334197'}, {'offsetInBeginSection': 1870, 'offsetInEndSection': 2037, 'text': 'CONCLUSIONS: In two phase 3 trials involving patients with severe alopecia areata, oral baricitinib was superior to placebo with respect to hair regrowth at 36 weeks. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35334197'}]\n\n\n             'Is Baricitinib effective for Alopecia Areata?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Yes. In two phase 3 trials involving patients with severe alopecia areata, oral baricitinib was superior to placebo with respect to hair regrowth at 36 weeks."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 12, 'offsetInEndSection': 253, 'text': 'This study was to explore the clinical efficacy and safety of darbepoetin alfa injection replacing epoetin alfa injection (recombinant human erythropoietin injection, rHuEPO) for the treatment of anemia associated with chronic kidney failure', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35774427'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 62, 'text': 'Anaemia is a common manifestation ofa chronic kidney failure. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21877597'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 91, 'text': 'The hormone deficiency that underlies anemia in chronic kidney failure can now be corrected', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/2010480'}, {'offsetInBeginSection': 919, 'offsetInEndSection': 1058, 'text': 'We call this interrelationship between congestive heart failure, chronic kidney insufficiency, and anemia the Cardio-Renal Anemia syndrome.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15467179'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 72, 'text': 'Anemia is a major problem in patients with chronic kidney insufficiency.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15467179'}, {'offsetInBeginSection': 551, 'offsetInEndSection': 841, 'text': \"Correction of the anemia with erythropoietin and intravenous iron led to a marked improvement in patients' functional status and their cardiac function, and to a marked fall in the need for hospitalization and for high-dose diuretics; renal function usually improved or at least stabilized.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15467179'}, {'offsetInBeginSection': 99, 'offsetInEndSection': 169, 'text': 'The anemia is very often associated with chronic kidney disease (CKD).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18670732'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 114, 'text': 'The role of anemia in congestive heart failure and chronic kidney insufficiency: the cardio renal anemia syndrome.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15467179'}, {'offsetInBeginSection': 116, 'offsetInEndSection': 271, 'text': 'While iron deficiency is often stated as a cause of anemia in chronic renal failure prior to end-stage renal disease, its relative contribution is debated.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9375826'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 115, 'text': 'Anemia in chronic renal failure is predominantly caused by diminished erythropoietin synthesis by diseased kidneys.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9375826'}, {'offsetInBeginSection': 1828, 'offsetInEndSection': 1938, 'text': 'We infer that impaired utilization of iron may be a significant factor in the anemia of chronic renal failure.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9375826'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 101, 'text': 'BACKGROUND: Kidney failure causes anemia and is associated with a very high risk of coronary heart di', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16442920'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 113, 'text': 'BACKGROUND: Kidney failure is known to cause anemia, which is associated with a higher risk of cardiac failure an', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12076240'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 156, 'text': 'The correction of anemia in patients with the combination of chronic kidney disease and congestive heart failure may prevent progression of both conditions.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18670732'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 120, 'text': 'BACKGROUND: Anemia, a common complication of chronic kidney disease, usually develops as a consequence of erythropoietin', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17108343'}, {'offsetInBeginSection': 101, 'offsetInEndSection': 215, 'text': 'In patients with CKD, anemia is often caused by decreased erythropoietin production relative to hemoglobin levels.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22536082'}, {'offsetInBeginSection': 1467, 'offsetInEndSection': 1551, 'text': 'Clearly more work is needed to clarify the relationship between anemia, CKD and CHF.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18670732'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 76, 'text': 'Use of EPOGEN for treatment of anemia associated with chronic renal failure.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/2357306'}, {'offsetInBeginSection': 200, 'offsetInEndSection': 270, 'text': ' Heart failure, anemia and chronic renal failure are mutually related.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16623112'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 90, 'text': 'Uremic Toxins Affect Erythropoiesis during the Course of Chronic Kidney Disease: A Review.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32899941'}, {'offsetInBeginSection': 817, 'offsetInEndSection': 924, 'text': ' Partial, but not complete, correction of anemia is associated with improved outcomes in patients with CKD.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19833421'}, {'offsetInBeginSection': 433, 'offsetInEndSection': 558, 'text': ' The high prevalence of anemia in chronic kidney disease is explained by a combination of erythropoietin and iron deficiency.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22454095'}, {'offsetInBeginSection': 91, 'offsetInEndSection': 181, 'text': ' Many advanced chronic kidney disease patients have both anemia and chronic heart failure.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22680636'}, {'offsetInBeginSection': 1669, 'offsetInEndSection': 1821, 'text': ' In conclusion, anemia is associated with a rapid decrease in kidney function in patients with heart failure, particularly in those with underlying CKD.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17437743'}, {'offsetInBeginSection': 151, 'offsetInEndSection': 284, 'text': ' This analysis was conducted to evaluate whether anemia is a risk factor for kidney function decrease in patients with heart failure.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17437743'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 86, 'text': 'Anemia as a risk factor for kidney function decline in individuals with heart failure.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17437743'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 204, 'text': 'End stage renal disease (ESRD) invariably leads to anemia which has been mainly attributed to compromised release of erythropoietin from the defective kidneys with subsequent impairment of erythropoiesis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29151105'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 121, 'text': 'Chronic kidney disease (CKD) is a widespread health problem in the world and anaemia of renal origin is a common problem.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20443766'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 199, 'text': 'Anemia is the most common hematologic complication in end-stage renal disease (ESRD). It is ascribed to decreased erythropoietin production, shortened red blood cell (RBC) lifespan, and inflammation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26948278'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 440, 'text': 'Anemia is one of the most characteristic and visable manifestations of chronic renal failure. Investigators in the past decade have provided a better understanding of this anemia. The etiology of the anemia of chronic renal failure has three facets: first is reduced erythropoietin production by damaged kidneys; second is the presence of inhibitors to red blood cell (RBC) production in uremic serum; and third is red blood cell hemolysis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7034633'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 378, 'text': 'Cardiovascular disease remains the major cause of mortality in patients with end stage renal disease (ESRD). The pathophysiology of cardiac dysfunction in ESRD is complex and not fully understood. However, it appears that the two major determinants of left ventricular (LV) hypertrophy and dysfunction are anemia and hypertension, both of which are very common in ESRD patients.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9241712'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 376, 'text': 'NGAL, also known as lipocalin 2, is a stress protein located on the cell surface that is known for its involvement in iron transport. This study is aimed to evaluate the correlation between the iron profile and NGAL concentration in serum among chronic kidney disease patients under dialysis in order to find its diagnostic value with regards to iron deficiency anaemia (IDA).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31994917'}]\n\n\n             'Anemia is not associated with chronic kidney failure'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Anemia is associated with chronic renal disease"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 1548, 'offsetInEndSection': 1645, 'text': 'We estimated reduced time and costs by online counseling with about 8% and 10-12%, respectively. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26785833'}]\n\n\n             'What is the estimated reduction in time when using online genetic counseling?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "The estimated reduction in the required time through online counseling is about 8%."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 1505, 'offsetInEndSection': 1779, 'text': 'Both daily prednisone and daily deflazacort were more effective than intermittent prednisone for the primary outcome (P\\u2009<\\u2009.001 for daily prednisone vs intermittent prednisone using a global test; P\\u2009=\\u2009.017 for daily deflazacort vs intermittent prednisone using a global test)', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35381069'}, {'offsetInBeginSection': 2790, 'offsetInEndSection': 3133, 'text': 'Among patients with Duchenne muscular dystrophy, treatment with daily prednisone or daily deflazacort, compared with intermittent prednisone alternating 10 days on and 10 days off, resulted in significant improvement over 3 years in a composite outcome comprising measures of motor function, pulmonary function, and satisfaction with treatment', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35381069'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 354, 'text': 'Deflazacort and prednisone/prednisolone are the current standard of care for patients with Duchenne muscular dystrophy (DMD) based on evidence that they improve muscle strength, improve timed motor function, delay loss of ambulation, improve pulmonary function, reduce the need for scoliosis surgery, delay onset of cardiomyopathy, and increase survival.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35723111'}, {'offsetInBeginSection': 885, 'offsetInEndSection': 1142, 'text': 'Evidence from randomized clinical trials, prospective studies, meta-analyses, and post-hoc analyses suggests that patients receiving deflazacort experience similar or slower rates of functional decline compared with those receiving prednisone/prednisolone. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35723111'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 148, 'text': 'Though Deflazacort and prednisone improve clinical endpoints in Duchenne muscular dystrophy (DMD) patients, Deflazacort produces fewer side effects.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19488064'}, {'offsetInBeginSection': 1497, 'offsetInEndSection': 1647, 'text': ' trial. Both daily prednisone and daily deflazacort were more effective than intermittent prednisone for the primary outcome (P\\u2009<\\u2009.001 for daily predn', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35381069'}]\n\n\n             'Is deflazacort more efficient than prednisone/prednisolone for the treatment of Duchenne muscular dystrophy?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "There are no sufficient evidence to support that deflazacort is more efficient that prednisone/prednisolone for the treatment of Duchenne muscular dystrophy."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 663, 'offsetInEndSection': 994, 'text': 'They combine two different monospecific antigen-binding regions that target CD20 on B cells and engage T cells via CD3 in a 1:1 or 2:1 CD20:CD3 antigen binding fragment (Fab) format. The results of different phase 1 trials with BsAbs, including mosunetuzumab, glofitamab, epcoritamab and odeonextamab, have been recently published.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35928819'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 174, 'text': 'Mosunetuzumab (Lunsumio\u00ae), an anti-CD20/CD3 T-cell engaging bispecific antibody, is being developed by Roche for the treatment of relapsed or refractory follicular lymphoma. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35947358'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 145, 'text': 'BACKGROUND: Mosunetuzumab is a CD20\\u2009\u00d7\\u2009CD3 T-cell-engaging bispecific monoclonal antibody that redirects T cells to eliminate malignant B cells. I', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35803286'}, {'offsetInBeginSection': 655, 'offsetInEndSection': 774, 'text': 'However, several CD20 \u00d7 CD3 BsAbs including odronextamab, mosunetuzumab, glofitamab, and epcoritamab emerged recently. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35182296'}]\n\n\n             'What are the targets of Mosunetuzumab?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Mosunetuzumab is an anti-CD20/CD3 T-cell engaging bispecific antibody, is being developed by Roche for the treatment of relapsed or refractory follicular lymphoma."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 335, 'text': 'Mast cells are important effector cells in allergic inflammatory reactions. The aggregation of the high-affinity IgE receptor (FcepsilonRI) on the surface of mast cells initiates a complex cascade of signaling events that ultimately leads to the release of various mediators involved in allergic inflammation and anaphylactic reactions', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19082920'}, {'offsetInBeginSection': 101, 'offsetInEndSection': 228, 'text': 'During the IgE-mediated anaphylactic reaction mast cells release proteases such as tryptase, histamine and vasoactive mediators', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17128671'}, {'offsetInBeginSection': 485, 'offsetInEndSection': 821, 'text': 'Histamine and other deleterious inflammatory mediators promote vascular permeability and smooth muscle contraction; they are readily released from sensitized mast cells and basophils challenged with antigen. Anaphylaxis may be triggered by a variety of antigens including insect and reptile venom, a variety of drugs, vaccines, and food', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23855441'}, {'offsetInBeginSection': 209, 'offsetInEndSection': 364, 'text': 'Earlier mast cells were only known for their important role in the type 1 allergic reactions (i.e. anaphylaxis or some contact hypersensitivity reactions) ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20678798'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 62, 'text': 'Anaphylaxis results from severe systemic mast cell activation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25841551'}, {'offsetInBeginSection': 165, 'offsetInEndSection': 478, 'text': 'In IgE-dependent and other examples of anaphylaxis, tissue mast cells and circulating basophilic granulocytes (basophils) are thought to represent major (if not the major) sources of the biologically active mediators that contribute to the pathology and, in unfortunate individuals, fatal outcome, of anaphylaxis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20519881'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 57, 'text': 'Mast cell activation syndromes presenting as anaphylaxis.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25841551'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 474, 'text': 'PURPOSE OF REVIEW: Mast cell activation syndrome (MCAS) and anaphylaxis are the result of a spontaneous or triggered pathological degranulation of mast cells (MCs) and might have as substrate normal or pathological MCs (increased burden, aberrant MCs or both).RECENT FINDINGS: This review summarizes the most recent evidence on immunoglobulin E (IgE)-mediated and non IgE-mediated mechanisms underlying MC activation and degranulation and highlights the importance of standa', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34292177'}, {'offsetInBeginSection': 422, 'offsetInEndSection': 612, 'text': 'Elevated mast cell mediators such as tryptase and histamine have been reported during episodes, and mast cells are considered the primary cells responsible for driving anaphylaxis in humans.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32276688'}, {'offsetInBeginSection': 479, 'offsetInEndSection': 719, 'text': 'In this chapter, we will describe the mechanisms of mast cell (and basophil) activation in anaphylaxis, with a focus on IgE-dependent activation, which is thought to be responsible for most examples of antigen-induced anaphylaxis in humans.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20519881'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 143, 'text': 'Anaphylaxis is a life-threatening syndrome resulting from the sudden release of mast cell- and basophil-derived mediators into the circulation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12209078'}, {'offsetInBeginSection': 1345, 'offsetInEndSection': 1599, 'text': 'Some usual clinical manifestations in anaphylaxis, such as angioedema or hypotension, or other less common, such as metrorrhagia, may be explained by the direct effect of the activation of the coagulation and contact system driven by mast cell mediators.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28798744'}, {'offsetInBeginSection': 1600, 'offsetInEndSection': 1732, 'text': 'Idiopathic anaphylaxis involves mast cell activation (acutely elevated urine histamine or serum tryptase) and activated lymphocytes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31690393'}, {'offsetInBeginSection': 461, 'offsetInEndSection': 564, 'text': 'When there is activation of mast cells and basophils in anaphylaxis, chemical mediators are detectable.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31690393'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 148, 'text': 'Systemic anaphylaxis arises when mast cells, possibly along with other cell types, are provoked to secrete mediators that evoke a systemic response.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15025392'}, {'offsetInBeginSection': 517, 'offsetInEndSection': 589, 'text': 'Anaphylaxis results from the massive activation of the mast cells (MCs).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35080312'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 115, 'text': 'Human mast cells, by elaborating vasoactive mediators and cytokines, are the primary effector cells of anaphylaxis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15025396'}, {'offsetInBeginSection': 163, 'offsetInEndSection': 441, 'text': ' Although the mast cell is considered the major effector cell during acute allergic reactions, more recent studies indicate a potentially important and specific role for basophils and their migration which occurs rapidly upon allergen challenge in humans undergoing anaphylaxis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29431885'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'Acute anaphylaxis to small molecule drugs is largely considered to be antibody-mediated with immunogloblin E (IgE) and mast cell activation being key.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34867939'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 71, 'text': 'Anaphylactic Degranulation of Mast Cells: Focus on Compound Exocytosis.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31011586'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 64, 'text': 'Idiopathic Anaphylaxis: A Form of Mast Cell Activation Syndrome.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32276688'}, {'offsetInBeginSection': 108, 'offsetInEndSection': 324, 'text': ' A precondition for the unfolding of the anaphylactic shock is the secretion of inflammatory mediators from mast cells in response to an allergen, mostly through activation of the cells via the IgE-dependent pathway.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31011586'}, {'offsetInBeginSection': 239, 'offsetInEndSection': 361, 'text': ' Beyond IgE-mediated activation of mast cells/basophils, further mechanisms are involved in the occurrence of anaphylaxis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28798744'}, {'offsetInBeginSection': 452, 'offsetInEndSection': 556, 'text': ' When there is activation of mast cells and basophils in anaphylaxis, chemical mediators are detectable.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22794697'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 170, 'text': 'Extensive activation of mast cells is the major switch that triggers systemic anaphylaxis, resulting in the subsequent release of anaphylactic mediators into circulation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33097573'}, {'offsetInBeginSection': 33, 'offsetInEndSection': 183, 'text': 'ed in the amplification of the mast cell response during anaphylaxis are unclear. Mouse models of anaphylaxis demonstrate the critical involvement of ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27906487'}, {'offsetInBeginSection': 77, 'offsetInEndSection': 227, 'text': 'phylaxis in 22-49%. In addition, monoclonal mast cell activation syndrome has been described presenting with anaphylaxis, especially in patients with ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22744266'}, {'offsetInBeginSection': 1253, 'offsetInEndSection': 1403, 'text': 'ol subjects. The severity of anaphylaxis was associated with mast cell degranulation, increased plasma heparin levels, the intensity of contact system', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25240785'}, {'offsetInBeginSection': 1017, 'offsetInEndSection': 1167, 'text': ' types. Finally, we discuss the possible reasons for the mast cell to utilize compound exocytosis during anaphylaxis, the conflicting evidence in diff', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31011586'}, {'offsetInBeginSection': 465, 'offsetInEndSection': 615, 'text': 'w clinical entities, such as the \u03b1-gal anaphylaxis. Anaphylaxis results from the massive activation of the mast cells (MCs). Thus, it is also necessar', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35080312'}, {'offsetInBeginSection': 342, 'offsetInEndSection': 492, 'text': 'ted that mast cell activation and anaphylaxis are negatively regulated by AMP-activated protein kinase (AMPK). However, little is known about the rela', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24948367'}, {'offsetInBeginSection': 186, 'offsetInEndSection': 336, 'text': 's not affected. Calcium-independent early activation events in mast cell anaphylaxis indicated on inhibitory influence of PK-treatment. Inhibition of ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/2661436'}, {'offsetInBeginSection': 77, 'offsetInEndSection': 237, 'text': 'phylaxis in 22-49%. In addition, monoclonal mast cell activation syndrome has been described presenting with anaphylaxis, especially in patients with hymenopter', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22744266'}, {'offsetInBeginSection': 1253, 'offsetInEndSection': 1428, 'text': 'ol subjects. The severity of anaphylaxis was associated with mast cell degranulation, increased plasma heparin levels, the intensity of contact system activation, and bradykin', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25240785'}, {'offsetInBeginSection': 1017, 'offsetInEndSection': 1247, 'text': ' types. Finally, we discuss the possible reasons for the mast cell to utilize compound exocytosis during anaphylaxis, the conflicting evidence in different mast cell models, and the open questions in the field which remain to be a', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31011586'}, {'offsetInBeginSection': 169, 'offsetInEndSection': 256, 'text': 'arepsilonRI) on mast cells. However, the regulatory mechanism of mast cell activation i', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20526344'}, {'offsetInBeginSection': 186, 'offsetInEndSection': 305, 'text': 's not affected. Calcium-independent early activation events in mast cell anaphylaxis indicated on inhibitory influence ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/2661436'}, {'offsetInBeginSection': 391, 'offsetInEndSection': 541, 'text': \"r, Ang-1's function in mast cell activation and anaphylaxis diseases is unknown. The results of our study suggest that Ang-1 decreased lipopolysacchar\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24586553'}, {'offsetInBeginSection': 1404, 'offsetInEndSection': 1734, 'text': '\u03b5RI-mediated mast cell activation and anaphylaxis that were insensitive to U0126 or activator 5-aminoimidazole-4-carboxamide-1-\u03b2-4-ribofuranoside, suggesting that the suppression of Fc\u03b5RI signals by the inhibition of the ERK1/2 pathway relies largely on AMPK activation. ERK1/2 controlled AMPK activity by regulating its subcellul', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24948367'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'Anaphylaxis results from severe systemic mast cell activation. In addition to IgE-mediated and physical triggers, it may occur with a clonal mast cell', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25841551'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 231, 'text': 'For half a century, it has been known that the mast cell is the cell responsible for the majority of anaphylactic events. Its mediators, taken as a whole, are capable of producing all of the clinical manifestations of these events.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26857018'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 220, 'text': 'Anaphylaxis results from severe systemic mast cell activation. In addition to IgE-mediated and physical triggers, it may occur with a clonal mast cell disease and in an idiopathic fashion without clear provoking factors.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25841551'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 248, 'text': 'Anaphylaxis is a rapidly developing, life-threatening, generalized or systemic allergic reaction that is classically elicited by antigen crosslinking of antigen-specific IgE bound to the high-affinity IgE receptor Fc\u03b5RI on mast cells and basophils.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27130857'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 296, 'text': 'Anaphylaxis is a rapidly evolving, acute, life-threatening reaction that occurs rapidly on contact with a trigger. Anaphylaxis is classically defined as an allergen-driven process that induces specific IgE and the activation of mast cells and basophils through the cross-linking of IgE receptors.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33832694'}]\n\n\n             'Is anaphylaxis a results of mast cell activation?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "yes, Mast cell activation syndrome (MCAS) is when your body's mast cells trigger the release of chemical mediators too frequently. When mast cells release too many chemical mediators, your body is flooded with them, and they trigger all sorts of reactions. These reactions can lead to anaphylaxis"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 876, 'offsetInEndSection': 1640, 'text': 'Approval was based on two randomized, open-label, active-controlled trials demonstrating statistically significant improvements in progression-free survival (PFS) and overall survival (OS) for patients randomized to pembrolizumab compared with chemotherapy. In KEYNOTE-024, patients with previously untreated mNSCLC who received pembrolizumab (200 mg intravenously [IV] every 3 weeks) had a statistically significant improvement in OS (hazard ratio [HR] 0.60; 95% confidence interval [CI]: 0.41-0.89; p\\u2009=\\u2009.005), and significant improvement in PFS (HR 0.50; 95% CI: 0.37-0.68; p\\u2009<\\u2009.001). In KEYNOTE-010, patients with disease progression on or after platinum-containing chemotherapy received pembrolizumab IV 2 mg/kg, 10 mg/kg, or docetaxel 75 mg/m2 every 3 weeks. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28835513'}]\n\n\n             'On which two clinical trials was the approval of Keytruda based?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Approval was based on two randomized, open-label, active-controlled trials demonstrating statistically significant improvements in progression-free survival (PFS) and overall survival (OS) for patients randomized to pembrolizumab compared with chemotherapy, namely KEYNOTE-024 and KEYNOTE-010."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 174, 'text': 'Viltolarsen is a phosphorodiamidate morpholino antisense oligonucleotide (PMO) designed to skip exon 53 of the DMD gene\\xa0for the treatment of Duchenne muscular dystrophy (DMD)', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36401022'}, {'offsetInBeginSection': 694, 'offsetInEndSection': 830, 'text': 'Viltolarsen restores the reading frame of the DMD gene by skipping \\xa0exon 53\\xa0and produces a truncated but functional form of dystrophin. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36401022'}, {'offsetInBeginSection': 505, 'offsetInEndSection': 693, 'text': 'After showing hopeful results in pre-clinical trials and several clinical trials across North America and Japan, it received US Food and Drug Administration (FDA) approval for DMD\\xa0in 2020.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36401022'}, {'offsetInBeginSection': 694, 'offsetInEndSection': 829, 'text': 'Viltolarsen restores the reading frame of the DMD gene by skipping \\xa0exon 53\\xa0and produces a truncated but functional form of dystrophin.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36401022'}, {'offsetInBeginSection': 48, 'offsetInEndSection': 198, 'text': 'ucleotide viltolarsen targets exon 53 of the dystrophin gene, and could be an effective treatment for patients with Duchenne muscular dystrophy (DMD).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33285037'}, {'offsetInBeginSection': 110, 'offsetInEndSection': 342, 'text': 'esulting in an absence of functional dystrophin protein. Viltolarsen, an exon 53 skipping therapy, has been shown to increase endogenous dystrophin levels. Herein, long-term (>2 years) functional outcomes in viltolarsen treated pati', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35634851'}]\n\n\n             'Is viltolarsen effective for the treatment of Duchenne muscular dystrophy?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Yes, viltolarsen is effective for the treatment of Duchenne muscular dystrophy."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 147, 'text': \"BACKGROUND: The superior mesenteric artery (SMA) syndrome, also known as Wilkie's syndrome, is one of the rarest causes of small bowel obstruction.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32116320'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 290, 'text': \"BACKGROUND Nutcracker syndrome and Wilkie's syndrome are rare vascular diseases due to the abnormal course of the superior mesenteric artery originating from the abdominal aorta with reduced angle (<22\u00b0) and consequent compression of the left renal vein (nutcracker) and duodenum (Wilkie). \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32317620'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 201, 'text': \"INTRODUCTION: Wilkie's Syndrome, also known as Superior Mesenteric Artery Syndrome (SMAS), is a rare cause of bowel obstruction that can contribute to vague abdominal symptoms on clinical presentation.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33655184'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 127, 'text': \"Superior mesenteric artery syndrome, or Wilkie's syndrome, is an unexpected cause of upper gastrointestinal tract obstruction. \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33083170'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 212, 'text': \"Introduction Superior mesenteric artery (SMA) or Wilkie's syndrome is a rare condition arising due to compression of the third part of the duodenum between the abdominal aorta and the superior mesenteric artery.\\xa0\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32821627'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 225, 'text': \"Superior mesenteric artery syndrome (SMA syndrome) or Wilkie's syndrome is a rare etiology of duodenal obstruction due to compression of the third portion of the duodenum between the superior mesenteric artery and the aorta. \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32399444'}]\n\n\n             'What is Wilkie's syndrome?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Wilkie's syndrome or Superior mesenteric artery (SMA) syndrome is a rare condition arising due to compression of the third part of the duodenum between the abdominal aorta and the superior mesenteric artery."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 123, 'text': 'PROteolysis TArgeting Chimeras (PROTACs) technology is a new protein-degradation strategy that has emerged in recent years.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35680848'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 362, 'text': 'Proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules consisting of one ligand that binds to a protein of interest (POI) and another that can recruit an E3 ubiquitin ligase. The chemically-induced proximity between the POI and E3 ligase results in ubiquitination and subsequent degradation of the POI by the ubiquitin-proteasome system (UPS).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35671157'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 175, 'text': 'Proteolysis targeting chimeras (PROTACs) are molecules that induce protein degradation via formation of ternary complexes between an E3 ubiquitin ligase and a target protein. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35412837'}, {'offsetInBeginSection': 171, 'offsetInEndSection': 362, 'text': 'Conversion of a FLT-3 inhibitor (quizartinib) into a proteolysis targeting chimera (PROTAC) results in a compound that induces degradation of FLT-3 ITD mutant at low nanomolar concentrations.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30427680'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 186, 'text': 'Proteolysis-targeting chimeras (PROTAC) are bifunctional molecules that hijack endogenous E3 ubiquitin ligases to induce ubiquitination and subsequent degradation of protein of interest.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31064868'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 117, 'text': 'Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32404196'}, {'offsetInBeginSection': 471, 'offsetInEndSection': 609, 'text': \"PROteolysis-TArgeting Chimera (PROTAC) is an innovative strategy that takes advantage by the cell's own Ubiquitin-Proteasome System (UPS).\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35242765'}, {'offsetInBeginSection': 223, 'offsetInEndSection': 410, 'text': 'Here we describe the design of a novel PROTAC (proteolysis targeting chimeric molecule) capable of simultaneously inducing the degradation of the X-protein, and antagonizing its function.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25305486'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 166, 'text': 'We have developed a heterobifunctional all-small molecule PROTAC (PROteolysis TArgeting Chimera) capable of inducing proteasomal degradation of the androgen receptor.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18752944'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 180, 'text': 'Proteolysis-targeting chimeras (PROTACs) are small molecules that specifically link E3 ubiquitin ligases to proteins of interest to mediate targeted ubiquitination and degradation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35500825'}, {'offsetInBeginSection': 503, 'offsetInEndSection': 781, 'text': 'We have previously reported a library of proteolysis targeting chimeras (PROTACs) incorporating a benzamide-based HDAC ligand (from CI-994), with an alkyl linker and ligand for the von Hippel-Lindau (VHL) E3 ubiquitin ligase that degrade HDAC1-3 at submicromolar concentrations.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35948047'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 128, 'text': 'We developed a first-in-class proteolysis targeting chimera (PROTAC) for selective degradation of histone deacetylase 8 (HDAC8).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35311871'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 91, 'text': 'Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32404196'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 100, 'text': 'Proteolysis-targeting chimeras (PROTACs) are engineered techniques for targeted protein degradation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35410300'}, {'offsetInBeginSection': 865, 'offsetInEndSection': 1272, 'text': 'PROTACs are the heterobifunctional nano molecules with size range of about 10 nanometres find application to eliminate the protein complexes formed by protein-protein interaction through large and flat surface generally defined as \"undruggable\" in conventional drug delivery system, which include around 85 % of proteins present in humans, suggesting their wide application in the field of drug development.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36321238'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 271, 'text': 'INTRODUCTION: PROTACs represent a novel class of heterobifunctional molecules that simultaneously bind to a target protein and to an E3 ligase complex, resulting in the transfer of ubiquitin and initiating a process ultimately causing the proteasomal degradation of the t', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33081540'}, {'offsetInBeginSection': 867, 'offsetInEndSection': 1089, 'text': 'A technology was developed known as Protac (Proteolysis Targeting Chimeric Molecule) that acts as a bridge, bringing together the SCF ubiquitin ligase with a protein target, resulting in its ubiquitination and degradation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16338398'}, {'offsetInBeginSection': 615, 'offsetInEndSection': 1117, 'text': \"uary 2013 through June 2020. Only English-language patent applications with exemplified PROTACs reported to degrade a target protein(s) were deemed in scope, and the definition of 'PROTAC' was restricted to a bifunctional molecule which contains a discrete binding element for a specific degradation target(s), as well as a separate discrete E3 ligase-binding moiety.EXPERT OPINION: Delivering on the enormous potential of PROTACs will require the development of PROTAC medicines that are differentiate\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33081540'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 220, 'text': 'Proteolysis targeting chimeras (PROTACs) are hetero-bifunctional molecules that could simultaneously bind to the target protein and the E3 ubiquitin ligase, thereby leading to selective degradation of the target protein.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31708096'}, {'offsetInBeginSection': 343, 'offsetInEndSection': 626, 'text': 'PROTACs (proteolysis targeting chimeras) emerge as a powerful class of therapeutic modalities, which rely on induced protein-protein interactions between the proteins of interest (POIs) and E3 ubiquitin ligases to aid the degradation of POIs by the ubiquitin-proteasome system (UPS).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34100597'}, {'offsetInBeginSection': 114, 'offsetInEndSection': 370, 'text': 'We assembled proteolysis targeting chimeras (PROTACs) from a cereblon (CRBN) and a von-Hippel-Lindau (VHL) ligase ligand and demonstrated a PROTAC-induced heterodimerization of the two E3 ligases leading to unidirectional and efficient degradation of CRBN.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30672516'}, {'offsetInBeginSection': 270, 'offsetInEndSection': 429, 'text': 'Proteolysis Targeting Chimeras (PROTACs) are a new promising class of small molecules that can effectively direct specific proteins to proteasomal degradation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34560429'}, {'offsetInBeginSection': 101, 'offsetInEndSection': 244, 'text': ' PROTAC proteolysis-targeting chimaera (PROTAC) technology may be the solution, considering its ability to selectively degrade target proteins.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32082969'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'Proteolysis targeting chimera (PROTAC), hijacking protein of interest (POI) and recruiting E3 ligase for target degradation via the ubiquitin-proteaso', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33160761'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'Proteolysis targeting chimeras (PROTACs), which harness the ubiquitin-proteasome system to selectively induce targeted protein degradation, represent ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36300631'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'Proteolysis-targeting chimeras (PROTACs), which selectively degrade targeted proteins by the ubiquitin-proteasome system, have emerged as a novel ther', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33010159'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. A bifunctional PROTAC molecule c', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32404196'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'PROTAC (proteolysis-targeting chimeras), which selectively degrades target proteins, has become the most popular technology for drug development in re', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36139095'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 248, 'text': 'Proteolysis targeting chimeras (PROTACs), which harness the ubiquitin-proteasome system to selectively induce targeted protein degradation, represent an emerging therapeutic technology with the potential to modulate traditional undruggable targets.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36300631'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 237, 'text': 'Proteolysis-targeting chimeras (PROTACs) represent a new direction in small-molecule therapeutics whereby a heterobifunctional linker to a protein of interest (POI) induces its ubiquitination-based proteolysis by recruiting an E3 ligase.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34081921'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 234, 'text': 'Proteolysis-targeting chimeras (PROTACs), which selectively degrade targeted proteins by the ubiquitin-proteasome system, have emerged as a novel therapeutic technology with potential advantages over traditional inhibition strategies.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33010159'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 161, 'text': 'PROTAC (proteolysis-targeting chimeras), which selectively degrades target proteins, has become the most popular technology for drug development in recent years.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36139095'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 317, 'text': 'Proteolysis targeting chimera (PROTAC), hijacking protein of interest (POI) and recruiting E3 ligase for target degradation via the ubiquitin-proteasome pathway, is a novel drug discovery paradigm which has been widely used as biological tools and medicinal molecules with the potential of clinical application value.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33160761'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'Proteolysis-targeting chimeras (PROTACs) degrade target proteins by engaging the ubiquitin-proteasome system. Assays detecting target-PROTAC-E3 ligase', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33860212'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 271, 'text': 'Here we report the development of a proteolysis targeting chimera (PROTAC) based on the combination of the unique features of the sirtuin rearranging ligands (SirReals) as highly potent and isotype-selective Sirt2 inhibitors with thalidomide, a bona fide cereblon ligand.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28379698'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 188, 'text': 'A parallel, one-pot assembly approach to proteolysis targeting chimeras (PROTACs) is demonstrated utilizing activated esters generated in situ, and traceless Staudinger ligation chemistry.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33406191'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'Development of proteolysis targeting chimeras (PROTACs) is emerging as a promising strategy for targeted protein degradation. However, the drug develo', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34240523'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 429, 'text': 'Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. A bifunctional PROTAC molecule consists of a ligand (mostly small-molecule inhibitor) of the protein of interest (POI) and a covalently linked ligand of an E3 ubiquitin ligase (E3). Upon binding to the POI, the PROTAC can recruit E3 for POI ubiquitination, which is subjected to proteasome-mediated degradation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32404196'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 331, 'text': 'Targeted protein degradation using Proteolysis Targeting Chimeras (PROTACs) has emerged as a novel therapeutic modality in drug discovery. PROTACs mediate the degradation of select proteins of interest (POIs) by hijacking the activity of E3 ubiquitin ligases for POI ubiquitination and subsequent degradation by the 26S proteasome.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31004963'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 312, 'text': 'Proteolysis-targeting chimeras (PROTACs) are engineered techniques for targeted protein degradation. A bifunctional PROTAC molecule with two covalently-linked ligands recruits target protein and E3 ubiquitin ligase together to trigger proteasomal degradation of target protein by the ubiquitin-proteasome system.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35410300'}]\n\n\n             'What is a PROTAC?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Proteolysis targeting chimeras (PROTACs) are molecules that induce protein degradation via formation of ternary complexes between an E3 ubiquitin ligase and a target protein."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 58, 'text': 'The \"Virtual Digital Twins\" Concept in Precision Nutrition', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32770212'}, {'offsetInBeginSection': 559, 'offsetInEndSection': 848, 'text': 'We herein discuss how genetic information combined with longitudinal metabolomic, immune, behavioral, and gut microbial parameters, and bioclinical variables could define a digital replica of oneself, a \"virtual digital twin,\" which could serve to guide nutrition in a personalized manner.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32770212'}]\n\n\n             'Can the concept of digital twins be applied in Precision Nutrition?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "A \"virtual digital twin\" could serve to guide nutrition in a personalized manner."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 198, 'text': 'BACKGROUND: Teclistamab is a T-cell-redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35661166'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 190, 'text': 'BACKGROUND: Teclistamab (JNJ-64007957), a B-cell maturation antigen \u00d7 CD3 bispecific antibody, displayed potent T-cell-mediated cytotoxicity of multiple myeloma cells in preclinical studies.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35749004'}, {'offsetInBeginSection': 224, 'offsetInEndSection': 406, 'text': 'The bispecific antibodies teclistamab (BCMA\u00d7CD3) and talquetamab (G protein-coupled receptor family C group 5 member D [GPRC5D]\u00d7CD3) are in clinical development as therapies for MM. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36006441'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 219, 'text': 'Teclistamab (TECVAYLI\u00ae), a bispecific antibody that targets CD3 and B cell maturation antigen (BCMA), is being developed by Janssen Research and Development for the treatment of relapsed or refractory multiple myeloma. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36352205'}]\n\n\n             'What is the mechanism of action of Teclistamab?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Teclistamab is a bispecific antibody that targets CD3 and B cell maturation antigen (BCMA) and is being developed for the treatment of relapsed or refractory multiple myeloma."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 228, 'text': 'Cholestasis of pregnancy is the commonest liver disease unique to pregnancy and is characterized by pruritus in the mother in late pregnancy, without any skin rashes. This is accompanied by an elevation of the serum bile acids. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10385057'}, {'offsetInBeginSection': 302, 'offsetInEndSection': 656, 'text': 'diagnosis of liver disease when conventional liver function test such as SGOT, alkaline phosphatase, bilirubin and albumin are still normal. Serum bile acid determinations have been shown to be particularly useful in the diagnosis of alcoholic liver disease, drug-induced liver disease, viral hepatitis and cholestasis of intra- and extrahepatic origin. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/493809'}, {'offsetInBeginSection': 1692, 'offsetInEndSection': 1967, 'text': 'CONCLUSIONS: Plasma bilirubin seems to be the best liver function test in distinguishing patients with malignant bile duct strictures from those with bile duct stones. This routine test should receive more attention in clinical decision-making than has previously been given.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17163822'}, {'offsetInBeginSection': 1390, 'offsetInEndSection': 1682, 'text': ' bilirubin proved to be the best laboratory test in differentiating patients (p=0.001 vs. alkaline phosphatase, p<0.001 vs. alanine aminotransferase and p<0.001 vs. gamma-glutamyltransferase). With a plasma bilirubin cutoff value of 145 micromol/L, four out of five patients were categorized ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17163822'}, {'offsetInBeginSection': 923, 'offsetInEndSection': 1138, 'text': 'Plasma bilirubin (p<0.001), alkaline phosphatase (p<0.001) and alanine aminotransferase (p=0.040) levels were significantly higher in patients with malignant bile duct strictures than in those with bile duct stones.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17163822'}, {'offsetInBeginSection': 769, 'offsetInEndSection': 913, 'text': 'Plasma alkaline phosphatase, gamma-glutamyltransferase, alanine aminotransferase and bilirubin values were determined in the morning before ERCP', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17163822'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 280, 'text': 'Intrahepatic cholestasis of pregnancy (ICP) is the most frequent pregnancy-specific liver disease. It is characterized by pruritus and an accompanying elevation of serum bile acid concentrations and/or alanine aminotransferase (ALT), which are the key parameters in the diagnosis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33896963'}, {'offsetInBeginSection': 836, 'offsetInEndSection': 994, 'text': ' The liver function test revealed elevated levels of serum total bile acids, bilirubin, and transaminases; however, the \u03b3-glutamyl transferase level was norma', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27530795'}, {'offsetInBeginSection': 252, 'offsetInEndSection': 480, 'text': 'Cholestasis is usually suspected clinically when a patient presenting with jaundice or pruritus is found to have an elevation in serum alkaline phosphatase activity disproportionate to increases in serum aminotransferase levels.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7583073'}, {'offsetInBeginSection': 2007, 'offsetInEndSection': 2202, 'text': 'The biochemical parameters traditionally used for the assessment of extrahepatic cholestasis, AP, GGT, and bilirubin, do not support the diagnosis of intrahepatic cholestasis caused by cirrhosis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9794902'}, {'offsetInBeginSection': 152, 'offsetInEndSection': 553, 'text': 'ase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin. These tests should be termed liver chemistries or liver tests. Hepatocellular injury is defined as disproportionate elevation of AST and ALT levels compared with alkaline phosphatase levels. Cholestatic injury is defined as disproportionate elevation of alkaline phosphatase level as compared with AST and ALT levels. Th', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27995906'}]\n\n\n             'The diagnosis of cholestasis is based on the elevations seen in what liver function tests?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Cholestasis is due to  an excess of bile in the liver  and is often due to a biliary obstruction. There are  disproportionate elevations in alkaline phosphatase (ALP) compared to alanine aminotransferase (ALT), aspartate aminotransferase (AST) and Serum bilirubin. In Cholestasis of pregnancy,  an elevation of the serum bile acids  is often seen"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 712, 'text': 'On October 24, 2016, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda; Merck & Co., Inc., https://www.merck.com) for treatment of patients with metastatic non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1) as determined by an FDA-approved test, as follows: (a) first-line treatment of patients with mNSCLC whose tumors have high PD-L1 expression (tumor proportion score [TPS] \u226550%), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations, and (b) treatment of patients with mNSCLC whose tumors express PD-L1 (TPS \u22651%), with disease progression on or after platinum-containing chemotherapy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28835513'}]\n\n\n             'Which company produces Keytruda?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Keytruda is produced by Merck & Co., Inc.."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 3711, 'offsetInEndSection': 3793, 'text': 'INTERPRETATION: Pioglitazone did not delay the onset of mild cognitive impairment.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34146512'}]\n\n\n             'Based on clinical trial data, can pioglitazone delay cognitive impairment for people at risk for Alzheimer's disease?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "No. Pioglitazone did not delay the onset of mild cognitive impairment."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 128, 'offsetInEndSection': 195, 'text': 'Cereblon is a well-known target of thalidomide and its derivatives.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36252444'}, {'offsetInBeginSection': 399, 'offsetInEndSection': 580, 'text': 'We have identified novel CRBN inhibitors, namely DHFO and its analogs, with structural features that are slightly different from thalidomide but stronger cereblon-binding affinity. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36252444'}, {'offsetInBeginSection': 98, 'offsetInEndSection': 338, 'text': ' It additionally modulates the anti-myeloma effect of the immunomodulatory drugs (IMiDs) thalidomide, lenalidomide, and pomalidomide. IMiDs bind to CRBN and recruit neo-substrates for their ubiquitination and proteasome-mediated degradation', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35045330'}, {'offsetInBeginSection': 162, 'offsetInEndSection': 443, 'text': '. Cereblon (CRBN)-targeting immunomodulatory agents (IMiDs\u00ae) lenalidomide (LEN) and pomalidomide (POM) play a central role in combination regimens due to their pleiotropic antitumor/immunomodulatory mechanisms that synergize with many anti-myeloma approved or developmental agents.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34316334'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 293, 'text': 'Thalidomide, well known for its potent teratogenicity, has been re-evaluated as a clinically effective drug for the treatment of multiple myeloma. Although the direct target of thalidomide had been unclear until recently, we identified cereblon (CRBN) as a primary direct target of this drug b', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31202702'}, {'offsetInBeginSection': 815, 'offsetInEndSection': 1076, 'text': 'The molecular mechanism of action of IMiDs remained unclear for a long time until 2010 when the protein cereblon (CRBN) was identified as a primary direct target. IMiDs binds to CRBN and alters the substrate specificity of the CRBN E3 ubiquitin ligase complex, ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31187860'}, {'offsetInBeginSection': 974, 'offsetInEndSection': 1307, 'text': 'These results strongly suggest that increased BK channel activity is the pathological mechanism of intellectual disability in CRBN mutations.SIGNIFICANCE STATEMENTCereblon (CRBN), a well known target of the immunomodulatory drug thalidomide, was originally identified as a gene that causes human intellectual disability when mutated.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29530986'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 123, 'text': 'Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22552008'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 208, 'text': 'Cereblon (CRBN), a substrate receptor for the cullin-RING ubiquitin ligase 4 (CRL4) complex, is a direct protein target for thalidomide teratogenicity and antitumor activity of immunomodulatory drugs (IMiDs).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26990986'}, {'offsetInBeginSection': 1246, 'offsetInEndSection': 1409, 'text': 'Our biophysical, biochemical and gene silencing studies show that CRBN is a proximate, therapeutically important molecular target of lenalidomide and pomalidomide.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22552008'}, {'offsetInBeginSection': 586, 'offsetInEndSection': 899, 'text': 'CRBN has been identified as a direct target for immunomodulatory drugs (IMiD) and plays a significant role in anti-proliferation, pro-apoptotic effects, anti-angiogenic activities, immunomodulatory activities and intervention of cell surface adhesion molecules between myeloma cells and bone marrow stromal cells.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26117057'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 265, 'text': 'Thalidomide and its derivatives lenalidomide and\\xa0pomalidomide, known as immunomodulatory drugs, (IMiDs)\\xa0bind\\xa0directly to cereblon (CRBN), a substrate receptor of an E3 ubiquitin ligase, resulting in the rapid ubiquitination and degradation of the substrate protein.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33938033'}, {'offsetInBeginSection': 268, 'offsetInEndSection': 321, 'text': 'Cereblon (CRBN) is a common primary target for IMiDs.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28978850'}, {'offsetInBeginSection': 241, 'offsetInEndSection': 397, 'text': 'Cereblon (CRBN), a substrate receptor of the CRL4 ubiquitin ligase complex, is the primary target by which IMiDs mediate anticancer and teratogenic effects.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27294876'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 161, 'text': 'Cereblon (CRBN) has recently been identified as a target for immunomodulatory drugs (IMiDs) and its downregulation has been linked to resistance to lenalidomide.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23565715'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 138, 'text': 'Cereblon (CRBN), originally identified as a gene associated with intellectual disability, was identified as primary target of thalidomide.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34033753'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 270, 'text': 'Clinical interest in the measurement of Cereblon (CRBN), the primary target of the IMiDs immunomodulatory drugs lenalidomide and pomalidomide, has been fueled by its essential requirement for antitumor or immunomodulatory activity of both drugs in multiple myeloma (MM).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26186254'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 133, 'text': 'Cereblon (CRBN), a substrate receptor for Cullin-ring E3 ubiquitin ligase (CRL), is a major target protein of immunomodulatory drugs.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32333926'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 162, 'text': 'Cereblon (CRBN), a substrate receptor of the Cullin 4 RING E3 ubiquitin ligase complex, is the target of the immunomodulatory drugs lenalidomide and pomalidomide.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26002965'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 240, 'text': 'Cereblon was identified as a direct target of thalidomide by Prof. H. Handa, and this pioneering work triggered active research on IMiDs (immunomodulatory drugs), which include thalidomide-derivatives, such as lenalidomide and pomalidomide.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25626321'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 169, 'text': 'The Cullin-RING ligase 4 E3 ubiquitin ligase component Cereblon (CRBN) is a well-established target for a class of small molecules termed immunomodulatory drugs (IMiDs).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35780831'}, {'offsetInBeginSection': 636, 'offsetInEndSection': 750, 'text': ' We identified a thalidomide-binding protein, cereblon (CRBN), as a primary target for thalidomide teratogenicity.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21207098'}, {'offsetInBeginSection': 359, 'offsetInEndSection': 567, 'text': ' Although the direct target of thalidomide was largely debated until recently, our groups discovered cereblon (CRBN), a substrate receptor of an E3 ubiquitin ligase as a primary target of thalidomide in 2010.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35831190'}, {'offsetInBeginSection': 267, 'offsetInEndSection': 321, 'text': ' Cereblon (CRBN) is a common primary target for IMiDs.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28978850'}, {'offsetInBeginSection': 172, 'offsetInEndSection': 322, 'text': 'd previously demonstrated that cereblon (CRBN) is the target of thalidomide embryopathy and acts as a substrate receptor for the E3 ubiquitin ligase c', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33777938'}, {'offsetInBeginSection': 333, 'offsetInEndSection': 483, 'text': 'dy recently identified cereblon (CRBN) as a primary target of thalidomide teratogenicity. Subsequently it was demonstrated that CRBN is also required ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22966948'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'Cereblon (CRBN) has recently been identified as a target for immunomodulatory drugs (IMiDs) and its downregulation has been linked to resistance to le', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23565715'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'Cereblon (CRBN), the molecular target of lenalidomide and pomalidomide, is a substrate receptor of the cullin ring E3 ubiquitin ligase complex, CRL4(C', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24328678'}, {'offsetInBeginSection': 163, 'offsetInEndSection': 313, 'text': 'eblon (CRBN) has been identified as the primary teratogenic target of thalidomide. Our studies demonstrate that thalidomide, lenalidomide and another ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22552008'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 156, 'text': 'Cereblon (CRBN), the molecular target of lenalidomide and pomalidomide, is a substrate receptor of the cullin ring E3 ubiquitin ligase complex, CRL4(CRBN) .', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24328678'}, {'offsetInBeginSection': 242, 'offsetInEndSection': 392, 'text': 'cluding multiple myeloma. Cereblon (CRBN) is a common primary target for IMiDs. It works as a substrate receptor of CRL4. Accumulating evidence has sh', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28978850'}, {'offsetInBeginSection': 92, 'offsetInEndSection': 242, 'text': 'ubiquitin ligase complex component. Cereblon is a well-known target of thalidomide and its derivatives. Cereblon is involved in multiple myeloma cell ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36252444'}]\n\n\n             'Cereblon (CRBN)  has been identified as the target for what type of drug?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Immunomodulatory drugs (IMiDs) thalidomide, lenalidomide, and pomalidomide. IMiDs bind to CRBN and recruit neo-substrates for their ubiquitination and proteasome-mediated degradation"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 80, 'text': 'SRRM4 Expands the Repertoire of Circular RNAs by Regulating Microexon Inclusion.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33207694'}, {'offsetInBeginSection': 1272, 'offsetInEndSection': 1572, 'text': 'Overexpressing SRRM4, known for regulating ME inclusion in mRNAs critical for neural differentiation, in human HEK293 cells resulted in the biogenesis of over 2000 novel ME-circRNAs, including ME-circEIF4G3, and changes in the abundance of many canonical circRNAs, including circSETDB2 and circLBRA. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33207694'}]\n\n\n             'Does silencing of SRRM4 promote microexon inclusion?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "No, silencing of SRRM4 does not promote microexon inclusion."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 207, 'text': 'AZD7442, a combination of two long-acting monoclonal antibodies (tixagevimab [AZD8895] and cilgavimab [AZD1061]), has been authorized for the prevention and treatment of coronavirus disease 2019 (COVID-19). ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35993765'}, {'offsetInBeginSection': 59, 'offsetInEndSection': 134, 'text': 'Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35914259'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 175, 'text': 'Association Between AZD7442 (Tixagevimab-Cilgavimab) Administration and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, Hospitalization, and Mortality.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35904210'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 199, 'text': 'BACKGROUND: Intramuscular AZD7442 (Tixagevimab-Cilgavimab, (Evusheld)) has been found effective among immunocompromised individuals (ICI) in reducing Sars-Cov-2 infection and severe disease in ICIs. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35904210'}]\n\n\n             'Which drugs are included in the AZD7442?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "AZD7442 is a combination of two long-acting monoclonal antibodies tixagevimab and cilgavimab. It has been authorized for the prevention and treatment of coronavirus disease 2019 (COVID-19)."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 233, 'offsetInEndSection': 324, 'text': '2 different programmed cell death protein 1 (PD-1) inhibitors, Nivolumab and Pembrolizumab.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32984529'}, {'offsetInBeginSection': 146, 'offsetInEndSection': 306, 'text': 'The first monoclonal antibodies against the immune checkpoint programmed death 1 (PD-1) receptor, nivolumab and pembrolizumab, are now approved for clinical use', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26822752'}, {'offsetInBeginSection': 100, 'offsetInEndSection': 289, 'text': 'e programmed cell death protein 1 (PD-1) inhibitors, nivolumab and pembrolizumab, have quickly been incorporated into clinical trials for first- and second-line therapy of Hodgkin lymphoma.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29222273'}, {'offsetInBeginSection': 361, 'offsetInEndSection': 570, 'text': 'The first programmed death 1 (PD-1) inhibitor, pembrolizumab, was recently approved by the United States Food and Drug Administration for the treatment of melanoma; nivolumab was previously approved in Japan. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25682878'}, {'offsetInBeginSection': 320, 'offsetInEndSection': 597, 'text': 'Early-phase studies investigating several humanized monoclonal IgG4 antibodies targeting PD-1 and PD-L1 in advanced solid tumors paved way for the development of the first PD-1 inhibitors, nivolumab and pembrolizumab, approved by the Food and Drug Administration (FDA) in 2014.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29357948'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 230, 'text': 'Nivolumab (Opdivo, Bristol Meyer Squibb, New York, NY) and pembrolizumab (Keytruda, Merck, Kenilworth, NJ) are the first two US Food and Drug Administration (FDA)-approved monoclonal antibodies targeting programmed death-1 (PD-1).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28923211'}, {'offsetInBeginSection': 531, 'offsetInEndSection': 677, 'text': 'The US Food and Drug Administration (FDA) has approved 2 PD-1 inhibitors, nivolumab and pembrolizumab, and several others are under investigation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27058852'}, {'offsetInBeginSection': 361, 'offsetInEndSection': 569, 'text': 'The first programmed death 1 (PD-1) inhibitor, pembrolizumab, was recently approved by the United States Food and Drug Administration for the treatment of melanoma; nivolumab was previously approved in Japan.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25682878'}, {'offsetInBeginSection': 244, 'offsetInEndSection': 380, 'text': 'other tumors. In 2014, nivolumab and pembrolizumab, two checkpoint inhibitors binding to PD-1, were approved for the treatment of metast', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33686894'}, {'offsetInBeginSection': 648, 'offsetInEndSection': 867, 'text': ' Pembrolizumab is one of the first immune checkpoint inhibitors approved by the FDA to treat NSCLC and is currently the only immunotherapy drug approved for first-line treatment of NSCLC in immune checkpoint inhibitors.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32388240'}, {'offsetInBeginSection': 124, 'offsetInEndSection': 313, 'text': ' A PD-1 antibody, nivolumab, was the first of these agents to be approved by the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan, as a new cancer drug for melanoma, in July 2014.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27795534'}, {'offsetInBeginSection': 447, 'offsetInEndSection': 597, 'text': 's paved way for the development of the first PD-1 inhibitors, nivolumab and pembrolizumab, approved by the Food and Drug Administration (FDA) in 2014.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29357948'}, {'offsetInBeginSection': 360, 'offsetInEndSection': 510, 'text': 'ministration (FDA) approved the first PD-1 targeting agent, namely pembrolizumab, shortly followed by nivolumab. Areas covered: Nivolumab is a fully h', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30304963'}]\n\n\n             'What were the first 2 PD-1 inhibitors approved by the FDA in 2014?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Pembrolizumab (Keytruda) and Nivolumab (Opdivo were the first 2 PD-1 inhibitors approved by the FDA in 2014"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 241, 'text': \"Dermatillomania or skin picking disorder (SPD) is a chronic, recurrent, and treatment resistant neuropsychiatric disorder with an underestimated prevalence that has a concerning negative impact on an individual's health and quality of life. \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33808008'}]\n\n\n             'What is the difference between dermatillomania and skin picking disorder?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Dermatillomania is also known as skin picking disorder (SPD)."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 189, 'text': 'Non-pathogenic Rickettsia species LON strains closely related to an agent of Japanese spotted fever (JSF), R. japonica, were isolated in Japan from Haemaphysalis longicornis ticks in 2001. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32863353'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 221, 'text': 'Severe fever with thrombocytopenia syndrome (SFTS) and Japanese spotted fever (JSF; a spotted fever group rickettsiosis) are tick-borne zoonoses that are becoming a significant public health threat in Japan and East Asia.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36016429'}, {'offsetInBeginSection': 153, 'offsetInEndSection': 288, 'text': 'Rickettsia japonica is a member of SFG rickettsiae causing Japanese spotted fever (JSF) and can transmit to humans via infected ticks. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35507925'}]\n\n\n             'What causes Japanese Spotted Fever?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Japanese Spotted Fever is caused by Rickettsia japonica."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 14, 'offsetInEndSection': 177, 'text': 'To compare the real-world safety profile of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors between younger and older patients', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35668012'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 164, 'text': 'Programmed Cell Death Receptor (PD-1) and its Ligand (PD-L1) pathway inhibitor therapy has been explored in the field of oncology treatment mainly for solid tumors.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30851544'}, {'offsetInBeginSection': 11, 'offsetInEndSection': 211, 'text': ' Inhibitors of programmed cell death-1 (PD-1) and its ligand (PD-L1) have been increasingly used in head and neck cancer therapy and reported to improve the outcomes with an acceptable safety profile.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31436392'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 250, 'text': 'Engagement of programmed death-1 (PD-1) with its two ligands [programmed death ligand-1 (PD-L1) and PD-L2] has been associated with the suppression of tumor-reactive T cells; however, the underlying mechanism for this T-cell dysfunction is not clear.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24031027'}, {'offsetInBeginSection': 155, 'offsetInEndSection': 204, 'text': 'PD-1 interacts with two ligands, PD-L1 and PD-L2.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20587542'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 137, 'text': 'Expression of the programmed death-1 (PD-1) ligand 1 (PD-L1) is used to select patients and analyze responses to anti-PD-1/L1 antibodies.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27903604'}, {'offsetInBeginSection': 124, 'offsetInEndSection': 336, 'text': 'PD-1 has two ligands: PD-1 ligand 1 (PD-L1), which is expressed broadly on hematopoietic and parenchymal cells, including pancreatic islet cells; and PD-L2, which is restricted to macrophages and dendritic cells.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16606670'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 183, 'text': 'BACKGROUND: Monoclonal antibodies against programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) are effective therapies in patients with non-small cell lung can', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28960263'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 142, 'text': 'PD-L1 and PD-L2 are ligands for PD-1, a costimulatory molecule that plays an inhibitory role in regulating T cell activation in the periphery.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12697896'}, {'offsetInBeginSection': 72, 'offsetInEndSection': 198, 'text': 'PD-1 has two ligands: PD-L1, expressed on hematopoietic and nonhematopoietic cells, and PD-L2, limited to DCs and macrophages.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21097698'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 151, 'text': 'Programmed death-1 (PD-1) is an immune checkpoint that is able to inhibit the immune system by binding to its ligand programmed death-ligand 1 (PD-L1).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30547271'}, {'offsetInBeginSection': 902, 'offsetInEndSection': 1106, 'text': 'Finally, we could demonstrate that PD-L1 and PD-L2 competed for PD-1 binding and conversely, an antagonist PD-1 mAb blocked both PD-L1 and PD-L2 binding to PD-1 and strongly enhanced T-cell proliferation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20587542'}, {'offsetInBeginSection': 181, 'offsetInEndSection': 360, 'text': 'ast cancer. Programmed death-1 (PD-1) and its ligand, programmed death-ligand 1\\xa0(PD-L1), seem to have prognostic and predictive values in a variety of cancers, including female br', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30519815'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 135, 'text': 'Importance: Immune checkpoint inhibitors of programmed cell death 1 (PD-1) and its ligand (PD-L1) have led to a paradigm shift in cance', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31876895'}, {'offsetInBeginSection': 103, 'offsetInEndSection': 285, 'text': 'osuppression. Programmed death-1 (PD1) and its ligand programmed death ligand-1 (PD-L1) exert inhibitory function by regulating the balance among T cell activation, tolerance, and im', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21118528'}, {'offsetInBeginSection': 111, 'offsetInEndSection': 148, 'text': 'PD-1 has two ligands PD-L1 and PD-L2.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17924994'}]\n\n\n             'What is the difference between PD-1 and PD-L1?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "PD-1 and PD-L1 inhibitors act to inhibit the association of the programmed death-ligand 1 (PD-L1) with its receptor, programmed cell death protein 1 (PD-1). PD-L1 is the receptor that binds to the PD-L1 protein"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 559, 'offsetInEndSection': 968, 'text': 'We herein discuss how genetic information combined with longitudinal metabolomic, immune, behavioral, and gut microbial parameters, and bioclinical variables could define a digital replica of oneself, a \"virtual digital twin,\" which could serve to guide nutrition in a personalized manner. Such a model may revolutionize the management of obesity and its comorbidities, and provide a pillar for healthy aging.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32770212'}]\n\n\n             'What would be the benefits of using a virtual digital twin in nutrition?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "A \"virtual digital twin,\" could serve to guide nutrition in a personalized manner, thus revolutionizing the management of obesity and its comorbidities, and providing a pillar for healthy aging."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 2720, 'offsetInEndSection': 3018, 'text': 'INTERPRETATION: Levosimendan was not superior to placebo in maintaining respiratory function in a broad population with amyotrophic lateral sclerosis. Although levosimendan was generally well tolerated, increased heart rate and headache occurred more frequently with levosimendan than with placebo.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34536404'}, {'offsetInBeginSection': 1464, 'offsetInEndSection': 1668, 'text': 'CONCLUSIONS: Levosimendan did not achieve the primary endpoint of improving sitting SVC in ALS. Headache and increased heart rate were increased on levosimendan, although it was otherwise well tolerated. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31315908'}]\n\n\n             'Is levosimendan effective for amyotrophic lateral sclerosis?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "No. Levosimendan was not superior to placebo in maintaining respiratory function in a broad population with amyotrophic lateral sclerosis. Although levosimendan was generally well tolerated, increased heart rate and headache occurred more frequently with levosimendan than with placebo."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 221, 'text': 'X-linked ornithine transcarbamylase deficiency (OTCD) is the most common urea cycle defect. The disease severity ranges from asymptomatic carrier state to severe neonatal presentation with hyperammonaemic encephalopathy. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36362876'}, {'offsetInBeginSection': 11, 'offsetInEndSection': 273, 'text': 'Ornithine transcarbamylase deficiency (OTC-D) is an X-linked metabolic disease and the most common urea cycle disorder. Due to high phenotypic heterogeneity, ranging from lethal neonatal hyperammonemic events to moderate symptoms and even asymptomatic individual', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36217298'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 96, 'text': 'Deficiency of ornithine transcarbamylase, an enzyme in the urea cycle, results in hyperammonemia', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/3826955'}, {'offsetInBeginSection': 342, 'offsetInEndSection': 589, 'text': 'extreme irritability (100 percent), episodic vomiting and lethargy (100 percent), protein avoidance (92 percent), ataxia (77 percent), Stage II coma (46 percent), delayed physical growth (38 percent), developmental delay (38 percent), and seizures', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/3945292'}, {'offsetInBeginSection': 230, 'offsetInEndSection': 359, 'text': 'Ornithine transcarbamylase deficiency causes vomiting, lethargy, hyperventilation, and even death, mainly in the neonatal period.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17845164'}]\n\n\n             'What are the clinical symptoms of an ornithine transcarbamylase deficiency?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Symptoms of Ornithine transcarbamylase deficiency include hyperammonaemic encephalopathy, hyperammonemia, extreme irritability, episodic vomiting and lethargy, protein avoidance,  ataxia , Stage II coma, delayed physical growth, developmental delay, and seizures"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 107, 'text': 'Alternative splicing of HSPA12A pre-RNA by SRSF11 contributes to metastasis potential of colorectal cancer.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36394206'}, {'offsetInBeginSection': 1600, 'offsetInEndSection': 1923, 'text': 'SRSF11 exerts pro-metastatic effects in CRC by inhibiting the AS of HSPA12A pre-RNA. Our findings point to SRSF11-regulated HSPA12A splicing as a novel relationship between SRSF11-regulated splicing and CRC metastasis and suggest a PAK5/SRSF11/HSPA12A axis as a potential therapeutic target and prognostic biomarker in CRC.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36394206'}]\n\n\n             'How does SRSF11 contribute to metastasis potential of colorectal cancer?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "SRSF11 exerts pro-metastatic effects in colorectal cancer by inhibiting the AS of HSPA12A pre-RNA."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 240, 'text': 'Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34344706'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 154, 'text': 'OBJECTIVE: To evaluate the efficacy and safety of olokizumab (OKZ) in patients with active rheumatoid arthritis despite treatment with methotrexate (MTX).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34344706'}, {'offsetInBeginSection': 1387, 'offsetInEndSection': 1586, 'text': 'CONCLUSIONS: Treatment with OKZ was associated with significant improvement in signs, symptoms and physical function of rheumatoid arthritis without discernible differences between the two regimens. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34344706'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 64, 'text': 'Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36001712'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 245, 'text': 'BACKGROUND: The cytokine interleukin-6 is involved in the pathogenesis of rheumatoid arthritis. Olokizumab, a humanized monoclonal antibody targeting the interleukin-6 cytokine directly, is being tested for the treatment of rheumatoid arthritis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36001712'}, {'offsetInBeginSection': 2389, 'offsetInEndSection': 2722, 'text': 'CONCLUSIONS: In patients with rheumatoid arthritis who were receiving maintenance methotrexate, olokizumab was superior to placebo and noninferior to adalimumab in producing an ACR20 response at 12 weeks. Larger and longer trials are required to determine the efficacy and safety of olokizumab in patients with rheumatoid arthritis. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36001712'}]\n\n\n             'Olokizumab is tested for which disease?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Olokizumab, a monoclonal antibody against interleukin 6, improves outcomes of rheumatoid arthritis."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 1, 'offsetInEndSection': 114, 'text': 'ROAP regulates cell cycle and promotes tumor progression through Wnt/\u03b2-Catenin signaling pathway in glioma cells.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34077623'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 178, 'text': 'Trophinin associated protein (TROAP) is a cytoplasmic protein required for spindle assembly and cell invasion; however, its biological function in cancer remains to be elucidated', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29956806'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 174, 'text': 'Trophinin-associated protein (TROAP) was a protein first identified to mediate the process of embryo transplantation and later found to be involved in microtubule regulation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29117881'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 171, 'text': 'Purpose: Trophinin-associated protein (TROAP) is a cytoplasmic protein that plays a significant role in the processes of embryo transplantation and microtubule regulation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30854102'}, {'offsetInBeginSection': 138, 'offsetInEndSection': 338, 'text': 'on subtype. Trophinin-associated protein (TROAP) is a cytoplasmic protein first identified to mediate the process of embryo transplantation, which has been recently found to be involved in microtubule', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31285897'}, {'offsetInBeginSection': 142, 'offsetInEndSection': 329, 'text': 'Trophinin associated protein (TROAP) is essential for centrosome integrity and proper bipolar organisation of spindle assembly during mitosis and plays an essential role in proliferation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30431120'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 156, 'text': 'BACKGROUND: Trophinin-associated protein (TROAP) mediates embryonic transfer, regulates microtubules, and is associated with the biological behavior of vari', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35708862'}, {'offsetInBeginSection': 1101, 'offsetInEndSection': 1199, 'text': 'Taken together, these results indicate that TROAP suppresses cellular growth and migration in HCC.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29117881'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 155, 'text': 'Downregulated Trophinin-Associated Protein Plays a Critical Role in Human Hepatocellular Carcinoma Through Upregulation of Tumor Cell Growth and Migration.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29117881'}, {'offsetInBeginSection': 623, 'offsetInEndSection': 793, 'text': 'TROAP depletion significantly enhanced the proliferation and colony formation abilities, whereas TROAP overexpression had an inhibitory effect on the growth of HCC cells.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29117881'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 236, 'text': 'Trophinin-associated protein (TROAP) is a cytoplasmic protein required for microtubular cytoskeleton regulation and spindle assembly, and its expression plays a critical role in the initiation and progression of various types of cancer.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31198787'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 179, 'text': 'Trophinin associated protein (TROAP) is a cytoplasmic protein required for spindle assembly and cell invasion; however, its biological function in cancer remains to be elucidated.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29956806'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 543, 'text': 'BACKGROUND: Trophinin-associated protein (TROAP) is a cytoplasmic protein that functions as an adhesion molecule in processes such as embryo implantation, spindle formation, and cancer.OBJECTIVE: To evaluate the relationship of TROAP expression in hepatocellular carcinoma (HCC) tissue with clinicopathologic parameters and survival time in liver cancer patients based on an analysis of The Cancer Genome Atlas Liver Hepatocellular Carcinoma (TCGA-LIHC) data.METHODS: RNA-sequencing (RNA-Seq) expression data and clinical information were down', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30284652'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 86, 'text': 'TROAP regulates prostate cancer progression via the WNT3/survivin signalling pathways.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30431120'}, {'offsetInBeginSection': 1601, 'offsetInEndSection': 1744, 'text': 'Conclusions: Elevated TROAP expression predicted a poor prognosis, and TROAP may serve as a potential biomarker for application in oncotherapy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30854102'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 111, 'text': 'The Upregulation of Trophinin-Associated Protein (TROAP) Predicts a Poor Prognosis in Hepatocellular Carcinoma.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30854102'}, {'offsetInBeginSection': 1454, 'offsetInEndSection': 1600, 'text': 'Altogether, our results show that TROAP is a novel crucial regulator of HCC progression and is a potential therapeutic biomarker for HCC patients.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30854102'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 111, 'text': 'Trophinin and tastin, a novel cell adhesion molecule complex with potential involvement in embryo implantation.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7758945'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 118, 'text': 'Trophinin-associated protein (TROAP) has been shown to be overexpressed and promotes tumor progression in some tumors.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33692939'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'BACKGROUND: Trophinin-associated protein (TROAP) mediates embryonic transfer, regulates microtubules, and is associated with the biological behavior o', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35708862'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 162, 'text': 'sociated protein (TROAP) has been shown to be overexpressed and promotes tumor progression in some tumors. We performed this study to assess the biolo', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33692939'}, {'offsetInBeginSection': 132, 'offsetInEndSection': 282, 'text': 'ctopic expression of trophinin-associated protein (TROAP) dramatically drove HCC cell growth assessed by foci formation in monolayer culture, colony f', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33500384'}, {'offsetInBeginSection': 1099, 'offsetInEndSection': 1249, 'text': '. Taken together, these results indicate that TROAP suppresses cellular growth and migration in HCC. This discovery will further our understanding of ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29117881'}, {'offsetInBeginSection': 177, 'offsetInEndSection': 327, 'text': 'n (TROAP) is a cytoplasmic protein first identified to mediate the process of embryo transplantation, which has been recently found to be involved in ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31285897'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 167, 'text': 'BACKGROUND: Trophinin-associated protein (TROAP) mediates embryonic transfer, regulates microtubules, and is associated with the biological behavior of various cancers', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35708862'}, {'offsetInBeginSection': 177, 'offsetInEndSection': 377, 'text': 'n (TROAP) is a cytoplasmic protein first identified to mediate the process of embryo transplantation, which has been recently found to be involved in microtubule regulation. However, limited informati', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31285897'}, {'offsetInBeginSection': 49, 'offsetInEndSection': 268, 'text': 'l role of TROAP (Trophinin-associated protein) in regulating the cell proliferation of multiple tumors, while TROAP expression and function were largely unknown in glioma. We aimed to investigate the oncogenic role of T', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34077623'}, {'offsetInBeginSection': 26, 'offsetInEndSection': 210, 'text': 'ciated protein (TROAP) is a cytoplasmic protein that functions as an adhesion molecule in processes such as embryo implantation, spindle formation, and cancer.OBJECTIVE: To evaluate th', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30284652'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 220, 'text': 'AIMS: Experimental evidence demonstrated a crucial role of TROAP (Trophinin-associated protein) in regulating the cell proliferation of multiple tumors, while TROAP expression and function were largely unknown in glioma.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34077623'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 261, 'text': 'Clear cell renal cell carcinoma (ccRCC) is a subtype of renal cell cancer with the highest mortality, infiltration, and metastasis rate, threatening human health. Despite oncogenic role of TROAP in various cancers, its function in ccRCC remains to be unraveled.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34287099'}, {'offsetInBeginSection': 2, 'offsetInEndSection': 102, 'text': 'ophinin-associated protein expression is an independent prognostic biomarker in lung adenocarcinoma.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31285897'}, {'offsetInBeginSection': 1506, 'offsetInEndSection': 1603, 'text': ': Our results suggested that TROAP is an independent prognostic biomarker of poor survival in LAC', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31285897'}]\n\n\n             'Please summarize the function of Trophinin-associated protein (TROAP)'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Trophinin-associated protein (TROAP) mediates embryonic transfer, regulates microtubules and cell cycle, and is associated with the biological behavior of various cancers."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 49, 'text': 'Alternative splicing of HSPA12A pre-RNA by SRSF11', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36394206'}, {'offsetInBeginSection': 1600, 'offsetInEndSection': 1923, 'text': 'SRSF11 exerts pro-metastatic effects in CRC by inhibiting the AS of HSPA12A pre-RNA. Our findings point to SRSF11-regulated HSPA12A splicing as a novel relationship between SRSF11-regulated splicing and CRC metastasis and suggest a PAK5/SRSF11/HSPA12A axis as a potential therapeutic target and prognostic biomarker in CRC.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36394206'}]\n\n\n             'How does SRSF11 promote metastasis of colon cancer?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "SRSF11 exerts pro-metastatic effects in CRC by inhibiting the AS of HSPA12A pre-RNA."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 91, 'text': 'Structural and Mechanistic Bases of Viral Resistance to HIV-1 Capsid Inhibitor Lenacapavir.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36190128'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 79, 'text': 'Lenacapavir (LEN) is a long-acting, highly potent HIV-1 capsid (CA) inhibitor. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36190128'}, {'offsetInBeginSection': 803, 'offsetInEndSection': 1012, 'text': 'The investigational drug lenacapavir accesses unoccupied hydrophobic pockets in the complex to potently impair HIV-1 inside the nucleus without displacing the tightly bound cellular cofactor from virus cores. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36202818'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 145, 'text': 'Lenacapavir (Sunlenca\u00ae) is a long-acting capsid inhibitor of human immunodeficiency virus type\\xa01 (HIV-1) being developed by Gilead Sciences Inc. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36272024'}, {'offsetInBeginSection': 301, 'offsetInEndSection': 696, 'text': 'In August 2022, lenacapavir received its first approval in the EU for use in combination with other antiretroviral(s) in adults with multi-drug resistant HIV infection, for whom it is otherwise not possible to construct a suppressive anti-viral regimen. This article summarizes the milestones in the development of lenacapavir leading to this first approval for the treatment of HIV-1 infection.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36272024'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 53, 'text': 'Lenacapavir: a first-in-class HIV-1 capsid inhibitor.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34871187'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 496, 'text': 'PURPOSE OF REVIEW: This review summarizes available data for lenacapavir, an investigational first-in-class agent that disrupts functioning of HIV capsid protein across multiple steps in the viral life cycle.RECENT FINDINGS: Lenacapavir demonstrated picomolar potency in vitro with no cross resistance to existing antiretroviral classes and potent antiviral activity in persons with HIV-1. In persons with HIV-1, there was no preexisting resistance to lenacapavir regardless of treatment history.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34871187'}, {'offsetInBeginSection': 600, 'offsetInEndSection': 1015, 'text': 'In heavily treatment-experienced persons with multidrug-resistant HIV-1 and in treatment-naive persons with HIV-1, lenacapavir in combination with other antiretroviral agents led to high rates of virologic suppression and was well tolerated.SUMMARY: Ongoing studies are evaluating long-acting dosing of lenacapavir for treating HIV-1 in combination with other antiretrovirals and preventing HIV-1 as a single agent.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34871187'}]\n\n\n             'What disease can be treated with Lenacapavir?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Lenacapavir is a long-acting, highly potent HIV-1 capsid (CA) inhibitor that is approved for treatment of HIV-1."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 155, 'text': 'Intravenous iron therapy is increasingly being used worldwide to treat anemia in chronic kidney disease and more recently iron deficiency in heart failure.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36165109'}, {'offsetInBeginSection': 49, 'offsetInEndSection': 145, 'text': ' iron deficiency in patients with chronic kidney disease (CKD), either with or without anaemia. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36166211'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 140, 'text': 'Iron deficiency, both functional and absolute, is common in patients with chronic kidney disease (CKD), especially those requiring dialysis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28153964'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 135, 'text': 'Treatment with iron preparations remains one of the main directions in the treatment of anemia in patients with chronic kidney disease.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29533917'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 143, 'text': 'This work presents an update on the management of iron deficiency in patients with chronic renal failure (CRF), either with or without anaemia.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33516607'}, {'offsetInBeginSection': 1, 'offsetInEndSection': 101, 'text': 'ron replacement therapy in the management of anaemia in non-dialysis chronic renal failure patients:', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33516607'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 80, 'text': 'Iron deficiency anemia is a common complication of chronic kidney disease (CKD).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30970355'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 49, 'text': 'Iron Deficiency Anemia in Chronic Kidney Disease.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30970355'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 171, 'text': 'BACKGROUND: Iron deficiency anemia (IDA) is a common manifestation of chronic kidney disease (CKD), affecting most patients on hemodialysis and imposing a substantial clin', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28372549'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 85, 'text': 'Anemia is a common complication of chronic kidney disease (CKD) in predialysis stage.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21684231'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 88, 'text': 'Anemia is a common and clinically important consequence of chronic kidney disease (CKD).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27236129'}, {'offsetInBeginSection': 775, 'offsetInEndSection': 1022, 'text': 'Among CKD patients, absolute iron deficiency is defined when the transferrin saturation (TSAT) is \u226420% and the serum ferritin concentration is \u2264100 ng/mL among predialysis and peritoneal dialysis patients or \u2264200 ng/mL among hemodialysis patients.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30970355'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 94, 'text': 'BACKGROUND: Iron deficiency anemia is a common complication in patients with chronic kidney di', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18824288'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 146, 'text': 'Iron deficiency anemia (IDA) is a frequent complication of chronic kidney disease (CKD) and is associated with adverse outcomes in these patients.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31477258'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 149, 'text': 'Iron deficiency anemia is a common complication in end-stage renal disease (ESRD) and impairs the therapeutic efficacy of recombinant erythropoietin.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19776721'}, {'offsetInBeginSection': 424, 'offsetInEndSection': 502, 'text': 'Anemia in CKD is associated with an increased risk of morbidity and mortality.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30970355'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 528, 'text': 'BACKGROUND: Iron deficiency anemia and serum phosphate levels > 4.0mg/dL are relatively common in chronic kidney disease stages 3 to 5 and are associated with higher risks of progressive loss of kidney function, cardiovascular events, and mortality.STUDY DESIGN: Double-blind, placebo-controlled, randomized trial.SETTING & PARTICIPANTS: 149 patients with estimated glomerular filtration rates < 60 mL/min/1.73 m(2), iron deficiency anemia (hemoglobin, 9.0-12.0 g/dL; transferrin saturation [TSAT]\u2264 30%, serum ferritin \u2264 300 ng/', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25468387'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 125, 'text': 'Anemia resulting from iron and erythropoietin deficiencies is a common complication of advanced chronic kidney disease (CKD).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20630409'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 121, 'text': 'Iron deficiency is common in individuals with chronic kidney disease and plays a major role in the development of anemia.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34514189'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 158, 'text': 'Iron deficiency anemia is a common occurrence in patients with chronic kidney disease and many patients do not respond well to supplementation with oral iron.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20126670'}, {'offsetInBeginSection': 392, 'offsetInEndSection': 740, 'text': 'However, the diagnosis of iron-deficiency anemia in CKD patients is complicated by the relatively poor predictive ability of easily obtained routine serum iron indices (eg, ferritin and transferrin saturation) and more invasive gold standard measures of iron deficiency (eg, bone marrow iron stores) or erythropoietic response to supplemental iron.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27236129'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 131, 'text': 'Iron deficiency in patients with chronic kidney disease: potential role for intravenous iron therapy independent of erythropoietin.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17106764'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 198, 'text': 'Iron deficiency anemia is common in people with chronic kidney disease (CKD) and its importance in supporting erythropoiesis is unquestioned especially in those patients treated with erythropoietin.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17804903'}, {'offsetInBeginSection': 209, 'offsetInEndSection': 380, 'text': ' Limited data suggest that iron deficiency is common in patients with chronic kidney disease with anemia; this lack of iron can hinder the effectiveness of erythropoiesis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17533016'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 52, 'text': 'Anemia is a frequent complication of kidney disease.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32556307'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 58, 'text': 'Anemia is a common complication of chronic kidney disease.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16949463'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 85, 'text': 'Severe anemia and iron deficiency are common complications in chronic kidney disease.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29481308'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'Iron deficiency anemia is common in people with chronic kidney disease (CKD) and its importance in supporting erythropoiesis is unquestioned especiall', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17804903'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'Iron deficiency anemia is a common complication of chronic kidney disease (CKD). CKD patients suffer from both absolute and functional iron deficiency', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30970355'}, {'offsetInBeginSection': 58, 'offsetInEndSection': 208, 'text': ' diabetic nephropathy is a leading cause of CKD. One of the most common complications of CKD is anemia, the frequency and severity of which increase a', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22303745'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'Anemia is as a frequent complication in patients with chronic kidney disease, which gains in importance in the treatment of patients with renal diseas', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16470356'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'Severe anemia and iron deficiency are common complications in chronic kidney disease. The cause of renal anemia is multifactorial and includes decreas', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29481308'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'Anemia is a common complication in patients with chronic kidney disease (CKD), mainly due to inadequate renal production of erythropoietin. In hemodia', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26342303'}, {'offsetInBeginSection': 316, 'offsetInEndSection': 466, 'text': 'o anemia. The other cause of anemia is deficiency of iron. Iron deficiency anemia is common in people with CKD and its importance in supporting erythr', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19325171'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 152, 'text': 'Anemia is as a frequent complication in patients with chronic kidney disease, which gains in importance in the treatment of patients with renal disease.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16470356'}, {'offsetInBeginSection': 223, 'offsetInEndSection': 373, 'text': ' development and treat complications including anemia. Anemia is one of the common complication of chronic kidney disease (CKD), which is a significan', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35058395'}, {'offsetInBeginSection': 748, 'offsetInEndSection': 1006, 'text': 'The diagnosis of iron deficiency anemia in patients with CKD is complicated due to the relatively low predictive ability of routine serum iron markers (e.g., ferritin and transferrin saturation) and more invasive measurements such as bone marrow iron stores.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35058395'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'Anemia is a frequent complication in chronic kidney disease (CKD), and it is often accompanied by various clinical symptoms. The primary cause of anem', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28682026'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 151, 'text': 'Iron deficiency anemia is a common complication of chronic kidney disease (CKD). CKD patients suffer from both absolute and functional iron deficiency.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30970355'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 84, 'text': 'Anemia is a frequent complication during the later stages of chronic kidney disease.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29336855'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 85, 'text': 'Anemia in chronic kidney disease is common and iron deficiency is an important cause.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28403561'}, {'offsetInBeginSection': 1, 'offsetInEndSection': 32, 'text': 'nemia in chronic kidney disease', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28412770'}, {'offsetInBeginSection': 1, 'offsetInEndSection': 98, 'text': 'nemia is common and associated with adverse outcomes in children with chronic kidney disease (CKD', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28412770'}, {'offsetInBeginSection': 18, 'offsetInEndSection': 66, 'text': 'e treatment of anemia in chronic kidney disease.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20126670'}, {'offsetInBeginSection': 13, 'offsetInEndSection': 279, 'text': 'he prevalence of iron deficiency and its contribution to the anemia of end stage renal disease has been extensively studied, but much less is known about the role of iron deficiency in the pathogenesis of the anemia of chronic kidney disease in predialysis patients.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17106764'}, {'offsetInBeginSection': 1, 'offsetInEndSection': 47, 'text': 'nemia in renal disease: diagnosis and manageme', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19833421'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 162, 'text': 'Anemia is a very common clinical problem in patients with chronic kidney disease (CKD) and is associated with increased morbidity and mortality in these patients.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19325171'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 99, 'text': 'Safety issues with intravenous iron products in the management of anemia in chronic kidney disease.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19325171'}, {'offsetInBeginSection': 195, 'offsetInEndSection': 264, 'text': ' Deciding on the appropriate treatment for anemia associated with CKD', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27236129'}, {'offsetInBeginSection': 1, 'offsetInEndSection': 32, 'text': 'nemia in chronic kidney disease', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20630409'}, {'offsetInBeginSection': 10, 'offsetInEndSection': 50, 'text': 'Anemia in ESRD and Earlier Stages of CKD', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29336855'}, {'offsetInBeginSection': 3, 'offsetInEndSection': 40, 'text': ' Ferumoxytol for Anemia of CKD Trial ', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28372549'}, {'offsetInBeginSection': 104, 'offsetInEndSection': 165, 'text': ' anemia and reduction of serum phosphate in patients with CKD', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25468387'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 108, 'text': 'Chronic kidney disease (CKD) is a widespread health problem in the world and anemia is a common complication', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19833421'}, {'offsetInBeginSection': 1, 'offsetInEndSection': 89, 'text': 'nemia in diabetic kidney disease - underappreciated but still clinically relevant proble', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29696955'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 46, 'text': 'Anemia in children with chronic kidney disease', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16198278'}, {'offsetInBeginSection': 1, 'offsetInEndSection': 112, 'text': 'nemia in children with chronic kidney disease (CKD) is common secondary to inadequate erythropoietin production', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16198278'}, {'offsetInBeginSection': 1, 'offsetInEndSection': 27, 'text': 'echanisms of anemia in CKD', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22935483'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 64, 'text': 'Anemia is a common feature of CKD associated with poor outcomes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22935483'}, {'offsetInBeginSection': 66, 'offsetInEndSection': 150, 'text': 'he current management of patients with anemia in CKD is controversial, with recent c', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22935483'}, {'offsetInBeginSection': 259, 'offsetInEndSection': 346, 'text': 'Here, we examine recent insights into the molecular mechanisms underlying anemia of CKD', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22935483'}, {'offsetInBeginSection': 1, 'offsetInEndSection': 65, 'text': 'nemia of Inflammation with An Emphasis on Chronic Kidney Disease', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31614529'}, {'offsetInBeginSection': 33, 'offsetInEndSection': 93, 'text': ' Treatment of Anemia in Patients with Chronic Kidney Disease', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32762831'}, {'offsetInBeginSection': 1, 'offsetInEndSection': 135, 'text': 'nemia is a common complication of chronic kidney disease (CKD), and its prevalence has shown a tendency to increase in many countries.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32762831'}, {'offsetInBeginSection': 2, 'offsetInEndSection': 81, 'text': 'ythropoietin resistance in the treatment of the anemia of chronic renal failure', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16893403'}, {'offsetInBeginSection': 1, 'offsetInEndSection': 122, 'text': 'esistance to erythropoietin therapy is a common complication of the modern management of anemia in chronic kidney disease', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16893403'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 79, 'text': 'spectrum of anemia in non-dialysis-dependent chronic kidney disease', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31464252'}, {'offsetInBeginSection': 1, 'offsetInEndSection': 152, 'text': ' retrospective study was conducted over seven years and it aimed to find out various causes of anemia among patients with chronic kidney disease (CKD).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31464252'}, {'offsetInBeginSection': 4, 'offsetInEndSection': 89, 'text': 'safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16164657'}, {'offsetInBeginSection': 4, 'offsetInEndSection': 53, 'text': 'options for the anemia of chronic kidney disease.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30675430'}, {'offsetInBeginSection': 1, 'offsetInEndSection': 57, 'text': 'nemia is a common complication of chronic kidney disease', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30675430'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 64, 'text': 'Urology and nephrology update: anemia of chronic kidney disease.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24432707'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 128, 'text': 'Anemia is associated with chronic kidney disease (CKD) at all stages, and it is nearly universal among patients with stage 5 CKD', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24432707'}, {'offsetInBeginSection': 1, 'offsetInEndSection': 34, 'text': 'nemia in Chronic Kidney Disease: ', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33842503'}, {'offsetInBeginSection': 1, 'offsetInEndSection': 114, 'text': 'nemia is a common complication in chronic kidney disease (CKD), and is associated with a reduced quality of life,', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33842503'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 129, 'text': 'Anemia and its predictors among adult non-dialysis chronic kidney disease patients in Southern Ethiopia: a cross-sectional study.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34860142'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 98, 'text': 'Anemia is an adverse outcome and common complication in chronic kidney disease patient', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34860142'}, {'offsetInBeginSection': 1, 'offsetInEndSection': 162, 'text': 'Prevalence of malnutrition and absolute and functional iron deficiency anemia in nondialysis-dependent chronic kidney disease and hemodialysis Algerian patients]', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35644772'}, {'offsetInBeginSection': 2, 'offsetInEndSection': 178, 'text': ' chronic kidney disease, anemia and malnutrition coupled with inflammation as malnutrition-inflammation complex syndrom are common and considered as morbidity-mortality factors', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35644772'}, {'offsetInBeginSection': 8, 'offsetInEndSection': 65, 'text': 'f Anemia in Chronic Kidney Disease: Beyond Erythropoietin', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33123967'}, {'offsetInBeginSection': 1, 'offsetInEndSection': 65, 'text': 'nemia is a frequent comorbidity of chronic kidney disease (CKD) ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33123967'}]\n\n\n             'Is Iron deficiency anemia a common complication of chronic kidney disease?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "iron deficiency anemia is common in patients with chronic kidney disease (CKD)."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 1547, 'offsetInEndSection': 1758, 'text': 'Amiloride regulates IKs and APs with transmural differences and reduces arrhythmogenicity through the modulation of KCNQ1 splicing. We suggested that the modulation of KCNQ1 splicing may help prevent arrhythmia.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23608591'}]\n\n\n             'Can modulation of KCNQ1 splicing prevent arrhythmias?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Amiloride reduces arrhythmogenicity through the modulation of KCNQ1 splicing. Therefore, the modulation of KCNQ1 splicing may help prevent arrhythmias."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 367, 'offsetInEndSection': 485, 'text': 'Catamenial pneumothorax is one of the most frequent manifestation in terms of a thoracic endometriosis syndrome (TES).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35924495'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 108, 'text': 'Catamenial Pneumothorax as the First Expression of Thoracic Endometriosis Syndrome and Pelvic Endometriosis.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35268286'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 234, 'text': 'OBJECTIVE: The menstrual-related catamenial pneumothorax (CP) can be the first expression of thoracic endometriosis syndrome (TES), which is the presence of endometriotic lesions in the lungs and pleura, and pelvic endometriosis (PE).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35268286'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 63, 'text': 'Catamenial pneumothorax: a rare manifestation of endometriosis.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35774053'}, {'offsetInBeginSection': 176, 'offsetInEndSection': 297, 'text': 'Thoracic endometriosis is a rare extrapelvic location of endometriosis and the leading cause of catamenial pneumothorax. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35774053'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 164, 'text': 'BACKGROUND: Catamenial pneumothorax (CP) is defined as a recurrent, spontaneous pneumothorax occurring within a day before or 72\\xa0h after the onset of menstruation. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35286587'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 142, 'text': 'OBJECTIVES: Catamenial pneumothorax CP is a rare form of spontaneous pneumothorax in females forming part of thoracic endometriosis syndrome. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36179536'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 225, 'text': 'OBJECTIVE: This review aimed to categorize thoracic endometriosis syndrome (TES) according to whether the presenting symptoms were catamenial and to evaluate whether such a categorization enables a better management strategy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34375738'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 267, 'text': 'Thoracic endometriosis syndrome (TES) is a rare disorder characterized by the presence of ectopic endometrial tissue in the chest cavity. The typical clinical manifestation is a spontaneous pneumothorax, which usually presents with chest pain, dyspnea, and/or cough. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35037874'}]\n\n\n             'What is Catamenial pneumothorax?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Catamenial pneumothorax is defined as a recurrent, spontaneous pneumothorax occurring within a day before or 72 h after the onset of menstruation. It is a manifestation of a thoracic endometriosis syndrome."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 544, 'text': 'In contrast to the traditional mechanism of drug action that relies on the reversible, noncovalent interaction of a ligand with its biological target, a targeted covalent inhibitor (TCI) is designed such that the initial, reversible association is followed by the formation of a covalent bond between an electrophile on the ligand and a nucleophilic center in the protein. Although this approach offers a variety of potential benefits (high potency and extended duration of action), concerns over the possible toxicological consequences of prot', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27539547'}, {'offsetInBeginSection': 487, 'offsetInEndSection': 676, 'text': \"Her particular hepatic metabolism further increased the drugs' concentration, favoring the haptenization of liver proteins, eventually leading to the development of an autoimmune hepatitis.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23928507'}, {'offsetInBeginSection': 976, 'offsetInEndSection': 1221, 'text': 'Drug presentation via antigen-presenting cells to T cells can either involve the classical pathway of haptenization of endogenous proteins or be directly mediated via noncovalent binding to immune receptors (MHC molecules or T cell receptors), t', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22613852'}]\n\n\n             'Please summarize haptenization.'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Haptenization is the reaction of an antigenic compound (a hapten) with a carrier protein in order to stimulate an immune response."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 150, 'offsetInEndSection': 337, 'text': 'The disease affects mainly female patients, who often deny the habit, and it usually presents with a bizarre pattern nonscarring patchy alopecia with short hair and a negative pull test. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35118122'}]\n\n\n             'Is trichotillomania encountered with equali frequency in males and females?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "No, the disease affects mainly female patients."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 192, 'text': 'Eagle-Barrett Syndrome (EBS) is a rare congenital condition characterized by the triad of absent or defective abdominal wall muscles, urinary tract abnormalities, and bilateral cryptorchidism.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35429431'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 236, 'text': 'BACKGROUND: Prune belly syndrome (PBS), also known as Eagle-Barrett syndrome (EGBRS), is a rare congenital disease characterized by deficiency or absence of abdominal wall muscles, urological abnormalities, and bilateral cryptorchidism.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35526214'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 287, 'text': 'Prune Belly syndrome (PBS) or Eagle-Barrett syndrome is an anatomo-radiological syndrome consisting of a complex and rare malformation characterized by the following triad of symptoms: deficiency of the abdominal muscles, malformations of the urinary tract, and bilateral cryptorchidism.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30560020'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 223, 'text': 'Prune belly syndrome (PBS), also known as Eagle-Barrett syndrome, is a rare congenital disorder characterized by absence or hypoplasia of the abdominal wall musculature, urinary tract anomalies, and cryptorchidism in males.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29174092'}]\n\n\n             'What is the triad of the Eagle-Barrett Syndrome?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Eagle-Barrett Syndrome (EBS) is a rare congenital condition characterized by the triad of absent or defective abdominal wall muscles, urinary tract abnormalities, and bilateral cryptorchidism."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 129, 'text': 'Mantle cell lymphoma (MCL) is a relatively rare B-cell non-Hodgkin lymphoma, typically presenting with extensive lymphadenopathy,', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32774275'}, {'offsetInBeginSection': 207, 'offsetInEndSection': 483, 'text': 'Activity has been demonstrated in many subtypes of B-cell lymphoma, including diffuse large cell lymphoma, follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), lymphocyte-predominant Hodgkin lymphoma, and Waldenstr\u00f6m macroglobulinemia (WM)', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28203581'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 102, 'text': \"Mantle cell lymphoma (MCL) is a subtype of B-cell non-Hodgkin's lymphoma seen predominantly in males. \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26604506'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 189, 'text': 'Mantle cell lymphoma is an aggressive, non-curable B-cell lymphoma, characterized by the translocation t(11;14)(q13;q32) involving CCND1 and a high number of additional genetic alterations.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22555177'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 126, 'text': \"Mantle cell lymphoma (MCL) is a B cell non-Hodgkin's lymphoma, characterized by a poor response to therapy and short survival.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10942246'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 173, 'text': 'Mantle cell lymphoma is a B cell lymphoproliferative disorder cytogenetically characterized by the t(11;14)(q13;q32) which at molecular level involves the Bcl-1/PRAD-1 gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8649059'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 131, 'text': 'BACKGROUND: Mantle zone lymphoma (MZL) is a B-cell proliferation regarded as the follicular variant of intermediate lymphocytic lym', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8277026'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'BACKGROUND: Mantle cell lymphoma is a mature, virgin B-cell neoplasm characterized immunologically by a panB+, CD5+, CD23-, cyclin D1+ phenotype and g', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10463985'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 231, 'text': 'BACKGROUND: Mantle cell lymphoma is a mature, virgin B-cell neoplasm characterized immunologically by a panB+, CD5+, CD23-, cyclin D1+ phenotype and genetically by t(11;14)(q13;q32) with overexpression of the cyclin D1 (bcl-1) gene', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10463985'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 286, 'text': 'Mantle cell lymphoma (MCL) is a unique subtype of B-cell non-Hodgkin lymphoma with a generally aggressive and heterogeneous clinical course. Chemokines are one of the complex components in the tumor microenvironment (TME), and they play a vital role in tumor progression and metastasis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33197439'}]\n\n\n             'What cells proliferate in Mantle Cell Lymphoma'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Mantle Cell lymphoma is an aggressive (fast-growing) type of B-cell non-Hodgkin lymphoma"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 1548, 'offsetInEndSection': 1644, 'text': 'We estimated reduced time and costs by online counseling with about 8% and 10-12%, respectively.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26785833'}]\n\n\n             'What is the estimated cost reduction when using telegenetics?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "The estimated cost reduction by online counseling is about 10-12%."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 181, 'offsetInEndSection': 402, 'text': 'METHODS: In this phase 2, double-blind, placebo-controlled trial, we investigated the efficacy and safety of BI 1015550, an oral preferential inhibitor of the PDE4B subtype, in patients with idiopathic pulmonary fibrosis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35569036'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 143, 'text': 'Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36299369'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 101, 'text': 'Introduction: BI 1015550 is a phosphodiesterase 4 (PDE4) inhibitor that has antifibrotic properties. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36299369'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 118, 'text': 'BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35517783'}, {'offsetInBeginSection': 351, 'offsetInEndSection': 441, 'text': 'BI 1015550 is a novel PDE4 inhibitor showing a preferential enzymatic inhibition of PDE4B.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35517783'}, {'offsetInBeginSection': 2098, 'offsetInEndSection': 2401, 'text': 'In summary, the unique preferential inhibition of PDE4B by BI 1015550 and its anticipated improved tolerability in humans, plus its anti-inflammatory and antifibrotic potential, suggest BI 1015550 to be a promising oral clinical candidate for the treatment of IPF and other fibro-proliferative diseases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35517783'}]\n\n\n             'What is the target of BI 1015550?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "BI 1015550 is a preferential phosphodiesterase 4B inhibitor that is used for patients with idiopathic pulmonary fibrosis."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 1496, 'offsetInEndSection': 1750, 'text': 'Both REMS and RMPs provide positive guidance for identification, monitoring, and minimization of risk to patient safety. Currently, neither agency provides specific guidance on how risk should be related to benefit either qualitatively or quantitatively.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23244814'}, {'offsetInBeginSection': 393, 'offsetInEndSection': 630, 'text': 'REMS requirements include medication guides, communication plans, elements to ensure safe use, implementation systems, and specified assessment intervals. RMP requirements are increased pharmacovigilance and risk minimization activities.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23244814'}]\n\n\n             'Please summarize the difference between REMS and RMPs'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "REMS is the Food and Drug Administration's (FDA's) Risk Evaluation and Mitigation Strategies (REMS) and RMP is European Medicines Agency's (EMA's) Risk Management Plan (RMP) Both REMS and RMPs provide positive guidance for identification, monitoring, and minimization of risk to patient safety. RMP has requirements not included in REMS were specific adverse event reporting , prospective registry studies, prospective epidemiology studies, additional trial data (28%), and Summary of Product Characteristics contraindications ."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 106, 'text': 'Microexon alternative splicing of small GTPase regulators: Implication in central nervous system diseases.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34155820'}, {'offsetInBeginSection': 1278, 'offsetInEndSection': 1447, 'text': 'We further discuss the emerging evidence for dysregulation of the Rho GTPase pathway in CNS diseases and the consequences contributed by the mis-splicing of microexons. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34155820'}]\n\n\n             'Does microexon alternative splicing of small GTPase regulators have implication in central nervous system diseases?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Yes, microexon mis-splicing leads to dysregulation of the Rho GTPase pathway with implications in central nervous system diseases."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 393, 'text': 'Recessive dystrophic epidermolysis bullosa (RDEB) is a lifelong genodermatosis associated with blistering, wounding, and scarring caused by mutations in COL7A1, the gene encoding the anchoring fibril component, collagen VII (C7). Here, we evaluated beremagene geperpavec (B-VEC), an engineered, non-replicating COL7A1 containing herpes simplex virus type 1 (HSV-1) vector, to treat RDEB skin. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35347281'}, {'offsetInBeginSection': 1370, 'offsetInEndSection': 1528, 'text': 'These studies show that B-VEC is an easily administered, safely tolerated, topical molecular corrective therapy promoting wound healing in patients with RDEB.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35347281'}]\n\n\n             'Beremagene Geperpavec is tested for which disease?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Beremagene Geperpavec was tested for recessive dystrophic epidermolysis bullosa."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 212, 'text': '\"Hairpatches\" (Hpt) is a naturally occurring, autosomal semi-dominant mouse mutation. Hpt/Hpt homozygotes die in utero, while Hpt/+ heterozygotes exhibit progressive renal failure accompanied by patchy alopecia. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23301070'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 171, 'text': 'Hairpatches, a single gene mutation characterized by progressive renal disease and alopecia in the mouse. A potential model for a newly described heritable human disorder.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1836514'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 167, 'text': 'Retrotransposon insertion in the T-cell acute lymphocytic leukemia 1 (Tal1) gene is associated with severe renal disease and patchy alopecia in Hairpatches (Hpt) mice.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23301070'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 105, 'text': 'Hairpatches, a single gene mutation characterized by progressive renal disease and alopecia in the mouse.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1836514'}]\n\n\n             'Hairpatches is a single gene mutation associated with what disease?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Hairpatches is a single gene mutation characterized by progressive renal disease and alopecia in the mouse"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 107, 'text': 'Alternative splicing of HSPA12A pre-RNA by SRSF11 contributes to metastasis potential of colorectal cancer.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36394206'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 102, 'text': 'Alternative microexon splicing by RBFOX2 and PTBP1 is associated with metastasis in colorectal cancer.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34346508'}, {'offsetInBeginSection': 638, 'offsetInEndSection': 1073, 'text': 'RNA interference-mediated knockdown experiments identified two splicing factors, RBFOX2 and PTBP1, as regulators of microexon splicing in CRC cells. RBFOX2 and PTBP1 were found to directly bind to microexon-containing pre-mRNAs and to control their splicing in such cells. Differential microexon splicing was shown to be due, at least in part, to altered expression of RBFOX2 and PTBP1 in CRC tissue compared to matched normal tissue. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34346508'}, {'offsetInBeginSection': 1178, 'offsetInEndSection': 1320, 'text': 'Our data thus suggest that altered expression of RBFOX2 and PTBP1 might influence CRC metastasis through the regulation of microexon splicing.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34346508'}]\n\n\n             'What is the alternative microexon splicing by RBFOX2 and PTBP1 associated with?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Alternative microexon splicing by RBFOX2 and PTBP1 is associated with metastasis in colorectal cancer"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 102, 'text': 'Cribriform Appearance of White Matter in Canavan Disease Associated with Novel Mutations of ASPA Gene.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36267868'}, {'offsetInBeginSection': 652, 'offsetInEndSection': 837, 'text': 'Genetic analysis revealed novel mutations in the aspartoacylase or ASPA gene that possibly accounts for the severe form of Canavan disease, which probably explains the imaging findings.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36267868'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 121, 'text': 'Canavan disease (CD) is an inherited leukodystrophy resulting from mutations in the gene encoding aspartoacylase (ASPA). ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35636725'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 290, 'text': 'Canavan disease (CD) is a devastating neurological disease that lacks effective therapy. Because CD is caused by mutations of the aspartoacylase (ASPA) gene, we introduced the wild-type (WT) ASPA gene into patient iPSCs through lentiviral transduction or CRISPR/Cas9-mediated gene editing. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35637731'}, {'offsetInBeginSection': 1284, 'offsetInEndSection': 1453, 'text': 'The compound heterozygous variants of the ASPA gene probably underlay the Canavan disease in this patient, and the result has enabled prenatal diagnosis for this family.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35929936'}]\n\n\n             'Which gene is implicated in Canavan disease?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Canavan disease is an inherited leukodystrophy resulting from mutations in the gene encoding aspartoacylase (ASPA)."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 128, 'text': 'Prosopagnosia is a visual agnosia characterized by an inability to recognize previously known human faces and to learn new faces', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29213721'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 212, 'text': 'Prosopagnosia is a type of visual agnosia with inability to identify faces, usually secondary to brain lesion in associative cortex areas, but there is also a congenital form known as developmental prosopagnosia.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29213598'}, {'offsetInBeginSection': 1305, 'offsetInEndSection': 1522, 'text': 'These results indicate that, in some subjects with developmental prosopagnosia, the face recognition deficit is not an isolated impairment but is associated with deficits in other domains, such as auditory perception.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30625291'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 100, 'text': 'Prosopagnosia (PA) or face blindness is characterized by a deficiency in identifying familiar faces.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17186317'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 88, 'text': 'The apparent selectivity of agnosia for faces is termed prosopagnosia or face blindness.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17981784'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 153, 'text': 'In recent years, prosopagnosia is defined as the \"loss of ability to recognize the well-acquainted persons like the family members by their physiognomy.\"', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/2684250'}, {'offsetInBeginSection': 582, 'offsetInEndSection': 699, 'text': 'The patient is unable to recognize faces or cars, consistent with his prosopagnosia and object agnosia, respectively.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20850465'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 197, 'text': 'Anecdotally, it has been reported that individuals with acquired prosopagnosia compensate for their inability to recognize faces by using other person identity cues such as hair, gait or the voice.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20850465'}, {'offsetInBeginSection': 170, 'offsetInEndSection': 364, 'text': 'Visual object agnosia refers to the inability to recognize objects and prosopagnosia to the failure to recognize faces that are well familiar to the patient, when stimuli are visually perceived.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/2697897'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 297, 'text': 'Since face recognition is the most powerful source of information for identifying familiar people, patients showing a multimodal defect in people recognition have been sometimes considered as affected by \"prosopagnosia\"-namely, by a form of visual agnosia, specifically affecting face recognition.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20182942'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 110, 'text': 'Prosopagnosia is a selective visual agnosia characterized by the inability to recognize the identity of faces.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28539812'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 96, 'text': 'Prosopagnosia is a rare neurological sign, characterized by disturbance of recognition of faces.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1796436'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 181, 'text': 'INTRODUCTION: The prosopagnosia has generally been defined as an incapacity to recognize familiar faces, or faces previously known, due to certain lesions to certain areas of the ce', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15098192'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 104, 'text': 'Developmental prosopagnosia (DP) is a condition characterised by lifelong face recognition difficulties.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33184411'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 209, 'text': 'BACKGROUND: Developmental prosopagnosia is a disorder of face recognition that is believed to reflect impairments of visual mechanisms. However, voice recognition has rarely been evaluated in developmental pro', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26321070'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 88, 'text': 'Prosopagnosia is a selective impairment of the visual learning and recognition of faces.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17402670'}, {'offsetInBeginSection': 586, 'offsetInEndSection': 683, 'text': ' This rarely studied form of prosopagnosia ensures that deficits are limited to face recognition.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16767465'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'Prosopagnosia is the inability to recognize someone by the face alone in the absence of sensory or intellectual impairment. In contrast to the acquire', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16767465'}]\n\n\n             'Is prosopagnosia also known as lack of auditory recognition?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Prosopagnosia is a visual agnosia characterized by an inability to recognize previously known human faces and to learn new faces"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 287, 'text': 'Telegenetics involves the use of technology (generally video conferencing) to remotely provide genetic services. A telegenetics platform is critical for those with limitations or vulnerabilities compromising their ability to attend clinic in-person, including individuals in rural areas.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33817891'}]\n\n\n             'What is telegenetics?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Telegenetics involves the use of technology (generally video conferencing) to remotely provide genetic services. A telegenetics platform is critical for those with limitations or vulnerabilities compromising their ability to attend clinic in-person, including individuals in rural areas"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 107, 'text': 'A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35576529'}, {'offsetInBeginSection': 104, 'offsetInEndSection': 333, 'text': 'In activating red blood cell pyruvate kinase and glycolysis, mitapivat (AG-348) increases adenosine triphosphate (ATP) levels and decreases the 2,3-diphosphoglycerate (2,3-DPG) concentration, an upstream precursor in glycolysis. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35576529'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 186, 'text': 'Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent \u03b1-thalassaemia or \u03b2-thalassaemia: an open-label, multicentre, phase 2 study.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35964609'}, {'offsetInBeginSection': 259, 'offsetInEndSection': 478, 'text': 'We aimed to investigate the safety and efficacy of mitapivat (Agios Pharmaceuticals, Cambridge, MA, USA), a pyruvate kinase activator, in adults with non-transfusion-dependent (NTD) \u03b1-thalassaemia or NTD \u03b2-thalassaemia.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35964609'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 249, 'text': 'BACKGROUND: Mitapivat, an oral activator of pyruvate kinase (PK) in red blood cells (RBCs), has shown significant improvements in haemoglobin and haemolysis among patients with pyruvate kinase deficiency who were not receiving regular transfusions. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35988546'}]\n\n\n             'What is the mechanism of action of Mitapivat?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Mitapivat, an oral activator of pyruvate kinase in red blood cells, has shown significant improvements in haemoglobin and haemolysis among patients with pyruvate kinase deficiency who were not receiving regular transfusions."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 314, 'text': 'Necroptosis is a form of caspase-independent programmed cell death that arises from disruption of cell membranes by the mixed lineage kinase domain-like (MLKL) pseudokinase after its activation by the upstream kinases, receptor interacting protein kinase (RIPK)-1 and RIPK3, within a complex known as the necrosome', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35365636'}, {'offsetInBeginSection': 677, 'offsetInEndSection': 814, 'text': 'Thus, cells undergoing necroptosis need to overcome these independent suppressive mechanisms before plasma membrane disruption can occur.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31138766'}, {'offsetInBeginSection': 1263, 'offsetInEndSection': 1556, 'text': 'Taken together, these results confirm the active role of VLCFAs during necroptosis and point to multiple potential mechanisms of membrane disruption including direct permeabilization via bilayer disruption and permeabilization by targeting of proteins to cellular membranes by fatty acylation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31490656'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 315, 'text': 'Necroptosis is a form of caspase-independent programmed cell death that arises from disruption of cell membranes by the mixed lineage kinase domain-like (MLKL) pseudokinase after its activation by the upstream kinases, receptor interacting protein kinase (RIPK)-1 and RIPK3, within a complex known as the necrosome.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35365636'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 173, 'text': 'Necroptosis is a form of regulated cell death which results in loss of plasma membrane integrity, release of intracellular contents, and an associated inflammatory response.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31490656'}, {'offsetInBeginSection': 197, 'offsetInEndSection': 385, 'text': 'Here, we show that, during necroptosis, MLKL-dependent calcium (Ca2+) influx and phosphatidylserine (PS) exposure on the outer leaflet of the plasma membrane preceded loss of PM integrity.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28388412'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 70, 'text': 'Membrane Disruption by Very Long Chain Fatty Acids during Necroptosis.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31490656'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 196, 'text': 'The activation of mixed lineage kinase-like (MLKL) by receptor-interacting protein kinase-3 (RIPK3) results in plasma membrane (PM) disruption and a form of\\xa0regulated necrosis, called necroptosis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28388412'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 131, 'text': 'Necroptosis is a highly inflammatory form of programmed cell death that results from MLKL-mediated disruption of the cell membrane.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28388403'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 283, 'text': 'Necroptosis, a form of programmed cell death, is characterized by the loss of membrane integrity and release of intracellular contents, the execution of which depends on the membrane-disrupting activity of the Mixed Lineage Kinase Domain-Like protein (MLKL) upon its phosphorylation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32839552'}, {'offsetInBeginSection': 324, 'offsetInEndSection': 556, 'text': 'Here we report that, following sciatic nerve injury, MLKL, a pseudokinase known to rupture cell membranes during necroptotic cell death, is induced and targets the myelin sheath membrane of Schwann cells to promote myelin breakdown.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30344099'}, {'offsetInBeginSection': 689, 'offsetInEndSection': 794, 'text': 'Under conditions of necroptotic cell death, ESCRT-III controls the duration of plasma membrane integrity.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28388412'}, {'offsetInBeginSection': 108, 'offsetInEndSection': 198, 'text': 'Necroptosis induction leads to cell membrane disruption, inflammation and vascularization.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31766571'}, {'offsetInBeginSection': 464, 'offsetInEndSection': 657, 'text': ' Both necrosis and necroptosis show similar morphological features and are characterized by an increase in cell volume, cell membrane permeabilization, and rupture that lead to cellular demise.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30341907'}, {'offsetInBeginSection': 676, 'offsetInEndSection': 814, 'text': ' Thus, cells undergoing necroptosis need to overcome these independent suppressive mechanisms before plasma membrane disruption can occur.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31138766'}, {'offsetInBeginSection': 905, 'offsetInEndSection': 1055, 'text': 'chanisms by which the essential, and possibly terminal, necroptotic effector, MLKL, triggers the disruption of cellular membranes to cause cell lysis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27158445'}, {'offsetInBeginSection': 484, 'offsetInEndSection': 634, 'text': 'uring necroptosis. We show that MLKL and phosphoMLKL, key for membrane permeabilization, are exclusively acylated during necroptosis. Reducing the lev', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33848465'}, {'offsetInBeginSection': 235, 'offsetInEndSection': 385, 'text': 'anslocates to and disrupts the plasma membrane, thereby causing necroptotic cell lysis. Herein, we show that activation of necroptosis in mouse dermal', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30709919'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 260, 'text': 'Necroptosis is a programmed cell death pathway triggered by activation of receptor interacting protein kinase 3 (RIPK3), which phosphorylates and activates the mixed lineage kinase-like domain pseudokinase, MLKL, to rupture or permeabilize the plasma membrane.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30148498'}, {'offsetInBeginSection': 171, 'offsetInEndSection': 410, 'text': ' non-inflammatory process while necrosis triggers inflammation. Recent studies on necroptosis and pyroptosis, two types of programmed necrosis, revealed that plasma membrane rupture is mediated by MLKL channels during necroptosis but depen', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29076500'}]\n\n\n             'Do cells undergoing necroptosis show disruption of their cell membranes?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Necroptosis is a form of caspase-independent programmed cell death that arises from disruption of cell membranes"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 241, 'text': \"Dermatillomania or skin picking disorder (SPD) is a chronic, recurrent, and treatment resistant neuropsychiatric disorder with an underestimated prevalence that has a concerning negative impact on an individual's health and quality of life. \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33808008'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 160, 'text': 'Dermatillomania is a pathologic grooming disorder characterized by repetitive, ritualistic, impulsive skin picking without an underlying dermatologic condition.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21323095'}]\n\n\n             'What is the definition of dermatillomania?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Dermatillomania is a condition that leads to repetitive picking of their skin ending up in skin and soft tissue damage. It is a chronic, recurrent, and treatment resistant neuropsychiatric disorder with an underestimated prevalence that has a concerning negative impact on an individual's health and quality of life."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 78, 'text': 'Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35626120'}, {'offsetInBeginSection': 361, 'offsetInEndSection': 624, 'text': 'In this study, we evaluated the safety and efficacy of a monotherapy with the bispecific CD20xCD3 antibody glofitamab in patients who progressed after CAR T treatment. We report nine consecutive patients with progressive DLBCL after preceding CAR T-cell therapy. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35626120'}, {'offsetInBeginSection': 1106, 'offsetInEndSection': 1284, 'text': 'Our data suggest that glofitamab treatment is well tolerated and effective in patients with DLBCL relapsing after CAR T-cell therapy and can enhance residual CAR T-cell activity.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35626120'}, {'offsetInBeginSection': 674, 'offsetInEndSection': 976, 'text': 'Bispecific antibodies such as epcoritamab, mosunetuzumab, and glofitamab, anti-CD19 antibody drug tafasitamab combined with lenalidomide, CD19 antibody drug conjugate loncastuximab tesirine, oral selective inhibitor of nuclear export selinexor, and several new agents have been investigated for DLBCL. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36198538'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 200, 'text': 'Glofitamab, a novel CD20xCD3, T-cell-engaging bispecific antibody, exhibited single-agent activity in Study NP30179, a first-in-human, phase 1 trial in relapsed/refractory B-cell non-Hodgkin lymphoma.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34941996'}]\n\n\n             'What disease can be treated with Glofitamab?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Glofitamab is being tested for treatment of DLBCL after CAR T-Cell Therapy"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 2839, 'offsetInEndSection': 3023, 'text': 'INTERPRETATION: Erenumab did not reduce pain intensity compared with placebo in patients with trigeminal neuralgia and CGRP probably does not have an important role in paroxysmal pain.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36113495'}, {'offsetInBeginSection': 2356, 'offsetInEndSection': 2656, 'text': 'There was no difference between groups in the number of responders at 4 weeks in the intention-to-treat population (14 [35%] of 40 with erenumab vs 18 [45%] of 40 with placebo; estimated effect size -10% [95% CI -31 to 11]; p=0\u00b736). 20 (50%) of 40 participants reported adverse events in each group. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36113495'}]\n\n\n             'Is erenumab effective for trigeminal neuralgia?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "No. In a randomized clinical trial erenumab was not effective for treatment of trigeminal neuralgia."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 400, 'offsetInEndSection': 508, 'text': 'Lurasidone is an atypical antipsychotic drug that was initially developed for the treatment of schizophrenia', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26771990'}, {'offsetInBeginSection': 1, 'offsetInEndSection': 168, 'text': 'he Effectiveness of Lurasidone Add-On for Residual Aggressive Behavior and Obsessive Symptoms in Antipsychotic-Treated Children and Adolescents with Tourette Syndrome:', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33572131'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 296, 'text': 'This article briefly reviews the novel atypical second-generation antipsychotic drugs iloperidone (Fanapt\u00ae), asenapine (Saphris\u00ae), and lurasidone (Latuda\u00ae), all of which have been approved by the U.S. Food and Drug Administration since 2009. Each is indicated for the treatment of schizophrenia, ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21446639'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 265, 'text': 'Lurasidone (Latuda(\u00ae)), a benzisothiazole derivative antipsychotic, is approved in the USA and Canada for the treatment of adults with major depressive episodes (MDE) associated with bipolar I disorder; this article reviews studies of lurasidone in this indication.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25698146'}, {'offsetInBeginSection': 400, 'offsetInEndSection': 509, 'text': 'Lurasidone is an atypical antipsychotic drug that was initially developed for the treatment of schizophrenia.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26771990'}, {'offsetInBeginSection': 453, 'offsetInEndSection': 610, 'text': 'Lurasidone is a drug in the benzisothiazole class approved by the US Food and Drug Administration in June 2013 for the acute treatment of bipolar depression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26316760'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 236, 'text': 'The U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application Lurasidone (Latuda, Sunovion Pharmaceuticals), an atypical antipsychotic, for the treatment of schizophrenia in adolescents 13-17 years of age.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29962579'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 121, 'text': 'Lurasidone is one of several antipsychotics approved in the recent past by the US FDA for the treatment of schizophrenia.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22364325'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 304, 'text': 'Lurasidone is a novel benzoisothiazol antipsychotic that has recently been approved for the treatment of schizophrenia in the U.S. Like many other second-generation antipsychotics, it has a high affinity for dopamine D(2) and serotonin 5-HT(2A) receptors as well as a high affinity for 5-HT(7) receptors.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22146224'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 326, 'text': 'Lurasidone is a novel antipsychotic agent approved for the treatment of schizophrenia in a number of countries including the UK, and is also approved in the USA and Canada for the treatment of major depressive episodes associated with bipolar I disorder as either a monotherapy or adjunctive therapy with lithium or valproate.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26755968'}, {'offsetInBeginSection': 207, 'offsetInEndSection': 333, 'text': 'Recently, lurasidone was approved to treat bipolar depression either as monotherapy or adjunctively with lithium or valproate.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25852975'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 139, 'text': 'Lurasidone is a second-generation antipsychotic newly approved by the U.S. Food and Drug Administration for the treatment of schizophrenia.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21177242'}, {'offsetInBeginSection': 99, 'offsetInEndSection': 276, 'text': 'cide risk. Lurasidone is an atypical antipsychotic agent indicated for the treatment of schizophrenia and for the treatment of major depressive episodes associated with bipolar ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24955752'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 93, 'text': 'Update on the development of lurasidone as a treatment for patients with acute schizophrenia.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22675261'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 53, 'text': 'Lurasidone: a new treatment option for schizophrenia.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22146224'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 188, 'text': 'Lurasidone is an important antipsychotic drug indicated for the treatment of schizophrenia and bipolar disorder, with an oral bioavailability of 9-19% owing to its poor aqueous solubility.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34534629'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 104, 'text': 'Background: Lurasidone is an atypical antipsychotic approved for the treatment of schizophrenia in 2010.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34860899'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 167, 'text': 'Lurasidone was approved by the United States Food and Drug Administration (FDA) for the treatment of schizophrenia, as well as for the treatment of bipolar depression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32124704'}]\n\n\n             'What is the first indication for lurasidone?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Lurasidone is an atypical antipsychotic drug that was initially developed for the treatment of schizophrenia and bipolar depression."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 3147, 'offsetInEndSection': 3590, 'text': 'Concomitant vaccination with ChAdOx1 or BNT162b2 plus an age-appropriate influenza vaccine raises no safety concerns and preserves antibody responses to both vaccines. Concomitant vaccination with both COVID-19 and influenza vaccines over the next immunisation season should reduce the burden on health-care services for vaccine delivery, allowing for timely vaccine administration and protection from COVID-19 and influenza for those in need.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34774197'}, {'offsetInBeginSection': 11, 'offsetInEndSection': 535, 'text': 'It is unknown if the efficacy of the coronavirus disease-19 (COVID-19) vaccine is affected by the co-administration of other vaccines. The Centers for Disease Control and Prevention (CDC) has shifted their recommendations recently, allowing for the co-administration of the currently available COVID-19 vaccines with other vaccines. This is based on the experience with non-COVID-19 vaccines, where the immunogenicity and adverse event profiles were generally similar when vaccines are administered simultaneously or alone. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34304240'}, {'offsetInBeginSection': 1188, 'offsetInEndSection': 1387, 'text': 'Although the administration of Tdap with COVID-19 vaccine in our case caused delay in immunogenicity, it did not negate the ability of the BNT162B2 mRNA vaccine to elicit an adequate immune response.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34304240'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 243, 'text': 'Concomitant administration of COVID-19 and influenza vaccines could reduce burden on health-care systems. We aimed to assess the safety of concomitant administration of ChAdOx1 or BNT162b2 plus an age-appropriate influenza vaccine.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34774197'}, {'offsetInBeginSection': 252, 'offsetInEndSection': 571, 'text': 'In this multicentre, randomised, controlled, phase 4 trial, adults in receipt of a single dose of ChAdOx1 or BNT162b2 were enrolled at 12 UK sites and randomly assigned (1:1) to receive concomitant administration of either an age-appropriate influenza vaccine or placebo alongside their second dose of COVID-19 vaccine.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34774197'}]\n\n\n             'Can other vaccines be given with COVID-19 vaccine?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Although there are no data regarding safety and efficacy when COVID-19 vaccines are co-administered with other vaccines, the Centers for Disease Control and Prevention (CDC) has stated that COVID-19 vaccines can be administered at any time in relation to other non-COVID-19 vaccines, and if needed, can be administered on the same day as other vaccines. This is based on the experience with non-COVID-19 vaccines, where the immunogenicity and adverse event profiles were generally similar when vaccines are administered simultaneously or alone.\n\nFurthermore, in a randomized trial, frequency of adverse effects and immunogenicity were largely similar when a COVID-19 vaccine (BNT162b2 or ChAdOx1) was given concomitantly with either an influenza vaccine or placebo."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 1293, 'offsetInEndSection': 1472, 'text': 'Sublocade\u00ae is a one-month-long depot formulation that is indicated in switch from sublingual buprenorphine, and which proposes only two dose schemes, i.e., 100 and 300mg monthly. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32499082'}]\n\n\n             'What is Sublocade?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Sublocade\u00ae is a one-month-long depot formulation that is indicated in switch from sublingual buprenorphine, and which proposes only two dose schemes, i.e., 100 and 300mg monthly."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 950, 'offsetInEndSection': 1328, 'text': 'This review supports the beneficial effects of music-based interventions on the health of preterm infants in a neonatal intensive care unit; however, it also offers suggestions for future studies in order to increase the number of interventions with music therapists, since the results of music therapy approaches were more consistent for physiological and behavioural outcomes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34919292'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 96, 'text': 'No effect of a musical intervention on stress response to venepuncture in a neonatal population.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31532835'}, {'offsetInBeginSection': 1359, 'offsetInEndSection': 1496, 'text': 'Our findings did not support the additional benefit of music intervention on neonatal stress response to venepuncture in preterm infants.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31532835'}, {'offsetInBeginSection': 1547, 'offsetInEndSection': 1686, 'text': 'BF could significantly reduce pain response in healthy-term neonates during heel lance. MT did not enhance the effect of pain relief of BF.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25467598'}]\n\n\n             'Is music therapy effective for pain management in neonates?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "No, although there are beneficial effects of music-based interventions, there are no clear evidence of their effectiveness on pain management in neonates."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 631, 'offsetInEndSection': 980, 'text': 'Many of the hopeful predictions outlined in our AML review of 2018 are now therapeutic realities: gemtuzumab ozogamicin, venetoclax, FLT3 inhibitors (midostaurin, gilteritinib), IDH inhibitors (ivosidenib, enasidenib), CPX-351, glasdegib, oral decitabine, and oral azacitidine. Others may soon be (quizartinib, APR246 magrolimab, menin inhibitors). ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34350585'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 253, 'text': 'The fms-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib is indicated for relapsed or refractory (R/R) FLT3-mutated acute myeloid leukemia (AML), based on its observed superior response and survival outcomes compared with salvage chemotherapy (SC). ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35637252'}, {'offsetInBeginSection': 729, 'offsetInEndSection': 961, 'text': 'Similarly high rates of composite complete remission (CRc) were observed in patients who received a FLT3 TKI before gilteritinib (CHRYSALIS, 42%; ADMIRAL, 52%) and those without prior FLT3 TKI therapy (CHRYSALIS, 43%; ADMIRAL, 55%).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35637252'}, {'offsetInBeginSection': 130, 'offsetInEndSection': 522, 'text': 'In this study, to identify therapeutic targets responsible for the survival and proliferation of leukemic cells (blasts) with FLT3 mutations after gilteritinib (GILT, a 2nd generation tyrosine kinase inhibitor (TKI)) treatment, we performed proteomic screening of cytokine release and in vitro/ex vivo studies to investigate their associated signaling pathways and transcriptional regulation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35625776'}]\n\n\n             'What is the mechanisms of action of Gilteritinib?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "The fms-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib is indicated for relapsed or refractory FLT3-mutated acute myeloid leukemia."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 193, 'offsetInEndSection': 507, 'text': 'Two decades after the discovery of the RNA interference mechanism, the first siRNA drugs received approval for clinical use by the US Food and Drug Administration and the European Medicines Agency between 2018 and 2022. These are mainly based on an siRNA conjugation with a targeting moiety for liver hepatocytes, ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35997897'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 168, 'text': 'Small interfering RNAs (siRNAs) with N-acetylgalactosamine (GalNAc) conjugation for improved liver uptake represent an emerging class of drugs to treat liver diseases. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35867041'}, {'offsetInBeginSection': 1272, 'offsetInEndSection': 1591, 'text': 'Patisiran (hereditary transthyretin-mediated amyloidosis) was the first licensed siRNA, followed by givosiran (acute hepatic porphyria), lumasiran (primary hyperoxaluria type 1) and inclisiran (familial hypercholesterolaemia), which all use N-acetylgalactosamine (GalNAc) linkage for effective liver-directed delivery. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36250252'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 226, 'text': 'Conjugation of oligonucleotide therapeutics, including small interfering RNAs (siRNAs) or antisense oligonucleotides, to N-acetylgalactosamine (GalNAc) ligands has become the primary strategy for hepatocyte-targeted delivery, ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34154993'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 220, 'text': 'We recently demonstrated that siRNAs conjugated to triantennary N-acetylgalactosamine (GalNAc) induce robust RNAi-mediated gene silencing in the liver, owing to uptake mediated by the asialoglycoprotein receptor (ASGPR).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25786782'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 209, 'text': 'Conjugation of small interfering RNA (siRNA) to an asialoglycoprotein receptor ligand derived from N-acetylgalactosamine (GalNAc) facilitates targeted delivery of the siRNA to hepatocytes in vitro and in vivo.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25434769'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 261, 'text': 'Inclisiran is a novel N-acetylgalactosamine (GalNAc) conjugated small-interfering ribonucleic acid (siRNA) therapy designed to specifically target proprotein convertase subtilisin/kexin type 9 (PCSK9) mRNA in the liver for the treatment of hypercholesterolemia.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36281788'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 190, 'text': 'N-Acetylgalactosamine (GalNAc) conjugated short interfering RNAs (siRNAs) are a leading RNA interference (RNAi) platform allowing targeted inhibition of disease-causing genes in hepatocytes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34091052'}, {'offsetInBeginSection': 379, 'offsetInEndSection': 568, 'text': 'GalNAc binds the asialoglycoprotein receptor (ASGPR) that is highly expressed on hepatocytes and exploits this scavenger receptor to deliver siRNA across the plasma membrane by endocytosis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35505960'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 205, 'text': 'Asialoglycoprotein receptor (ASGPR) mediated delivery of triantennary N-acetylgalactosamine (GalNAc) conjugated short interfering RNAs (siRNAs) to hepatocytes is a promising paradigm for RNAi therapeutics.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25730476'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 145, 'text': 'Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25786782'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 167, 'text': 'Small interfering RNAs (siRNAs) with N-acetylgalactosamine (GalNAc) conjugation for improved liver uptake represent an emerging class of drugs to treat liver diseases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35867041'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 184, 'text': 'Conjugation of triantennary N-acetyl galactosamine (GalNAc) to oligonucleotide therapeutics results in marked improvement in potency for reducing gene targets expressed in hepatocytes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26011654'}, {'offsetInBeginSection': 239, 'offsetInEndSection': 521, 'text': ' The conjugation of ASOs to a receptor ligand can dramatically increase their entry into certain cells and tissues, as demonstrated by the implementation of N-acetylgalactosamine (GalNAc)-conjugated ASOs for Asialoglycoprotein Receptor (ASGR)-mediated uptake into liver hepatocytes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29069408'}, {'offsetInBeginSection': 345, 'offsetInEndSection': 550, 'text': ' In pre-clinical models, attachment of a triantennary N-acetylgalactosamine (GalNAc) ligand to an siRNA mediates hepatocyte uptake via the asialoglycoprotein receptor enabling RNAi-mediated gene silencing.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28129130'}, {'offsetInBeginSection': 260, 'offsetInEndSection': 480, 'text': ' The development of GalNAc-siRNA conjugates, in which a synthetic triantennary N-acetylgalactosamine-based ligand is conjugated to chemically modified siRNA, has enabled efficient, ASGPR-mediated delivery to hepatocytes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28988716'}, {'offsetInBeginSection': 258, 'offsetInEndSection': 457, 'text': ' One example is the targeted delivery of ASOs to hepatocytes, achieved with N-acetylgalactosamine (GalNAc) conjugation to ASO, which results in selective uptake by asialoglycoprotein receptor (ASGR).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31303442'}, {'offsetInBeginSection': 993, 'offsetInEndSection': 1198, 'text': ' Moreover, we found that conjugation of \u03b1-N-acetylgalactosamine (GalNAc) with two lncRNA-directed siRNAs allows for direct liver cell targeting of this lncRNA and functional enhanced uptake of cholesterol.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31279228'}, {'offsetInBeginSection': 475, 'offsetInEndSection': 592, 'text': ' Foremost of these has been the development of N-acetylgalactosamine (GalNAc) siRNA conjugates for delivery to liver.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29792572'}, {'offsetInBeginSection': 105, 'offsetInEndSection': 240, 'text': ' This is particularly the result of successful and efficient delivery of N-acetylgalactosamine (GalNAc)-conjugated siRNAs to the liver.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32771924'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 180, 'text': 'Conjugation of small interfering RNA (siRNA) to tris N-acetylgalactosamine [(GalNAc)3] can enable highly selective, potent, and durable knockdown of targeted proteins in the liver.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34413198'}, {'offsetInBeginSection': 422, 'offsetInEndSection': 572, 'text': \"conjugated to an N-acetylgalactosamine (GalNAc) ligand for targeted delivery to hepatocytes. Exposure to 2'-F-monomer metabolites was low and transien\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30820542'}, {'offsetInBeginSection': 344, 'offsetInEndSection': 494, 'text': 'd to a trivalent N-acetylgalactosamine (GalNAc) ligand for targeted delivery to hepatocytes. Sense and antisense strands of the parent duplex were syn', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32170309'}, {'offsetInBeginSection': 94, 'offsetInEndSection': 244, 'text': 'from N-acetylgalactosamine (GalNAc) facilitates targeted delivery of the siRNA to hepatocytes in vitro and in vivo. The ligands derived from GalNAc ar', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25434769'}, {'offsetInBeginSection': 1380, 'offsetInEndSection': 1530, 'text': 'ine (GalNAc) moieties to ASOs or siRNAs facilitates receptor-mediated uptake by the asialoglycoprotein receptor. In summary, ATTR is a progressive dis', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36345805'}, {'offsetInBeginSection': 106, 'offsetInEndSection': 240, 'text': 'This is particularly the result of successful and efficient delivery of N-acetylgalactosamine (GalNAc)-conjugated siRNAs to the liver.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32771924'}]\n\n\n             'What is the reason for N-acetylgalactosamine (GalNAc) conjugation of siRNAs?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "N-acetylgalactosamine (GalNAc) is used as a targeting moiety for Hepatocytes. Small interfering RNAs (siRNAs) with N-acetylgalactosamine (GalNAc) conjugation for improved liver uptake represent an emerging class of drugs to treat liver diseases and this has become a primary strategy for hepatocyte-targeted delivery,"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 373, 'text': 'Two genes are synthetic lethal if mutation of either alone is compatible with viability but mutation of both leads to death. So, targeting a gene that is synthetic lethal to a cancer-relevant mutation should kill only cancer cells and spare normal cells. Synthetic lethality therefore provides a conceptual framework for the development of cancer-specific cytotoxic agents.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16110319'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 115, 'text': 'Synthetic lethality occurs when the simultaneous perturbation of two genes results in cellular or organismal death.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21094158'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 359, 'text': 'A synthetic lethal interaction occurs between two genes when the perturbation of either gene alone is viable but the perturbation of both genes simultaneously results in the loss of viability. Key to exploiting synthetic lethality in cancer treatment are the identification and the mechanistic characterization of robust synthetic lethal genetic interactions.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28649135'}, {'offsetInBeginSection': 249, 'offsetInEndSection': 455, 'text': 'Synthetic lethality describes the phenomenon of the interplay between two genes in which deficiency of a single gene does not abolish cell viability but combined deficiency of two genes leads to cell death.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34050264'}, {'offsetInBeginSection': 416, 'offsetInEndSection': 558, 'text': 'Synthetic lethality refers to cell death caused by simultaneous perturbations of two genes while change of any one of them alone is nonlethal.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34070674'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 243, 'text': 'Synthetic lethality is an extreme form of negative genetic epistasis that arises when a combination of functional deficiency in two or more genes results in cell death, whereas none of the single genetic perturbations are lethal by themselves.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30594981'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 215, 'text': 'Synthetic lethality-an interaction between two genetic events through which the co-occurrence of these two genetic events leads to cell death, but each event alone does not-can be exploited for cancer therapeutics1.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30971823'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 202, 'text': 'Synthetic lethality is a genetic interaction that results in cell death when two genetic deficiencies co-occur but not when either deficiency occurs alone, which can be co-opted for cancer therapeutics.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36069976'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 168, 'text': 'Synthetic lethality is inviability of a double-mutant combination of two fully viable single mutants, commonly interpreted as redundancy at an essential metabolic step.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18586941'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 254, 'text': 'Synthetic dosage lethality (SDL) is a type of genetic interaction that occurs when increasing the expression of a gene causes a fitness defect, such as lethality, in a specific mutant background but has little effect on fitness in a wild-type background.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34590269'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 145, 'text': 'Synthetic lethality is a genetic interaction wherein two otherwise nonessential genes cause cellular inviability when knocked out simultaneously.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26451775'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 191, 'text': 'Synthetic lethality is a potential strategy for cancer treatment by specifically promoting the death of cancer cells with particular defects such as the loss of the RB (RB1) tumor suppressor.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23447678'}, {'offsetInBeginSection': 668, 'offsetInEndSection': 836, 'text': 'Synthetic lethality occurs when simultaneous inactivation of two genes or their products causes cell death whereas individual inactivation of either gene is not lethal.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29421999'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 249, 'text': 'Synthetic lethality (SL) is a type of genetic interaction between two genes such that simultaneous perturbations of the two genes result in cell death or a dramatic decrease of cell viability, while a perturbation of either gene alone is not lethal.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26516187'}, {'offsetInBeginSection': 298, 'offsetInEndSection': 542, 'text': 'Synthetic lethality is a type of genetic interaction between two genes such that simultaneous perturbations of the two genes result in cell death or a dramatic decrease of cell viability, while a perturbation of either gene alone is not lethal.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31675556'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 162, 'text': 'Synthetic lethality refers to a lethal phenotype that results from the simultaneous disruptions of two genes, while the disruption of either gene alone is viable.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29171189'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 100, 'text': 'Synthetic lethality arises when a combination of mutations in two or more genes leads to cell death.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26431531'}, {'offsetInBeginSection': 376, 'offsetInEndSection': 493, 'text': \" Global analysis of synthetic lethality promises to identify cellular pathways that 'buffer' each other biologically.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16309778'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 72, 'text': 'Synthetic lethality is the synthesis of mutations leading to cell death.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30125975'}, {'offsetInBeginSection': 184, 'offsetInEndSection': 366, 'text': 'Exploiting a phenomenon known as synthetic lethality, in which simultaneous loss of two interacting genes leads to loss of viability, aids in the investigation of these interactions.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22107871'}, {'offsetInBeginSection': 123, 'offsetInEndSection': 265, 'text': 'One such genetic interaction is synthetic lethality, in which the combination of two non-lethal mutations leads to loss of organism viability.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17189863'}, {'offsetInBeginSection': 199, 'offsetInEndSection': 349, 'text': 'pment of novel anticancer therapies. SL can be described as lethality (cell death) resulting from the combination of the two mutations, wherein the mu', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26211783'}, {'offsetInBeginSection': 282, 'offsetInEndSection': 471, 'text': ' Synthetic lethality occurs when inhibition or mutation in two or more separate genes leads to cell death while inhibition or mutations of either gene alone has no lethal effect on the cell', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26630128'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 136, 'text': 'Synthetic lethality is a promising strategy for specific targeting of cancer cells that carry mutations that are absent in normal cells.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22864477'}, {'offsetInBeginSection': 470, 'offsetInEndSection': 613, 'text': 'Synthetic lethality exploits cancer cell dependency on a protein or pathway, which arises when the function of a tumor suppressor is defective.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34163025'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 160, 'text': 'Synthetic lethality is based on the incompatibility of cell survival with the loss of function of two or more genes, not with loss of function of a single gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21737609'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 96, 'text': 'Synthetic lethality is a proven effective antitumor strategy that has attracted great attention.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34589394'}, {'offsetInBeginSection': 9, 'offsetInEndSection': 150, 'text': 'Synthetic lethality is a state when simultaneous loss of two genes is lethal to a cancer cell, while the loss of the individual genes is not.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30059974'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 251, 'text': 'Synthetic lethality describes a genetic interaction between two perturbations, leading to cell death, whereas neither event alone has a significant effect on cell viability. This concept can be exploited to specifically target tumor cells.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34454516'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 338, 'text': 'Synthetic lethality describes a relationship between two genes where single loss of either gene does not trigger significant impact on cell viability, but simultaneous loss of both gene functions results in lethality. Targeting synthetic lethal interactions with drug combinations promises increased efficacy in tumor therapy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30682083'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 418, 'text': 'Synthetic lethality (SL) refers to the genetic interaction between two or more genes where only their co-alteration (e.g. by mutations, amplifications or deletions) results in cell death. In recent years, SL has emerged as an attractive therapeutic strategy against cancer: by targeting the SL partners of altered genes in cancer cells, these cells can be selectively killed while sparing the normal cells.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26427375'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 356, 'text': 'Synthetic lethality defines a genetic interaction where the combination of mutations in two or more genes leads to cell death. The implications of synthetic lethal screens have been discussed in the context of drug development as synthetic lethal pairs could be used to selectively kill cancer cells, but leave normal cells relatively unharmed.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18789146'}]\n\n\n             'What is synthetic lethality?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Synthetic lethality occurs between two genes when the perturbation of either gene alone is viable but the perturbation of both genes simultaneously results in the loss of viability. So, two genes are synthetic lethal if mutation of either alone is compatible with viability but mutation of both leads to death. Targeting a gene that is synthetic lethal to a cancer-relevant mutation should kill only cancer cells and spare normal cells. Therefore, synthetic lethality provides a conceptual framework for the development of cancer-specific cytotoxic agents."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 711, 'offsetInEndSection': 1109, 'text': 'Recent results from the PEACHTREE trial (ClinicalTrials.gov Identifier: NCT02595398), a phase III trial with two suprachoroidal injections of CLS-TA at 0 and 12 weeks with follow up lasting 24 weeks, showed the significant improvement in visual acuity and reduction in central subfield thickness, all without increasing the risk of elevated intraocular pressure or accelerated cataract progression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34322164'}]\n\n\n             'How many injections of CLS-TA did the patients participating in the PEACHTREE trial receive?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "The patients participating in the PEACHTREE trial received two suprachoroidal injections of CLS-TA at 0 and 12 weeks."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 184, 'offsetInEndSection': 289, 'text': 'Whole-exome sequencing was utilized to detect disease-causing variants in 40 MLPA-negative DMD patients. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35218518'}, {'offsetInBeginSection': 421, 'offsetInEndSection': 524, 'text': 'WES analysis revealed that nonsense variant was the most common type in our study (23/36 of the cases).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35218518'}, {'offsetInBeginSection': 818, 'offsetInEndSection': 992, 'text': '. The present study has demonstrated the importance of performing WES to detect disease-causing point mutations in MLPA-negative DMD patients and to identify carrier females.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35218518'}, {'offsetInBeginSection': 146, 'offsetInEndSection': 299, 'text': 'Whole exome sequencing (WES) and multiple ligation-dependent probe amplification (MLPA) were used to detect potential deletions in the STS and DMD genes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35929940'}, {'offsetInBeginSection': 462, 'offsetInEndSection': 619, 'text': 'The newborns with retest positive result were recalled again for serum creatine kinase (CK) and multiplex ligation-dependent probe amplification (MLPA) test.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36281417'}, {'offsetInBeginSection': 620, 'offsetInEndSection': 684, 'text': 'Whole exon sequencing was performed when MLPA test was negative.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36281417'}, {'offsetInBeginSection': 247, 'offsetInEndSection': 446, 'text': ' In this study we aimed to determine the mutational spectrum of multiplex ligation-dependent probe amplification (MLPA)-negative muscular dystrophy patients in Pakistan using whole-exome sequencing. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33734897'}, {'offsetInBeginSection': 1665, 'offsetInEndSection': 1803, 'text': 'Whole-exome sequencing identified a nonsense variant in Pakistani muscular dystrophy patients, which is amenable to treatment by Ataluren ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33734897'}, {'offsetInBeginSection': 220, 'offsetInEndSection': 345, 'text': ' We used the combination of multiplex ligation-dependent probe amplification (MLPA) and sequencing analysis of the DMD gene. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34327855'}, {'offsetInBeginSection': 422, 'offsetInEndSection': 592, 'text': 'We performed DNA tests in 152 patients, checking first exon deletion/duplication by MLPA, and subsequently, if negative, samples were sequenced to detect point mutations.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34327855'}, {'offsetInBeginSection': 387, 'offsetInEndSection': 628, 'text': 'The strategy for molecular diagnostic testing for DMD involves initial screening for deletions/duplications using microarray-based comparative genomic hybridization (array-CGH) followed by full-sequence analysis of DMD for sequence variants.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25271841'}, {'offsetInBeginSection': 762, 'offsetInEndSection': 1045, 'text': 'Thus, NGS-based multigene panel testing for muscular dystrophy-associated genes or clinical exome sequencing rather than targeted DMD gene sequencing appears to be a more cost-effective testing modality with better diagnostic yield, for MLPA-negative patients with the DMD phenotype.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33552634'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 416, 'text': 'OBJECTIVE: To optimize the methods for genetic detection and prenatal diagnosis of Duchenne muscular dystrophy (DMD).METHODS: Denaturing high-performance liquid chromatography (DHPLC), multiplex PCR (mPCR), sequencing and other molecular techniques were used in combination for molecular diagnosis of 8 cases diagnosed as DMD.RESULTS: Among the 8 cases, 4 have carried large deletions, 3 have point mutations, among ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26037351'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 228, 'text': 'BACKGROUND: Genetic testing for Duchenne/Becker muscular dystrophy (DMD/BMD) mutations initially involved multiplex polymerase chain reaction (mPCR), which targeted two mutation hotspots in the gene and detected deletions in aff', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24300647'}, {'offsetInBeginSection': 1080, 'offsetInEndSection': 1344, 'text': 'Most frequently performed first step diagnostic tests in Group I and Group II were muscle biopsy and MLPA.Our study reflects the change in the age at genetic diagnosis and diagnostic approach to nm-DMD depending on the advances and availability of genetic testing.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30453357'}, {'offsetInBeginSection': 555, 'offsetInEndSection': 729, 'text': ' Dystrophin testing in muscle is the most sensitive test for identification of dystrophinopathy patients, although gene deletion studies can make the diagnosis in most cases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8745379'}, {'offsetInBeginSection': 572, 'offsetInEndSection': 713, 'text': 'Diagnostic use of Xp21 probes is now as necessary as EMG, muscle biopsy and serum CK assay for the definition of Duchenne muscular dystrophy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/2669113'}]\n\n\n             'What are the most commonly used diagnostic tests for the diagnosis of Duchenne muscular dystrophy?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "The most commonly used diagnostic tests for the diagnosis of Duchenne muscular dystrophy are multiple ligation-dependent probe amplification (MLPA), Whole-Exome Sequencing (WES) and Next Generation Sequencing (NGS)."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 464, 'offsetInEndSection': 720, 'text': 'ACANTHOSIS NIGRICANS MALIGNA: Symmetrical mainly intertriginous hyperpigmentation with partially verrucous hyperplasia and lichenification mostly in association with gastric adenocarcinoma. Special forms are florid cutaneous papillomatosis and tripe palms.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33660024'}, {'offsetInBeginSection': 505, 'offsetInEndSection': 720, 'text': 'Bladder cancer with AN concomitant with tripe palms (TP) and/or mucosal involvement is relatively rare and, to our knowledge, only seven cases of AN with bladder cancer have been reported in the English literature. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33603399'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 129, 'text': 'BACKGROUND: Tripe palms (TP) is one of the rare cutaneous paraneoplastic manifestations of various intra-abdominal malignancies. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33074559'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 204, 'text': 'BACKGROUND: Acanthosis nigricans (AN), Leser-Tr\u00e9lat sign, and tripe palm are all skin diseases. To date, reports of these appearing as a paraneoplastic syndrome in a gastric cancer patient are quite rare.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33344554'}, {'offsetInBeginSection': 1036, 'offsetInEndSection': 1501, 'text': 'Finally, yet another collection of paraneoplastic skin disorders can associate themselves with anatomically-diverse malignancies (Leser-Trelat syndrome, Trousseau syndrome, dermatomyositis, erythema gyratum repens, hypertrichosis lanuginosa acquisita, papuloerythroderma of Ofuji, tripe palms, and multicentric reticulohistiocytosis). Recognition of these processes by the pathologist can be a valuable step in the characterization of underlying malignant diseases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30736994'}]\n\n\n             'Is there any association between Tripe palms and cancer?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Yes. Tripe palms sign is associated with cancer."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 204, 'text': 'Prosopagnosia is the inability to recognize someone by the face alone in the absence of sensory or intellectual impairment. In contrast to the acquired form of prosopagnosia we studied the congenital form', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16767465'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 242, 'text': 'Congenital prosopagnosia (cPA) is a selective impairment in the visual learning and recognition of faces without detectable brain damage or malformation. There is evidence that it can be inherited in an autosomal dominant mode of inheritance.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19429021'}, {'offsetInBeginSection': 134, 'offsetInEndSection': 286, 'text': 'Here we report a follow-up examination on M.T., suffering from acquired prosopagnosia following a large unilateral right-hemispheric lesion in frontal, ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36202621'}, {'offsetInBeginSection': 124, 'offsetInEndSection': 205, 'text': 'In contrast to the acquired form of prosopagnosia we studied the congenital form.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16767465'}, {'offsetInBeginSection': 67, 'offsetInEndSection': 257, 'text': 'Acquired prosopagnosia results after brain damage, developmental or congenital prosopagnosia (CP) is not caused by brain lesion, but has presumably been present from early childhood onwards.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19823580'}, {'offsetInBeginSection': 56, 'offsetInEndSection': 216, 'text': 'Acquired prosopagnosia is the loss of familiarity for facial identity and has several functional variants, namely apperceptive, amnestic, and associative forms.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33832676'}, {'offsetInBeginSection': 327, 'offsetInEndSection': 478, 'text': 'A selective deficit in the visual learning and recognition of faces is known as prosopagnosia, which can be found both in acquired and congenital form.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19334306'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 78, 'text': 'Congenital prosopagnosia--a common hereditary cognitive dysfunction in humans.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17981784'}, {'offsetInBeginSection': 921, 'offsetInEndSection': 1029, 'text': 'Thus, the face recognition impairment of the hereditary prosopagnosics is reflected in their gaze behaviour.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16767465'}, {'offsetInBeginSection': 684, 'offsetInEndSection': 846, 'text': 'Whereas the control participants focused their gaze on the central facial features, the hereditary prosopagnosics showed a significantly different gaze behaviour.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16767465'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 155, 'text': 'BACKGROUND: Prosopagnosia is a selective deficit in facial identification which can be either acquired, (e.g., after brain damage), or present from birth (', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20657764'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 142, 'text': 'Prosopagnosia is an impairment in the ability to recognize faces and can be acquired after a brain lesion or occur as a developmental variant.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31231507'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 121, 'text': 'Previous studies have shown that acquired prosopagnosia is characterized by impairment at holistic/configural processing.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21366884'}, {'offsetInBeginSection': 538, 'offsetInEndSection': 687, 'text': ' This served to investigate whether congenital prosopagnosia results from process-specific deficiencies, or whether it is a face-specific impairment.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20689639'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 81, 'text': 'Prosopagnosia refers to an acquired or developmental deficit in face recognition.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30389553'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 152, 'text': 'BACKGROUND: Congenital prosopagnosia is a severe face perception impairment which is not acquired by a brain lesion and is presumably present from birth', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18523592'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 225, 'text': 'Three patients with prosopagnosia, and acquired inability to recognize familiar faces usually resulting from cerebrovascular insufficiency, had left-sided visual field defects and color vision abnormalities of central origin.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7091286'}, {'offsetInBeginSection': 1042, 'offsetInEndSection': 1161, 'text': 'The segregation pattern of this hereditary prosopagnosia (HPA) is fully compatible with autosomal dominant inheritance.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16817175'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 195, 'text': 'A Quick guide to developmental prosopagnosia, a condition definied by problems in recognising faces that, in contrast with acquired prosopagnosia, develop in the absence of manifest brain injury.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27115682'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 166, 'text': 'BACKGROUND: Prosopagnosia is a selective deficit in facial identification which can be either acquired, (e.g., after brain damage), or present from birth (congenital)', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20657764'}, {'offsetInBeginSection': 506, 'offsetInEndSection': 656, 'text': 'ing clinically significant impairments in facial recognition. Cases of acquired prosopagnosia were identified through a systematic literature search a', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31740940'}, {'offsetInBeginSection': 171, 'offsetInEndSection': 326, 'text': 'Reflecting this, acquired prosopagnosia is not a single entity but a family of disorders with different anatomic lesions and different functional deficits.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24389150'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 163, 'text': 'BACKGROUND: Acquired prosopagnosia is a rare condition characterized by the loss of familiarity with previously known faces and the inability to recognize new ones', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33392335'}, {'offsetInBeginSection': 545, 'offsetInEndSection': 930, 'text': 'Three key findings emerged: (a) Individuals with more severe prosopagnosia spent less time examining the internal facial region, (b) as observed in acquired prosopagnosia, some DPs spent less time examining the eyes and more time examining the mouth than controls, and (c) SRs spent more time examining the nose-a measure that also correlated with face recognition ability in controls.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26933872'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 167, 'text': 'Acquired prosopagnosia is usually a consequence of bilateral or right hemisphere lesions and is often associated with topographical disorientation and dyschromatopsia.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32648048'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'Prosopagnosia is a deficit in recognizing people from their faces. Acquired prosopagnosia results after brain damage, developmental or congenital pros', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19823580'}, {'offsetInBeginSection': 117, 'offsetInEndSection': 197, 'text': 'Cases of acquired prosopagnosia have often been described over the last century.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20689639'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 118, 'text': 'Acquired prosopagnosia is usually associated with bilateral or right-sided lesions of the occipital or temporal lobes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18374372'}, {'offsetInBeginSection': 640, 'offsetInEndSection': 864, 'text': 'Most subjects with developmental prosopagnosia were normal on the Old/New Tests: for acquired prosopagnosia, subjects with occipitotemporal lesions often showed impairments while those with anterior temporal lesions did not.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30947609'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 217, 'text': \"We studied a male with acquired prosopagnosia using a battery of Implicit Association Tests (IATs) to investigate whether observing faces varying by social category would activate the patient's implicit social biases.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21414330'}]\n\n\n             'is prosopagnosia inherited or  acquired?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Prosopagnosia can be both inherited and acquired"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 204, 'text': \"A promoter is a short region of DNA (100-1,000 bp) where transcription of a gene by RNA polymerase begins. It is typically located directly upstream or at the 5' end of the transcription initiation site. \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31750297'}, {'offsetInBeginSection': 274, 'offsetInEndSection': 369, 'text': 'Promoters mark the start of every transcript and are an important class of regulatory elements.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15899964'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 193, 'text': 'A promoter is a region in the DNA sequence that defines where the transcription of a gene by RNA polymerase initiates, which is typically located proximal to the transcription start site (TSS).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33227813'}, {'offsetInBeginSection': 107, 'offsetInEndSection': 203, 'text': \"It is typically located directly upstream or at the 5' end of the transcription initiation site.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31750297'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 176, 'text': 'A key step in the transcription of RNA is the binding of the RNA polymerase protein complex to a short promoter sequence that is typically upstream of the gene to be expressed.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36099980'}, {'offsetInBeginSection': 834, 'offsetInEndSection': 1023, 'text': 'Promoter regions are located within ~2\\xa0kb upstream of the transcriptional start site, whereas enhancers may be located at some distance from promoter sequences and exert long-range effects.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30414142'}, {'offsetInBeginSection': 111, 'offsetInEndSection': 245, 'text': 'These sequences are typically located in promoters, which are regions of variable length upstream of the open reading frames of genes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19258451'}, {'offsetInBeginSection': 674, 'offsetInEndSection': 857, 'text': 'Most of these promoters display the changes of DNA methylation in their Ups-regions, which are between +500 and +2000 bp upstream from the transcription start site (TSS) of the genes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25448745'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 130, 'text': 'Promoters are fundamental components of synthetic gene circuits. They are DNA segments where transcription initiation takes place.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34071849'}]\n\n\n             'Where are promoters typically found in DNA?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "A promoter is an important regulatory element which marks the region that transcription of a gene by RNA polymerase begins. It is typically located directly upstream or at the 5' end of the transcription initiation site."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 711, 'offsetInEndSection': 1109, 'text': 'Recent results from the PEACHTREE trial (ClinicalTrials.gov Identifier: NCT02595398), a phase III trial with two suprachoroidal injections of CLS-TA at 0 and 12 weeks with follow up lasting 24 weeks, showed the significant improvement in visual acuity and reduction in central subfield thickness, all without increasing the risk of elevated intraocular pressure or accelerated cataract progression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34322164'}]\n\n\n             'What was the duration of the follow-up period of patients in the PEACHTREE clinical trial?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "The patient follow-up period in the PEACHTREE trial lasted 24 weeks (6 months)."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 201, 'offsetInEndSection': 377, 'text': 'In most cases the condition initially presents with facial and proximal weakness of the upper limbs, but over the course of the disease involves lower limb and truncal muscles.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32327287'}, {'offsetInBeginSection': 378, 'offsetInEndSection': 464, 'text': 'Weakness is progressive and frequently asymmetric, which is a hallmark of the disease.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32327287'}, {'offsetInBeginSection': 599, 'offsetInEndSection': 700, 'text': '5 major FSHD symptoms: facial, periscapular, foot dorsiflexor, hip girdle weakness, and hearing loss.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32327287'}, {'offsetInBeginSection': 768, 'offsetInEndSection': 1340, 'text': ' patients with FSHD. Sponsors of treatments for FSHD patients should be aware of some of the common misconceptions associated with FSHD drug development with the goal of optimizing the chance to prove safety and efficacy for each potential treatment for FSHD in the clinical trial setting.RESULTS: Four major topics with potential clinical manifestations for patients with FSHD will be discussed related to muscle weakness, respiratory issues, animal models and prevalence.CONCLUSION: The authors offer multiple solutions to help counteract misconceptions with each scenar', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32008231'}, {'offsetInBeginSection': 465, 'offsetInEndSection': 700, 'text': 'Here we performed an analysis of 643 FSHD1 patients in the UK FSHD patient registry, investigating factors affecting rate of onset of 5 major FSHD symptoms: facial, periscapular, foot dorsiflexor, hip girdle weakness, and hearing loss.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32327287'}, {'offsetInBeginSection': 848, 'offsetInEndSection': 1100, 'text': 'FAT1 lies near the critical locus involved in causing FSHD, and Fat1 mutant mice also show retinal vasculopathy, mimicking another symptom of FSHD, and showed abnormal inner ear patterning, predictive of deafness, reminiscent of another burden of FSHD.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23785297'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 151, 'text': 'RATIONALE: Early-onset facioscapulohumeral muscular dystrophy (FSHD) is defined as facial weakness before the age of 5 and shoulder weakness before the', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34964760'}, {'offsetInBeginSection': 1179, 'offsetInEndSection': 1471, 'text': 'A classical presentation (74%) and 3 facial sparing phenotypes: a mild presentation (5%) with later facial and periscapular involvement, an early shoulder presentation (10%) with accelerated periscapular weakness and an early foot presentation (9%) with accelerated foot dorsiflexor weakness.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32327287'}, {'offsetInBeginSection': 1471, 'offsetInEndSection': 1774, 'text': 'Patients with FSHD also had reduced systemic antioxidative response molecules, such as low levels of zinc (a SOD cofactor), selenium (a GPx cofactor involved in the elimination of lipid peroxides), and vitamin C. Half of them had a low ratio of gamma/alpha tocopherol and higher ferritin concentrations.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22796148'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 148, 'text': 'Facioscapulohumeral muscular dystrophy (FSHD) is characterized by progressive weakness and wasting of facial, shoulder-girdle and upper arm muscles.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15050443'}, {'offsetInBeginSection': 122, 'offsetInEndSection': 483, 'text': 'Typically, FSHD patients present with a recognizable constellation of signs including weakness of facial, shoulder and pelvic girdle, humeral, and anterior foreleg muscles; preservation of some muscles including the deltoids; and other characteristic features including prominent scapular winging, anterior axillary folds, and horizontally positioned clavicles.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11353419'}, {'offsetInBeginSection': 241, 'offsetInEndSection': 500, 'text': 'physiology. Typically, progressive skeletal muscle weakness becomes noticeable in the second or third decade of life, yet there are many individuals who are genetically FSHD but develop symptoms much later in life or remain relatively asymptomatic throughout ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32278354'}, {'offsetInBeginSection': 68, 'offsetInEndSection': 218, 'text': 't neuromuscular disorder characterized by progressive weakness of the facial, shoulder and upper arm muscles. The major gene involved has been mapped ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11592052'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 168, 'text': 'We report an 18-year-old female with facioscapulohumeral dystrophy (FSHD), who had sensorineural deafness, retinal vessel abnormality, mental retardation, and epilepsy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1908258'}, {'offsetInBeginSection': 82, 'offsetInEndSection': 232, 'text': 'cular dystrophy characterized by progressive weakness and wasting of the facial, shoulder-girdle and upper arm muscles. The gene locus for FSHD is map', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12134683'}, {'offsetInBeginSection': 53, 'offsetInEndSection': 203, 'text': 'nherited myopathy clinically characterized by weakness in the facial, shoulder girdle and upper a muscles. FSHD is caused by chromatin relaxation of t', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34559225'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 234, 'text': 'PURPOSE: Severe manifestations of facioscapulohumeral dystrophy (FSHD) may be associated with sleep-disordered breathing (SDB), including obstructive sleep apnea (OSA) and nocturnal hypoventilation (NH), but prevalence data are scarce', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31025273'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 374, 'text': 'Consensual diagnostic criteria for facioscapulohumeral dystrophy (FSHD) include onset of the disease in facial or shoulder girdle muscles, facial weakness in more than 50% of affected family members, autosomal dominant inheritance in familial cases, and evidence of myopathic disease in at least one affected member without biopsy features specific to alternative diagnoses.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10864616'}, {'offsetInBeginSection': 61, 'offsetInEndSection': 211, 'text': 'onset facioscapulohumeral muscular dystrophy (FSHD) present epilepsy and mental retardation. This suggests a functional involvement of central nervous', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14659411'}, {'offsetInBeginSection': 138, 'offsetInEndSection': 218, 'text': ' The major symptom of FSHD is progressive weakening and loss of skeletal muscles', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32008231'}, {'offsetInBeginSection': 35, 'offsetInEndSection': 185, 'text': 'phy (FSHD) is an autosomal dominant disorder characterized by progressive muscle weakness. Adenine nucleotide translocator 1 (ANT1), the only 4q35 gen', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36030628'}, {'offsetInBeginSection': 258, 'offsetInEndSection': 408, 'text': 'l symptoms are extremely variable including facial sparing type, limb-girdle type, and distal myopathy type. Most of the FSHD patients have a deletion', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15050443'}]\n\n\n             'Which are some symptoms of FSHD?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Some symptoms of FSHD are the following: asymmetric weakness,  facial and proximal weakness of the upper limbs, and lower limb and truncal muscles weakness, facial, periscapular, foot dorsiflexor, hip girdle weakness, and hearing loss."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 122, 'text': 'BACKGROUND: Adagrasib, a KRASG12C inhibitor, irreversibly and selectively binds KRASG12C, locking it in its inactive state', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35658005'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 70, 'text': 'Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35658005'}, {'offsetInBeginSection': 1726, 'offsetInEndSection': 1863, 'text': 'CONCLUSIONS: In patients with previously treated KRASG12C -mutated NSCLC, adagrasib showed clinical efficacy without new safety signals. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35658005'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 220, 'text': 'In the phase II KRYSTAL-1 trial, the KRASG12C inhibitor adagrasib yielded an overall response rate of 43% and a disease control rate of 80% in patients with previously treated KRASG12C-mutant non-small cell lung cancer. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35666594'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 328, 'text': 'The activity of KRAS inhibitors against brain metastases is relatively unexplored. The recent work on preclinical models and preliminary data from the ongoing KRYSTAL-1 phase Ib clinical trial support the potential of adagrasib (MRTX849) to penetrate the central nervous system and provide control of KRASG12C brain metastases. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35608481'}, {'offsetInBeginSection': 1332, 'offsetInEndSection': 1473, 'text': 'There are other KRAS-targeted agents currently under study, including adagrasib, with growing interest in targeting KRAS downstream pathways.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35938195'}]\n\n\n             'What is the mechanism of action of Adagrasib?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Adagrasib is a KRASG12C inhibitor that irreversibly and selectively binds KRASG12C, locking it in its inactive state."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 130, 'text': 'Approximately 2% of amyotrophic lateral sclerosis (ALS) cases are caused by mutations in the super oxide dismutase 1 (SOD1) gene a', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15189359'}, {'offsetInBeginSection': 718, 'offsetInEndSection': 795, 'text': '. The two most widely studied ALS/FTLD models, super-oxide dismutase 1 (SOD1)', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30509290'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 189, 'text': 'A novel mutation of the SOD-1 gene which encodes the enzyme copper-zinc superoxide dismutase was identified in a family manifesting amyotrophic lateral sclerosis (ALS) in three generations.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24283821'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 219, 'text': 'Mutations in the Cu/Zn superoxide dismutase gene (SOD-1) are reported in 20% of familial amyotrophic lateral sclerosis (ALS) cases, but no definite report of a mutation in a \"truly\" sporadic case of ALS has been proved.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12402272'}, {'offsetInBeginSection': 140, 'offsetInEndSection': 287, 'text': 'Copper-zinc superoxide dismutase 1 (SOD1) is one of the most commonly mutated genes in ALS, and more than 160 mutations in SOD1 have been reported.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27297615'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'Mutations of the Cu/Zn superoxide dismutase (SOD-1) gene were recently implicated in the pathogenesis of familial amyotrophic lateral sclerosis (ALS).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7820674'}, {'offsetInBeginSection': 577, 'offsetInEndSection': 660, 'text': 'Over 30 different mutations of SOD-1 have now been identified in families with ALS.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24283821'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 82, 'text': 'A novel mutation of SOD-1 (Gly 108 Val) in familial amyotrophic lateral sclerosis.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24283821'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 242, 'text': 'Approximately 2% of amyotrophic lateral sclerosis (ALS) cases are caused by mutations in the super oxide dismutase 1 (SOD1) gene and transgenic mice for these mutations recapitulate many features of this devastating neurodegenerative disease.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15189359'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 166, 'text': 'Mutations of the gene SOD-1, which encodes the enzyme copper-zinc superoxide dismutase, occur in patients with a familial form of amyotrophic lateral sclerosis (ALS).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9065559'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 152, 'text': 'Autosomal-dominant familial amyotrophic lateral sclerosis (FALS) is associated with mutation in the gene that encodes Cu/Zn superoxide dismutase (SOD1).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10624810'}, {'offsetInBeginSection': 379, 'offsetInEndSection': 631, 'text': '(1996) (Morita, M., Aoki, M., Abe, K., Hasegawa, T., Sakuma, R., Onodera, Y., Ichikawa, N., Nishizawa, M. and Itoyama, Y., A novel two-base mutation in the Cu/Zn superoxide dismutase gene associated with familial amyotrophic lateral sclerosis in Japan.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10624810'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 152, 'text': 'Mutations of the SOD1 gene, which encodes the enzyme copper/zinc superoxide dismutase, are associated with familial amyotrophic lateral sclerosis (ALS).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9455977'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 102, 'text': 'Familial ALS is associated with mutations in all exons of SOD1: a novel mutation in exon 3 (Gly72Ser).', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9455977'}, {'offsetInBeginSection': 542, 'offsetInEndSection': 786, 'text': 'Here we report tight genetic linkage between FALS and a gene that encodes a cytosolic, Cu/Zn-binding superoxide dismutase (SOD1), a homodimeric metalloenzyme that catalyzes the dismutation of the toxic superoxide anion O2.- to O2 and H2O2 (ref.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8446170'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 188, 'text': 'Familial amyotrophic lateral sclerosis (FALS), a degenerative disorder of motor neurons, is associated with mutations in the Cu/Zn superoxide dismutase gene SOD1 in some affected families.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7951249'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 159, 'text': 'Eight of 38 patients (21%) with familial and 5 of 175 patients (3%) with sporadic amyotrophic lateral sclerosis (ALS) had missense mutations in the SOD-1 gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9506558'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 168, 'text': 'The SOD1 gene encoding the superoxide dismutase 1 (SOD1) protein is mutated in approximately 15% of familial amyotrophic lateral sclerosis (ALS) and 3% of sporadic ALS.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23954173'}, {'offsetInBeginSection': 212, 'offsetInEndSection': 344, 'text': 'About 20% of ALS families are associated with mutations in the gene for superoxide dismutase-1 (SOD1) encoded on chromosome 21q22.1.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11464949'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 142, 'text': 'The superoxide dismutase-1 (SOD1) gene is the first gene for familial amyotrophic lateral sclerosis (ALS) with autosomal dominant inheritance.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24611504'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 146, 'text': 'Dominant mutations in Cu/Zn-superoxide dismutase (SOD1) gene have been shown to cause a familial form of amyotrophic lateral sclerosis (SOD1-ALS).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27556028'}, {'offsetInBeginSection': 334, 'offsetInEndSection': 497, 'text': ' Mutations in the gene encoding Cu/Zn-superoxide dismutase (SOD-1) have been identified in cases of familial amyotrophic lateral sclerosis linked to chromosome 21.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7554432'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 145, 'text': 'Mutations in the Cu, Zn superoxide dismutase (SOD1) gene have been reported in some pedigrees with Familial Amyotrophic Lateral Sclerosis (FALS).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7917302'}, {'offsetInBeginSection': 138, 'offsetInEndSection': 278, 'text': ' Genetic mutations in Cu/Zn superoxide dismutase (SOD1) have been associated with one kind of familial amyotrophic lateral sclerosis (ALS1).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24838187'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 197, 'text': 'Accumulated evidence implies that mutations in the gene coding for Cu/Zn superoxide dismutase (SOD) are associated with the pathogenesis of the familial form of amyotrophic lateral sclerosis (ALS).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8981308'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 167, 'text': ' have reported point mutations in the cytosolic Cu/Zn superoxide dismutase (SOD 1) gene in some families with familial amyotrophic lateral sclerosis (ALS).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9263219'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 157, 'text': 'All mutations in the human gene for CuZn superoxide dismutase (CuZnSOD) reported to date are associated with the disease amyotrophic lateral sclerosis (ALS).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9062909'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 154, 'text': 'Mutations in the Cu/Zn superoxide dismutase 1 (SOD1) gene have been reported to cause adult-onset autosomal dominant amyotrophic lateral sclerosis (FALS).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18608106'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 274, 'text': 'We report the absence of superoxide dismutase (SOD-1) gene mutations in 30 patients with amyotrophic lateral sclerosis (ALS) including individuals with a confirmed family history of ALS (familial ALS/FALS), ALS with an unclear family history (UFALS) and sporadic ALS (SALS).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10202988'}, {'offsetInBeginSection': 860, 'offsetInEndSection': 1042, 'text': 'A predilection for disease onset in the lower limbs appears to be a distinguishing feature of familial ALS with SOD-1 mutations, and accords with findings in transgenic mouse models.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9065559'}, {'offsetInBeginSection': 645, 'offsetInEndSection': 747, 'text': 'is a new type of SOD1 mutation which may be associated with familial amyotrophic lateral sclerosis.CON', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15079798'}, {'offsetInBeginSection': 702, 'offsetInEndSection': 989, 'text': 'To delineate ALS associated with this particular CuZn-SOD mutation from ALS without mutations, we performed a detailed neurophysiological study of the corticomotoneuronal function using peristimulus time histograms (PSTHs) in eight ALS patients homozygous for the D90A CuZn-SOD mutation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10869061'}, {'offsetInBeginSection': 102, 'offsetInEndSection': 252, 'text': 'ateral sclerosis (ALS) cases, but no definite report of a mutation in a \"truly\" sporadic case of ALS has been proved. We present the first case of a n', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12402272'}, {'offsetInBeginSection': 208, 'offsetInEndSection': 301, 'text': 'It has been reported that mutations in the superoxide dismutase (SOD) 1 gene can lead to ALS.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31928838'}, {'offsetInBeginSection': 134, 'offsetInEndSection': 253, 'text': 'Mutations in the superoxide dismutase-1 (SOD1) gene have been found in 12%-23% of patients diagnosed with familial ALS.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20385392'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 167, 'text': 'INTRODUCTION: Mutations in the gene encoding the free radical scavenging enzyme CuZn-superoxide dismutase have been associated with amyotrophic lateral sclerosis (ALS)', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11675874'}, {'offsetInBeginSection': 121, 'offsetInEndSection': 262, 'text': 'Up to 20% of ALS cases are inherited (familial, fALS) and associated with mutations, usually of the superoxide dismutase type 1 (SOD-1) gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15679043'}]\n\n\n             'Can Amyotrophic Lateral Sclerosis (ALS) be associated with a mutation of the Super Oxide Dismutase 1 (SOD) gene?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Amyotrophic Lateral Sclerosis (ALS) can be associated with a mutation of the Super Oxide Dismutase 1 (SOD) gene, in a small percentage of cases."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 313, 'text': 'Enhancers are cis-regulatory elements in the genome that cooperate with promoters to control target gene transcription. Unlike promoters, enhancers are not necessarily adjacent to target genes and can exert their functions regardless of enhancer orientations, positions and spatial segregations from target genes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31993419'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 206, 'text': 'Enhancers are important cis-acting elements that can regulate gene transcription and cell fate alongside promoters. In fact, many human cancers and diseases are associated with the malfunction of enhancers.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35170113'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 127, 'text': 'Enhancers are cis-acting elements with many sites bound by transcription factors and activate transcription over long distance.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31944157'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 99, 'text': 'Enhancers are cis-acting elements that have the ability to increase the expression of target genes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30026829'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 376, 'text': 'Enhancers are cis-acting elements that play major roles in upregulating eukaryotic gene expression by providing binding sites for transcription factors and their complexes. Because enhancers are highly cell/tissue specific, lack common motifs, and are far from the target gene, the systematic and precise identification of enhancer regions in DNA sequences is a big challenge.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28239713'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 153, 'text': 'Enhancers are short noncoding segments of DNA (100-1000\\xa0bp) that control the temporal and spatial activity of genes in an orientation-independent manner.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29583027'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 115, 'text': 'Enhancers are important cis-acting elements that can regulate gene transcription and cell fate alongside promoters.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35170113'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 128, 'text': 'Transcriptional enhancers drive cell-type-specific gene expression patterns, and thus play key roles in development and disease.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30758829'}, {'offsetInBeginSection': 269, 'offsetInEndSection': 472, 'text': 'One consequence of the variability in the distance separating enhancers and their target promoters is that it is difficult to determine which elements are involved in the regulation of a particular gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29583027'}, {'offsetInBeginSection': 168, 'offsetInEndSection': 389, 'text': 'Enhancers can stimulate gene activity at great genomic distances from their targets, raising questions about how enhancers communicate with specific gene promoters and what molecular mechanisms underlie enhancer function.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32197056'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 118, 'text': 'Enhancers are DNA sequences that enable complex temporal and tissue-specific regulation of genes in higher eukaryotes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33431820'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 183, 'text': 'Transcriptional enhancers are DNA regulatory elements that are bound by transcription factors and act to positively regulate the expression of nearby or distally located target genes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27662874'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 87, 'text': 'Enhancers are DNA sequences that can activate gene transcription from remote positions.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16002789'}, {'offsetInBeginSection': 103, 'offsetInEndSection': 295, 'text': 'Transcriptional enhancers are a key group of such elements in eukaryotes and are DNA regions that form physical contacts with gene promoters and precisely orchestrate gene expression programs.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32664620'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 186, 'text': 'Transcriptional enhancers are short segments of genomic DNA (50 bp to 1 kb in length) that can work over long distances (\u22651 Mb) to regulate gene expression in specific cells and tissues.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27325706'}, {'offsetInBeginSection': 570, 'offsetInEndSection': 800, 'text': 'Enhancers likely play an important role in the activation of genes by functioning as a primary point of contact for transcriptional activators, and by making physical contact with gene promoters often by means of a chromatin loop.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23124110'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 140, 'text': 'Enhancers are DNA sequences composed of transcription factor binding sites that drive complex patterns of gene expression in space and time.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33037064'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 124, 'text': 'Enhancers are genomic cis-regulatory sequences that integrate spatiotemporal signals to control gene expression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21737276'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 311, 'text': 'Enhancers are a type of cis-acting DNA elements that enhance transcriptional activity of target genes. However, the uncertainty in the orientation and distance between enhancers and target genes could post significant difficulties in identifying the target genes and the regulatory mechanisms of the enhancers. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32952117'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 99, 'text': 'Enhancers regulate transcription of target genes, causing a change in expression level.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34879086'}]\n\n\n             'What are enhancers?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Enhancers are important cis-acting elements that can regulate gene transcription and cell fate alongside promoters by providing binding sites for transcription factors and their complexes. Unlike promoters, enhancers are not necessarily adjacent to target genes and can exert their functions regardless of enhancer orientations, positions and spatial segregations from target genes. In fact, because enhancers are highly cell/tissue specific, lack common motifs, and are far from the target gene, the systematic and precise identification of enhancer regions in DNA sequences is a big challenge. Despite that, many human cancers and diseases have been shown to be associated with the malfunction of enhancers."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 513, 'text': 'Drug delivery to the suprachoroidal space (SCS\u00ae) has become a clinical reality after the 2021 FDA approval of CLS-TA, a triamcinolone acetonide injectable suspension for suprachoroidal use (XIPERE\u00ae), administered via a microneedle-based device, the SCS Microinjector\u00ae. Suprachoroidal (SC) delivery facilitates targeting, compartmentalization, and durability of small molecule suspensions, thereby potentially addressing some of the efficacy, safety, and treatment burden limitations of current retinal therapies. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35868358'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 101, 'text': 'Suprachoroidal delivery enables targeting, localization and durability of small molecule suspensions.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35868358'}]\n\n\n             'What is the mode of delivery of the drug XIPERE?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "XIPERE is administered via a microneedle-based device, the SCS Microinjector, in the suprachoroidal space."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 210, 'offsetInEndSection': 398, 'text': ' Congenital muscular dystrophies (CMD) include dystroglycanopathies, merosin-deficient CMD, collagen VI-deficient CMD, SELENON-related rigid spine muscular dystrophy, and LMNA-related CMD.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35562158'}, {'offsetInBeginSection': 399, 'offsetInEndSection': 606, 'text': 'Childhood and adult-onset muscular dystrophies include dystrophinopathies, limb-girdle muscular dystrophies, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy, and myotonic dystrophy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35562158'}, {'offsetInBeginSection': 521, 'offsetInEndSection': 887, 'text': 'g more heavily on genetic findings. This article reviews the clinical and genetic features of the most common congenital muscular dystrophies including laminin subunit alpha 2 (LAMA2)-related (merosin deficient), collagen VI-related, and \u03b1-dystroglycan-related congenital muscular dystrophies and reviews the most common congenital myopathies including nemaline rod,', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31794464'}, {'offsetInBeginSection': 349, 'offsetInEndSection': 946, 'text': 'otypic correlates. This article discusses the epidemiology, clinical features, and diagnosis of these disorders.RECENT FINDINGS: Some important recent advancements include (1) a much greater understanding of the pathogenetic pathways underlying facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1; (2) the publication of diagnostic and treatment guidelines for Duchenne muscular dystrophy; and (3) further clarification of the many genetic muscle disorders presenting a limb-girdle pattern of weakness.SUMMARY: Muscular dystrophies are genetic, progressive, degenerative disorders', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24305447'}, {'offsetInBeginSection': 127, 'offsetInEndSection': 519, 'text': 'The most common are Duchenne muscular dystrophy and Becker muscular dystrophy, which result from mutations within the gene encoding dystrophin; myotonic dystrophy type 1, which results from an expanded trinucleotide repeat in the myotonic dystrophy protein kinase gene; and facioscapulohumeral dystrophy, which is associated with contractions in the subtelomeric region of human chromosome 1.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19555515'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 181, 'text': 'Myotonic dystrophy (DM) and facioscapulohumeral muscular dystrophy (FSHD) are the two most common adult muscular dystrophies and have progressive and often disabling manifestations.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27734165'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 145, 'text': 'Duchenne Muscular Dystrophy (DMD), the most common form of muscular dystrophies, is characterized by progressive and generalized muscle weakness.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36121164'}, {'offsetInBeginSection': 676, 'offsetInEndSection': 914, 'text': \"re included in this study. 102 (27.8%) out of the 366 patients were affected by Duchenne muscular dystrophy (DMD), 42 (11.5%) by congenital muscular dystrophy (CMD), 42 (11.5%) by Charcot Marie Tooth disease (CMT) and 24 (6.5%) by Becker'\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32095889'}, {'offsetInBeginSection': 558, 'offsetInEndSection': 924, 'text': 'his article reviews the clinical and genetic features of the most common congenital muscular dystrophies including laminin subunit alpha 2 (LAMA2)-related (merosin deficient), collagen VI-related, and \u03b1-dystroglycan-related congenital muscular dystrophies and reviews the most common congenital myopathies including nemaline rod, core, and centronuclear myopathies. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31794464'}, {'offsetInBeginSection': 548, 'offsetInEndSection': 628, 'text': 'EAS COVERED: Duchenne muscular dystrophy is the most common muscular dystrophy. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27340611'}, {'offsetInBeginSection': 333, 'offsetInEndSection': 420, 'text': 'Myotonic muscular dystrophy is the most common of the adult-onset muscular dystrophies.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/3728255'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 125, 'text': 'Myotonic dystrophy type 1 (DM1) and type 2 (DM2) represent the most frequent multisystemic muscular dystrophies in adulthood.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29770119'}, {'offsetInBeginSection': 856, 'offsetInEndSection': 1063, 'text': 'We discuss the involvement of the immune system in the most common muscular dystrophy, Duchenne muscular dystrophy, and show that the immune system influences muscle death and fibrosis as disease progresses.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30215857'}, {'offsetInBeginSection': 477, 'offsetInEndSection': 572, 'text': \"Duchenne's muscular dystrophy is the most common form of inherited muscle disease of childhood.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28427100'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 167, 'text': 'Duchenne muscular dystrophy (DMD), the most common muscular dystrophy, is a severe muscle disorder, causing muscle weakness, loss of independence, and premature death.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35089797'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 208, 'text': 'Duchenne muscular dystrophy (DMD), the most common and most severe form of all muscular dystrophies, leads to progressive muscle fiber necrosis, fibroblast proliferation, and growth of fibrous tissue and fat.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25955813'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 100, 'text': 'Duchenne and Becker muscular dystrophies are the most common clinical forms of muscular dystrophies.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24213305'}, {'offsetInBeginSection': 235, 'offsetInEndSection': 385, 'text': ' cause exercise intolerance to some degree. Here, we focus on Duchenne muscular dystrophy (DMD), the most common form of muscular dystrophy, as a para', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23733645'}, {'offsetInBeginSection': 62, 'offsetInEndSection': 212, 'text': 'ied by progressive skeletal muscle weakness and degeneration. Duchenne muscular dystrophy (DMD) is the most common and severe form of muscular dystrop', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27073590'}, {'offsetInBeginSection': 36, 'offsetInEndSection': 186, 'text': ' debilitating disorders caused by progressive muscle wasting. Duchenne muscular dystrophy (DMD) is the most common type. DMD is a well-characterized g', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35360042'}]\n\n\n             'What are the most common muscular dystrophies?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "The most common muscular dystrophies include the congenital muscular dystrophies (CMD)  and the childhood and adult-onset muscular dystrophies. The CMD include dystroglycanopathies, merosin-deficient CMD, collagen VI-deficient CMD, SELENON-related rigid spine muscular dystrophy, and LMNA-related CMD. Childhood and adult-onset muscular dystrophies include dystrophinopathies, limb-girdle muscular dystrophies, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy, and myotonic dystrophy."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 75, 'text': 'Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35748699'}, {'offsetInBeginSection': 286, 'offsetInEndSection': 464, 'text': 'This open-label, phase 2 trial investigated the safety and efficacy of fazirsiran, an RNA interference therapeutic, in patients with liver disease associated with AAT deficiency.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35748699'}, {'offsetInBeginSection': 1680, 'offsetInEndSection': 1870, 'text': 'CONCLUSIONS: In this small trial, fazirsiran was associated with a strong reduction of Z-AAT concentrations in the serum and liver and concurrent improvements in liver enzyme concentrations.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35748699'}]\n\n\n             'Which disease is targeted by Fazirsiran?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Fazirsiran is an RNA interference therapeutic that was developed for Liver Disease Associated with Alpha1-Antitrypsin Deficiency."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 203, 'offsetInEndSection': 365, 'text': 'We explored the direct impact of T1AM on cardiomyocytes with a focus on the regulation of the intracellular temperature and natriuretic peptide (NP) expression. A', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35882940'}, {'offsetInBeginSection': 1458, 'offsetInEndSection': 1705, 'text': 'In hypertrophic cardiomyocytes, after up-regulating the expression of miR-145, the relative messenger ribonucleic acid (mRNA) and protein expressions of atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) induced by PE decreased.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35693619'}, {'offsetInBeginSection': 401, 'offsetInEndSection': 579, 'text': 'Stretching of cultured cardiomyocytes up-regulates the expression of brain natriuretic peptide (BNP). Intracellular calcium-elevating agents such as the calcium ionophore A23187,', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12732268'}, {'offsetInBeginSection': 460, 'offsetInEndSection': 571, 'text': 'Atrial natriuretic peptide (ANP) and brain (or B-type) natriuretic peptide (BNP) are of myocardial cell origin.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14574050'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 220, 'text': 'Brain (or B-type) natriuretic peptide (BNP) is a cardiac hormone produced in the heart and an established biochemical marker for heart failure (HF) because the level in plasma increases in proportion to disease severity.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30135320'}, {'offsetInBeginSection': 572, 'offsetInEndSection': 768, 'text': 'BNP is released mainly from the left ventricle in response to volume overload and has become the first biochemical marker for the identification of individuals with congestive heart failure (CHF).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14574050'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 268, 'text': 'BACKGROUND: B-type or brain natriuretic peptide (BNP) is a novel natriuretic peptide secreted from the heart that forms a peptide family with A-type or atrial natriuretic peptide (ANP), and its plasma level has been shown to be increased in patients with congestive he', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8025996'}, {'offsetInBeginSection': 174, 'offsetInEndSection': 335, 'text': 'Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are of myocardial cell origin and C-type natriuretic peptide (CNP) is of endothelial origin.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10519161'}, {'offsetInBeginSection': 496, 'offsetInEndSection': 620, 'text': ' ANP and BNP are elucidated to be the cardiac hormone mainly secreted from the atrium, and from the ventricle, respectively.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8100590'}, {'offsetInBeginSection': 659, 'offsetInEndSection': 830, 'text': ' In contrast to atrial natriuretic peptides (ANP/NT-proANP), which originate mainly from atrial tissue, BNP related peptides are produced mainly from ventricular myocytes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14987573'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 72, 'text': 'Atrial and brain natriuretic peptides: Hormones secreted from the heart.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29859763'}, {'offsetInBeginSection': 459, 'offsetInEndSection': 571, 'text': ' Atrial natriuretic peptide (ANP) and brain (or B-type) natriuretic peptide (BNP) are of myocardial cell origin.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14574050'}, {'offsetInBeginSection': 145, 'offsetInEndSection': 309, 'text': 'Atrial natriuretic peptide (ANP) and brain (or B-type) natriuretic peptide (BNP) are secreted from cardiomyocytes in response to atrial or ventricular wall stretch.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15478621'}, {'offsetInBeginSection': 98, 'offsetInEndSection': 248, 'text': 'riuretic peptide (BNP) are primarily produced by, and secreted from, heart tissue. They maintain cardiovascular homeostasis by binding to natriuretic ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30120963'}, {'offsetInBeginSection': 744, 'offsetInEndSection': 894, 'text': 'rom atrial tissue, BNP related peptides are produced mainly from ventricular myocytes. Ventricular (NT-pro)BNP production is strongly upregulated in c', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14987573'}, {'offsetInBeginSection': 121, 'offsetInEndSection': 271, 'text': ') and brain natriuretic peptide (BNP) are delivered predominantly by the heart. Two C-type natriuretic peptides (CNPs) are paracrine messengers, notab', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29978892'}, {'offsetInBeginSection': 289, 'offsetInEndSection': 439, 'text': 'tic and renin-angiotensin systems. Although originally isolated from porcine brain, the BNP gene is expressed in a specific manner in cardiac myocytes', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11558673'}, {'offsetInBeginSection': 88, 'offsetInEndSection': 366, 'text': 'Unlike other members, i.e., atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), which are cardiac hormones secreted from the atrium and ventricle of the heart, respectively, CNP is regarded as an autocrine/paracrine regulator with broad expression in the body.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35741432'}, {'offsetInBeginSection': 111, 'offsetInEndSection': 418, 'text': 'However, there is an accumulating evidence that B-type natriuretic peptide (BNP) and its N-terminal fragment (NT-proBNP) may originate from right ventricle and their concentrations are elevated in patients with acute pulmonary embolism (APE) especially when resulting in right ventricular dysfunction (RVD).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18706401'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 135, 'text': 'B-type natriuretic peptide (BNP) is a hormone mainly secreted by cardiac ventricle myocytes and which is increased in cardiac diseases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12084525'}, {'offsetInBeginSection': 191, 'offsetInEndSection': 341, 'text': 'vasoconstrictive molecules. The major source of plasma BNP is the cardiac ventricles. Elevated plasma BNP concentrations correlate with increased left', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16689366'}, {'offsetInBeginSection': 484, 'offsetInEndSection': 634, 'text': 'de (ANP) and brain (or B-type) natriuretic peptide (BNP) are of myocardial cell origin. BNP is released mainly from the left ventricle in response to ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14574050'}]\n\n\n             'Where does Brain (or B type) Natriuretic Protein, BNP usually originate from?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "cardiomyocyte stress up-regulates the expression of brain natriuretic peptide (BNP)."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 9, 'offsetInEndSection': 317, 'text': 'Casirivimab/imdevimab (REGN-COV), a cocktail of neutralizing antibodies against the receptor-binding domain of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, was shown to be an effective treatment and post-exposure prophylaxis measure for coronavirus disease 2019 (COVID-19).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35181864'}, {'offsetInBeginSection': 1248, 'offsetInEndSection': 1385, 'text': 'The high titer of IgGSP supports the clinical benefit of therapeutic and prophylactic use of REGN-COV from the serological point of view.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35181864'}, {'offsetInBeginSection': 503, 'offsetInEndSection': 636, 'text': 'We collected serological data of patients with COVID-19 who were treated with REGN-COV 1200\\xa0mg (casirivimab 600\\xa0mg/imdevimab 600\\xa0mg).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35181864'}, {'offsetInBeginSection': 6283, 'offsetInEndSection': 6437, 'text': 'Based on the current very low- to low-certainty evidence, we are uncertain about the efficacy and safety of ivermectin used to treat or prevent COVID-19. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34318930'}, {'offsetInBeginSection': 6587, 'offsetInEndSection': 6747, 'text': 'Overall, the reliable evidence available does not support the use ivermectin for treatment or prevention of COVID-19 outside of well-designed randomized trials.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34318930'}, {'offsetInBeginSection': 337, 'offsetInEndSection': 471, 'text': 'Currently, evidence on efficacy and safety of ivermectin for prevention of SARS-CoV-2 infection and COVID-19 treatment is conflicting.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34318930'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 182, 'text': 'We report primary results of a phase 3 trial of AZD7442 (tixagevimab/cilgavimab) for post-exposure prophylaxis to prevent symptomatic coronavirus disease 2019 (COVID-19).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36411267'}, {'offsetInBeginSection': 1503, 'offsetInEndSection': 1637, 'text': 'This study did not meet the primary efficacy endpoint of post-exposure prevention of symptomatic COVID-19 with AZD7442 versus placebo.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36411267'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 110, 'text': 'This systematic review was performed to determine the population that benefited from prophylactic ivermectin. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36399336'}, {'offsetInBeginSection': 968, 'offsetInEndSection': 1444, 'text': 'Ivermectin was associated with a lower risk of COVID-19 (OR, 0.22; 95% CI, 0.12-0.40) in the pre-exposure population, whereas no protective effect was observed in the post-exposure population (OR, 0.39; 95% CI, 0.09-1.67). In summary, prophylactic ivermectin did not prevent COVID-19 in the post-exposure population. Although the protective effect of ivermectin was shown in the overall and pre-exposure populations, the results were unreliable owing to poor-quality evidence.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36399336'}, {'offsetInBeginSection': 2052, 'offsetInEndSection': 2251, 'text': 'This rigorous randomized controlled trial among persons with recent exposure excluded a clinically meaningful effect of hydroxychloroquine as postexposure prophylaxis to prevent SARS-CoV-2 infection.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33284679'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 203, 'text': 'Effective prevention against coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently limited to nonpharmaceutical strategies.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33284679'}, {'offsetInBeginSection': 373, 'offsetInEndSection': 453, 'text': 'To test hydroxychloroquine as postexposure prophylaxis for SARS-CoV-2 infection.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33284679'}, {'offsetInBeginSection': 11, 'offsetInEndSection': 383, 'text': 'Chloroquine or hydroxychloroquine has demonstrated no effect on the treatment of hospitalized COVID-19 patients. This study aimed to answer questions related to the use of hydroxychloroquine for pre-exposure or post-exposure prophylaxis of SARS-CoV-2 infection and in the treatment of patients with mild COVID-19 in terms of hospitalization, adverse events, and mortality.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34669839'}, {'offsetInBeginSection': 1382, 'offsetInEndSection': 1515, 'text': 'The use of hydroxychloroquine for prophylaxis of SARS-CoV-2 infection or treatment of patients with mild COVID-19 is not recommended.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34669839'}, {'offsetInBeginSection': 774, 'offsetInEndSection': 946, 'text': 'No statistically significant differences were found between the hydroxychloroquine and control groups in terms of pre- or post-exposure prophylaxis of SARS-CoV-2 infection.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34669839'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 296, 'text': 'Rapidly emerging SARS-CoV-2 variants jeopardize antibody-based countermeasures. Although cell culture experiments have demonstrated a loss of potency of several anti-spike neutralizing antibodies against variant strains of SARS-CoV-21-3, the in vivo importance of these results remains uncertain.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34153975'}, {'offsetInBeginSection': 1302, 'offsetInEndSection': 1476, 'text': 'Therefore, many-but not all-of the antibody products with Emergency Use Authorization should retain substantial efficacy against the prevailing variant strains of SARS-CoV-2.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34153975'}, {'offsetInBeginSection': 548, 'offsetInEndSection': 950, 'text': 'Although some individual mAbs showed reduced or abrogated neutralizing activity in cell culture against B.1.351, B.1.1.28, B.1.617.1 and B.1.526 viruses with mutations at residue E484 of the spike protein, low prophylactic doses of mAb combinations protected against infection by many variants in K18-hACE2 transgenic mice, 129S2 immunocompetent mice and hamsters, without the emergence of resistance. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34153975'}, {'offsetInBeginSection': 183, 'offsetInEndSection': 375, 'text': 'Hydroxychloroquine (HCQ) has been tried against COVID-19 owing to its in vitro virucidal action against SARS-CoV-2, but the role of HCQ as post-exposure prophylaxis (PEP) remains inconclusive.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33166694'}]\n\n\n             'Are any medications available to prevent COVID-19 following exposure?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Currently, no. Certain monoclonal antibodies had previously been demonstrated to prevent SARS-CoV-2 infection after exposure, but they mostly lack activity against circulating SARS-CoV-2 variants.\n\nOther agents (e.g., Hydroxychloroquine, Ivermectin, Tixagevimab/Cilgavimab) have not been shown to be effective."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 727, 'offsetInEndSection': 959, 'text': 'Forced overexpression of HO-1, pharmacological activation of HO-1 with the agonists RTA-408 (omaveloxolone, an FDA-approved drug) and RTA-402 repressed cell death, and treatment with HO-1 antagonist SnPP exacerbated the cell death. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33971103'}]\n\n\n             'Has RTA 408 received FDA approval?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Yes, RTA 408 is FDA approved."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 136, 'offsetInEndSection': 266, 'text': 'DM type 2 (DM2) is considered less severe than DM type 1 (DM1), but it is unknown whether this applies uniformly to all features. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35778789'}, {'offsetInBeginSection': 182, 'offsetInEndSection': 393, 'text': 'There are two genetically distinct types of myotonic dystrophy: myotonic dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2), both dominantly inherited with significant overlap in clinical manifestations.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35205411'}, {'offsetInBeginSection': 109, 'offsetInEndSection': 330, 'text': 'The unstable repeat expansions of (CTG)n or (CCTG)n in the DMPK and ZNF9 genes cause the two known subtypes of myotonic dystrophy: (i) myotonic dystrophy type 1 (DM1) and (ii) myotonic dystrophy type 2 (DM2) respectively.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23570879'}, {'offsetInBeginSection': 128, 'offsetInEndSection': 321, 'text': 'Congenital myotonic dystrophy (CDM1) and myotonic dystrophy of type 1 (DM1) or of type 2 (DM2) are caused by the expression of mutant RNAs containing expanded CUG or CCUG repeats, respectively.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21623381'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 125, 'text': 'Myotonic dystrophy type 1 (DM1) and type 2 (DM2) represent the most frequent multisystemic muscular dystrophies in adulthood.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29770119'}, {'offsetInBeginSection': 200, 'offsetInEndSection': 440, 'text': 'To date, two types of myotonic dystrophy, type 1 (DM1) and type 2 (DM2), are known to exist; both are autosomal dominant disorders caused by expansion of an untranslated short tandem repeat DNA sequence (CTG)(n) and (CCTG)(n), respectively.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21496635'}, {'offsetInBeginSection': 435, 'offsetInEndSection': 609, 'text': 'Myotonic dystrophies MD1 and MD2 are multisystem diseases with numerous symptoms and high interfamily variability, resulting from the fact that different organs are affected.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20514907'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 243, 'text': \"There are currently two clinically and molecularly defined forms of myotonic dystrophy: (1) myotonic dystrophy type 1 (DM1), also known as 'Steinert's disease'; and (2) myotonic dystrophy type 2 (DM2), also known as proximal myotonic myopathy.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20176601'}, {'offsetInBeginSection': 531, 'offsetInEndSection': 878, 'text': 'Phenotypes of DM1 and DM2 are similar but there are some important differences, most conspicuously in the severity of the disease (including the presence or absence of the congenital form), muscles primarily affected (distal versus proximal), involved muscle fiber types (type 1 versus type 2 fibers), and some associated multisystemic phenotypes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21496635'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 139, 'text': 'Myotonic dystrophy types 1 (DM1) and 2 (DM2) are autosomal dominant, microsatellite repeat expansion disorders that affect muscle function.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27727437'}, {'offsetInBeginSection': 123, 'offsetInEndSection': 480, 'text': \"There are two forms identified: myotonic dystrophy type 1 (DM1), caused by an expansion of a CTG repeat in the 3' untranslated region of the myotonin-protein kinase (DMPK) gene on chromosome 19, and myotonic dystrophy type 2 (DM2), caused by an expansion of a CCTG repeat in intron 1 of the cellular nucleic acid-binding protein (CNBP) gene on chromosome 3.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19360700'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 99, 'text': 'Myotonic dystrophy type 1 (DM1) and type II (DM2) are dominantly inherited multisystemic disorders.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19632331'}, {'offsetInBeginSection': 512, 'offsetInEndSection': 748, 'text': ' For the enormous understanding of the molecular pathogenesis of myotonic dystrophy type 1 and myotonic dystrophy type 2, these diseases are now called \"spliceopathies\" and are mediated by a primary disorder of RNA rather than proteins.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33458578'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 300, 'text': \"This review demonstrates genetic and phenotypic heterogeneity in all of the multisystemic myotonic disorders collectively called 'myotonic dystrophies' according to the new nomenclature: myotonic dystrophy type 1, myotonic dystrophy type 2, proximal myotonic myopathy and proximal myotonic dystrophy.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11073357'}, {'offsetInBeginSection': 65, 'offsetInEndSection': 215, 'text': 'progress in elucidating the disease mechanism in myotonic dystrophy type 1 and type 2.RECENT FINDINGS: Research on myotonic dystrophy has led to the r', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17885447'}, {'offsetInBeginSection': 203, 'offsetInEndSection': 326, 'text': 'The 2 major genetic forms of myotonic dystrophy, type 1 and type 2, differ in genetic etiology yet share clinical features.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32067592'}, {'offsetInBeginSection': 901, 'offsetInEndSection': 1075, 'text': 'CENT FINDINGS: An active approach to screening and management of myotonic dystrophies type 1 and type 2 requires a multidisciplinary medical, rehabilitative and social team. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25121518'}, {'offsetInBeginSection': 30, 'offsetInEndSection': 180, 'text': 'onest adult muscular dystrophy. Myotonic dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2) are often discussed jointly, and although they sha', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24435591'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 148, 'text': 'PURPOSE OF REVIEW: Myotonic dystrophies type 1 and type 2 are progressive multisystem genetic disorders with clinical and genetic features in common', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25121518'}, {'offsetInBeginSection': 149, 'offsetInEndSection': 302, 'text': 'Two genetically distinct forms of DM are identified - type 1 (DM1), the classic form first described by Steinert, and type 2 (DM2), identified by Ricker.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20625963'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 149, 'text': 'Myotonic dystrophy types 1 and 2 are a group of complex genetic disorders resulting from the expansion of (CTG)n nucleotide repeats in the DMPK gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35243403'}, {'offsetInBeginSection': 1613, 'offsetInEndSection': 1763, 'text': 'ers of subjects, sometimes even not separating Myotonic Dystrophy Type 1 from Type 2. But this heterogeneity may also support the current point of vie', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30186217'}, {'offsetInBeginSection': 1081, 'offsetInEndSection': 1241, 'text': 'Despite clinical and genetic similarities, myotonic dystrophy type 1 and type 2 are distinct disorders requiring different diagnostic and management strategies.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22995693'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 144, 'text': 'BACKGROUND AND OBJECTIVE: Myotonic dystrophy types 1 and 2 are progressive multisystem genetic disorders whose core clinical feature is myotonia', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34840883'}]\n\n\n             'Which are the types of myotonic dystrophy?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "There are two types of myotonic dystrophy: myotonic dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2)."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 583, 'offsetInEndSection': 854, 'text': 'Recently, a new dual anti-PD-1 (Nivolumab) and anti-LAG-3 (Relatimab) treatment developed by Bristol Myers Squibb (Opdualag), was approved by the Food and Drug Administration (FDA) as the first LAG-3 blocking antibody combination for unresectable or metastatic melanoma. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35954196'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 218, 'text': 'Nivolumab plus relatlimab (nivolumab and relatlimab-rmbw; Opdualag\u2122) is a fixed-dose, combination immunotherapy treatment being developed by Bristol Myers Squibb for the treatment of multiple types of advanced cancers.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35543970'}, {'offsetInBeginSection': 201, 'offsetInEndSection': 377, 'text': 'DATA SOURCES: A search of PubMed conducted from August 2019 to August 2022 with the search terms Opdualag, nivolumab AND relatlimab, and BMS-986016 resulted in 14 publications.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36268952'}]\n\n\n             'What are the active components of Opdualag?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Opdualag is a new dual anti-PD-1 (Nivolumab) and anti-LAG-3 (Relatimab) treatment approved as the first LAG-3 blocking antibody combination for unresectable or metastatic melanoma."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 184, 'offsetInEndSection': 402, 'text': \" This retrospective case series included patients with PCG who underwent trabeculotomy using an illuminated microcatheter with the intent of catheterizing the full circumference of Schlemm's canal in a single procedure\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33488009'}, {'offsetInBeginSection': 9, 'offsetInEndSection': 195, 'text': \"To study the effect of 3 Schlemm's canal (SC) microinvasive glaucoma surgery (MIGS) devices on outflow facility.DESIGN: Paired comparisons, randomized design, baseline-controlled study.P\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32672594'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 85, 'text': \"Outflow Facility Effects of 3 Schlemm's Canal Microinvasive Glaucoma Surgery Devices.\", 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32672594'}, {'offsetInBeginSection': 146, 'offsetInEndSection': 282, 'text': \"Previously, blood reflux from Schlemm's canal (SC) after long-standing glaucoma surgery was reported in eyes treated with excisional LOT\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33613251'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 241, 'text': \"AIM: to comparatively evaluate the hypotensive effect of minimally invasive (type 1) and basic (type 2) subscleral removing of the external wall of Schlemm's canal with subsequent laser trabeculopuncture in patients with open-angle glaucoma \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28291197'}, {'offsetInBeginSection': 139, 'offsetInEndSection': 397, 'text': \"Schlemm's canal (SC) is a large, lymphatic-like vessel in the anterior chamber of the eye, which is essential for aqueous humor drainage required to maintain intraocular pressure and is sensitive to defects in blood and lymphatic vascular signaling pathways.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30242758'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 161, 'text': \"Schlemm's canal (SC) is a specialized vascular structure in the eye that functions to drain aqueous humor from the intraocular chamber into systemic circulation.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25061877'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 166, 'text': \"Schlemm's canal (SC) is a unique vascular structure that functions to maintain fluid homeostasis by draining aqueous humor from the eye into the systemic circulation.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25061871'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 409, 'text': \"We have tried to answer the question of whether the endothelium of Schlemm's canal is derived from and retains properties of blood vessels by studying: (1) the development of Schlemm's canal in human fetal eyes; (2) the existence of Weibel-Palade bodies in human neonatal, adult human and adult monkey eyes; and (3) the presence of blood coagulation Factor VIII-related antigen in adult human and monkey eyes.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1426078'}, {'offsetInBeginSection': 1450, 'offsetInEndSection': 1628, 'text': \"Our results indicate that the endothelium of Schlemm's canal is derived from a vascular origin and that even in the adult eye it retains some of the properties of a blood vessel.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1426078'}, {'offsetInBeginSection': 1258, 'offsetInEndSection': 1449, 'text': \"(3) Blood coagulation Factor VIII-related antigen was detected in the endothelium of the collector channels and Schlemm's canal, as well as in the blood vessels of the other parts of the eye.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1426078'}, {'offsetInBeginSection': 454, 'offsetInEndSection': 579, 'text': \" Injecting fluorescein directly in Schlemm's canal proves that in cadaver eyes without glaucoma the lumen is open all around.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/729457'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 182, 'text': \"Differences in parameters of ciliary body and Schlemm's canal in different meridians of the eyeball has been described using histotopographic methods on 20 eyeballs of human corpses.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10581564'}]\n\n\n             'Where in the body would  Schlemm's canal be found'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Schlemm's canal  is in the eye"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 14, 'offsetInEndSection': 322, 'text': 'A precise estimate of the frequency and severity of SARS-CoV-2 reinfections would be critical to optimize restriction and vaccination policies for the hundreds of millions previously infected subjects. We performed a meta-analysis to evaluate the risk of reinfection and COVID-19 following primary infection.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35904405'}, {'offsetInBeginSection': 921, 'offsetInEndSection': 1185, 'text': 'Reinfection rates were still 0.66% after \u226512\\u2009months from first infection, and the risk was substantially lower among vaccinated subjects (0.32% vs. 0.74% for unvaccinated individuals). During the first 3\\xa0months of Omicron wave, the reinfection rates reached 3.31%.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35904405'}, {'offsetInBeginSection': 1357, 'offsetInEndSection': 1683, 'text': 'A strong natural immunity follows the primary infection and may last for more than one year, suggesting that the risk and health care needs of recovered subjects might be limited. Although the reinfection rates considerably increased during the Omicron wave, the risk of a secondary severe or lethal disease remained very low.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35904405'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 302, 'text': 'Despite over 140\\xa0million SARS-CoV-2 infections worldwide since the beginning of the pandemic, relatively few confirmed cases of SARS-CoV-2 reinfection have been reported. While immunity from SARS-CoV-2 infection is probable, at least in the short term, few studies have quantified the reinfection risk.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34043841'}, {'offsetInBeginSection': 1006, 'offsetInEndSection': 1627, 'text': 'Reinfection was an uncommon event (absolute rate 0%-1.1%), with no study reporting an increase in the risk of reinfection over time. Only one study estimated the population-level risk of reinfection based on whole genome sequencing in a subset of patients; the estimated risk was low (0.1% [95% CI: 0.08-0.11%]) with no evidence of waning immunity for up to 7\\xa0months following primary infection. These data suggest that naturally acquired SARS-CoV-2 immunity does not wane for at least 10\\xa0months post-infection. However, the applicability of these studies to new variants or to vaccine-induced immunity remains uncertain.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34043841'}, {'offsetInBeginSection': 227, 'offsetInEndSection': 339, 'text': 'The risk of reinfection increased almost 18-fold following emergence of the Omicron variant compared with Delta.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35593164'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 120, 'text': 'Better understanding of the protective duration of prior SARS-CoV-2 infection against reinfection is needed.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35233580'}, {'offsetInBeginSection': 2153, 'offsetInEndSection': 2375, 'text': 'This large US population-based study demonstrates that SARS-CoV-2 reinfection is uncommon among individuals with laboratory evidence of a previous infection. Protection from SARS-CoV-2 reinfection is stable up to one year.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35233580'}, {'offsetInBeginSection': 1807, 'offsetInEndSection': 1926, 'text': 'The duration of protection against reinfection was stable over the median 5 months and up to 1-year follow-up interval.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35233580'}, {'offsetInBeginSection': 2800, 'offsetInEndSection': 3066, 'text': 'Among >22 million individuals tested February 2020 through April 2021, the relative risk of reinfection among those with prior infection was 87% lower than the risk of infection among individuals without prior infection. This protection was durable for up to a year.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35233580'}, {'offsetInBeginSection': 275, 'offsetInEndSection': 695, 'text': 'The aim of this study was a comparison of antibody level after infection caused by Delta and Omicron variants. The study included 203 persons who underwent mild COVID-19 despite two doses of vaccine. The obtained results indicate that a significantly lower titer was observed in patients with the Omicron variant infection. Therefore, these patients may be at risk of reinfection with new strains of the Omicron variant.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36298593'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 199, 'text': 'SARS-CoV-2 infection does not confer long immunity. However, studies suggest that prior infection is associated with lower risk of reinfection and milder outcomes of recurrent infections.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36275814'}, {'offsetInBeginSection': 2115, 'offsetInEndSection': 2343, 'text': 'Reinfection with the SARS-CoV-2 Delta variant resulted in fewer hospitalizations compared to the primary Delta infection, suggesting that primary infection may, to some extent, produce at least short lasting protective immunity.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36275814'}, {'offsetInBeginSection': 1386, 'offsetInEndSection': 1705, 'text': 'The vast majority of anti-spike IgG positive individuals remain anti-spike IgG positive for at least 8 months regardless of initial COVID-19 disease severity. The presence of anti-spike IgG antibodies is associated with a substantially reduced risk of reinfection up to 9 months following asymptomatic to mild COVID-19.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34459525'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 266, 'text': 'Emerging data support detectable immune responses for months after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and vaccination, but it is not yet established to what degree and for how long protection against reinfection lasts.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34459525'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 107, 'text': 'Comparative genomic analysis demonstrates that true reinfection following SARS-CoV-2 infection is possible.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35262003'}, {'offsetInBeginSection': 758, 'offsetInEndSection': 974, 'text': 'Our findings indicate that reinfection results in restricted SARS-CoV-2 replication despite substantial levels of humoral immunity, denoting the potential for transmission through reinfected asymptomatic individuals.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35263638'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 188, 'text': 'Prior to the emergence of antigenically distinct SARS-CoV-2 variants, reinfections were reported infrequently - presumably due to the generation of durable and protective immune responses.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33791729'}, {'offsetInBeginSection': 90, 'offsetInEndSection': 212, 'text': ' It is currently unclear whether the previous infection with SARS-CoV-2 provides protection against reinfection with VOCs.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34120579'}, {'offsetInBeginSection': 1257, 'offsetInEndSection': 1402, 'text': 'Our case supports the hypothesis that SARS-CoV-2 reinfection may occur once antibody titers decrease or following the emergence of a new variant.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35935779'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 213, 'text': 'Reinfection with SARS-CoV-2 has been well documented, yet little is known about the degree of protection a previous infection provides against reinfection, especially against Variants of Concern (VOC).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35935779'}, {'offsetInBeginSection': 1286, 'offsetInEndSection': 1506, 'text': 'Reinfection with SARS-CoV-2 is a strong possibility. This case raises concerns that asymptomatic infections may not provide long-term protective immunity to all patients, which could make them susceptible to reinfection.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33257644'}, {'offsetInBeginSection': 1149, 'offsetInEndSection': 1319, 'text': 'The rate of reinfection with SARS-CoV-2 is relatively low. The protection against SARS-CoV-2 after natural infection is comparable to that estimated for vaccine efficacy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34908003'}, {'offsetInBeginSection': 1497, 'offsetInEndSection': 1669, 'text': 'SARS-CoV-2 reinfection can occur but is a rare phenomenon suggestive of protective immunity against reinfection that lasts for at least a few months post primary infection.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33315061'}, {'offsetInBeginSection': 1593, 'offsetInEndSection': 1751, 'text': 'Reinfection by SARS-CoV-2 under endemic conditions would likely occur between 3 months and 5\u00b71 years after peak antibody response, with a median of 16 months.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34632431'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 318, 'text': 'It is currently unclear whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection will remain a rare event, only occurring in individuals who fail to mount an effective immune response, or whether it will occur more frequently when humoral immunity wanes following primary infection.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33315049'}]\n\n\n             'Can reinfection occur after SARS-CoV-2 infection?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Protective and detectable immune responses are induced after SARS-CoV-2 infection but it is not yet established to what degree and for how long protection against reinfection lasts. Evidence suggests that some of these responses can be detected for at least a year following infection.\n\nThe short-term risk of reinfection (e.g., within the first several months after initial infection) is low. Several studies estimated the risk of reinfection to be less than 1 percent in the subsequent 5-8 months following initial infection. The risk of reinfection may be greater with the Omicron variant."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 155, 'text': \"Friedreich's Ataxia (FRDA) is an autosomal recessive neurodegenerative disorder, affecting dorsal root ganglia (DRG), cerebellar dentate nuclei and heart. \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30065630'}]\n\n\n             'What is the mode of inheritance of Friedreich\u2019s ataxia?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Friedreich's Ataxia (FRDA) is an autosomal recessive neurodegenerative disorder."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 263, 'text': 'Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are X-linked recessive disorders caused by mutations of the DMD gene located at Xp21. In DMD patients, dystrophin is virtually absent; whereas BMD patients have 10% to 40% of the normal amount.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19461958'}, {'offsetInBeginSection': 538, 'offsetInEndSection': 708, 'text': 'Clinical data confirm some well known differences between Duchenne and Becker muscular dystrophy concerning the age of onset, severity of disease and rate of progression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10422002'}, {'offsetInBeginSection': 768, 'offsetInEndSection': 918, 'text': 'cular dystrophy, where there is absence of dystrophin in Duchenne muscular dystrophy and reduced amounts in Becker muscular dystrophy. Not all of the ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8894415'}, {'offsetInBeginSection': 358, 'offsetInEndSection': 471, 'text': 'Ribosome concentration was normal in Duchenne and facioscapulohumeral and decreased in Becker muscular dystrophy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/164552'}]\n\n\n             'What is the difference between Duchenne muscular Dystrophy and Becker muscular dystrophy?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "DMD patients do not produce dystrophin whereas BMD patients produce 10-40% of the normal amount of dystrophin."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 65, 'text': 'Lance Adams Syndrome After Hypoxic Cardiac Arrest: A Case Report.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35952340'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 131, 'text': 'Lance-Adams syndrome (chronic post-hypoxic myoclonus) is a rare syndrome occurring in patients after cardiopulmonary resuscitation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35952340'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 193, 'text': 'Hypoxic myoclonus, also known as Lance Adams syndrome, is a rare syndrome that results from the serious brain damage caused by cerebral hypoxia that often follows cardiopulmonary resuscitation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35220777'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 79, 'text': 'Lance Adams syndrome is the term used to describe late post-hypoxic myoclonus. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36213707'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 254, 'text': 'Lance-Adams syndrome (LAS) is a rare complication of successful cardiopulmonary resuscitation, often accompanied by action myoclonus. Myoclonus may occur as generalized, focal, or multifocal movements and can include the face, trunk, and/or extremities. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35530854'}]\n\n\n             'What is Lance-Adams syndrome?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Lance-Adams syndrome is a rare complication of successful cardiopulmonary resuscitation, often accompanied by action myoclonus. Myoclonus may occur as generalized, focal, or multifocal movements and can include the face, trunk, and/or extremities."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 96, 'text': 'Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34987744'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 348, 'text': 'Mitapivat (AG-348) is a novel, first-in-class oral small molecule allosteric activator of the pyruvate kinase enzyme. Mitapivat has been shown to significantly upregulate both wild-type and numerous mutant forms of erythrocyte pyruvate kinase (PKR), increasing adenosine triphosphate (ATP) production and reducing levels of 2,3-diphosphoglycerate. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34987744'}, {'offsetInBeginSection': 112, 'offsetInEndSection': 202, 'text': 'Mitapivat is an oral, small-molecule allosteric activator of pyruvate kinase in red cells.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31483964'}, {'offsetInBeginSection': 142, 'offsetInEndSection': 294, 'text': 'mitapivat, an oral, first-in-class activator of erythrocyte pyruvate kinase, increased the hemoglobin level in patients with pyruvate kinase deficiency.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35417638'}, {'offsetInBeginSection': 118, 'offsetInEndSection': 347, 'text': 'Mitapivat has been shown to significantly upregulate both wild-type and numerous mutant forms of erythrocyte pyruvate kinase (PKR), increasing adenosine triphosphate (ATP) production and reducing levels of 2,3-diphosphoglycerate.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34987744'}, {'offsetInBeginSection': 104, 'offsetInEndSection': 332, 'text': 'In activating red blood cell pyruvate kinase and glycolysis, mitapivat (AG-348) increases adenosine triphosphate (ATP) levels and decreases the 2,3-diphosphoglycerate (2,3-DPG) concentration, an upstream precursor in glycolysis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35576529'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 117, 'text': 'Mitapivat (AG-348) is a novel, first-in-class oral small molecule allosteric activator of the pyruvate kinase enzyme.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34987744'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 236, 'text': 'BACKGROUND: Mitapivat, an oral activator of pyruvate kinase (PK) in red blood cells (RBCs), has shown significant improvements in haemoglobin and haemolysis among patients with pyruvate kinase deficiency who were not receiving regular t', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35988546'}, {'offsetInBeginSection': 110, 'offsetInEndSection': 490, 'text': 'tic anemia. In a phase 2 study, mitapivat, an oral, first-in-class activator of erythrocyte pyruvate kinase, increased the hemoglobin level in patients with pyruvate kinase deficiency.METHODS: In this global, phase 3, randomized, placebo-controlled trial, we evaluated the efficacy and safety of mitapivat in adults with pyruvate kinase deficiency who were not receiving regular r', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35417638'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 175, 'text': 'Kuo and colleagues1 evaluated the safety and efficacy of mitapivat, an oral pyruvate kinase activator, in\\xa0adults with non-transfusion-dependent \u03b1-thalassemia or \u03b2-thalassemia.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36260990'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 186, 'text': 'Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent \u03b1-thalassaemia or \u03b2-thalassaemia: an open-label, multicentre, phase 2 study.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35964609'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 180, 'text': 'AG-348 (Mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31974203'}, {'offsetInBeginSection': 853, 'offsetInEndSection': 962, 'text': 'Mitapivat, a pyruvate kinase activator, represents a unique mechanism to mitigate ineffective erythropoiesis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34889443'}, {'offsetInBeginSection': 258, 'offsetInEndSection': 477, 'text': ' We aimed to investigate the safety and efficacy of mitapivat (Agios Pharmaceuticals, Cambridge, MA, USA), a pyruvate kinase activator, in adults with non-transfusion-dependent (NTD) \u03b1-thalassaemia or NTD \u03b2-thalassaemia', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35964609'}, {'offsetInBeginSection': 754, 'offsetInEndSection': 899, 'text': 'RT OPINION: Mitapivat is a first-in-class allosteric activator of pyruvate kinase and the first FDA-approved disease directed therapy for PKD. It', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36124781'}, {'offsetInBeginSection': 121, 'offsetInEndSection': 293, 'text': ' In a phase 2 study, mitapivat, an oral, first-in-class activator of erythrocyte pyruvate kinase, increased the hemoglobin level in patients with pyruvate kinase deficiency', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35417638'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 247, 'text': 'BACKGROUND: Mitapivat, an oral activator of pyruvate kinase (PK) in red blood cells (RBCs), has shown significant improvements in haemoglobin and haemolysis among patients with pyruvate kinase deficiency who were not receiving regular transfusions', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35988546'}]\n\n\n             'What does mitapivat do?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Mitapivat is a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemia"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 336, 'text': 'Coordinated gene expression allows spatiotemporal control of cellular processes and is achieved by the cotranscription/translation of functionally related genes/proteins. Prokaryotes evolved polycistronic messages (operons) to confer expression from a single promoter to efficiently cotranslate proteins functioning on the same pathway.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35934590'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 212, 'text': 'The arrangement of functionally-related genes in operons is a fundamental element of how genetic information is organized in prokaryotes. This organization ensures coordinated gene expression by co-transcription.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32209657'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 106, 'text': 'Clustering of functionally related genes in operons allows for coregulated gene expression in prokaryotes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24012761'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 124, 'text': 'Operons are clusters of genes that are transcribed as a single message, and regulated by the same gene expression machinery.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16755590'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 208, 'text': 'Bacterial genes are commonly encoded in clusters, known as operons, which share transcriptional regulatory control and often encode functionally related proteins that take part in certain biological pathways.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21690561'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 136, 'text': 'In prokaryotic genomes, related genes are frequently clustered in operons and higher-order arrangements that reflect functional context.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15487932'}, {'offsetInBeginSection': 956, 'offsetInEndSection': 1213, 'text': ' Genes in operons are located next to each other in the same DNA strand, and thus their presence should result in a higher proportion of predicted functional interactions among adjacent genes in the same strand than among adjacent genes in opposite strands.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17671982'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 141, 'text': 'Genes that are part of the same operon in prokaryotes, or have the same expression pattern in eukaryotes, are transcriptionally co-regulated.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12220896'}, {'offsetInBeginSection': 809, 'offsetInEndSection': 956, 'text': 'The presence of operons (polycistronic transcription units formed of functionally related genes) in prokaryotic genomes offers such an alternative.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17671982'}]\n\n\n             'In prokaryotes, functionally related genes are sometimes positioned adjacent to each other in the genome and can be under the control of the same regulatory machinery. What are these called?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Prokaryotes often have functionally-related genes joined together under the direction of a single promoter. These structures are called operons. Clustering of functionally-related genes in operons allows for coordinated gene expression and spatiotemporal control of cellular processes."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 269, 'text': 'Drug delivery to the suprachoroidal space (SCS\u00ae) has become a clinical reality after the 2021 FDA approval of CLS-TA, a triamcinolone acetonide injectable suspension for suprachoroidal use (XIPERE\u00ae), administered via a microneedle-based device, the SCS Microinjector\u00ae. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35868358'}]\n\n\n             'What is the active ingredient of Xipere?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "The active ingredient of Xipere is triamcinolone acetonide."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 889, 'offsetInEndSection': 956, 'text': 'Distal hotspot exons 47, 48 and 50 were the commonly deleted exons.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35359537'}, {'offsetInBeginSection': 11, 'offsetInEndSection': 149, 'text': 'Duchenne muscular dystrophy (DMD) exon 45-55 deletion (del45-55) has been postulated as a model that could treat up to 60% of DMD patients', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35897138'}, {'offsetInBeginSection': 1662, 'offsetInEndSection': 1803, 'text': 'We confirmed that del45-55 segregates a high proportion of benign phenotypes, severe cases, and isolated cardiac and cognitive presentations.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35897138'}, {'offsetInBeginSection': 218, 'offsetInEndSection': 285, 'text': 'In particular, exons 45-52 constitute a hotspot for DMD mutations. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33531685'}, {'offsetInBeginSection': 1099, 'offsetInEndSection': 1238, 'text': 'An exon deletion hotspot, located in exons 45-54, was observed in DMD, and intron 44 was the most frequent deletion starting point (26.5%).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33101180'}, {'offsetInBeginSection': 383, 'offsetInEndSection': 563, 'text': 'In-frame exon skipping of dystrophin exons 45-55 represents a significant approach to treating DMD, as a large proportion of patients harbor mutations within this \"hotspot\" region.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29771942'}, {'offsetInBeginSection': 783, 'offsetInEndSection': 1045, 'text': 'Here, we provide an update on DMD genotype-phenotype associations using a global DMD database and further provide the rationale for multiple exon skipping development, particularly for exons 45\u207b55 skipping and an emerging therapeutic concept, exons 3\u207b9 skipping.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30544634'}, {'offsetInBeginSection': 494, 'offsetInEndSection': 649, 'text': ' A deletion of exons 3-9 encompassing a mutational hot spot in the DMD gene was detected, and dystrophin protein expression was \u223c15% that of control level.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27009627'}]\n\n\n             'What are the most common mutation locations in dystrophin gene in Duchenne muscular dystrophy?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "The most common mutation locations in DMD gene are exons 3-9 and 45-55."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 780, 'offsetInEndSection': 923, 'text': 'RESULTS: Seven infants were diagnosed with SCID, yielding an incidence of 1 in 22,819 live births. Four of these infants had Artemis-type SCID.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35729475'}, {'offsetInBeginSection': 288, 'offsetInEndSection': 426, 'text': 'Artemis deficiency disrupts development of adaptive immunity and leads to radiosensitive T- B- severe combined immunodeficiency (RS-SCID).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35801871'}, {'offsetInBeginSection': 507, 'offsetInEndSection': 667, 'text': 'Encouraging data for X-SCID and preclinical work for Artemis-SCID and RAG1-SCID are paving the way for the therapy to become a viable curative treatment option.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35773051'}, {'offsetInBeginSection': 111, 'offsetInEndSection': 350, 'text': 'Pathogenic variants in DCLRE1C encoding Artemis cause T-B-NK+ severe combined immunodeficiency (SCID), and patients with Artemis-deficient SCID (ART-SCID) require definitive therapy with allogeneic hematopoietic cell transplantation (HCT).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36385359'}]\n\n\n             'Does mutation of ARTEMIS gene causes severe combined immunodeficiency?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Artemis mutation disrupts development of adaptive immunity and leads to severe combined immunodeficiency."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 155, 'offsetInEndSection': 261, 'text': \"Wilson's disease (WD), an inherited disorder of copper metabolism that mostly affects the liver and brain;\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35322347'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 111, 'text': 'Wilsons disease is a rare autosomal recessive disorder of copper transportation, which is fatal if not treated.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8757902'}, {'offsetInBeginSection': 398, 'offsetInEndSection': 570, 'text': 'Wilsons disease and idiopathic toxicosis are examples of severe chronic liver diseases that are the results of genetic predisposition to the hepatic accumulation of copper.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30646728'}, {'offsetInBeginSection': 19, 'offsetInEndSection': 116, 'text': 'Wilson disease is a genetic copper storage disorder that causes hepatic and neurologic symptoms. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23542331'}, {'offsetInBeginSection': 483, 'offsetInEndSection': 536, 'text': \"Wilson's disease represents a copper storage disease.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8984578'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 130, 'text': 'Hereditary hemochromatosis and Wilson disease are autosomal recessive storage disorders of iron and copper overload, respectively.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24266916'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 224, 'text': \"Hereditary deposition of iron (primary haemochromatosis) or copper (Wilson's disease) are autosomal recessive metabolic disease characterized by progressive liver pathology and subsequent involvement of various other organs.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17505988'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 100, 'text': \"OBJECTIVES: Wilson's disease (WD) is a metabolic disorder leading to hepatic and extrahepatic copper\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31345362'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 73, 'text': \"Wilson's disease (WD) is a rare hereditary disorder of copper metabolism.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33555495'}, {'offsetInBeginSection': 748, 'offsetInEndSection': 884, 'text': \"Wilson's disease, a copper storage disorder, in which biliary copper excretion is reduced, is inherited as an autosomal recessive trait.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12508671'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 96, 'text': 'BACKGROUND & AIMS: Wilson disease is a genetic copper storage disorder that causes hepatic and n', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23542331'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 156, 'text': 'UNLABELLED: Wilson disease (WD) is a rare inherited disorder of copper metabolism, which can lead to severe liver failure and to a variety of neuropsychiatr', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22098612'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 206, 'text': 'Wilson disease (WD) (OMIM# 277900) is an autosomal recessive inherited disorder characterized by excess copper (Cu) storage in different human tissues, such as the brain, liver, and the corneas of the eyes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33573009'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 159, 'text': \"UNLABELLED: Wilson's disease (WND) and hereditary hemochromatosis (HH) are two metal loading diseases of copper and iron, respectively, and are both recessivel\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22774841'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 208, 'text': \"Wilson's disease is an autosomal recessive inherited disease with congenital copper metabolism disorder, characterized by decreased ceruloplasmin and increased urine copper, which can involve multiple organs.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36381061'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 176, 'text': \"Wilson's disease is an autosomal recessive disease of copper metabolism which is widely recognized as a disease occurring clinically in children, adolescents, and young adults.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8229372'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 110, 'text': \"Hereditary copper-associated hepatitis in dogs resembles Wilson's disease, a copper storage disease in humans.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23583003'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 105, 'text': \"Wilson's disease is a rare inherited disorder of copper metabolism causing severe damage to vital organs.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21886393'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 135, 'text': \"Inherited copper toxic disease, Wilson's disease, is an autosomal recessive disorder arising from a defect in biliary copper excretion.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9093597'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 102, 'text': \"Wilson's disease is a genetic disorder of copper metabolism with a hepatic or neurologic presentation.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14738953'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 81, 'text': \"Wilson's disease is an autosomal recessive disease of abnormal copper metabolism.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30271060'}, {'offsetInBeginSection': 579, 'offsetInEndSection': 683, 'text': \" Hemochromatosis and Wilson's disease are known as iron and copper accumulation disorders, respectively.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8114295'}, {'offsetInBeginSection': 482, 'offsetInEndSection': 536, 'text': \" Wilson's disease represents a copper storage disease.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8984578'}, {'offsetInBeginSection': 796, 'offsetInEndSection': 904, 'text': \" In the new paradigm, Wilson's disease is seen as a hereditary disorder associated with copper intoxication.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16466879'}, {'offsetInBeginSection': 434, 'offsetInEndSection': 584, 'text': \"ve determination of elevated liver iron content. Wilson's disease represents a copper storage disease. Prominent clinical features are hepatomegaly an\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8984578'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 177, 'text': \"Wilson's disease is an autosomal recessive disorder in which the liver does not properly release copper into bile, resulting in prominent copper accumulation in various tissues.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25704483'}, {'offsetInBeginSection': 337, 'offsetInEndSection': 498, 'text': \"Wilson's disease is one such\\xa0hereditary disease\\xa0that creates chaos in tissues, usually the brain and liver, via deposition of abnormal amounts of copper in them.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28168129'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 111, 'text': \"Wilson's disease is rare autosomal-recessive disorder originated on the basis of metabolic copper over-storage.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1306026'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 193, 'text': \"Wilson's disease is an autosomal-recessive disorder of copper metabolism caused by mutations in ATP7B and associated with neurological, psychiatric, ophthalmological and hepatic manifestations.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34341141'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 147, 'text': \"PROJECT: Wilson's disease (WD) is an inherited disorder of copper metabolism characterised by juvenile liver cirrhosis and by neurological symptoms\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11787982'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 78, 'text': \"OBJECTIVE: Wilson's disease (WD) is a hereditary disorder of copper metabolism\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33175593'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 117, 'text': \"Wilson's disease is an autosomal-recessive disorder of copper metabolism with neurological and hepatic presentations.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34289020'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 121, 'text': \"Wilson's disease is an inherited disorder associated with copper accumulation in the liver, brain and other vital organs.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32738633'}]\n\n\n             'Is Wilson's disease described as an iron storage disease?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Wilson's disease is a rare inherited disorder that causes copper to accumulate in your liver, brain and other vital organs."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 204, 'text': \"A promoter is a short region of DNA (100-1,000 bp) where transcription of a gene by RNA polymerase begins. It is typically located directly upstream or at the 5' end of the transcription initiation site. \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31750297'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 531, 'text': 'The RNA polymerase II core promoter is generally defined to be the sequence that directs the initiation of transcription. This simple definition belies a diverse and complex transcriptional module. There are two major types of core promoters - focused and dispersed. Focused promoters contain either a single transcription start site or a distinct cluster of start sites over several nucleotides, whereas dispersed promoters contain several start sites over 50-100 nucleotides and are typically found in CpG islands in vertebrates.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18436437'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 193, 'text': 'A promoter is a region in the DNA sequence that defines where the transcription of a gene by RNA polymerase initiates, which is typically located proximal to the transcription start site (TSS).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33227813'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 181, 'text': 'Promoters are crucial for gene regulation. They vary greatly in terms of associated regulatory elements, sequence motifs, the choice of transcription start sites and other features.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22392219'}, {'offsetInBeginSection': 253, 'offsetInEndSection': 710, 'text': 'Similarly, promoters are modular. They consist of combinations of cis-acting elements that are the binding sites for transcription factors. It is this promoter architecture that largely determines the expression pattern of a gene. The modular nature of promoters is supported by the observation that many cis-acting elements retain their activities when they are taken out of their native promoter context and used as building blocks in synthetic promoters.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27557757'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 252, 'text': 'The main function of gene promoters appears to be the integration of different gene products in their biological pathways in order to maintain homeostasis. Generally, promoters have been classified in two major classes, namely TATA and CpG.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23020586'}]\n\n\n             'What are promoters?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "A promoter is generally defined to be the sequence that directs the initiation of transcription. This simple definition belies a diverse and complex transcriptional module. There are two major types of core promoters - focused and dispersed. Focused promoters contain either a single transcription start site or a distinct cluster of start sites over several nucleotides, whereas dispersed promoters contain several start sites over 50-100 nucleotides.\n\nIn summary, promoters are short regions of DNA (100-1,000 bp) where transcription by RNA polymerase begins. They are typically located directly upstream or at the 5' end of the transcription initiation site."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 690, 'offsetInEndSection': 853, 'text': 'Omaveloxolone (RTA 408) is an activator of Nrf2 and an inhibitor of NF\u03baB, possessing antioxidative and anti-inflammatory activities in mitochondrial bioenergetics.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34573098'}]\n\n\n             'Is omaveloxolone an activator of NFkB?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "No, omaveloxolone is an inhibitor of NF\u03baB."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 634, 'offsetInEndSection': 736, 'text': ' Face, leg, activity, cry, and consolability (FLACC) scores for postoperative pain were also assessed.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35626783'}, {'offsetInBeginSection': 994, 'offsetInEndSection': 1051, 'text': 'The FLACC and COMFORT scales were utilized to assess pain', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33904220'}, {'offsetInBeginSection': 683, 'offsetInEndSection': 862, 'text': 'Postoperative pain was assessed using the Visual Analogue Scale (VAS), the Wong-Baker Faces Pain Rating Scale, and the Face, Legs, Activity, Cry, and Consolability (FLACC) scale. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35628840'}, {'offsetInBeginSection': 656, 'offsetInEndSection': 791, 'text': 'The pain experience (intense, moderate, or mild) was evaluated by the Face, Legs, Activity, Cry, Consolability-revised scale (FLACC-r).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34599744'}, {'offsetInBeginSection': 1301, 'offsetInEndSection': 1508, 'text': ' Daily assessment and documentation for pain (81%) and sedation (87%) was reported by most of the PICUs, using the preferred validated FLACC scale (54%) and the COMFORT Behavioural scale (48%), respectively.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35361254'}]\n\n\n             'What is the most commonly used pain scale for the measurement of pain in children?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "The most pain scale used to measure pain in children is FLACC (Face, leg, activity, cry, and consolability) score."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 217, 'offsetInEndSection': 363, 'text': 'Here, we examined driving performance following administration of daridorexant, a new dual orexin receptor antagonist developed to treat insomnia.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35426136'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 91, 'text': 'Daridorexant is a novel dual orexin receptor antagonist used in treating insomnia disorder.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36473030'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 173, 'text': 'Assessment of the effect of the dual orexin receptor antagonist daridorexant on various indices of disease severity in patients with mild to moderate obstructive sleep apnea', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35306405'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 276, 'text': 'BACKGROUND: The dual orexin receptor antagonist daridorexant did not impact nighttime respiratory function as assessed by the apnea/hypopnea index (AHI) and nocturnal oxygen saturation (SpO2) and improved sleep in patients with mild to moderate obstructive sleep apnea (OSA). ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35306405'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 197, 'text': 'Daridorexant (Quviviq\u2122; Idorsia Pharmaceuticals Ltd.) is an orally administered dual orexin type 1 and type 2 (OX1 and OX2) receptor antagonist (DORA) being developed for the treatment of insomnia.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35298826'}]\n\n\n             'What is the mechanism of action of daridorexant?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Daridorexant is an orally administered dual orexin type 1 and type 2 (OX1 and OX2) receptor antagonist that is being developed for the treatment of insomnia."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 139, 'offsetInEndSection': 327, 'text': 'We utilised a novel DILI causality assessment tool (DILI-CAT), which uses drug-specific liver injury phenotypes, to examine potential DILI in early phase ximelagatran clinical development.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35266155'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 144, 'text': 'A novel phenotype-based drug-induced liver injury causality assessment tool (DILI-CAT) allows for signal confirmation in early drug development.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35266155'}, {'offsetInBeginSection': 1633, 'offsetInEndSection': 1808, 'text': \"DILI-CAT, a clinically intuitive, data-driven, computer-assisted scoring algorithm, is a useful tool for early detection of drug's hepatotoxicity in clinical drug development.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35266155'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 102, 'text': 'A novel quantitative computer-assisted drug-induced liver injury causality assessment tool (DILI-CAT).', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36174069'}]\n\n\n             'What is DILI-CAT used for?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "DILI-CAT, ia a clinically intuitive, data-driven, computer-assisted scoring algorithm and is a useful tool for early detection of drug's hepatotoxicity in clinical drug development."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 1265, 'offsetInEndSection': 1486, 'text': 'SARS-COV-2 RNA shedding can be prolonged, yet high heterogeneity exists. Detection of viral RNA may not correlate with infectivity since available viral culture data suggests shorter durations of shedding of viable virus.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33077007'}, {'offsetInBeginSection': 681, 'offsetInEndSection': 1252, 'text': 'Among 28 studies, the overall pooled median duration of RNA shedding from respiratory sources was 18.4 days (95% CI, 15.5-21.3; I2 = 98.87%; P < .01). When stratified by disease severity, the pooled median duration of viral RNA shedding from respiratory sources was 19.8 days (95% CI, 16.2-23.5; I2 = 96.42%; P < .01) among severely ill patients and 17.2 days (95% CI, 14.0-20.5; I2 = 95.64%; P < .01) in mild-to-moderate illness. Viral RNA was detected up to 92 days after symptom onset. Viable virus was isolated by culture from -6 to 20 days relative to symptom onset.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33077007'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 366, 'text': 'Immunocompromised adults can have prolonged acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive RT-PCR results, long after the initial diagnosis of coronavirus disease 2019 (COVID-19). This study aimed to determine if SARS-CoV-2 virus can be recovered in viral cell culture from immunocompromised adults with persistently positive SARS-CoV-2 RT-PCR tests.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35186791'}, {'offsetInBeginSection': 753, 'offsetInEndSection': 961, 'text': 'Of 20 patients, 10 (50%) had a solid organ transplant and 5 (25%) had a hematologic malignancy. For most patients, RT-PCR Ct values increased over time. There were 2 patients with positive viral cell cultures', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35186791'}, {'offsetInBeginSection': 327, 'offsetInEndSection': 900, 'text': ' Many patients, however, have persistently positive RT-PCR tests for weeks to months following clinical recovery, and multiple studies now indicate that these generally do not reflect replication-competent virus. SARS-CoV-2 appears to be most contagious around the time of symptom onset, and infectivity rapidly decreases thereafter to near-zero after about 10 days in mild-moderately ill patients and 15 days in severely-critically ill and immunocompromised patients. The longest interval associated with replication-competent virus thus far is 20 days from symptom onset.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33029620'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 299, 'text': 'We describe a case of chronic coronavirus disease 2019 (COVID-19) in a patient with lymphoma and associated B-cell immunodeficiency. Viral cultures and sequence analysis demonstrate ongoing replication of infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for at least 119 days.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33089317'}, {'offsetInBeginSection': 601, 'offsetInEndSection': 733, 'text': 'This case highlights challenges in managing immunocompromised hosts, who may act as persistent shedders and sources of transmission.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33089317'}, {'offsetInBeginSection': 1038, 'offsetInEndSection': 1325, 'text': 'COVID-19 patients with mild-to-moderate illness are highly unlikely to be infectious beyond 10 days of symptoms. However, evidence from a limited number of studies indicates that patients with severe-to-critical illness or who are immunocompromised, may shed infectious virus for longer.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33049331'}, {'offsetInBeginSection': 328, 'offsetInEndSection': 539, 'text': 'Many patients, however, have persistently positive RT-PCR tests for weeks to months following clinical recovery, and multiple studies now indicate that these generally do not reflect replication-competent virus.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33029620'}, {'offsetInBeginSection': 1029, 'offsetInEndSection': 1243, 'text': 'The study evidenced that most patients tested positive for more than 2 weeks and that persistence of viral RNA is not necessarily associated with severe disease but may result from a weaker immune response instead.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32484958'}, {'offsetInBeginSection': 646, 'offsetInEndSection': 848, 'text': ' Prolonged viral shedding currently has unclear implications on the management and isolation decisions-the role of the cycle threshold (Ct) value in guiding therapeutic decisions is yet to be clarified.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33626020'}, {'offsetInBeginSection': 327, 'offsetInEndSection': 539, 'text': ' Many patients, however, have persistently positive RT-PCR tests for weeks to months following clinical recovery, and multiple studies now indicate that these generally do not reflect replication-competent virus.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33029620'}, {'offsetInBeginSection': 125, 'offsetInEndSection': 273, 'text': 'However, replication competent live viruses were not recovered beyond two to three weeks from onset of symptoms in mild to severe cases of COVID-19.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34506421'}]\n\n\n             'What is the significance of a persistently positive RT-PCR for weeks after illness?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Patients diagnosed with COVID-19 can have detectable SARS-CoV-2 RNA in upper respiratory tract specimens for weeks after the onset of symptoms. However, prolonged viral RNA detection does not necessarily indicate prolonged infectiousness. In particular, isolation of infectious virus more than 10 days after illness onset is rare in patients whose symptoms have resolved.\n\nPeople with COVID-19 are thus generally felt to have low infectiousness after about 10 days, particularly after mild to moderate disease and in the absence of immunocompromise, regardless of whether they continue to have a positive reverse-transcription polymerase chain reaction (RT-PCR) test."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 90, 'text': 'Molecular Mechanisms and Therapeutics for the GAA\u00b7TTC Expansion Disease Friedreich Ataxia.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31317428'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 179, 'text': 'Friedreich ataxia (FRDA), the most common inherited ataxia, is caused by transcriptional silencing of the nuclear FXN gene, encoding the essential mitochondrial protein frataxin. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31317428'}, {'offsetInBeginSection': 244, 'offsetInEndSection': 460, 'text': 'Gene silencing in FRDA is due to hyperexpansion of the triplet repeat sequence GAA\u00b7TTC in the first intron of the FXN gene, which results in chromatin histone modifications consistent with heterochromatin formation. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31317428'}]\n\n\n             'What is the genetic cause of Freidreich's ataxia?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Friedreich ataxia is caused by hyperexpansion of the triplet repeat sequence GAA\u00b7TTC in the first intron of the FXN gene."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 751, 'offsetInEndSection': 922, 'text': 'In most cases, once FSHD is clinically suspected, the diagnosis can be genetically confirmed with a DNA test using Southern Blotting and hybridization to a set of probes. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24011979'}, {'offsetInBeginSection': 1199, 'offsetInEndSection': 1332, 'text': 'In the absence of genetic confirmation, other investigations, mainly EMG and muscle biopsy, are needed to rule out another diagnosis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24011979'}, {'offsetInBeginSection': 159, 'offsetInEndSection': 270, 'text': 'Molecular diagnosis is based mainly on the detection of deletions of a 3.3 kb-tandem repeat array in the locus.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16144755'}, {'offsetInBeginSection': 388, 'offsetInEndSection': 584, 'text': 'We describe a convenient non-radioactive protocol which requires a simple PCR probe synthesis and labelling procedure, thus facilitating and accelerating the standard Southern blot based DNA test.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16144755'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 215, 'text': 'The molecular diagnosis of facioscapulohumeral muscular dystrophy (FSHD) relies on detecting contractions of the unique D4Z4 repeat array at the chromosome 4q35 locus in the presence of a permissive 4q35A haplotype.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34384893'}, {'offsetInBeginSection': 1000, 'offsetInEndSection': 1108, 'text': 'The Southern blot analysis with DNA probe p13E-11 has created a valuable molecular diagnostic test for FSHD.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9192267'}, {'offsetInBeginSection': 239, 'offsetInEndSection': 385, 'text': 'The gene whose defect causes FSHD has not been identified, but molecular diagnosis can be made by analyzing D4Z4 repeat length on chromosome 4q35.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22109111'}, {'offsetInBeginSection': 277, 'offsetInEndSection': 456, 'text': 'Here, we present a comprehensive analysis of the currently used diagnostic methods (Southern blotting and molecular combing) against a new qPCR-based approach for FSHD1 diagnosis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34071558'}, {'offsetInBeginSection': 719, 'offsetInEndSection': 889, 'text': 'llelic variant of chromosome 4. In most cases, once FSHD is clinically suspected, the diagnosis can be genetically confirmed with a DNA test using Southern Blotting and h', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24011979'}, {'offsetInBeginSection': 552, 'offsetInEndSection': 780, 'text': 'In this report we describe a protocol that can be used for DNA testing in well defined familial cases or proven de novo cases, and in the differential diagnosis of muscular dystrophy patients clinically suspected of having FSHD.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8825045'}, {'offsetInBeginSection': 451, 'offsetInEndSection': 663, 'text': 'A valuable molecular diagnostic test for FSHD has been created with the use of p13E-11 probe to detect the EcoR I/Bln I double digestion fragment which is usually smaller in FSHD patient than in normal indivdual.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11592052'}, {'offsetInBeginSection': 805, 'offsetInEndSection': 946, 'text': 'Molecular diagnosis for FSHD is usually offered with 98% accuracy but because of its complexity, a much more simple test would be preferable.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11962336'}, {'offsetInBeginSection': 646, 'offsetInEndSection': 755, 'text': ' Molecular diagnostic testing is appropriate to confirm the diagnosis of FSHD without need for muscle biopsy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21567298'}, {'offsetInBeginSection': 576, 'offsetInEndSection': 726, 'text': ' number of repetitive elements (D4Z4) on chromosome 4q35 (4qA allele). Molecular diagnostic testing is appropriate to confirm the diagnosis of FSHD wi', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21567298'}, {'offsetInBeginSection': 1302, 'offsetInEndSection': 1452, 'text': 'and the homologous 10q26 regions were also detected.CONCLUSION: Molecular diagnosis of FSHD became a routine approach in Hungary thus supporting the w', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21920844'}, {'offsetInBeginSection': 418, 'offsetInEndSection': 568, 'text': '5.7+/-12.3 years (range: 26-72). The diagnosis of FSHD was confirmed by genetic tests. All patients underwent medical and neurological evaluations, su', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19501370'}]\n\n\n             'Which diagnostic tests are used for the diagnosis of FSHD?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "FSHD is diagnosed with a Southern blot based DNA test. In the absence of genetic confirmation, other investigations, mainly EMG and muscle biopsy, are needed to rule out another diagnosis."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 1567, 'offsetInEndSection': 1733, 'text': 'Efgartigimod is an FcRn inhibitor recently approved for MG treatment, and rozanolixizumab, nipocalimab and batoclimab are other agents in clinical trial development. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35639288'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 400, 'text': 'Efgartigimod (efgartigimod alfa-fcab, Vyvgart\u2122) is a first-in-class neonatal Fc receptor antagonist being developed by argenx for the treatment of autoimmune diseases including myasthenia gravis. In December 2021, intravenous efgartigimod received its first approval in the USA for the treatment of generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody positive.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35179720'}, {'offsetInBeginSection': 979, 'offsetInEndSection': 1118, 'text': 'This article summarizes the milestones in the development of efgartigimod leading to this first approval for generalized myasthenia gravis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35179720'}, {'offsetInBeginSection': 2951, 'offsetInEndSection': 3062, 'text': 'INTERPRETATION: Efgartigimod was well tolerated and efficacious in patients with generalised myasthenia gravis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34146511'}]\n\n\n             'Can Efgartigimod be used for myasthenia gravis?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Yes. Efgartigimod is effective, approved and can be used for myasthenia gravis."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 86, 'text': 'Quercetin-biapigenin nanoparticles are effective to penetrate the blood-brain barrier.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33709285'}, {'offsetInBeginSection': 436, 'offsetInEndSection': 757, 'text': ' The present study aimed to investigate the potential protective effect of quercetin-biapigenin encapsulated into poly(\u0190-polycaprolactone) (PCL) nanoparticles against t-BOOH-induced oxidative stress in several brain cell lines, as well as evaluate the permeability of those active molecules through an in vitro BBB model.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33709285'}, {'offsetInBeginSection': 1170, 'offsetInEndSection': 1288, 'text': 'As of our knowledge, this is the first report of quercetin-biapigenin PCL-loaded nanoparticle activity in brain cells.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33709285'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 242, 'text': \"Microbubbles in combination with focused ultrasound for the delivery of quercetin-modified sulfur nanoparticles through the blood brain barrier into the brain parenchyma and relief of endoplasmic reticulum stress to treat Alzheimer's disease.\", 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32154811'}]\n\n\n             'Have Quercetin-biapigenin nanoparticles been shown to be effective in penetrating the blood-brain barrier'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Yes, Quercetin-biapigenin nanoparticles been shown to be effective in penetrating the blood-brain barrier"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 562, 'offsetInEndSection': 756, 'text': 'These results suggest that metabolite-binding mRNAs are possibly involved in eukaryotic gene regulation and that some riboswitches might be representatives of an ancient form of genetic control.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12756322'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 399, 'text': 'Genetic control by metabolite-binding mRNAs is widespread in prokaryotes. These riboswitches are typically located in noncoding regions of mRNA, where they selectively bind their target compound and subsequently modulate gene expression. We have identified mRNA elements in fungi and in plants that match the consensus sequence and structure of thiamine pyrophosphate-binding domains of prokaryotes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12756322'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 311, 'text': 'Metabolite-sensing mRNAs, or \"riboswitches,\" specifically interact with small ligands and direct expression of the genes involved in their metabolism. Riboswitches contain sensing \"aptamer\" modules, capable of ligand-induced structural changes, and downstream regions, harboring expression-controlling elements.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15610857'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 291, 'text': 'Riboswitches are a class of RNA motifs in the untranslated regions of bacterial messenger RNAs (mRNAs) that can adopt different conformations to regulate gene expression. The binding of specific small molecule or ion ligands, or other RNAs, influences the conformation the riboswitch adopts.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36227561'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'Metabolite-sensing mRNAs, or \"riboswitches,\" specifically interact with small ligands and direct expression of the genes involved in their metabolism.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15610857'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 190, 'text': 'Bacteria make extensive use of riboswitches to sense metabolites and control gene expression, and typically do so by modulating premature transcription termination or translation initiation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17468745'}, {'offsetInBeginSection': 141, 'offsetInEndSection': 384, 'text': 'Riboswitches possess a metabolite-sensing system that controls gene regulation in a cis-acting fashion at the initiation of transcriptional/translational level by binding with a specific metabolite and controlling various biochemical pathways.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36275359'}, {'offsetInBeginSection': 151, 'offsetInEndSection': 311, 'text': 'Riboswitches contain sensing \"aptamer\" modules, capable of ligand-induced structural changes, and downstream regions, harboring expression-controlling elements.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15610857'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 148, 'text': 'Regulatory mRNA elements or riboswitches specifically control the expression of a large number of genes in response to various cellular metabolites.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19303767'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 185, 'text': 'The discovery of metabolite-sensing RNA domains with gene regulatory functions, so-called riboswitches, has greatly expanded our view of the structural and functional complexity of RNA.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20009507'}, {'offsetInBeginSection': 435, 'offsetInEndSection': 760, 'text': 'Organisms from all three domains of life, including bacteria, plants and fungi, use TPP-sensing riboswitches to control genes responsible for importing or synthesizing thiamine and its phosphorylated derivatives, making this riboswitch class the most widely distributed member of the metabolite-sensing RNA regulatory system.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16728979'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 164, 'text': 'Riboswitches are metabolite-sensing RNAs, typically located in the non-coding portions of messenger RNAs, that control the synthesis of metabolite-related proteins.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16728979'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 101, 'text': 'Structured mRNA elements called riboswitches control gene expression by binding to small metabolites.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18072940'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 219, 'text': 'Riboswitches are motifs in the untranslated regions (UTRs) of RNA transcripts that sense metabolite levels and modulate the expression of the corresponding genes for metabolite import, export, synthesis, or degradation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22219369'}, {'offsetInBeginSection': 998, 'offsetInEndSection': 1221, 'text': ' The discovery of a riboswitch in eukaryotes that is composed of a single class of thiamine pyrophosphate (TPP) suggests that additional ligand-sensing RNAs may be present to control eukaryotic or mammalian gene expression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31741723'}, {'offsetInBeginSection': 379, 'offsetInEndSection': 604, 'text': ' Newly discovered metabolite-sensing riboswitches have revealed that cellular processes extensively make use of RNA structural modulation to regulate gene expression in response to subtle changes in metabolite concentrations.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19101979'}, {'offsetInBeginSection': 74, 'offsetInEndSection': 237, 'text': 'These riboswitches are typically located in noncoding regions of mRNA, where they selectively bind their target compound and subsequently modulate gene expression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12756322'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 142, 'text': 'Riboswitches are mRNA regulatory elements that control gene expression by altering their structure in response to specific metabolite binding.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23169642'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 225, 'text': \"Riboswitches are gene control elements typically located in the 5' untranslated regions of bacterial mRNAs where they modulate the expression of associated genes in response to elevated concentrations of cellular metabolites.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20061809'}]\n\n\n             'What process involves metabolite-sensing mRNAs to control gene expression?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Riboswitches are metabolite-sensing gene-control elements that are typically located in non-coding portions of mRNAs, where they selectively bind their target compound and subsequently modulate gene expression. In eukaryotes, a well-characterized riboswitch senses the vitamin B1 derivative TPP (thiamine pyro-phosphate)."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 268, 'text': 'The aim was to assess the bioequivalence of Sandoz methylphenidate osmotic-controlled release (OCR) tablets (Sandoz [Methylphenidate[ MPH OCR) with Concerta\u00ae, a methylphenidate formulation indicated for the treatment of attention deficit/hyperactivity disorder (ADHD).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25692005'}]\n\n\n             'What is Concerta\u00ae?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Concerta\u00ae is a methylphenidate formulation indicated for the treatment of attention deficit/hyperactivity disorder (ADHD)."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 795, 'offsetInEndSection': 925, 'text': ' In DMD, there was a prevalence of 7.0% of ASDs, 18.0% of ADHD, 11.0% of depression, 24.0% of anxiety disorders, and 12.0% of OCD.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35839922'}, {'offsetInBeginSection': 11, 'offsetInEndSection': 287, 'text': 'To estimate the prevalence of neuropsychiatric disorders, including autism spectrum disorders (ASDs), attention-deficit hyperactivity disorder (ADHD), depression, anxiety disorders, and obsessive-compulsive disorder (OCD), in populations with Duchenne muscular dystrophy (DMD)', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35839922'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 143, 'text': 'Duchenne muscular dystrophy (DMD) is associated with neuropsychiatric disorders, and patients often present with autism spectrum disorder (ASD)', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34148958'}, {'offsetInBeginSection': 107, 'offsetInEndSection': 244, 'text': 'Neuropsychiatric phenotype associated to DMD gene mutations include now low IQ scores, epilepsy, autism, and attention deficit disorder. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33741226'}, {'offsetInBeginSection': 107, 'offsetInEndSection': 243, 'text': 'Neuropsychiatric phenotype associated to DMD gene mutations include now low IQ scores, epilepsy, autism, and attention deficit disorder.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33741226'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 268, 'text': 'Increased rates of clinically significant internalizing disorders (obsessive compulsive disorder, anxiety, and depression) have been demonstrated in males with Duchenne muscular dystrophy, and a Duchenne muscular dystrophy neuropsychiatric syndrome has been suggested.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29779439'}, {'offsetInBeginSection': 183, 'offsetInEndSection': 385, 'text': 'disability. In males with Duchenne muscular dystrophy, neuropsychiatric disorders have also been observed: attention deficit disorder and hyperactivity, autism spectrum disorders, and obsessive-compulsi', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29795071'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 720, 'text': 'OBJECTIVE: To estimate the prevalence of neuropsychiatric disorders, including autism spectrum disorders (ASDs), attention-deficit hyperactivity disorder (ADHD), depression, anxiety disorders, and obsessive-compulsive disorder (OCD), in populations with Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD).DATA SOURCES: MEDLINE (via PubMed), Scopus, Web of Science, and Cochrane Library from inception to November 2021.STUDY SELECTION: Observational studies of individuals with DMD or BMD that estimated the prevalence of ASDs, ADHD, depression, anxiety disorders, and OCD in each population.DATA EXTRACTION: A random-effects meta-analysis was performed on each outcome and each population (ie, DMD, BM', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35839922'}]\n\n\n             'What are the most common neuropsychiatric disorders associated with Duchenne muscular dystrophy?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "The most common neuropsychiatric disorders associated with Duchenne muscular dystrophy are autism spectrum disorders (ASDs), epilepsy, attention-deficit hyperactivity disorder (ADHD), depression, anxiety disorders and obsessive-compulsive disorder (OCD)."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 164, 'offsetInEndSection': 369, 'text': 'Dupilumab, a monoclonal antibody targeting the interleukin (IL)-4 receptor alpha to inhibit IL-4 and IL-13 signaling, has recently been shown to significantly improve the condition of patients with CRSwNP.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36214075'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 119, 'text': 'BACKGROUND: Dupilumab is an antibody against interleukin-4 receptor \u03b1, used in the treatment of atopic dermatitis (AD).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34358343'}, {'offsetInBeginSection': 711, 'offsetInEndSection': 976, 'text': 'The development of new therapies received great impetus by an ample research of the pathophysiological mechanisms, leading to a new era in the treatment of severe atopic eczema due to targeted treatments, e.g. the IL-4R alpha specific monoclonal antibody dupilumab.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34236520'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 136, 'text': 'BACKGROUND: The human monoclonal antibody dupilumab blocks interleukin (IL)-4 andIL-13, key and central drivers of type 2 inflammation. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33993501'}, {'offsetInBeginSection': 538, 'offsetInEndSection': 806, 'text': ' An emerging therapeutic option is dupilumab, a monoclonal antibody for adults and adolescents with moderate-to-severe atopic dermatitis, that inhibits interleukin-4 receptor alpha subunit (IL4-R\u03b1) and the signaling pathways activated by interleukin (IL)-4 and IL-13. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33588666'}]\n\n\n             'Which interleukins are affected by Dupilumab?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Dupilumab is a monoclonal antibody for adults and adolescents with moderate-to-severe atopic dermatitis, that inhibits interleukin-4 receptor alpha subunit (IL4-R\u03b1) and the signaling pathways activated by interleukin (IL)-4 and IL-13."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 120, 'offsetInEndSection': 309, 'text': ' Current approaches to regeneration and tissue engineering of articular cartilage include the use of chondrocytes, stem cells, scaffolds and signals, including morphogens and growth factors', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24710539'}, {'offsetInBeginSection': 514, 'offsetInEndSection': 732, 'text': ' Autologous cartilage regeneration is a cell-based therapy in which autogenous chondrocytes or other chondrogenic cells are cultured to constitute cartilaginous tissue according to the principles of tissue engineering.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19251544'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 166, 'text': 'Cartilage engineered from chondrocytes requires a scaffold to keep the cells in the cartilage defect and to act as a support for inducing hyaline cartilage formation ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17454427'}, {'offsetInBeginSection': 462, 'offsetInEndSection': 667, 'text': 'To address these challenges, the focus of gene therapy for bone and cartilage repair has shifted in recent years to the use of autologous cells, typically osteocytes or chondrocytes, or their progenitors, ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19649985'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 151, 'text': 'Articular Cartilage Chondrocytes are more Advantageous for Generating Hyaline-like Cartilage than Mesenchymal Cells Isolated from Microfracture Repairs', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15256927'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 126, 'text': 'Influence of gel properties on neocartilage formation by auricular chondrocytes photoencapsulated in hyaluronic acid networks.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16482551'}, {'offsetInBeginSection': 238, 'offsetInEndSection': 307, 'text': 'affect neocartilage formation by encapsulated auricular chondrocytes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16482551'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 140, 'text': 'Transplanting human umbilical cord mesenchymal stem cells and hyaluronate hydrogel repairs cartilage of osteoarthritis in the minipig model.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30692826'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 156, 'text': 'Osteoarthritis (OA) is a chronic disease of degenerative joints. Mesenchymal stem cells (MSCs) have been used for cartilage regeneration in OA. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30692826'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 129, 'text': 'BACKGROUND: Mesenchymal stem cells (MSCs) and/or biological scaffolds have been used to regenerate articular cartilage with varia', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30603587'}, {'offsetInBeginSection': 130, 'offsetInEndSection': 451, 'text': 'le success. In the present study we evaluated cartilage regeneration using a combination of bone marrow (BM)-MSCs, HyalofastTM and/or native cartilage tissue following full thickness surgical cartilage defect in rabbits.METHODS: Full-thickness surgical ablation of the medial-tibial cartilage was performed in New Zealand', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30603587'}, {'offsetInBeginSection': 80, 'offsetInEndSection': 604, 'text': 'as increased. Mesenchymal Stem Cells (MSCs) have been proposed to be an attractive alternative candidate in the tissue engineering of articular cartilage primarily due to its abundant source, reduced cartilage donor site morbidity, and strong capacity for proliferation and potential to differentiate toward a chondrogenic phenotype.AREAS COVERED: A current overview of human, in vivo, and in vitro evidence on the use of MSCs in cartilage tissue engineering.EXPERT OPINION: We demonstrate robust evidence that MSCs have the', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22784026'}, {'offsetInBeginSection': 1770, 'offsetInEndSection': 2248, 'text': 'In this article, we review the progress on stem cell therapies for arthritic disorders, focusing on the various stem cell populations previously used for cartilage regeneration, successful cases of stem cell therapies in muscle and hemopoietic disorders, some of the reasons why these other fields have been successful (i.e., \"lessons learned\" to be applied to OA stem cell therapy), and finally, novel potential sources of stem cells for regenerating damaged cartilage in vivo.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35711627'}, {'offsetInBeginSection': 466, 'offsetInEndSection': 623, 'text': 'Here, we provide an overview of the current status of cord blood cells and induced pluripotent stem cells derived from these cells in cartilage regeneration.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30251563'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 161, 'text': 'Combination of Mesenchymal Stem Cells, Cartilage Pellet and Bioscaffold Supported Cartilage Regeneration of a Full Thickness Articular Surface Defect in Rabbits.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30603587'}, {'offsetInBeginSection': 309, 'offsetInEndSection': 417, 'text': 'The use of autologous mesenchymal stem cells (MSCs) for cartilage regeneration has been widely investigated.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33607469'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 211, 'text': 'Bone marrow-derived mesenchymal stem cells (BMSCs) are a good cell source for regeneration of cartilage as they can migrate directly to the site of cartilage injury and differentiate into articular chondrocytes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24759682'}, {'offsetInBeginSection': 142, 'offsetInEndSection': 422, 'text': 'Alginate microbeads containing adipose stem cells (ASCs) pretreated with chondrogenic media have been used successfully to regenerate hyaline cartilage in critical size defects in rat xiphoid suggesting that they may be used to treat defects in elastic cartilages such as the ear.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29766656'}, {'offsetInBeginSection': 106, 'offsetInEndSection': 254, 'text': 'Articular chondrocytes, cartilage progenitor cells, embryonic stem cells, and mesenchymal stem cells are candidate cells for cartilage regeneration.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26000333'}, {'offsetInBeginSection': 957, 'offsetInEndSection': 1295, 'text': 'This review briefly summarizes chemokines and growth factors that induce recruitment, proliferation, and differentiation of endogenous progenitor cells, endogenous cell sources for regenerating cartilage, scaffolds for delivery of bioactive factors, and bioadhesive materials that are necessary to bring about endogenous cartilage repair.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26559963'}, {'offsetInBeginSection': 87, 'offsetInEndSection': 380, 'text': 'Mesenchymal stem cells derived from synovium have been shown to be a superior cell source for cartilage regeneration to those from other mesenchymal tissues due to their higher rates of colony formation, proliferation potential with autologous serum, and in vitro/vivo chondrogenic potentials.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21628803'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 79, 'text': '[Use of bone marrow mesenchymal stem cells for ex vivo cartilage regeneration].', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17333068'}, {'offsetInBeginSection': 216, 'offsetInEndSection': 319, 'text': 'Here we show resident fibrocartilage stem cells (FCSCs) can be used to regenerate and repair cartilage.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27721375'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 96, 'text': 'Exploiting endogenous fibrocartilage stem cells to regenerate cartilage and repair joint injury.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27721375'}, {'offsetInBeginSection': 684, 'offsetInEndSection': 821, 'text': 'Regenerated cartilage can be derived from various cell types, including chondrocytes, pluripotent stem cells, and mesenchymal stem cells.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23637149'}, {'offsetInBeginSection': 208, 'offsetInEndSection': 372, 'text': 'There are several cell sources being investigated to promote cartilage regeneration: mature articular chondrocytes, chondrocyte progenitors, and various stem cells.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29018484'}, {'offsetInBeginSection': 328, 'offsetInEndSection': 669, 'text': 'In this study, we aimed to evaluate and compare the in vitro characteristics and chondrogenic capacity of some easily available adult cell sources for use in cartilage repair which includes: bone marrow-derived mesenchymal stem cells (MSC), adipose tissue-derived MSC, articular chondrocyte progenitors, and nasal septum-derived progenitors.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26507473'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 95, 'text': 'Chondrocytes or adult stem cells for cartilage repair: the indisputable role of growth factors.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21696723'}, {'offsetInBeginSection': 215, 'offsetInEndSection': 319, 'text': ' Here we show resident fibrocartilage stem cells (FCSCs) can be used to regenerate and repair cartilage.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27721375'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 174, 'text': 'The use of mesenchymal stromal cells (MSCs) for tissue engineering of hyaline cartilage is a topical area of regenerative medicine that has already entered clinical practice.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34829895'}, {'offsetInBeginSection': 69, 'offsetInEndSection': 201, 'text': ' Currently, ex vivo expanded chondrocytes or bone marrow-derived mesenchymal stem cells are used to regenerate the damaged cartilage', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28129782'}, {'offsetInBeginSection': 612, 'offsetInEndSection': 758, 'text': 'In this investigation, we assessed the chondrogenic ability of human dental pulp stem cells (hDPSCs) to regenerate cartilage in vitro and in vivo.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28951745'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 219, 'text': 'Multipotent mesenchymal stromal cells (MSCs) are primitive cells capable of restoring damaged mesenchyme and with the ability to differentiate into mature cells of bone, cartilage, muscle, fat, nerve or fibrous tissues.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24726343'}]\n\n\n             'What cells are used to regenerate cartilage?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Current approaches to regeneration and tissue engineering of articular cartilage include the use of chondrocytes, stem cells, scaffolds and signals, including morphogens and growth factors."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 405, 'text': 'Epigenetic modifications have received increasing attention and have been shown to be extensively involved in kidney development and disease progression. Among them, the most common RNA modification, N6 -methyladenosine (m6 A), has been shown to dynamically and reversibly exert its functions in multiple ways, including splicing, export, decay and translation initiation efficiency to regulate mRNA fate.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36196023'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 311, 'text': 'N6-methyladenosine (m6A) methylation is the most abundant mammalian mRNA modification. m6A regulates RNA processing, splicing, nucleation, translation and stability by transferring, removing and recognizing m6A methylation sites, which are critical for cancer initiation, progression, metabolism and metastasis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36314059'}, {'offsetInBeginSection': 10, 'offsetInEndSection': 259, 'text': 'The methyltransferase-like 3 (Mettl3) is a key component of the large N6-adenosine-methyltransferase complex in mammalian responsible for RNA N6-methyladenosine (m6A) modification, which plays an important role in gene post-transcription modulation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34130310'}, {'offsetInBeginSection': 116, 'offsetInEndSection': 223, 'text': 'Methylation of the N6 position of adenosine (m6A) is a post-transcriptional epigenetic modification of RNA.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31188932'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 260, 'text': 'N6-methyladenosine (m6A) is a dynamic reversible methylation modification of the adenosine N6 position and is the most common chemical epigenetic modification among mRNA post-transcriptional modifications, including methylation, demethylation, and recognition.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35032318'}, {'offsetInBeginSection': 219, 'offsetInEndSection': 298, 'text': 'N6-adenosine methylation (m6A) is one of the most common modifications on mRNA.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35748227'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 154, 'text': 'N6-methyladenosine (m6A) is methylation that occurs in the N6-position of adenosine, which is the most prevalent internal modification on eukaryotic mRNA.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31801551'}, {'offsetInBeginSection': 182, 'offsetInEndSection': 362, 'text': 'The N6-methyl adenosine (m6A) is an important epigenetic modification primarily present on mRNA that controls the levels of transcripts and efficiency of translation in eukaryotes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32867812'}]\n\n\n             'Is adenosine methylation an epigenetic modification?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Adenosine methylation is the most common mammalian epigenetic modification of mRNAs that is directed by a large methyltransferase complex containing Mettl3."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 269, 'text': 'Drug delivery to the suprachoroidal space (SCS\u00ae) has become a clinical reality after the 2021 FDA approval of CLS-TA, a triamcinolone acetonide injectable suspension for suprachoroidal use (XIPERE\u00ae), administered via a microneedle-based device, the SCS Microinjector\u00ae. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35868358'}]\n\n\n             'Which year was XIPERE approved by the FDA?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "XIPERE was approved by the FDA in 2021."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 1396, 'offsetInEndSection': 1557, 'text': 'The duration between breastfeeding and heel lance may influence the perception of pain in newborns. Keeping this period short, may reduce the perception of pain.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34983147'}, {'offsetInBeginSection': 983, 'offsetInEndSection': 1122, 'text': \"Breastfeeding and mother's heartbeat sounds, which are non-pharmacological pain relief methods, are effective in neonatal pain management. \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35620884'}, {'offsetInBeginSection': 1046, 'offsetInEndSection': 1165, 'text': 'The best non-pharmacological methods are breastfeeding followed by non-nutritive sucking coupled with sucrose sucking. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36291504'}, {'offsetInBeginSection': 868, 'offsetInEndSection': 1045, 'text': ' Non-pharmacological interventions, particularly breastfeeding and non-nutritive sucking as primary strategies for pain management in neonates are useful strategies to consider.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36291504'}]\n\n\n             'Can breastfeeding be used to alleviate the procedural pain in neonates?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Yes, breastfeeding is effective for pain management in neonates."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 208, 'text': 'PURPOSE OF REVIEW: This review summarizes available data for lenacapavir, an investigational first-in-class agent that disrupts functioning of HIV capsid protein across multiple steps in the viral life cycle.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34871187'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 145, 'text': 'Lenacapavir (Sunlenca\u00ae) is a long-acting capsid inhibitor of human immunodeficiency virus type\\xa01 (HIV-1) being developed by Gilead Sciences Inc. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36272024'}, {'offsetInBeginSection': 301, 'offsetInEndSection': 554, 'text': 'In August 2022, lenacapavir received its first approval in the EU for use in combination with other antiretroviral(s) in adults with multi-drug resistant HIV infection, for whom it is otherwise not possible to construct a suppressive anti-viral regimen.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36272024'}]\n\n\n             'Can lenacapavir be used for HIV?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Yes, lenacapavir can be used for HIV."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 529, 'offsetInEndSection': 842, 'text': 'Here we report that targeting the codon-optimized form of the light-driven chloride pump halorhodopsin from the archaebacterium Natronomas pharaonis (hereafter abbreviated Halo) to genetically-specified neurons enables them to be silenced reliably, and reversibly, by millisecond-timescale pulses of yellow light.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17375185'}, {'offsetInBeginSection': 661, 'offsetInEndSection': 891, 'text': 'By using Cal-Light to drive expression of the inhibitory receptor halorhodopsin (eNpHR), which responds to yellow light, we temporarily inhibit the lever-pressing behavior, confirming that the labeled neurons mediate the behavior.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28650460'}, {'offsetInBeginSection': 465, 'offsetInEndSection': 723, 'text': 'We introduced enhanced halorhodopsin (eNpHR), a yellow light-sensitive, membrane-targeting chloride pump, into mouse retinal ganglion cells (RGCs) by intravitreously injecting an adeno-associated virus serotype-2 vector carrying the CMV-eNpHR-EYFP construct.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21483674'}, {'offsetInBeginSection': 597, 'offsetInEndSection': 912, 'text': 'Hippocampal pyramidal neurons were transduced in vivo with a virus carrying an enhanced halorhodopsin (eNpHR), a yellow light activated chloride pump, and acute seizure progression was then monitored behaviorally and electrophysiologically in the presence and absence of illumination delivered via an optical fiber.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23637949'}, {'offsetInBeginSection': 1223, 'offsetInEndSection': 1360, 'text': 'Similarly, archaeon Natronomonas pharaonis (NpHR) expresses a monovalent Cl- channel protein halorhodopsin that responds to yellow light.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27905012'}, {'offsetInBeginSection': 141, 'offsetInEndSection': 380, 'text': 'Towards achieving this goal, light-activated channelrhodopsin-2 (ChR2), a cation channel activated with 480 nm light, and a first generation halorhodopsin (NpHR1.0), an anion pump activated by 580 nm light, have been introduced into hiPSC.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23366158'}, {'offsetInBeginSection': 485, 'offsetInEndSection': 645, 'text': 'In analogy, other excitable cells can be inhibited by expressing Halorhodopsin from Natronomonas pharaonis (NpHR) and subsequent illumination with yellow light.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22815873'}, {'offsetInBeginSection': 140, 'offsetInEndSection': 303, 'text': ' Towards achieving this goal, light-activated channelrhodopsin-2 (ChR2), a cation channel activated with 480 nm light, and a first generation halorhodopsin (NpHR1.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23366158'}, {'offsetInBeginSection': 441, 'offsetInEndSection': 591, 'text': ' retino-tectal pathway. We introduced enhanced halorhodopsin (eNpHR), a yellow light-sensitive, membrane-targeting chloride pump, into mouse retinal g', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21483674'}, {'offsetInBeginSection': 724, 'offsetInEndSection': 1042, 'text': 'Several weeks after the injection, whole-cell recordings made from sSC neurons in slice preparations revealed that yellow laser illumination of the eNpHR-expressing retino-tectal axons, putatively synapsing onto the recorded cells, effectively inhibited EPSCs evoked by electrical stimulation of the optic nerve layer.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21483674'}]\n\n\n             'What color light does the the inhibitory receptor halorhodopsin (eNpHR) respond to?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Halorhodopsin responds to yellow light."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 181, 'text': 'A critical regulatory element in many promoters transcribed by RNA polymerase II is the \"TATA\" box, which is located 25-30 nucleotides upstream of the transcription initiation site.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1409643'}, {'offsetInBeginSection': 722, 'offsetInEndSection': 921, 'text': 'About 24% of human genes have a TATA-like element and their promoters are generally AT-rich; however, only approximately 10% of these TATA-containing promoters have the canonical TATA box (TATAWAWR).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17123746'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 104, 'text': 'TBP binding to the TATA box induces a specific downstream unwinding site that is targeted by pluramycin.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9383448'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 281, 'text': 'The TATA-binding protein (TBP) is one of the major components of the human TFIID multiprotein complex. It is important in directing the initiation of RNA transcription at a site immediately downstream of the TATA sequence (TATA box) found in many eukaryotic promoters. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9383448'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 171, 'text': 'The TATA box-binding factor TFIID plays a primary role in the process of transcription initiation by RNA polymerase II and its regulation by various gene-specific factors.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1736286'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 211, 'text': 'The canonical core promoter elements consist of the TATA box, initiator (Inr), downstream core promoter element (DPE), TFIIB recognition element (BRE) and the newly-discovered motif 10 element (MTE).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16522199'}]\n\n\n             'What regulatory element promotes RNA polymerase II binding as well as the binding of factors that facilitate the unwinding of DNA prior to translation?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Found in about 24% of human gene promoters, the TATA box is a critical regulatory element that is mostly found in genes transcribed by RNA polymerase II, and as such, recruits this enzyme to the promoter. Additionally, the TATA-binding protein aids in unwinding DNA."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 352, 'offsetInEndSection': 498, 'text': \"We conducted a phase I/II double-blind, comparator-controlled trial with 2 doses of RT001 in Friedreich's ataxia patients (9 subjects each cohort)\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29624723'}, {'offsetInBeginSection': 825, 'offsetInEndSection': 920, 'text': 'Nineteen patients enrolled in the trial, and 18 completed all safety and efficacy measurements.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29624723'}]\n\n\n             'How many patients with Friedreich's ataxia were included in each cohort of the phase I/II double-blind, comparator-controlled trial of RT001.'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Each cohort of the phase I/II double-blind, comparator-controlled trial of RT001 involved 9 Friedreich's ataxia patients. In total nineteen patients enrolled in the trial, and 18 completed all safety and efficacy measurements."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 127, 'text': 'Facioscapulohumeral Muscular Dystrophy (FSHD) is in the top three list of all dystrophies with an approximate 1:8000 incidence.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34315378'}, {'offsetInBeginSection': 171, 'offsetInEndSection': 322, 'text': 'It is present worldwide, with a prevalence of around 4 per 100000 and an incidence of about 1 in 20000. Overall lifespan is not affected significantly.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21496633'}]\n\n\n             'What is the incidence of Facioscapulohumeral Muscular Dystrophy?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Facioscapulohumeral Muscular Dystrophy has and incidence of 1:8000 to 1:20000."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 513, 'offsetInEndSection': 781, 'text': 'Risdiplam (Evrysdi)-an orally bioavailable, small molecule approved by the US Food and Drug Administration and more recently by the European Medicines Agency for the treatment of patients \u22652 months of age with spinal muscular atrophy-is presented here as a case study.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34620695'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 94, 'text': 'An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35567422'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 248, 'text': 'OBJECTIVE: The US risdiplam expanded access program (EAP; NCT04256265) was opened to provide individuals with Type 1 or 2 spinal muscular atrophy (SMA) who had no satisfactory treatment options access to risdiplam prior to commercial availability. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35567422'}, {'offsetInBeginSection': 152, 'offsetInEndSection': 560, 'text': 'SMN1 produces SMN, a ubiquitously expressed protein, that is essential for the development and survival of motor neurons. Major advances and developments in SMA therapeutics are shifting the natural history of the disease. With three relatively new available therapies, nusinersen (Spinraza), onasemnogene abeparvovec (Zolgensma), and risdiplam (Evrysdi), patients survive longer and have improved outcomes. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35614235'}]\n\n\n             'Risdiplam is used for treatment of which disease?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Risdiplam is approved for treatment of spinal muscular atrophy."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 27, 'offsetInEndSection': 244, 'text': 'To evaluate the predictive value of serum neurofilament light chain (sNfL) and CSF NfL (cNfL) in patients with radiologically isolated syndrome (RIS) for evidence of disease activity (EDA) and clinical conversion (CC)', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36280258'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 107, 'text': 'Neurofilament Light Chain Levels Are Predictive of Clinical Conversion in Radiologically Isolated Syndrome.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36280258'}, {'offsetInBeginSection': 28, 'offsetInEndSection': 241, 'text': 'eurodegeneration and astrocytic activation are pathologic hallmarks of progressive multiple sclerosis (MS) and can be quantified by serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36376097'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 132, 'text': 'Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36376097'}, {'offsetInBeginSection': 2219, 'offsetInEndSection': 2325, 'text': 'sNfL reflected acute disease activity in patients with MS at high risk of underlying progressive pathology', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36376097'}, {'offsetInBeginSection': 2327, 'offsetInEndSection': 2487, 'text': 'Thus, sGFAP and sNfL levels may be used to stratify patients with progressive MS for clinical research studies and clinical trials and may inform clinical care.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36376097'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 100, 'text': 'Associations between neurofilament light-chain protein, brain structure, and chronic kidney disease.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34274959'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 350, 'text': 'Neurofilament light-chain (NfL) protein is a blood-based marker of neuroaxonal injury. We sought to (1) compare plasma NfL levels in children with chronic kidney disease (CKD) and healthy peers, (2) characterize the relationship between NfL level and kidney function, and (3) evaluate NfL as a predictor of abnormal brain structure in CKD', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34274959'}, {'offsetInBeginSection': 1742, 'offsetInEndSection': 1928, 'text': 'Within the CKD sample, NfL level is associated with abnormal kidney function and brain structure. Decreased kidney function may be linked to abnormal neuronal integrity in pediatric CKD.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34274959'}, {'offsetInBeginSection': 471, 'offsetInEndSection': 644, 'text': 'Using single-molecule array assays, we evaluated longitudinal changes of serum neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and GFAP/NfL levels.R', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34212756'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 118, 'text': 'Serum neurofilament light chain or glial fibrillary acidic protein in the diagnosis and prognosis of brain metastases.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34283286'}, {'offsetInBeginSection': 1394, 'offsetInEndSection': 1633, 'text': 'erum NfL and GFAP could be potential diagnostic biomarkers for BM in patients with lung cancer. We established a model that can provide individual diagnoses of BM. Higher NfL level may be associated with poor prognosis of patients with BM.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34283286'}, {'offsetInBeginSection': 10, 'offsetInEndSection': 410, 'text': \" The 'Frontotemporal dementia-Amyotrophic lateral sclerosis Spectrum' (FAS) encompasses different phenotypes, including cognitive disorders (frontotemporal dementia, FTD) and/or motor impairments (amyotrophic lateral sclerosis, ALS). The aim of this study was to apprehend the specific uses of neurofilaments light chain (NfL) and phosphorylated neurofilaments heavy chain (pNfH) in a context of FAS.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34313819'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 97, 'text': 'Comparative diagnosis interest of NfL and pNfH in CSF and plasma in a context of FTD-ALS spectrum', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34313819'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 87, 'text': 'Neurofilament Light Chain Is a Biomarker of Neurodegeneration in Ataxia Telangiectasia.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33893614'}, {'offsetInBeginSection': 1014, 'offsetInEndSection': 1122, 'text': 'NfL is a new potential progression biomarker in blood for neurodegeneration in A-T which increases with age.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33893614'}, {'offsetInBeginSection': 11, 'offsetInEndSection': 134, 'text': ' The neurofilament light chain (NfL) has emerged as a versatile biomarker for CNS-diseases and is approaching clinical use.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33759425'}, {'offsetInBeginSection': 10, 'offsetInEndSection': 134, 'text': ': Serum neurofilament light (sNfL) chain is a promising biomarker reflecting neuro-axonal injury in multiple sclerosis (MS).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35658739'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 95, 'text': 'Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35658739'}, {'offsetInBeginSection': 1179, 'offsetInEndSection': 1352, 'text': 'Serum NfL concentration was the only factor associated with disease worsening, indicating that sNfL is a useful biomarker in MS that might be relevant in a clinical setting.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35658739'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 257, 'text': 'Patients with Langerhans cell histiocytosis (LCH) may develop progressive neurodegeneration in the central nervous system (ND-CNS-LCH). Neurofilament light protein (NFL) in cerebrospinal fluid (CSF) is a promising biomarker to detect and monitor ND-CNS-LCH.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35582775'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 100, 'text': 'Screening for neurodegeneration in Langerhans cell histiocytosis with neurofilament light in plasma.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35582775'}, {'offsetInBeginSection': 541, 'offsetInEndSection': 705, 'text': 'Thus, our results suggest that p-NFL may be used to screen for ND-CNS-LCH. Further studies are encouraged, including the role of p-NFL for monitoring of ND-CNS-LCH.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35582775'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 135, 'text': 'Elevated serum Neurofilament Light chain (NfL) as a potential biomarker of neurological involvement in Myotonic Dystrophy type 1 (DM1).', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35575811'}, {'offsetInBeginSection': 666, 'offsetInEndSection': 836, 'text': 'Circulating Neurofilament light chain (NfL) levels have been recognized as a sensitive prognostic and monitoring biomarker of neuroaxonal damage in various CNS disorders.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35575811'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 147, 'text': 'Neurofilament light chain and total tau in the differential diagnosis and prognostic evaluation of acute and chronic inflammatory polyneuropathies.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35638376'}, {'offsetInBeginSection': 24, 'offsetInEndSection': 150, 'text': 'To investigate the diagnostic and prognostic value of axonal injury biomarkers in patients with inflammatory polyneuropathies.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35638376'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 709, 'text': \"BACKGROUND: A growing body of evidence suggests that the plasma concentration of the neurofilament light chain (NfL) might be considered a plasma biomarker for the screening of neurodegeneration in Alzheimer's disease (AD).METHODS: With a single molecule array method (Simoa, Quanterix), plasma NfL concentrations were measured in 99\\xa0subjects with AD at the stage of mild cognitive impairment (MCI-AD; n\\u2009=\\u200925) or at the stage of early dementia (ADD; n\\u2009=\\u200933), and in nondemented controls (n\\u2009=\\u200941); in all patients, the clinical diagnoses were in accordance with the results of the four core cerebrospinal fluid (CSF) biomarkers (amyloid \u03b2 (A\u03b2)1-42, A\u03b242/40, Tau, and pTau181), interpreted according to the Erla\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30055655'}, {'offsetInBeginSection': 110, 'offsetInEndSection': 418, 'text': 'The levels of neurofilament light chain (NfL) in both cerebrospinal fluid (CSF) and plasma have been related to degeneration in several neurodegenerative conditions including frontotemporal dementia (FTD) and NfL is currently considered as the most promising diagnostic and prognostic fluid biomarker in FTD.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33108404'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 96, 'text': \"Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease.\", 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30055655'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 218, 'text': \"Neurofilament light chain (NfL) is a marker of brain atrophy and predictor of disease progression in rare diseases such as Huntington Disease, but also in more common neurological disorders such as Alzheimer's disease.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33636389'}, {'offsetInBeginSection': 1634, 'offsetInEndSection': 1715, 'text': 'In conclusion, NfL plasma levels are elevated during ECM confirming brain damage.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35750882'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 114, 'text': 'Neurofilament light chain plasma levels are associated with area of brain damage in experimental cerebral malaria.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35750882'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 277, 'text': 'Background: Neurofilament light chain (NfL) is an axonal cytoskeletal protein that is released into the extracellular space following neuronal or axonal injury associated with neurological conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and oth', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35959400'}, {'offsetInBeginSection': 191, 'offsetInEndSection': 345, 'text': ' Increased levels of circulating neurofilament light chain (NfL), a biomarker of neuro-axonal injury, have been observed in patients with severe COVID-19.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35075461'}, {'offsetInBeginSection': 374, 'offsetInEndSection': 661, 'text': 'Our results shown that plasma NfL levels increased with an increase in cognitive impairment across the three groups of PD patients: PD with normal cognition (PD-NC), 17.9\\xa0\u00b1\\xa08.9\\xa0pg/ml; PD with mild cognitive impairment (PD-MCI),21.9\\xa0\u00b1\\xa010.3\\xa0pg/ml; and PD dementia (PDD), 35.7\\xa0\u00b1\\xa021.7\\xa0pg/ml.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34311152'}, {'offsetInBeginSection': 194, 'offsetInEndSection': 330, 'text': \" In Alzheimer's disease (AD), neurofilament light chain (NFL), a neurofilament subunit, is elevated in the cerebrospinal fluid and blood\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29630554'}, {'offsetInBeginSection': 1749, 'offsetInEndSection': 1846, 'text': 'the CKD sample, NfL level is associated with abnormal kidney function and brain structure. Decrea', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34274959'}]\n\n\n             'Please list the diseases associated with elevations in the plasma Neurofilament Light chain (NfL).'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Neurofilament light chain (NfL) is a biomarker of neurodegeneration and is associated with many diseases such as MS, CKD, Ataxia telangiectasia, Langerhans cell histiocytosis (LCH) and acute and chronic inflammatory polyneuropathies"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 290, 'text': 'Accessible chromatin often represents gene regulatory elements, including promoters and enhancers, essential for gene expression. Assay for Transposase Accessible Chromatin sequencing (ATAC-seq) is one of the most popular techniques to investigate chromatin accessibility across the genome.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36173566'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 767, 'text': 'Functional cis-regulatory elements (CREs) act as precise transcriptional switches for fine-tuning gene transcription. Identification of CREs is critical for understanding regulatory mechanisms of gene expression associated with various biological processes in eukaryotes. It is well known that CREs reside in open chromatin that exhibits hypersensitivity to enzyme cleavage and physical shearing. Currently, high-throughput methodologies, such as DNase-seq, ATAC-seq, and FAIRE-seq, have been widely applied in mapping open chromatin in various eukaryotic genomes. More recently, differential MNase (micrococcal nuclease) treatment has been successfully employed to map open chromatin in addition to profiling nucleosome landscape in both mammalian and plant species.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36264486'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 331, 'text': \"Micrococcal nuclease (MNase) originating from Staphylococcus aureus is a calcium dependent ribo- and desoxyribonuclease which has endo- and exonucleolytic activity of low sequence preference. MNase is widely used to analyze nucleosome positions in chromatin by probing the enzyme's DNA accessibility in limited digestion reactions.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35796986'}, {'offsetInBeginSection': 1120, 'offsetInEndSection': 1384, 'text': 'In this review, we discuss techniques for determining DNA accessibility and nucleosome positioning (DNase-seq, FAIRE-seq, MNase-seq, and ATAC-seq) and techniques for detecting and functionally characterizing chromatin-bound proteins (ChIP-seq, DamID, and CUT&RUN).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31776829'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 520, 'text': 'Recent advancements in next-generation sequencing technologies and accompanying reductions in cost have led to an explosion of techniques to examine DNA accessibility and protein localization on chromatin genome-wide. Generally, accessible regions of chromatin are permissive for factor binding and are therefore hotspots for regulation of gene expression; conversely, genomic regions that are highly occupied by histone proteins are not permissive for factor binding and are less likely to be active regulatory regions.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31776829'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 207, 'text': 'The ATAC-seq assay has emerged as the most useful, versatile, and widely adaptable method for profiling accessible chromatin regions and tracking the activity of cis-regulatory elements (cREs) in eukaryotes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33606259'}, {'offsetInBeginSection': 356, 'offsetInEndSection': 655, 'text': 'We have developed a method for profiling the accessibility of individual chromatin fibers, a single-molecule long-read accessible chromatin mapping sequencing assay (SMAC-seq), enabling the simultaneous, high-resolution, single-molecule assessment of chromatin states at multikilobase length scales.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32042188'}, {'offsetInBeginSection': 327, 'offsetInEndSection': 509, 'text': 'Recently, ATAC-seq (assay for transposase-accessible chromatin using sequencing) has emerged as one of the most powerful approaches for genome-wide chromatin accessibility profiling.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30948010'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 167, 'text': 'Assay for transposase-accessible chromatin using sequencing data (ATAC-seq) is an efficient and precise method for revealing chromatin accessibility across the genome.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33584814'}, {'offsetInBeginSection': 124, 'offsetInEndSection': 260, 'text': 'We previously developed a single-cell DNase-seq assay (scDNase-seq) to profile accessible chromatin in a limited number of single cells.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33693880'}, {'offsetInBeginSection': 688, 'offsetInEndSection': 770, 'text': 'DNase-seq and the more recent ATAC-seq are two assays that are gaining popularity.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27008018'}, {'offsetInBeginSection': 510, 'offsetInEndSection': 691, 'text': 'This method assesses DNA accessibility using hyperactive Tn5 transposase, which simultaneously cuts DNA and inserts sequencing adaptors, preferentially in regions of open chromatin.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30948010'}, {'offsetInBeginSection': 178, 'offsetInEndSection': 426, 'text': 'For example, assay for transposase accessible chromatin sequencing (ATAC-seq) identifies nucleosome-depleted (open) chromatin, which harbors potentially active gene regulatory sequences; and bisulfite sequencing (BS-seq) quantifies DNA methylation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31160376'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 111, 'text': 'Characterization of chromatin accessibility with a transposome hypersensitive sites sequencing (THS-seq) assay.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26846207'}, {'offsetInBeginSection': 343, 'offsetInEndSection': 471, 'text': 'We present a transposome hypersensitive sites sequencing assay for highly sensitive characterization of chromatin accessibility.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26846207'}, {'offsetInBeginSection': 145, 'offsetInEndSection': 261, 'text': 'DNase I and Tn5 transposase assays require thousands to millions of fresh cells for comprehensive chromatin mapping.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26846207'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 232, 'text': 'The assay for transposase-accessible chromatin using sequencing (ATAC-seq) provides a simple and scalable way to detect the unique chromatin landscape associated with a cell type and how it may be altered by perturbation or disease.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35478247'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 154, 'text': 'Assay for Transposase-Accessible Chromatin using sequencing (ATAC-Seq) is a method to investigate the accessibility of chromatin in a genome-wide fashion.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34382186'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 189, 'text': 'The assay for transposase-accessible chromatin using sequencing (ATAC-seq) has become the preferred method for mapping chromatin accessibility due to its time and input material efficiency.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32213349'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 200, 'text': 'Chromatin accessibility profiling assays such as ATAC-seq and DNase1-seq offer the opportunity to rapidly characterize the regulatory state of the genome at a single nucleotide resolution.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30064353'}, {'offsetInBeginSection': 186, 'offsetInEndSection': 414, 'text': \"Chromatin accessibility experiments such as DNaseI sequencing (DNase-seq) and Assay for Transposase Accessible Chromatin sequencing (ATAC-seq) produce genome-wide data that include distinct 'footprint' patterns at binding sites.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27993786'}]\n\n\n             'What are the most common assays to profile chromatin accessibility?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Recent advancements in next-generation sequencing technologies and accompanying reductions in cost have led to an explosion of techniques to examine chromatin accessibility genome-wide. Generally, accessible regions of chromatin are permissive for factor binding and are therefore hotspots for regulation of gene expression. Therefore, identification of these regions is critical for understanding regulatory mechanisms of gene expression associated with various biological processes in eukaryotes.\n\nCurrently, high-throughput methodologies, such as DNase-seq, ATAC-seq, FAIRE-seq, and MNase-seq have been widely applied in mapping open chromatin in various eukaryotic genomes."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 352, 'offsetInEndSection': 651, 'text': \"We conducted a phase I/II double-blind, comparator-controlled trial with 2 doses of RT001 in Friedreich's ataxia patients (9 subjects each cohort). Subjects were randomized 2:1 to receive either RT001 (1.8 or 9.0 g/day), or a matching dose of nondeuterated ethyl linoleate as comparator for 28 days.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29624723'}]\n\n\n             'What doses of RT001 were used in the phase I/II double-blind, comparator-controlled trial of Friedreich's ataxia patients?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "In the phase I/II double-blind, comparator-controlled trial of RT001 in Friedreich's ataxia patients two doses of the drug were evaluated 1.8 or 9.0 g/day."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 1037, 'offsetInEndSection': 1129, 'text': 'The tools used to control pain in infants in the article included PIPP,NFCS,NIPS AND NPASS. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35410609'}, {'offsetInBeginSection': 98, 'offsetInEndSection': 226, 'text': 'The Neonatal Pain, Agitation, and Sedation Scale (N-PASS) and the Neonatal Infant Pain Scale (NIPS) are valid measures of pain. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35362716'}, {'offsetInBeginSection': 526, 'offsetInEndSection': 758, 'text': 'Fifteen bedside nurses trained to use the N-PASS and the NIPS prospectively completed 202 pain/agitation and sedation assessments from a convenience sample of 88 infants, including chronically ventilated, medically fragile infants. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35362716'}, {'offsetInBeginSection': 11, 'offsetInEndSection': 311, 'text': 'The present study evaluated the correlation of Neonatal Infant Pain Scale (NIPS) and Premature Infant Pain Profile-Revised (PIPP-R), with changes in cerebral oxygenation (\u0394crSO2; measured by near-infrared spectroscopy) in preterm infants during acute painful procedures (heel lance and venepuncture).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36271296'}, {'offsetInBeginSection': 427, 'offsetInEndSection': 523, 'text': 'A cornerstone in pain assessment is the use of scales such as COMFORT, PIPP-R, NIPS and N-PASS. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36291504'}, {'offsetInBeginSection': 79, 'offsetInEndSection': 379, 'text': 'The aim of this study was to assess the reliability, validity, and clinical utility of the Neonatal Facial Coding System (NFCS), Douleur Aigu\u00eb du Nouveau-n\u00e9 (DAN) scale, Neonatal Infant Pain Scale (NIPS), and Premature Infant Pain Profile (PIPP) in premature infants undergoing heel blood collection.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32599608'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 462, 'text': \"BACKGROUND: Practical, valid and reliable pain measuring tools in neonates are required in clinical practice for effective pain management and prevention of the evaluator bias.METHODS: This prospective study was designed to cross-validate three pain scales: CRIES (cry, requires O(2), increased vital signs, expression, sleeplessness), CHIPPS (children's and infants' postoperative pain scale) and NIPS (neonatal infant pain scale) in terms of validity, reliabil\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16885171'}, {'offsetInBeginSection': 2163, 'offsetInEndSection': 2517, 'text': \"natal Infant Acute Pain Assessment Scale perform better in reliability. The Neonatal Pain, Agitation, and Sedation Scale appears to be a better choice for frontier nurses to assess procedural pain in ventilated neonates based on its good feasibility, utility and nurses' preference.RELEVANCE TO CLINICAL PRACTICE: Choosing a valid, reliable, feasible and\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29945293'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 542, 'text': 'OBJECTIVE: To temporally assess a painful stimulus in premature infants using 3 neonatal pain scales.METHODS: A total of 83 premature infants were observed during airway aspiration by 3 evaluators (E1, E2 and E3) using 3 pain assessment scales (Neonatal Facial Coding System - NFCS; Neonatal Infant Pain Scale - NIPS; and Premature Infant Pain Profile - PIPP) at 5 time points: T1 (before airway aspiration), T2 (during airway aspiration), T3 (1 minute after airway aspiration), T4 (3 minutes after airway aspiration), and T5 (5 minutes after', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32401971'}, {'offsetInBeginSection': 737, 'offsetInEndSection': 946, 'text': \"e frequently than Norwegian units. The most frequently used scales were different versions of Astrid Lindgren's Pain Scale (ALPS) in Sweden and Echelle Douleur Inconfort Noveau-Ne (EDIN), ALPS and Premature In\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29282767'}, {'offsetInBeginSection': 1766, 'offsetInEndSection': 2162, 'text': 'r than those of the Premature Infant Pain Profile-Revised. The Neonatal Pain, Agitation, and Sedation Scale was mostly preferred by 55.9% of the nurses, followed by the Neonatal Infant Acute Pain Assessment Scale (23.5%) and the Premature Infant Pain Profile-Revised (20.6%).CONCLUSIONS: The three scales are all reliable and valid, but the Neonatal Pain, Agitation, and Sedation Scale and the Ne', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29945293'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 247, 'text': 'OBJECTIVE: This study evaluated neonatal pain scales during procedures commonly performed in a neonatal intensive care unit.DESIGN: Evaluated were the Neonatal Infant Pain Scale (NIPS), the Comfort scale, and a new scale known as the Scale for Use', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9535312'}, {'offsetInBeginSection': 288, 'offsetInEndSection': 517, 'text': 'uded in the study. Video recordings of infants during heel prick blood sampling were evaluated by two observers according to the Neonatal Infant Pain Scale (NIPS), the Neonatal Facial Coding System (NFCS), and the Douleur Aigu\u00eb d', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18446656'}, {'offsetInBeginSection': 616, 'offsetInEndSection': 832, 'text': 'Pain was assessed using indicators from three previously established scales (CRIES, the Premature Infant Pain Profile, and the Neonatal Infant Pain Scale), as well as the COVERS Scale, depending upon gestational age.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20976299'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 171, 'text': '[Measures for the assessment of pain in neonates as well as a comparison between the Bernese Pain Scale for Neonates (BPSN) with the Premature Infant Pain Profile (PIPP)].', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14747965'}, {'offsetInBeginSection': 427, 'offsetInEndSection': 522, 'text': 'A cornerstone in pain assessment is the use of scales such as COMFORT, PIPP-R, NIPS and N-PASS.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36291504'}, {'offsetInBeginSection': 1783, 'offsetInEndSection': 1933, 'text': 'he Premature Infant Pain Profile-Revised. The Neonatal Pain, Agitation, and Sedation Scale was mostly preferred by 55.9% of the nurses, followed by th', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29945293'}]\n\n\n             'What are the most common pain scales used to measure pain in neonates?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "The most common pain scales used to measure pain in neonates are the following: Premature Infant Pain Profile-Revised (PIPP), Premature Infant Pain Profile-Revised (PIPP-R), Neonatal Facial Coding System (NFCS), Neonatal Infant Pain Scale (NIPS), Neonatal Pain, Agitation, and Sedation Scale (NPASS), COMFORT and Douleur Aigu\u00eb du Nouveau-n\u00e9 (DAN)."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 2858, 'offsetInEndSection': 2995, 'text': 'INTERPRETATION: Prehospital treatment with transdermal GTN does not seem to improve functional outcome in patients with presumed stroke. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30738649'}, {'offsetInBeginSection': 1718, 'offsetInEndSection': 1823, 'text': 'Conclusions- Prehospital treatment with GTN worsened outcomes in patients with intracerebral hemorrhage. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31587658'}]\n\n\n             'Was prehospital transdermal glyceryl trinitrate effective for stroke in the RIGHT-2 trial?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "No. Prehospital treatment with transdermal glyceryl trinitrate did not improve functional outcome in patients with presumed stroke."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 250, 'text': \"Friedreich's ataxia (FRDA) is an autosomal recessive disease caused by an intronic guanine-adenine-adenine (GAA) triplet expansion in the frataxin (FXN) gene, which leads to reduced expression of full-length frataxin (1-210) also known as isoform 1. \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35573317'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 147, 'text': \"Friedreich's ataxia (FRDA) is an inherited, multisystemic disorder predominantly caused by GAA hyper expansion in intron 1 of frataxin (FXN) gene. \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35663795'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 184, 'text': 'Friedreich ataxia, the most common hereditary ataxia, is a neuro- and cardio-degenerative disorder caused, in most cases, by decreased expression of the mitochondrial protein frataxin.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36107856'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 133, 'text': \"Simultaneous Quantification of Mitochondrial Mature Frataxin and Extra-Mitochondrial Frataxin Isoform E in Friedreich's Ataxia Blood.\", 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35573317'}, {'offsetInBeginSection': 1338, 'offsetInEndSection': 1454, 'text': 'We now report a quantitative assay for frataxin proteoforms in whole blood from healthy controls and FRDA patients. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35573317'}, {'offsetInBeginSection': 1925, 'offsetInEndSection': 2122, 'text': 'The mean levels of mature frataxin in whole blood from healthy controls and homozygous FRDA patients were significantly different (p < 0.0001) at 7.5 \u00b1 1.5 ng/mL and 2.1 \u00b1 1.2 ng/mL, respectively. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35573317'}, {'offsetInBeginSection': 2315, 'offsetInEndSection': 2511, 'text': 'he mean levels of total frataxin in whole blood from healthy controls and homozygous FRDA patients were significantly different (p < 0.0001) at 34.2 \u00b1 4.3 ng/mL and 6.8 \u00b1 4.0 ng/mL, respectively. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35573317'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 123, 'text': \"Friedreich's ataxia is caused by mutations in the FRDA gene that encodes frataxin, a nuclear-encoded mitochondrial protein.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10982187'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 203, 'text': \"Friedreich's ataxia (FRDA) is a progressive neurodegenerative disorder caused by a homozygous GAA repeat expansion mutation in intron 1 of the frataxin gene (FXN), which instigates reduced transcription.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32582297'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 113, 'text': 'Friedreich Ataxia (FA) is a rare neuro-cardiodegenerative disease caused by mutations in the frataxin (FXN) gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35038030'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 154, 'text': \"Friedreich's ataxia, characterized by decreased expression of frataxin protein, is caused by GAA trinucleotide repeats within intron 1 in 98% of patients.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31020006'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 144, 'text': \"Friedreich's ataxia is a neurodegenerative disorder associated with a GAA trinucleotide repeat expansion in intron 1 of the frataxin (FXN) gene.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30159187'}, {'offsetInBeginSection': 124, 'offsetInEndSection': 315, 'text': 'Most patients are homozygous for the expansion of a GAA triplet repeat within the FRDA gene, but a few patients show compound heterozygosity for a point mutation and the GAA-repeat expansion.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10982187'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 190, 'text': \"Friedreich's ataxia (FRDA) is a genetic neurodegenerative disease that is caused by guanine-adenine-adenine (GAA) nucleotide repeat expansions in the first intron of the frataxin (FXN) gene.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32291635'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 198, 'text': \"Friedreich's ataxia (FRDA), the most common autosomal recessively inherited ataxia, is due to a homozygous GAA triplet repeat expansion in the first intron of the FRDA gene in about 96% of patients.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15340363'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 94, 'text': \"Friedreich's ataxia is due to loss of function mutations in the gene encoding frataxin (FRDA).\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9241270'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 113, 'text': 'Friedreich ataxia, an autosomal recessive neurodegenerative disease, is the most common of the inherited ataxias.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10633128'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 101, 'text': \"Mutations in Frataxin (FXN) cause Friedreich's ataxia (FRDA), a recessive neurodegenerative disorder.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27343351'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 148, 'text': 'The genetic mutation in Friedreich ataxia (FRDA) is a hyperexpansion of the triplet-repeat sequence GAA\u00b7TTC within the first intron of the FXN gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22798143'}, {'offsetInBeginSection': 415, 'offsetInEndSection': 575, 'text': \"The expansion of a GAA triplet repeat within the first intron of the frataxin gene, which causes Friedreich's ataxia, was not identified in any of the patients.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10686465'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 208, 'text': \"BACKGROUND: Friedreich's ataxia is an autosomal-recessive cerebellar ataxia caused by mutation of the frataxin gene, resulting in decreased frataxin expression, mitochondrial dysfunction, and oxidative stress\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30624801'}]\n\n\n             'What gene is mutated in Friedreich's ataxia?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Friedreich's ataxia (FRDA) is an inherited, multisystemic disorder predominantly caused by GAA hyper expansion in intron 1 of the frataxin (FXN) gene"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 141, 'text': 'The Effects of Two Nrf2 Activators, Bardoxolone Methyl and Omaveloxolone, on Retinal Ganglion Cell Survival during Ischemic Optic Neuropathy.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34573098'}, {'offsetInBeginSection': 690, 'offsetInEndSection': 853, 'text': 'Omaveloxolone (RTA 408) is an activator of Nrf2 and an inhibitor of NF\u03baB, possessing antioxidative and anti-inflammatory activities in mitochondrial bioenergetics.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34573098'}]\n\n\n             'Is omaveloxolone a suppressor of Nrf2?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "No, omaveloxolone is an activator of Nrf2."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 1377, 'offsetInEndSection': 1604, 'text': 'We observed the increase in SC concentrations in response to painful stimulus. The presence of a correlation between NIPS scores and SC increase suggests that SC can be used as an objective parameter to assess pain in neonates.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36282969'}]\n\n\n             'Can salivary cortisol be used to evaluate pain in neonates?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Yes, salivary cortisol concentrations can be used to evaluate pain in neonates."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 2743, 'offsetInEndSection': 2938, 'text': 'INTERPRETATION: The addition of nintedanib to chemotherapy was safe but did not improve the rate of pathological complete response in muscle-invasive bladder cancer.FUNDING: Boehringer Ingelheim.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35421369'}]\n\n\n             'Does nintedanib improve response rate in patients with bladder cancer?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "No. The addition of nintedanib to chemotherapy was safe but did not improve the rate of pathological complete response in muscle-invasive bladder cancer."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 254, 'offsetInEndSection': 494, 'text': 'Three types of nucleic acid-based gene silencing molecules can be distinguished, including DNA-base antisense oligonucleotides (ASO), nucleic acid enzymes (ribozyme and DNAzyme) and double-stranded small interfering RNA (siRNA or microRNA).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18508540'}, {'offsetInBeginSection': 228, 'offsetInEndSection': 545, 'text': 'Antisense oligonucleotides are synthetic single stranded strings of nucleic acids that bind to RNA and thereby alter or reduce expression of the target RNA while siRNAs, on the other hand, are double-stranded RNA molecules which can hybridize with a specific mRNA sequence and block the translation of numerous genes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28064104'}, {'offsetInBeginSection': 176, 'offsetInEndSection': 415, 'text': 'However, in practice the term \"antisense\" has been used to describe single stranded oligonucleotides (ss ASOs) designed to hybridize to RNAswhile the term \"siRNA\" has come to mean double stranded oligonucleotides designed to activate Ago2.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32800852'}]\n\n\n             'What is the difference between siRNA and Antisense oligonucleotide therapeutics'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "DNA-base antisense oligonucleotides (ASO) arw single stranded in contrast to double-stranded small interfering RNA (siRNA or microRNA)"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 108, 'text': 'Preliminary evaluation of YUTIQ\u2122 (fluocinolone acetonide intravitreal implant 0.18\\xa0mg) in posterior uveitis.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31663454'}, {'offsetInBeginSection': 568, 'offsetInEndSection': 792, 'text': 'This article will review the pharmacology and preliminary clinical data of the 0.18\\xa0mg fluocinolone acetonide intravitreal implant (YUTIQ\u2122), to show its efficacy and safety in the treatment of noninfectious posterior uveitis', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31663454'}]\n\n\n             'What is Yutiq?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Yutiq is a 0.18 mg fluocinolone acetonide intravitreal implant (YUTIQ\u2122) used in the treatment of noninfectious posterior uveitis."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 12, 'offsetInEndSection': 152, 'text': 'Duchenne muscular dystrophy (DMD/Duchenne) is a progressive X-linked muscular disease with an overall incidence of 1:5,000 live male births.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35562557'}, {'offsetInBeginSection': 966, 'offsetInEndSection': 1094, 'text': 'The cumulative incidence of disease was 19.7 per 100,000 male live births and 1 in 5076 live born males were diagnosed with DMD.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35754057'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 209, 'text': 'Duchenne muscular dystrophy is a genetically determined disease, linked to the X chromosome, c haracterized clinically by producing progressive muscle weakness, with an incidence of 1 per 3500-6000 males born.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31603849'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 218, 'text': 'Duchenne muscular dystrophy (DMD) is a progressive wasting disease of skeletal and cardiac muscles, representing one of the most common recessive fatal inherited genetic diseases with 1:3500-1:5000 in yearly incidence.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29386334'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 190, 'text': 'INTRODUCTION: Duchenne muscular dystrophy is the most common form of muscular dystrophy, with an incidence of 1/3300 male live births and a prevalence rate in the total population of 3/10000', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25996334'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 177, 'text': 'Duchenne/Becker muscular dystrophy is a severe, recessive, X-linked neuromuscular disease with an incidence of 1/3500 (Duchenne type) and 1/30,000 (Becker type) in newborn boys.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18055393'}, {'offsetInBeginSection': 283, 'offsetInEndSection': 474, 'text': 'Statistics Canada data on annual male births in Nova Scotia were obtained for each year.The overall incidence of 1 per 4700 male births remained stable during the 30-year period of the study.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20080524'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 214, 'text': 'Duchenne muscular dystrophy (DMD) is inherited in an X-linked recessive pattern and occurs at an incidence of 1 in 3500 male births, which means that it is a so-called \"orphan\" or rare disease (frequency < 1/2000).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16114258'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 244, 'text': 'Duchenne muscular dystrophy (DMD) is the most common fatal muscle disease, with an estimated incidence of 1/3500-1/5000 male births, and it is associated with mutations in the X-linked DMD gene encoding dystrophin, the largest known human gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36012442'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 117, 'text': 'Duchenne muscular dystrophy (DMD) is a common inherited disease with a worldwide incidence of 1 in 3,500 male births.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8629099'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 149, 'text': 'Duchenne muscular dystrophy (DMD) is one of the most common and severe X-linked disorders with an incidence of approximately 1 in 3500 newborn males.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7705851'}, {'offsetInBeginSection': 701, 'offsetInEndSection': 955, 'text': 'The cumulative birth incidence of Becker muscular dystrophy (at least 1 in 18 450 male live births) was about one third that of Duchenne muscular dystrophy (1 in 5618 male live births), suggesting that the disorder is more common than previously thought.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1673177'}, {'offsetInBeginSection': 57, 'offsetInEndSection': 207, 'text': 'scular dystrophy in childhood, with a worldwide incidence of one in 5000 live male births. It is due to mutations in the dystrophin gene leading to ab', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28802771'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 203, 'text': 'INTRODUCTION: Duchenne muscular dystrophy is the most common form of muscular dystrophy, with an incidence of 1/3300 male live births and a prevalence rate in the total population of 3/100000 individuals', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25996334'}, {'offsetInBeginSection': 577, 'offsetInEndSection': 727, 'text': 'ur region too. The incidence of Duchenne muscular dystrophy was 1 in 4827 liveborn boys. The figure is in the range of the published data of the incid', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7922631'}, {'offsetInBeginSection': 258, 'offsetInEndSection': 408, 'text': 'ular dystrophies the authors estimate the incidence of DMD at 1/6500 living new born boys. The number of false positives (1,5 p. 1000) is little and, ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7334342'}]\n\n\n             'What is the incidence of Duchenne Muscular Dystrophy?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "The incidence of Duchenne Muscular Dystrophy is approximately 1:5,000 live male births"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 154, 'text': 'Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35940183'}, {'offsetInBeginSection': 349, 'offsetInEndSection': 1031, 'text': 'METHODS: TRICOTEL was a multicentre, open-label, single-arm, phase 2 study done in two cohorts: a BRAFV600 wild-type cohort and a BRAFV600 mutation-positive cohort, recruited at 21 hospitals and oncology centres in Brazil, France, Germany, Hungary, Italy, Spain, and Switzerland. Eligible patients were aged 18 years or older with previously untreated metastatic melanoma, CNS metastases of 5 mm or larger in at least one dimension, and an Eastern Cooperative Oncology Group performance status of 2 or less. Patients in the BRAFV600 wild-type cohort received intravenous atezolizumab (840 mg, days 1 and 15 of each 28-day cycle) plus oral cobimetinib (60 mg once daily, days 1-21). ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35940183'}]\n\n\n             'Which drugs were studied in the TRICOTEL study?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "TRICOTEL trial studied atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 197, 'text': 'Amniotic fluid (AF) is created by the flow of fluid from the fetal lung and bladder and reabsorbed in part by fetal swallowing and partly by the transfer across the amnion to the fetal circulation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22425592'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 232, 'text': 'Amniotic fluid contains large amounts of proteins produced by amnion epithelial cells, fetal tissues, fetal excretions and placental tissues; thus, it is an important potential source of biomarkers for identifying fetal pathologies.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29684686'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 401, 'text': 'Amniotic fluid (AF), routinely used for prenatal diagnosis, contains large amounts of proteins produced by the amnion epithelial cells, fetal tissues, fetal excretions and placental tissuesAlthough many amniotic fluid proteins have been identified and are currently used to detect potential fetal anomalies, little is known about the functions of these proteins and how they interact with one another.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22439042'}, {'offsetInBeginSection': 225, 'offsetInEndSection': 304, 'text': 'Amniotic fluid is created by the flow of fluid from the fetal lung and bladder.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17254633'}, {'offsetInBeginSection': 155, 'offsetInEndSection': 255, 'text': 'Amniotic fluid is produced by fetal urines with small aliquots from fetal membranes and lung fluids.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15301291'}, {'offsetInBeginSection': 331, 'offsetInEndSection': 482, 'text': 'As fetal urine and perhaps lung liquid combine to produce amniotic fluid, maternal dehydration may affect the amniotic fluid volume and/or composition.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/2286751'}, {'offsetInBeginSection': 225, 'offsetInEndSection': 304, 'text': 'Amniotic fluid is created by the flow of fluid from the fetal lung and bladder.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17303237'}]\n\n\n             'How is amniotic fluid produced?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Amniotic fluid (AF) is created by the flow of fluid from the fetal lung and bladder and reabsorbed in part by fetal swallowing and partly by the transfer across the amnion to the fetal circulation."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 109, 'text': 'Bacillus Calmette-Guerin for the Treatment of Non-muscle Invasive Bladder Cancer: History and Current Status.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36274226'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 302, 'text': 'In the past decades, the bacillus Calmette-Guerin (BCG) treatment for non-muscle invasive bladder cancer, especially for intermediate and high-risk groups, is increasingly accepted by multiple guidelines. Currently, the front-line setting for the high-risk group is still intravesical BCG instillation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36274226'}]\n\n\n             'Which cancer is the BCG vaccine used for?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "The Bacillus Calmette-Guerin vaccine is used for the teatment of non-muscle invasive bladder cancer."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 211, 'offsetInEndSection': 398, 'text': 'Congenital muscular dystrophies (CMD) include dystroglycanopathies, merosin-deficient CMD, collagen VI-deficient CMD, SELENON-related rigid spine muscular dystrophy, and LMNA-related CMD.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35562158'}, {'offsetInBeginSection': 190, 'offsetInEndSection': 451, 'text': 'This chapter reviews the most common forms of congenital muscular dystrophies, including laminin \u03b1-2 (merosin) deficiency, Ullrich congenital muscular dystrophy, fukutin-related proteinopathy, rigid spine syndrome, and glycosylation disorders of \u03b1-dystroglycan.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23622361'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 290, 'text': 'OBJECTIVES: The collagen VI related muscular dystrophies (COL6-RD), Ullrich congenital muscular dystrophy (UCMD) and Bethlem myopathy (BM) are among the most common congenital muscular dystrophies and are characterized by distal joint laxity and a combination of distal and proximal joint c', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29244830'}, {'offsetInBeginSection': 521, 'offsetInEndSection': 887, 'text': 'g more heavily on genetic findings. This article reviews the clinical and genetic features of the most common congenital muscular dystrophies including laminin subunit alpha 2 (LAMA2)-related (merosin deficient), collagen VI-related, and \u03b1-dystroglycan-related congenital muscular dystrophies and reviews the most common congenital myopathies including nemaline rod,', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31794464'}, {'offsetInBeginSection': 630, 'offsetInEndSection': 871, 'text': 'In this review, we summarize the clinical features of two of the most common congenital muscular dystrophies, COL6-related dystrophies and LAMA2-related dystrophies, which are caused by mutations in muscle ECM and basement membrane proteins.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29933045'}, {'offsetInBeginSection': 334, 'offsetInEndSection': 441, 'text': 'Mutations in LAMA2 cause the most common type of congenital muscular dystrophies, called LAMA2 MD or MDC1A.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29191403'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 258, 'text': 'Dystroglycanopathies are a clinically and genetically diverse group of recessively inherited conditions ranging from the most severe of the congenital muscular dystrophies, Walker-Warburg syndrome, to mild forms of adult-onset limb-girdle muscular dystrophy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23288328'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 192, 'text': 'Congenital muscular dystrophy type 1A (MDC1A), the most common congenital muscular dystrophy in Western countries, is caused by recessive mutations in LAMA2, the gene encoding laminin alpha 2.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34568901'}, {'offsetInBeginSection': 607, 'offsetInEndSection': 784, 'text': ' most common forms were those with \u03b1-dystroglycan glycosylation deficiency (40.18%) followed by those with laminin \u03b12 deficiency (24.11%) and collagen VI deficiency (20.24%). Th', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25653289'}, {'offsetInBeginSection': 558, 'offsetInEndSection': 924, 'text': 'his article reviews the clinical and genetic features of the most common congenital muscular dystrophies including laminin subunit alpha 2 (LAMA2)-related (merosin deficient), collagen VI-related, and \u03b1-dystroglycan-related congenital muscular dystrophies and reviews the most common congenital myopathies including nemaline rod, core, and centronuclear myopathies. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31794464'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 217, 'text': \"Congenital LAMA2 related muscular dystrophy (LAMA2-RD), the most commonly recognized type of congenital muscular dystrophies, has been described in patients' cohorts from Europe and the UK but not from Middle-Eastern.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32444167'}, {'offsetInBeginSection': 386, 'offsetInEndSection': 536, 'text': 's and degeneration apparent at birth or in the first 6 months of life. LAMA2 MD is the most common congenital muscular dystrophy, affecting approximat', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31308722'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 227, 'text': 'Fukuyama congenital muscular dystrophy is one of the most common autosomal recessive disorders in the Japanese population, characterized by congenital muscular dystrophy in combination with cortical dysgenesis (micropolygyria).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10734260'}, {'offsetInBeginSection': 157, 'offsetInEndSection': 307, 'text': 's in Laminin a2. Turk J Pediatr 2017; 59: 338-341. Laminin \u03b12 related congenital muscular dystrophy is one of the most common congenital muscular dyst', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29376585'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 213, 'text': 'LAMA2-related congenital muscular dystrophy (MDC1A), the most commonly recognized type of congenital muscular dystrophies, is a severe neonatal onset muscle disease caused by recessive mutations in the LAMA2 gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36334577'}]\n\n\n             'What are the most common congenital muscular dystrophies?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "The most common congenital muscular dystrophies (CMD) are the following: dystroglycanopathies, merosin-deficient CMDs, collagen VI-deficient CMDs and LMNA-related CMDs."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 55, 'text': 'Teclistamab in Relapsed or Refractory Multiple Myeloma.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35661166'}, {'offsetInBeginSection': 199, 'offsetInEndSection': 345, 'text': 'In the phase 1 dose-defining portion of the study, teclistamab showed promising efficacy in patients with relapsed or refractory multiple myeloma.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35661166'}, {'offsetInBeginSection': 1946, 'offsetInEndSection': 2102, 'text': 'CONCLUSIONS: Teclistamab resulted in a high rate of deep and durable response in patients with triple-class-exposed relapsed or refractory multiple myeloma.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35661166'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 105, 'text': 'Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35749004'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 190, 'text': 'BACKGROUND: Teclistamab (JNJ-64007957), a B-cell maturation antigen \u00d7 CD3 bispecific antibody, displayed potent T-cell-mediated cytotoxicity of multiple myeloma cells in preclinical studies.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35749004'}]\n\n\n             'What disease can be treated with Teclistamab?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Teclistamab can be used for Multiple Myeloma."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 205, 'text': 'Nonlinear laser wave-mixing spectroscopy is demonstrated as a fast and sensitive detection method for heart-failure biomarkers, pro-atrial natriuretic peptide (proANP) and brain natriuretic peptide (BNP). ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36152606'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 380, 'text': 'Natriuretic peptides are biomarkers of myocardial stress and are frequently elevated among patients with severe respiratory illnesses, typically in the absence of elevated cardiac-filling pressures or clinical heart failure. Elevation of brain natriuretic peptide (BNP) or NT-proBNP is associated with worse outcomes among patients with Acute Respiratory Distress Syndrome (ARDS).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33520785'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 180, 'text': 'Natriuretic peptides (NPs, B-type natriuretic peptide /BNP and NT-proBNP) are universally used biomarkers with established cut-points to aid in the diagnosis of heart failure (HF).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33002457'}, {'offsetInBeginSection': 272, 'offsetInEndSection': 508, 'text': 'Eight natriuretic peptides have been described so far: ANP, BNP, CNP, DNP, urodilatin, uroguanylin, osteocrin, musculin and three receptors: NPR-A, NPR-B and NPR-C thanks to which these hormones accomplish their physiological functions.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33130802'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 195, 'text': 'The natriuretic peptide family consists of three biologically active peptides: atrial natriuretic peptide (ANP), brain (or B-type) natriuretic peptide (BNP), and C-type natriuretic peptide (CNP).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34871602'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 242, 'text': 'Natriuretic peptides (atrial natriuretic peptide, brain natriuretic peptide and C-type natriuretic peptide) are cardiac and vascular peptides with vasodilatory, diuretic, natriuretic, anti-inflammatory, antifibrotic and antimitogenic actions.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16548773'}, {'offsetInBeginSection': 135, 'offsetInEndSection': 411, 'text': 'There are four different groups NPs identified till date [atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), C-type natriuretic peptide (CNP) and dendroaspis natriuretic peptide, a D-type natriuretic peptide (DNP)], each with its own characteristic functions.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22145138'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 196, 'text': 'The natriuretic peptide family comprises atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), C-type natriuretic peptide (CNP), dendroaspis natriuretic peptide (DNP), and urodilatin.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17965966'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 164, 'text': 'The natriuretic system consists of the atrial natriuretic peptide (ANP) and four other similar peptides including the wrongly named brain natriuretic peptide (BNP).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23776857'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 201, 'text': 'The natriuretic peptide family is comprised of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), C-type natriuretic peptide (CNP), dendroaspis natriuretic peptide - DNP and urodilatin.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19747125'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 200, 'text': 'Four major natriuretic peptides have been isolated: atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), C-type natriuretic peptide (CNP), and Dendroaspis-type natriuretic peptide (DNP).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18703404'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 315, 'text': 'Atrial natriuretic peptides (ANPs) consist of a family of peptides (atrial natriuretic factor [ANF], long acting natriuretic peptide, vessel dilator, kaliuretic peptide, urodilatin, brain natriuretic peptide [BNP], and C type natriuretic peptide [CNP]) which are synthesized within the heart, except for urodilatin.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12189309'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 286, 'text': 'Since the discovery of the natriuretic effect of atrial natriuretic peptide (ANP), a family of other natriuretic peptides similar to ANP were isolated, including atriopeptin, vessel dilator, long-acting natriuretic peptide, urodilatin, and brain natriuretic peptide (BNP) to name a few.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11339846'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 364, 'text': 'The natriuretic peptide system is a complicated system comprising at least three endogenous peptides (atrial natriuretic peptide, brain natriuretic peptide and C-type natriuretic peptide) and three receptors [the atrial natriuretic peptide-A receptor (guanylyl cyclase A), the atrial natriuretic peptide-B receptor (guanylyl cyclase B) and the clearance receptor].', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8834155'}, {'offsetInBeginSection': 170, 'offsetInEndSection': 332, 'text': '126 amino acid atrial natriuretic peptide (ANP), 108 amino acid B-type natriuretic peptide (BNP) and 103 amino acid C-type natriuretic peptide (CNP) prohormones).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16487258'}, {'offsetInBeginSection': 336, 'offsetInEndSection': 707, 'text': \"The recent description of the C-type peptide CNP, the major brain-derived peptide, has suggested that original studies examining the endocrine actions of the natriuretic peptides using A-type (ANP) or B-type (BNP) isoforms might have underestimated some of the biopotency of the natriuretic peptides or even failed to detect the full spectrum of the family's bioactivity.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18407084'}, {'offsetInBeginSection': 274, 'offsetInEndSection': 496, 'text': 'The NP family includes atrial natriuretic peptide (ANP, 28AA), urodilatin (INN: Ularitide, 32 AA), B-type natriuretic peptide (BNP, 32AA), C-type natriuretic peptide (CNP, 22AA), and D-type natriuretic peptide (DNP, 38AA).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19149542'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 171, 'text': 'Atrial cardiocytes in the heart of mammals produce in a regulated manner the polypeptide hormones atrial natriuretic factor (ANF, ANP) and brain natriuretic peptide (BNP).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16269246'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 165, 'text': 'Three types of natriuretic peptides (NP) have been isolated: atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15758553'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 196, 'text': 'Natriuretic hormones (NH) include three groups of compounds: the natriuretic peptides (ANP, BNP and CNP), the gastrointestinal peptides (guanylin and uroguanylin), and endogenous cardiac steroids.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25506340'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 195, 'text': 'The natriuretic peptide family consists of three biologically active peptides: atrial natriuretic peptide (ANP), brain (or B-type) natriuretic peptide (BNP), and C-type natriuretic peptide (CNP).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29859763'}, {'offsetInBeginSection': 169, 'offsetInEndSection': 429, 'text': 'The family consists of an atrial natriuretic peptide (ANP) and a brain natriuretic peptide (BNP) of myocardial cell origin, a C-type natriuretic peptide (CNP) of endothelial origin, and a urodilatin (Uro) which is processed from a prohormone ANP in the kidney.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26961205'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 229, 'text': 'Natriuretic peptides family consists of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and C-type natriuretic peptide (CNP), while receptors for these natriuretic peptides comprise at least three subtypes, i.e.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8392634'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 196, 'text': 'Natriuretic peptide family consists of several hormones produced by cardiomyocyte, including atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and C-type natriuretic peptide (CNP).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22382054'}, {'offsetInBeginSection': 96, 'offsetInEndSection': 299, 'text': 'Four types of natriuretic peptides have been found thus far: atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), C-type natriuretic peptide (CNP) and Dendroaspis natriuretic peptide (DNP).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12843686'}, {'offsetInBeginSection': 111, 'offsetInEndSection': 351, 'text': 'The natriuretic peptides - atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide - comprise a family of proteins that participate in the integrated control of intravascular volume and arterial blood pressure.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11476733'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 144, 'text': 'The natriuretic peptide family consists of three members: atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7496058'}, {'offsetInBeginSection': 128, 'offsetInEndSection': 293, 'text': 'They consist of atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide and are elevated in patients with left ventricular dysfunction.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12783635'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 229, 'text': 'Cardiac natriuretic peptides (including ANP, BNP, CNP and urodilatin) constitute a family of peptide hormones and neurotransmitters, sharing similar chemical structure (characterized by a cysteine bridge) and biological function.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16565701'}, {'offsetInBeginSection': 183, 'offsetInEndSection': 333, 'text': ' that activate receptor guanylate cyclases, namely, natriuretic peptide receptor (NPR)-A and NPR-B. Exposure of cells to atrial natriuretic peptide (A', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8967430'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 168, 'text': 'BACKGROUND: In mammals, the natriuretic system contains three natriuretic peptides, NPPA, NPPB and NPPC, that bind to three transmembrane receptors, NPR1, NPR2 and NPR3', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31771521'}]\n\n\n             'Please list the natriuretic peptides.'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Natriuretic peptides (NPs, B-type natriuretic peptide /BNP and NT-proBNP) are universally used biomarkers with established cut-points to aid in the diagnosis of heart failure (HF)"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 88, 'text': 'Neuronal-specific microexon splicing of TAF1 mRNA is directly regulated by SRRM4/nSR100.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31559909'}, {'offsetInBeginSection': 688, 'offsetInEndSection': 964, 'text': \"Knockdown and ectopic expression experiments demonstrate that the neuronal-specific splicing factor SRRM4/nSR100 promotes the inclusion of microexon 34' into TAF1\\xa0mRNA, through the recognition of UGC sequences in the poly-pyrimidine tract upstream of the regulated microexon. \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31559909'}]\n\n\n             'Does SRRM4 regulate neuronal-specific microexon splicing of TAF1 mRNA?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Neuronal-specific microexon splicing of TAF1 mRNA is directly regulated by SRRM4/nSR100."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 544, 'offsetInEndSection': 811, 'text': 'FSHD type 1 (FSHD1) is due to a deletion on chromosome 4q, leading to hypomethylation and derepression of DUX4. FSHD type 2 (FSHD2) is due to mutations in SMCHD1 with resulting hypomethylation of the same subtelomeric region of chromosome 4q and derepression of DUX4.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31794465'}, {'offsetInBeginSection': 448, 'offsetInEndSection': 677, 'text': 'The molecular genetics of FSHD are complex, with current understanding focusing on epigenetic effects related to contraction-dependent (FSHD1) and contraction-independent (FSHD2) effects of a hypomethylated repeat sequence (D4Z4)', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21496633'}, {'offsetInBeginSection': 371, 'offsetInEndSection': 585, 'text': 'In FSHD1, partial deletion of the D4Z4 repeats on the 4th chromosome affects the expression of DUX4, whereas FSHD2 is caused by the mutations in the protein regulating the methylation status of chromatin - SMCHD1. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30871534'}, {'offsetInBeginSection': 213, 'offsetInEndSection': 370, 'text': 'There are two types of the disease: FSHD1 (MIM:158900) and FSHD2 (MIM: 158901), which have different genetic causes but are phenotypically indistinguishable.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30871534'}]\n\n\n             'What is the difference between Facioscapulohumeral Muscular Dystrophy type 1 (FSHD1) and type 2 (FSHD2)?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "FSHD type 1 (FSHD1) and FSHD type 2 (FSHD2)  have different genetic causes but are phenotypically indistinguishable. FSHD1 is caused by a deletion on chromosome 4q, leading to hypomethylation and derepression of DUX4. FSHD type 2 (FSHD2) is due to mutations in SMCHD1 with resulting hypomethylation of the same subtelomeric region of chromosome 4q and derepression of DUX4."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 164, 'offsetInEndSection': 279, 'text': 'In ECOSPOR III, SER-109, an investigational oral microbiome therapeutic, was superior to placebo in reducing rCDI. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35789381'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 85, 'text': 'SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35045228'}, {'offsetInBeginSection': 197, 'offsetInEndSection': 343, 'text': 'SER-109 is an investigational microbiome therapeutic composed of purified Firmicutes spores for the treatment of recurrent C. difficile infection.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35045228'}, {'offsetInBeginSection': 218, 'offsetInEndSection': 464, 'text': 'We report that the manufacturing steps for SER-109, a purified investigational microbiome therapeutic developed to reduce risk of Clostridioides difficile recurrence, inactivate porcine epidemic diarrhea virus, a model coronavirus for SARS-CoV-2.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36158136'}]\n\n\n             'SER-109 is developed for prevention of which disease?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "SER-109 is an investigational microbiome therapeutic composed of purified Firmicutes spores for the treatment of recurrent C. difficile infection."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 341, 'offsetInEndSection': 550, 'text': 'hey are genetically identical and those with twin-twin transfusion syndrome(TTTS) provide an ideal natural model in whom to study the influence of differing haemodynamic stresses on the developing vascular tre', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11869491'}, {'offsetInBeginSection': 13, 'offsetInEndSection': 278, 'text': 'n twin-to-twin transfusion syndrome (TTTS), genetically identical twins are exposed to different haemodynamic conditions during fetal life, which are considered to be the cause of prenatal and postnatal cardiovascular differences between the donor and the recipient', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24972991'}, {'offsetInBeginSection': 10, 'offsetInEndSection': 195, 'text': ' To test the hypothesis that identical twins show no inter-twin differences in cardiovascular structure or physiology in fetal life unless there has been twin-twin transfusion syndrome.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12181221'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 190, 'text': 'Twin-twin transfusion syndrome (TTTS) is an unusual and serious condition that occurs in twin pregnancies when identical twins share a placenta but develop discordant amniotic fluid volumes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34400890'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 143, 'text': 'Twin-twin transfusion syndrome (TTTS) is a severe complication of monozygotic (identical) twins, which share one single monochorionic placenta.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18296754'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 147, 'text': 'Twin-twin transfusion syndrome (TTTS) is a severe complication of monozygotic (identical) twin fetuses sharing one single (monochorionic) placenta.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18354242'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 180, 'text': 'OBJECTIVE: Twin-twin transfusion syndrome (TTTS) is a severe pregnancy complication of monochorionic (identical) twins that results in markedly discordant in utero environments for', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32858578'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 673, 'text': 'BACKGROUND: In twin-to-twin transfusion syndrome (TTTS), genetically identical twins are exposed to different haemodynamic conditions during fetal life, which are considered to be the cause of prenatal and postnatal cardiovascular differences between the donor and the recipient.OBJECTIVE: To assess intertwin differences on childhood cardiac outcome after intrauterine laser coagulation therapy (LC) of severe TTTS.DESIGN AND PATIENTS: Prospective, detailed, echocardiographic follow-up of 31 twin pairs aged 9.95\u00b10.8\\u2005years (mean\u00b1SD) with severe TTTS treated by LC, and the comparison with reference values.RESULTS: Cardiac function was normal and did not show intertwin d', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24972991'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 159, 'text': 'Twin-twin transfusion syndrome is a serious complication of monozygotic, monochorionic, diamniotic twins resulting from transplacental vascular communications.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14608856'}, {'offsetInBeginSection': 2656, 'offsetInEndSection': 2807, 'text': ' Most likely, the identical twin transfusion syndrome produces anoxia and brain damage during early prenatal development in the smaller identical twin.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/848859'}, {'offsetInBeginSection': 202, 'offsetInEndSection': 412, 'text': ' A likely explanation for the association between birthweight and intelligence among identical twins is the identical twin transfusion syndrome which occurs only between some monochorionic identical twin pairs.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/848859'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 90, 'text': 'The twin-twin transfusion syndrome is a rare but severe complication in monozygotic twins.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7789711'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 220, 'text': 'Monochorionic twins are at increased risk for unique complications including twin-twin transfusion syndrome (TTTS), selective intrauterine growth restriction (sIUGR), and twin-reversed arterial perfusion (TRAP) sequence.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22536818'}]\n\n\n             'In twin-twin transfusion syndrome, are the twins identical?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "In twin-to-twin transfusion syndrome (TTTS), genetically identical twins are exposed to different haemodynamic conditions during fetal life."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'Trichotillomania is defined as an obsessive-compulsive or related disorder in which patients recurrently pull out hair from any region of their body. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35118122'}]\n\n\n             'What is the definition of trichotillomania?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Trichotillomania is defined as an obsessive-compulsive or related disorder in which patients recurrently pull out hair from any region of their body."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 104, 'text': 'The dystrophin gene (DMD) is the largest gene in the human genome, mapping on the Xp21 chromosome locus.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28867298'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 155, 'text': 'Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are X-linked recessive disorders caused by mutations of the DMD gene located at Xp21.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19461958'}, {'offsetInBeginSection': 130, 'offsetInEndSection': 255, 'text': 'The disease is caused by deletion, duplication or point mutation of the dystrophin gene, located on the X chromosome (Xp21). ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18935728'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 96, 'text': 'DMD gene which is composed of 79 exons is the largest known gene located on X chromosome (Xp21).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24274981'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'Dystrophinopathies are allelic conditions caused by deletions, duplications and point-mutations in the DMD gene, located on the X chromosome (Xp21.2).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33870095'}, {'offsetInBeginSection': 197, 'offsetInEndSection': 276, 'text': 'The disease is caused by mutations in the DMD gene located on the X chromosome.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36361862'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 98, 'text': 'BACKGROUND: The Duchenne muscular dystrophy (DMD) gene is located in the short arm of the X chromo', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24627880'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 154, 'text': 'Duchenne muscular dystrophy (DMD) is an X-linked recessive neuromuscular disorder caused by mutations in the dystrophin DMD gene located at Xp21.1 region.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18471087'}, {'offsetInBeginSection': 401, 'offsetInEndSection': 678, 'text': 'Because the DMD gene is located at Xp21.2, which is one breakpoint of the inv(X), and because its defects are rarely associated with severe mental retardation, the other clinical features of this patient were deemed likely to be associated with the opposite breakpoint at Xq22.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12145744'}, {'offsetInBeginSection': 241, 'offsetInEndSection': 368, 'text': 'Long-range physical mapping has shown that the DMD gene, localized in Xp21, is extremely large, exceeding 2 million base pairs.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/2889148'}, {'offsetInBeginSection': 329, 'offsetInEndSection': 415, 'text': 'The DMD gene, located on Xp21, is the largest human gene in the human genome (2.3 Mb).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24014122'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 193, 'text': 'The Duchenne muscular dystrophy (DMD) gene has been localized to chromosome Xp21 and codes for a 14-kilobase (kb) transcript and a protein called dystrophin, of relative molecular mass 427,000.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/2541343'}, {'offsetInBeginSection': 640, 'offsetInEndSection': 772, 'text': ' The breakpoint in our patient is also located at Xp21, adding evidence for the assignment of this band as the site of the DMD gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/6655672'}, {'offsetInBeginSection': 328, 'offsetInEndSection': 409, 'text': ' The DMD gene, located on Xp21, is the largest human gene in the human genome (2.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24014122'}, {'offsetInBeginSection': 297, 'offsetInEndSection': 381, 'text': ' The present case supports the hypothesis that the DMD gene must be located at Xp21.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/3777020'}, {'offsetInBeginSection': 185, 'offsetInEndSection': 272, 'text': ' The causal gene of DMD is the largest one in human that locates in the region of Xp21.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28247611'}, {'offsetInBeginSection': 400, 'offsetInEndSection': 441, 'text': ' Because the DMD gene is located at Xp21.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12145744'}, {'offsetInBeginSection': 39, 'offsetInEndSection': 189, 'text': 'n coded by the Duchenne muscular dystrophy (DMD) gene located on the X-chromosome. Truncating mutations in the DMD gene cause loss of dystrophin and t', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28028563'}, {'offsetInBeginSection': 71, 'offsetInEndSection': 221, 'text': 'r disorder caused by mutations in the dystrophin DMD gene located at Xp21.1 region. Up to 65% of the patients present dystrophin gene deletions. Mothe', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18471087'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 161, 'text': 'BACKGROUND: Duchenne muscular dystrophy (DMD) is caused by a defective gene located on the X-chromosome, responsible for the production of the dystrophin protein', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28740938'}, {'offsetInBeginSection': 100, 'offsetInEndSection': 250, 'text': 'l muscle disorders, caused by mutations in the dystrophin gene located in Xp21. DMD occurs with the incidence 1:3500, BMD with the incidence of 1:18,5', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19837995'}, {'offsetInBeginSection': 17, 'offsetInEndSection': 167, 'text': 'ne (DMD) is the largest gene in the human genome, mapping on the Xp21 chromosome locus. It spans 2.2Mb and accounts for approximately 0,1% of the enti', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28867298'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 287, 'text': 'Duchenne muscular dystrophy (DMD), glycerol kinase deficiency (GKD), and adrenal hypoplasia congenita (AHC) can occur together as part of a contiguous gene syndrome located at chromosome Xp21, GKD can manifest with recurrent episodes of vomiting, acidemia, mental retardation, or stupor.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19078586'}, {'offsetInBeginSection': 77, 'offsetInEndSection': 227, 'text': 'inked recessive disorders caused by mutations of the DMD gene located at Xp21. In DMD patients, dystrophin is virtually absent; whereas BMD patients h', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19461958'}, {'offsetInBeginSection': 22, 'offsetInEndSection': 172, 'text': 'rophy (DMD) is a dystrophinopathy, and its associated gene is located on Xp21. Moreover, utrophin, a recently identified structural homologue of dystr', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12619170'}, {'offsetInBeginSection': 96, 'offsetInEndSection': 246, 'text': ' disease in children, resulting from a defect in the DMD gene located on Xp21.2. The new emerging treatment using exon skipping strategy is tailored t', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31661024'}, {'offsetInBeginSection': 303, 'offsetInEndSection': 453, 'text': \"resent case supports the hypothesis that the DMD gene must be located at Xp21. In this study, involvement of the father's chromosomes in the transloca\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/3777020'}, {'offsetInBeginSection': 364, 'offsetInEndSection': 514, 'text': ' only later was it diagnosed as DMD. Because the DMD gene is located at Xp21.2, which is one breakpoint of the inv(X), and because its defects are rar', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12145744'}, {'offsetInBeginSection': 124, 'offsetInEndSection': 274, 'text': 'letion, duplication or point mutation of the dystrophin gene located at Xp 21.2. In the present study DNA from seventy unrelated patients clinically d', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16936400'}, {'offsetInBeginSection': 60, 'offsetInEndSection': 210, 'text': 'inked diseases resulting from a defect in the dystrophin gene located on Xp21. DMD is the most frequent neuromuscular disease in humans (1/3500 male n', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12488581'}]\n\n\n             'Where is the DMD gene located?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "The DMD gene is located on the X chromosome, on the Xp21 locus."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 1023, 'offsetInEndSection': 1227, 'text': 'Recently, evobrutinib and tolebrutinib have shown efficacy in phase II clinical trials, and there are numerous ongoing phase III clinical trials of various BTKIs in relapsing and progressive forms of MS.\\xa0', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36301434'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 123, 'text': 'Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168).', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34724345'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 523, 'text': \"Bruton's tyrosine kinase (BTK), expressed in B cells and cells of innate immunity, including microglia, is an essential signaling element downstream of the B-cell receptor and Fc-receptors. Tolebrutinib (PRN2246, SAR442168) is a potent BTK inhibitor that covalently binds the kinase, resulting in durable inhibition with the potential to target inflammation in the periphery and central nervous system (CNS). Tolebrutinib crosses the blood-brain barrier and potently inhibits BTK in microglial cells isolated from the CNS. \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34724345'}]\n\n\n             'What is the mechanism of action of Tolebrutinib?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Bruton's tyrosine kinase (BTK), expressed in B cells and cells of innate immunity, including microglia, is an essential signaling element downstream of the B-cell receptor and Fc-receptors. Tolebrutinib is a potent BTK inhibitor that covalently binds the kinase, resulting in durable inhibition with the potential to target inflammation in the periphery and central nervous system (CNS). Tolebrutinib crosses the blood-brain barrier and potently inhibits BTK in microglial cells isolated from the CNS."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 12, 'offsetInEndSection': 170, 'text': 'Optogenetics allows the experimental manipulation of excitable cells by a light stimulus without the need for technically challenging and invasive procedures.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34429103'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 349, 'text': 'Optogenetics has revolutionized the capability of controlling genetically modified neurons in\\xa0vitro and in\\xa0vivo and has become an indispensable neuroscience tool. Using light as a probe for selective neuronal activation or inhibition and as a means to read out neural activity has dramatically enhanced our understanding of complex neural circuits. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35718324'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 123, 'text': 'Optogenetics controls neural activity and behavior in living organisms through genetically targetable actuators and light. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32543249'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 409, 'text': 'This is a review of the current state of optogenetics-based research in the field of ophthalmology and physiology of vision. Optogenetics employs an interdisciplinary approach that amalgamates gene engineering, optics, and physiology. It involves exogenous expression of a light-activated protein in a very particular retinal cell enabling regulation (stimulation vs. inhibition) of its physiological activity', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26310015'}, {'offsetInBeginSection': 583, 'offsetInEndSection': 901, 'text': 'In contrast, optogenetics leverages light-sensitive proteins to control cellular signaling dynamics and target gene expression and, by virtue of precise hardware control over illumination, offers the capacity to interrogate how spatiotemporally varying signals modulate gene regulatory networks and cellular behaviors.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35273478'}, {'offsetInBeginSection': 86, 'offsetInEndSection': 261, 'text': 'As light-gated protein switches, signaling photoreceptors provide the basis for optogenetics, a term that refers to the control of organismal physiology and behavior by light.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22245580'}, {'offsetInBeginSection': 546, 'offsetInEndSection': 840, 'text': 'In this review, we summarize the main optogenetic systems implemented in the budding yeast Saccharomyces cerevisiae, which allow orthogonal control (by light) of gene expression, protein subcellular localization, reconstitution of protein activity, and protein sequestration by oligomerization.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33119964'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 83, 'text': 'Optogenetics is the genetic approach for controlling cellular processes with light.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32601426'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 151, 'text': \"The recently introduced term 'optogenetics' describes a variety of techniques for expressing genes in nerve cells that render them responsive to light.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20971436'}, {'offsetInBeginSection': 92, 'offsetInEndSection': 238, 'text': 'Optogenetic expression systems can provide precise control over gene expression timing, location, and amplitude using light as the inducing agent.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34487118'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 70, 'text': 'Optogenetics refers to the control of biological processes with light.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33119964'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 203, 'text': 'Optogenetics refers to a technique that uses light to modulate neuronal activity with a high spatiotemporal resolution, which enables the manipulation of learning and memory functions in the human brain.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34423469'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 99, 'text': 'In optogenetics, as in nature, sensory photoreceptors serve to control cellular processes by light.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35998606'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 170, 'text': 'Optogenetics refers to the genetic modification of cells to express light-sensitive proteins, which mediate ion flow or secondary signalling cascades upon light exposure.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28255969'}, {'offsetInBeginSection': 231, 'offsetInEndSection': 360, 'text': ' Optogenetics involves the use of genetically encoded and optically active proteins, namely opsins, to control neuronal circuits.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28726577'}, {'offsetInBeginSection': 659, 'offsetInEndSection': 794, 'text': ' (3) A completely different interpretation of optogenetics refers to the light activated expression of a genetically induced construct.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32795553'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 69, 'text': 'Optogenetics is an innovative technique for optical control of cells.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26412943'}, {'offsetInBeginSection': 97, 'offsetInEndSection': 198, 'text': ' Optogenetics refers to techniques that use light to control the cellular activity of targeted cells.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35204770'}, {'offsetInBeginSection': 156, 'offsetInEndSection': 306, 'text': 'basis for optogenetics, a term that refers to the control of organismal physiology and behavior by light. We establish as novel optogenetic tools the ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22245580'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 128, 'text': 'Optogenetics refers to the ability to control cells that have been genetically modified to express light-sensitive ion channels.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27069384'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'Optogenetics refers to the control of biological processes with light. The activation of cellular phenomena by defined wavelengths has several advanta', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33119964'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 143, 'text': 'Optogenetics is the use of genetically coded, light-gated ion channels or pumps (opsins) for millisecond resolution control of neural activity.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29118219'}]\n\n\n             'Optogenetics refers to the study of gene expression optimization'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Optogenetics allows the experimental manipulation of excitable cells by a light stimulus without the need for technically challenging and invasive procedures."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 497, 'offsetInEndSection': 724, 'text': 'The combination of chemotherapy and immunotherapy is a potential therapeutic option for PD-L1-positive mTNBC, as the FDA recently approved atezolizumab (Tecentriq) and pembrolizumab (Keytruda) in combination with chemotherapy. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33983696'}]\n\n\n             'Which form of breast cancer has Keytruda been FDA approved for?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "FDA has approved pembrolizumab (Keytruda) for the treatment of triple-negative breast cancer in combination with chemotherapy."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 278, 'offsetInEndSection': 431, 'text': 'exon-skipping therapy including eteplirsen (brand name Exondys 51), a synthetic antisense oligonucleotide designed to skip exon 51 of the dystrophin gene', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34797383'}, {'offsetInBeginSection': 518, 'offsetInEndSection': 686, 'text': 'a phosphorodiamidate morpholino oligomer (PMO) antisense oligonucleotide eteplirsen received accelerated approval by the US Food and Drug Administration (FDA) in 2016. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34797383'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 134, 'text': 'Eteplirsen (Exondys\\xa051) is an antisense oligonucleotide designed to induce exon 51 skipping that is developed by Sarepta Therapeutics.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27807823'}, {'offsetInBeginSection': 380, 'offsetInEndSection': 662, 'text': 'In September 2016, the US Food and Drug Administration granted accelerated approval for eteplirsen (or Exondys 51), a drug that acts to promote dystrophin production by restoring the translational reading frame of DMD through specific skipping of exon 51 in defective gene variants.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28280301'}, {'offsetInBeginSection': 120, 'offsetInEndSection': 356, 'text': 'Recently, eteplirsen, a phosphorodiamidate morpholino oligomer-based splice-switching oligonucleotide (SSO) targeting DMD exon 51, was approved by the U.S. Food and Drug Administration as the first antisense-based drug for DMD patients.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29339778'}, {'offsetInBeginSection': 345, 'offsetInEndSection': 495, 'text': 'The FDA conditionally approved the first exon-skipping AON, called eteplirsen (brand name ExonDys51), targeting exon 51 of the DMD gene, in late 2016.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30171554'}, {'offsetInBeginSection': 321, 'offsetInEndSection': 519, 'text': 'In 2016, the US Food and Drug Administration (FDA) conditionally approved the first phosphorodiamidate morpholino oligomer (morpholino)-based AO drug, eteplirsen, developed for DMD exon 51 skipping.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28865998'}, {'offsetInBeginSection': 242, 'offsetInEndSection': 468, 'text': 'Currently, there is no cure, though exon-skipping therapy including eteplirsen (brand name Exondys 51), a synthetic antisense oligonucleotide designed to skip exon 51 of the dystrophin gene, is considered especially promising.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34797383'}, {'offsetInBeginSection': 362, 'offsetInEndSection': 733, 'text': 'in protein. Eteplirsen, a phosphorodiamidate morpholino oligomer (PMO), is designed to skip exon 51, restore the reading frame, and induce production of internally shortened dystrophin in patients with mutations amenable to such treatment.OBJECTIVE: Describe lung function assessed throughout eteplirsen studies 201/202.METHODS: Studies 201/202 included 12 patients treat', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29278896'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 371, 'text': 'We previously conducted a proof of principle; dose escalation study in Duchenne muscular dystrophy (DMD) patients using the morpholino splice-switching oligonucleotide AVI-4658 (eteplirsen) that induces skipping of dystrophin exon 51 in patients with relevant deletions, restores the open reading frame and induces dystrophin protein expression after intramuscular (i.m.)', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22086232'}]\n\n\n             'What is eteplirsen's mechanism of action?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Eteplirsen is a phosphorodiamidate morpholino oligomer (PMO) antisense oligonucleotide designed to skip exon 51 of the dystrophin gene."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 72, 'text': 'Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35767439'}, {'offsetInBeginSection': 322, 'offsetInEndSection': 503, 'text': 'METHODS: We conducted a single-center, dose-escalation study of DNX-2401, an oncolytic adenovirus that selectively replicates in tumor cells, in patients with newly diagnosed DIPG. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35767439'}, {'offsetInBeginSection': 1971, 'offsetInEndSection': 2236, 'text': 'CONCLUSIONS: Intratumoral infusion of oncolytic virus DNX-2401 followed by radiotherapy in pediatric patients with DIPG resulted in changes in T-cell activity and a reduction in or stabilization of tumor size in some patients but was associated with adverse events.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35767439'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 101, 'text': 'Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma Newly Diagnosed in Pediatric Patients.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29088386'}, {'offsetInBeginSection': 419, 'offsetInEndSection': 641, 'text': 'OBJECTIVE: To determine the safety, tolerability, and toxicity of an oncolytic adenovirus, DNX-2401, injected into the cerebellar peduncle in pediatric subjects with DIPG and to collect tumor samples of this type of tumor.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29088386'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 116, 'text': 'DNX-2401, an Oncolytic Virus, for the Treatment of Newly Diagnosed Diffuse Intrinsic Pontine Gliomas: A Case Report.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29594041'}, {'offsetInBeginSection': 824, 'offsetInEndSection': 1047, 'text': 'To this aim, we have designed a clinical Phase I trial for newly diagnosed pediatric DIPG to investigate the feasibility, safety, and preliminary efficacy of delivering DNX-2401 into tumors within the pons following biopsy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29594041'}, {'offsetInBeginSection': 1506, 'offsetInEndSection': 1620, 'text': ' To our knowledge, this is the first report of intratumoral DNX-2401 for a patient with DIPG in a clinical trial. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29594041'}]\n\n\n             'Was DNX-2401 tested for treatment of Diffuse Intrinsic Pontine Glioma?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Yes. DNX-2401 is tested for treatment of Diffuse Intrinsic Pontine Glioma."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 477, 'text': 'Blue diaper syndrome (BDS) (Online Mendelian Inheritance in Man number 211000) is an extremely rare disorder that was first described in 1964. The characteristic finding is a bluish discoloration of urine spots in the diapers of affected infants. Additional clinical features of the first described patients included diarrhea, inadequate weight gain, hypercalcemia, and nephrocalcinosis. An intestinal defect of tryptophan absorption was postulated as the underlying pathology.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29610180'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 120, 'text': 'We describe the ocular abnormalities seen in a new metabolic disease which is deficient in the transport of tryptophan. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1818237'}]\n\n\n             'Which amino acid in implicated in the Blue diaper syndrome?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Blue diaper syndrome is an extremely rare disorder with characteristic finding is a bluish discoloration of urine spots in the diapers of affected infants. An intestinal defect of tryptophan absorption was postulated as the underlying pathology."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 1369, 'offsetInEndSection': 1498, 'text': 'Targeted knockout of the SOX9 gene, which plays a role in the differentiation of mesenchymal progenitor cells into chondrocytes, ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35690812'}, {'offsetInBeginSection': 64, 'offsetInEndSection': 180, 'text': '. SOX9 is a transcription factor with critical roles during neurodevelopment, particularly within neural stem cells.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35562901'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 131, 'text': 'Epithelial SOX9 drives progression and metastases of gastric adenocarcinoma by promoting immunosuppressive tumour microenvironment.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36002248'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 226, 'text': 'any cancers engage embryonic genes for rapid growth and evading the immune system. SOX9 has been upregulated in many tumours, yet the role of SOX9 in mediating immunosuppressive tumour microenvironment is unclear. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36002248'}, {'offsetInBeginSection': 1454, 'offsetInEndSection': 1687, 'text': 'Epithelial SOX9 is critical in suppressing CD8+ T cell responses and modified macrophage function in GAC through the paracrine LIF factor. Cotargeting LIF/LIFR and CSF1R has great potential in targeting SOX9-mediated cancer stemness,', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36002248'}, {'offsetInBeginSection': 898, 'offsetInEndSection': 1171, 'text': 'S: In PCL of humans and mice, the expression of SP, SOX9, and MMP13 was upregulated as OA progressed, but their expression was downregulated in severe degeneration. SP and SOX9 were co-expressed in chondrocyte-like cells. In ligament cells, SP agonists downregulated SOX9, ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35856812'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 141, 'text': 'Sox9 plays an essential role in mammalian testis formation. It has been reported that gene expression in the testes is regulated by enhancers', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35921234'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 114, 'text': 'SOX9 and SRY binding sites on mouse mXYSRa/Enh13 enhancer redundantly regulate Sox9 expression to varying degrees.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35921234'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 137, 'text': 'Sox9 is involved in the thyroid differentiation program and is regulated by crosstalk between TSH, TGF\u03b2 and thyroid transcription factors', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35140269'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 120, 'text': 'SOX9 is an intestine crypt transcription factor, is regulated by the Wnt pathway, and represses the CDX2 and MUC2 genes.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15240568'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 118, 'text': 'Sox9 is a high-mobility group box-containing transcription factor that functions as a key regulator of chondrogenesis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22510437'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 191, 'text': 'A member of the Sry-related HMG-box family of transcription factors (SOX9) is a transcription factor that belongs to the superfamily of High Mobility Group (HMG) domain transcription factors.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28988015'}, {'offsetInBeginSection': 517, 'offsetInEndSection': 764, 'text': 'Sry-box transcription factor 9 (Sox9) is a member of the high-mobility group box family of DNA-binding transcription factors that are selectively expressed by epithelial cell progenitors to modulate branching morphogenesis during lung development.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34520400'}, {'offsetInBeginSection': 532, 'offsetInEndSection': 757, 'text': 'Transcription factor SOX9 plays essential roles during developmental steps from undifferentiated mesenchymal cells to proliferating chondrocytes, meanwhile, it inhibits transition of proliferating chondrocytes to hypertrophy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18692165'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 213, 'text': 'Sox9 encodes a HMG-box transcription factor that has been implicated in numerous developmental processes including chondrogenesis, formation of cardiac valves, and neural crest, testis and spinal cord development.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16678811'}, {'offsetInBeginSection': 263, 'offsetInEndSection': 430, 'text': 'SOX9 is a master transcription factor that participates in sequential events in chondrogenesis by regulating a series of downstream factors in a stage-specific manner.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32380234'}, {'offsetInBeginSection': 77, 'offsetInEndSection': 227, 'text': 'ng skeletal framework and articular joint formation. Sox9 is a key transcription factor that is essential for chondrocyte differentiation and chondroc', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12732631'}]\n\n\n             'Explain the function of SOX9'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "SOX9 is a transcription factor with critical roles during neurodevelopment, particularly within neural stem cells. Epithelial SOX9 drives progression and metastases of gastric adenocarcinoma by promoting immunosuppressive tumour microenvironment."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 355, 'text': 'Ubiquitination is a post-translational modification that generally directs proteins for degradation by the proteasome or by lysosomes. However, ubiquitination has been implicated in many other cellular processes, including transcriptional regulation, DNA repair, regulation of protein-protein interactions and association with ubiquitin-binding scaffolds.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21926471'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 349, 'text': 'Ubiquitin is best known for its function in targeting proteins for degradation by the proteasome. Recent studies have revealed several new functions of ubiquitin that are independent of proteasomal degradation. These functions include the novel signaling roles of ubiquitin in DNA repair and the activation of protein kinases such as IkappaB kinase.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15196553'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 146, 'text': 'Ubiquitination ofendogenous proteins is one of the key regulatory steps that guides protein degradation through regulation of proteasome activity.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20886764'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 130, 'text': 'Ubiquitination-the covalent conjugation of ubiquitin (Ub) to other cellular proteins-regulates a wide range of cellular processes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16608998'}, {'offsetInBeginSection': 100, 'offsetInEndSection': 411, 'text': 'Ubiquitination is a specific process associated with several highly regulated biological outcomes including cell cycle progression, differentiation, antigen presentation, retrovirus assembly, apoptosis, signal transduction, transcriptional activation, biological clocks, receptor downregulation and endocytosis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11182597'}, {'offsetInBeginSection': 263, 'offsetInEndSection': 532, 'text': 'Although targeting for proteasomal degradation is the best studied outcome of ubiquitylation, we now understand that modification of proteins with ubiquitin has numerous other cellular roles that alter protein function and that are unrelated to proteasomal degradation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18228479'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 157, 'text': 'Ubiquitination is a post-translational modification that regulates most cellular pathways and processes, including degradation of proteins by the proteasome.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26917723'}, {'offsetInBeginSection': 391, 'offsetInEndSection': 571, 'text': 'The most widely studied effect of ubiquitination of proteins is proteasome-mediated substrate degradation; however, ubiquitination can also alter protein localization and function.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33192571'}, {'offsetInBeginSection': 152, 'offsetInEndSection': 296, 'text': 'Ubiquitination is a highly selective post-translational modification that involves the covalent conjugation of ubiquitin to a substrate protein.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34645583'}, {'offsetInBeginSection': 476, 'offsetInEndSection': 664, 'text': 'In addition to proteasomal degradation, ubiquitination regulates other cellular processes, such as transcription, translation, endocytosis, receptor activity, and subcellular localization.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34645583'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 232, 'text': 'Ubiquitination is controlled by a series of E1, E2, and E3 enzymes that can ligate ubiquitin to cellular proteins and dictate the turnover of a substrate and the outcome of signalling events such as DNA damage repair and cell cycle.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35327659'}, {'offsetInBeginSection': 510, 'offsetInEndSection': 781, 'text': 'Ubiquitination is the covalent link of target proteins with the small protein ubiquitin and serves as a signal to target protein degradation by the proteasome or to other outcomes such as endocytosis, degradation by the lysosome or specification of cellular localization.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22827778'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 255, 'text': 'The covalent attachment of ubiquitin molecules to target proteins is a posttranslational modification that is involved not only in signaling processes leading to protein degradation but also in those resulting in activation, proliferation, and cell death.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22375051'}, {'offsetInBeginSection': 171, 'offsetInEndSection': 443, 'text': 'Two of the best characterized functions of protein ubiquitination are to mark proteins for degradation by cytosolic proteasome and to promote the internalization of certain plasma membrane proteins via the endocytotic pathway, followed by their degradation in the vacuole.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12896807'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 207, 'text': 'Ubiquitination is a post-translational modification that can dynamically alter the function, degradation and transport of a protein, as well as its interaction with other proteins, and activity of an enzyme.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31931110'}, {'offsetInBeginSection': 577, 'offsetInEndSection': 870, 'text': 'Ubiquitination, the covalent link of the small 76-amino acid protein ubiquitin to target proteins, serves as a signal for protein degradation by the proteasome or for other outcomes such as endocytosis, degradation by the lysosome or directing these proteins to specific cellular compartments.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22399444'}]\n\n\n             'What are the outcomes of ubiquitination?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Ubiquitination is a post-translational modification that generally directs proteins for degradation by the proteasome or by lysosomes. However, ubiquitination has been implicated in many other cellular processes, including transcriptional regulation, DNA repair, and regulation of protein-protein interactions."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 228, 'offsetInEndSection': 335, 'text': \"To evaluate the safety, pharmacokinetics, and preliminary efficacy of RT001 in Friedreich's ataxia patients\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29624723'}, {'offsetInBeginSection': 652, 'offsetInEndSection': 731, 'text': 'The primary endpoints were safety, tolerability, and pharmacokinetic analysis. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29624723'}]\n\n\n             'What were the primary endpoints of the phase I/II double-blind, comparator-controlled trial of RT001 in Friedreich's ataxia patients?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "The primary endpoints of the phase I/II double-blind, comparator-controlled trial of RT001 in Friedreich's ataxia patients were safety, tolerability, and pharmacokinetic analysis."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 232, 'text': \"Friedreich's ataxia (FRDA) is an autosomal recessive neurodegenerative disorder caused by a triplet guanine-adenine-adenine (GAA) repeat expansion in intron 1 of the FXN gene, which leads to decreased levels of the frataxin protein.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35850241'}, {'offsetInBeginSection': 225, 'offsetInEndSection': 403, 'text': \"The classic form of autosomal recessive ataxia, Friedreich's ataxia (FA), is now known to be due to an intronic expansion of a guanine-adenine-adenine (GAA)-trinucleotide repeat.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9630233'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 152, 'text': \"Friedreich's Ataxia (FA) is the commonest genetic cause of ataxia and is associated with the expansion of a GAA repeat in intron 1 of the frataxin gene.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16581313'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 110, 'text': \"Reduced expression of the mitochondrial protein Frataxin (FXN) is the underlying cause of Friedreich's ataxia.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25831023'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 161, 'text': 'Friedreich Ataxia (FA) is the most common hereditary ataxia, caused by abnormal expansion of the GAA triplet of the first intron of the X25 gene on chromosome 9.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24152405'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 162, 'text': 'BACKGROUND: Friedreich ataxia (FA), the most common hereditary ataxia, is caused by pathological expansion of GAA repeats in the first intron of the X25 gene on c', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16344344'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 113, 'text': 'Friedreich Ataxia (FA) is a rare neuro-cardiodegenerative disease caused by mutations in the frataxin (FXN) gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35038030'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 125, 'text': \"Friedreich's ataxia (FA) is an inherited neurodegenerative disorder caused by decreased expression of frataxin (FXN) protein.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35289725'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 173, 'text': 'BACKGROUND: Friedreich ataxia (FA), the most common hereditary ataxia, is caused by pathological expansion of GAA repeats in the first intron of the X25 gene on chromosome 9', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16344344'}]\n\n\n             'What is the cause of Friedreich's Ataxia (FA)?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Friedreich's ataxia (FRDA) is an autosomal recessive neurodegenerative disorder caused by a triplet guanine-adenine-adenine (GAA) repeat expansion in intron 1 of the FXN gene, which leads to decreased levels of the frataxin protein."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 178, 'text': 'Serpentine supravenous hyperpigmentation (SSH) is a unique type of chemotherapy-associated drug eruption, characterized by hyperpigmentation along the superficial venous network.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31168954'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 244, 'text': 'Serpentine supravenous hyperpigmentation (SSH) is a rare vasculo-cutaneous entity that has been associated with peripheral infusion of chemotherapy agents, in particular 5-FU1-3, but also seen with docetaxel4,5, fotemustine6, and vinorelbine7. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29951170'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 163, 'text': 'Serpentine supravenous hyperpigmentation is a peculiar cutaneous eruption that follows the path of vein after intravenous injection of the chemotherapeutic agent. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28878924'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 208, 'text': 'Serpentine erythematous or hyperpigmented streaks along the superficial venous network proximal to the site of injection may occur as a distinctive eruption after infusion of several chemotherapeutic agents. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22136872'}, {'offsetInBeginSection': 193, 'offsetInEndSection': 404, 'text': 'Serpentine supravenous hyperpigmentation was the term coined by Hrushesky to describe increased pigmentation of the skin immediately overlying the venous network used for intravenous infusion of 5-fluorouracil. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20134385'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 116, 'text': 'Two cases of serpentine supravenous hyperpigmentation developing in the area of fotemustine infusions are reported. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1559000'}, {'offsetInBeginSection': 695, 'offsetInEndSection': 913, 'text': 'The serpentine supravenous hyperpigmentation on the lower extremities was uniform in width and color, which contrasts with the darker discoloration near the site of infusion seen with PSSH associated with chemotherapy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23745227'}]\n\n\n             'What causes Serpentine Supravenous Hyperpigmentation?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Serpentine supravenous hyperpigmentationis a rare vasculo-cutaneous entity that has been associated with peripheral infusion of chemotherapy agents, in particular 5-fluorouracil, but also seen with docetaxel, fotemustine, and vinorelbine."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 535, 'text': \"Alpha-synuclein (a-syn) can aggregate and form toxic oligomers and insoluble fibrils which are the main component of Lewy bodies. Intra-neuronal Lewy bodies are a major pathological characteristic of Parkinson's disease (PD). These fibrillar structures can act as seeds and accelerate the aggregation of monomeric a-syn. Indeed, recent studies show that injection of preformed a-syn fibrils (PFF) into the rodent brain can induce aggregation of the endogenous monomeric a-syn resulting in neuronal dysfunction and eventual cell death. \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33352233'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 192, 'text': \"A variety of gene mutations can cause familial forms of Parkinson's disease (PD) or amyotrophic lateral sclerosis (ALS). Mutations in the synaptic protein alpha-synuclein (alpha-Syn) cause PD.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17593875'}, {'offsetInBeginSection': 516, 'offsetInEndSection': 914, 'text': 'In this review, we focus on a yeast model for synucleinopathies and summarize recent studies that not only provided new clues on how the misfolding of alpha-synuclein (alpha-syn) triggers toxicity and eventually cell death, but that also led to the identification of conserved suppressor proteins, which are effective in protecting cells, including neurons, from the alpha-syn-induced cytotoxicity.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20019751'}, {'offsetInBeginSection': 1108, 'offsetInEndSection': 1421, 'text': 'These findings suggest that alpha-syn aggregation is a key feature associated with decline of proteasome and lysosome and support the hypothesis that cell degeneration in PD involves proteosomal and lysosomal dysfunction, impaired protein clearance, and protein accumulation and aggregation leading to cell death.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19505575'}, {'offsetInBeginSection': 330, 'offsetInEndSection': 469, 'text': 'Here we show that \u03b1-Syn selectively interacts with TrkB receptors and inhibits BDNF/TrkB signaling, leading to dopaminergic neuronal death.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28923922'}, {'offsetInBeginSection': 1503, 'offsetInEndSection': 1714, 'text': 'In conclusion, we demonstrate that either endogenous or exogenous \u03b1-Syn can be neuroprotective against A\u03b2-induced cell death, suggesting a cell defence mechanism during the initial stages of the mixed pathology.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23389658'}, {'offsetInBeginSection': 1182, 'offsetInEndSection': 1399, 'text': 'This review article focuses on the mechanism associated with extracellular \u03b1-syn uptake in glial cells and the consequent glial cell activation that contributes to the neuronal death associated with synucleinopathies.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35625583'}, {'offsetInBeginSection': 321, 'offsetInEndSection': 534, 'text': 'Indeed, recent studies show that injection of preformed a-syn fibrils (PFF) into the rodent brain can induce aggregation of the endogenous monomeric a-syn resulting in neuronal dysfunction and eventual cell death.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33352233'}, {'offsetInBeginSection': 251, 'offsetInEndSection': 378, 'text': 'Aggregated forms of \u03b1-syn are associated with multiple neurotoxic mechanisms, such as mitochondrial dysfunction and cell death.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34194605'}, {'offsetInBeginSection': 288, 'offsetInEndSection': 475, 'text': 'Although the exact mechanism of \u03b1-syn-mediated cell death remains elusive, recent research suggests that \u03b1-syn-induced alterations in neuronal excitability contribute to cell death in PD.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31768670'}, {'offsetInBeginSection': 313, 'offsetInEndSection': 486, 'text': 'Current thinking suggests that an interaction between alpha-syn and dopamine (DA) leads to the selective death of neuronal cells and the accumulation of misfolded alpha-syn.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19444607'}, {'offsetInBeginSection': 295, 'offsetInEndSection': 580, 'text': 'Our findings that brain and peripheral cells exposed to \u03b1-syn can lead to impaired mitochondrial function, leading to cellular degeneration and cell death, provides additional evidence for the involvement of mitochondrial dysfunction as a mechanism of toxicity of \u03b1-syn in human cells.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24093918'}, {'offsetInBeginSection': 324, 'offsetInEndSection': 522, 'text': '\u0391lpha-synuclein (\u03b1-syn) is a protein found to aggregate in the substantia nigra region of patients with PD, forming Lewy Body inclusions; its aggregation may contribute to neuronal cell death in PD.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32035284'}, {'offsetInBeginSection': 497, 'offsetInEndSection': 609, 'text': \"One hypothesis is that \u03b1-Syn aggregates disrupt the cell membrane's integrity, eventually leading to cell death.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29974096'}, {'offsetInBeginSection': 961, 'offsetInEndSection': 1108, 'text': ' The data suggest that the sustained population of oligomer formation and retention could be a major cause of cell death in \u03b1-Syn familial mutants.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29906099'}]\n\n\n             'Please summarize the relationship between a-syn and cell death.'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Alpha-synuclein (a-syn) can aggregate and form toxic oligomers and insoluble fibrils which are the main component of Lewy bodies. Intra-neuronal Lewy bodies are a major pathological characteristic of Parkinson's disease (PD). Injection of preformed a-syn fibrils (PFF) into the rodent brain can induce aggregation of the endogenous monomeric a-syn resulting in neuronal dysfunction and eventual cell death"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 331, 'text': 'Oncogenes are gain-of-function mutations of normal regulatory genes or proto-oncogenes. Originally discovered in retroviruses initiating a variety of animal and avian cancers, oncogenes are believed to be important contributors to human carcinogenesis. Proto-oncogenes are altered by point mutation, amplification or rearrangement.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10697588'}, {'offsetInBeginSection': 340, 'offsetInEndSection': 599, 'text': 'Aberrant proteolysis with oncogenic potential is elicited by two major mechanisms: defective degradation of positive cell cycle regulators (i.e., proto-oncoproteins) and enhanced degradation of negative cell cycle regulators (i.e., tumor suppressor proteins).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12665054'}]\n\n\n             'What are positive cell-cycle regulators that can cause cancer when mutated called?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Proto-oncogenes are normal regulatory genes that can be transformed - by gain-of-function mutations - to oncogenes which are important contributors to human carcinogenesis."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 125, 'text': 'Hereditary angioedema (HAE) is a rare autosomal dominant disorder caused by mutations of the SERPING1 or the Factor 12 genes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27965672'}]\n\n\n             'What is the inheritance pattern of hereditary angioedema?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Hereditary angioedema (HAE) is an autosomal dominant disorder."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 97, 'text': \"Friedreich's ataxia is classically considered a disease with onset in the first or second decade.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31467149'}, {'offsetInBeginSection': 57, 'offsetInEndSection': 218, 'text': \" age of 25. Rare variants have been described, such as late-onset Friedreich's ataxia and very-late-onset Friedreich's ataxia, occurring after 25 and 40 years, r\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26388117'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 108, 'text': 'The onset of Friedreich ataxia (FA) was before 10 years of age in 36 out of 95 personally observed patients.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8677022'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 299, 'text': 'Friedreich ataxia (FRDA), the most common autosomal recessive neurodegenerative disease among Europeans and people of European descent, is characterized by an early onset (usually before the age of 25), progressive ataxia, sensory loss, absence of tendon reflexes and pyramidal weakness of the legs.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11586299'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 137, 'text': \"Very late-onset Friedreich's ataxia (VLOFA) is characterized by symptomatic onset after 40 years of age and, usually, a benign phenotype.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16092110'}, {'offsetInBeginSection': 394, 'offsetInEndSection': 634, 'text': 'Onset is usually in the first or second decade of life; however, late-onset cases of Freidreich ataxia (LOFA), after the age of 25 years, and very late-onset cases of Freidreich ataxia (VLOFA), after the age of 40 years, have been reported.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25685137'}, {'offsetInBeginSection': 273, 'offsetInEndSection': 369, 'text': 'Disease begins after the age of 25 in occasional patients (late-onset Friedreich ataxia (LOFA)).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26754264'}, {'offsetInBeginSection': 871, 'offsetInEndSection': 1101, 'text': \"ing Scale and EQ-5D. The Friedreich's ataxia cohort was subdivided into three groups: early disease onset (\u226414 years), intermediate onset (15-24 years), and late onset (\u226525 years), which were compared for clinical characteristics \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25566998'}, {'offsetInBeginSection': 272, 'offsetInEndSection': 369, 'text': ' Disease begins after the age of 25 in occasional patients (late-onset Friedreich ataxia (LOFA)).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26754264'}]\n\n\n             'What is usually the onset age of Friedreich's Ataxia?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "During the first or second decade is usually the onset age of Friedreich's Ataxia."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 219, 'text': 'Cost-utility analysis of cemented hemiarthroplasty versus hydroxyapatite-coated uncemented hemiarthroplasty for the treatment of displaced intracapsular hip fractures : the World Hip Trauma Evaluation 5 (WHiTE 5) trial.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35909375'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 219, 'text': 'A randomized clinical trial of low dose single antibiotic-loaded cement versus high dose dual antibiotic-loaded cement in patients receiving a hip hemiarthroplasty after fracture: A protocol for the WHiTE 8 COPAL study.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33630700'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 137, 'text': 'The World Hip Trauma Evaluation Study 3: Hemiarthroplasty Evaluation by Multicentre Investigation - WHITE 3: HEMI - An Abridged Protocol.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26825319'}, {'offsetInBeginSection': 253, 'offsetInEndSection': 405, 'text': 'METHODS AND ANALYSIS: The World Hip Trauma Evaluation (WHiTE) was set up to measure outcome in a comprehensive cohort of UK patients with hip fracture. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27797994'}]\n\n\n             'What disease was the topic of the World Hip Trauma Evaluation (WHiTE) trial?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "The World Hip Trauma Evaluation (WHiTE) was set up to measure outcome of patients with hip fracture."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 110, 'text': 'Challenges to the Diagnosis of Functional Neurological Disorder: Feigning, Intentionality, and Responsibility.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36311548'}, {'offsetInBeginSection': 1, 'offsetInEndSection': 214, 'text': 'he diagnosis of Functional Neurological Disorder (FND) requires differentiation from other neurologic diseases/syndromes, and from the comparatively rare diagnosis of feigning (Malingering and Factitious Disorder)', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36311548'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 227, 'text': 'Functional neurological disorder reflects impairments in brain networks leading to distressing motor, sensory and/or cognitive symptoms that demonstrate positive clinical signs on examination incongruent with other conditions. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35653495'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 85, 'text': \"Functional neurological disorder and somatic symptom disorder in Parkinson's disease.\", 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34629180'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 208, 'text': 'The occurrence of Functional Neurological Disorder (FND) and Somatic Symptom Disorder (SSD) in PD was not commonly accepted until recently, despite some evidence that emerged in the pre and early L-Dopa era. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34629180'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 78, 'text': 'Maladaptive schemas of patients with functional neurological symptom disorder.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34585455'}, {'offsetInBeginSection': 13, 'offsetInEndSection': 122, 'text': 'he psychological underpinnings of functional neurological symptom disorders (FNSD) remain poorly understood. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34585455'}, {'offsetInBeginSection': 124, 'offsetInEndSection': 538, 'text': 'disintegration of explicit and implicit information processing in patients with FNSD has previously been suggested; however, this suggestion has so far received little empirical support. Trauma and maladaptive schemas probably reinforce disintegration in FNSD. The present study explored the occurrence of maladaptive schemas and investigated the impact of trauma-related maladaptive schemas in patients with FNSD.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34585455'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 191, 'text': 'Functional neurological symptom disorder (FND) remains a clinical challenge. It is one of the many mimics of cerebrovascular accidents, spinal cord disorders, and lower motor neuron disease. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35911352'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 151, 'text': 'Previous studies with adults suggest that aberrant communication between neural networks underpins functional neurological disorder (FND). ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36002964'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 254, 'text': 'Functional neurological disorder (FND) is a complex neuropsychiatric disorder characterized by abnormal or atypical sensorimotor, gait, dissociative, or special sensory symptoms in the absence of structural nervous system lesions to explain the symptoms.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32726111'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 220, 'text': 'Functional neurological disorders (FNDs), which are sometimes also referred to as psychogenic neurological disorders or conversion disorder, are common disabling neuropsychiatric disorders with limited treatment options.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33280274'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 234, 'text': 'Functional neurological disorder (FND) is a complex neuropsychiatric condition characterized by the presence of neurological symptoms and signs (either motor or sensory) that cannot be explained by any known medical or mental disease.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34188796'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 158, 'text': 'Functional neurological disorder (FND) is a rare neuropsychiatric illness that commonly presents to the medical setting as opposed to the psychiatric setting.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34806689'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 151, 'text': 'Historically, functional neurological disorder (FND) has been described in psychodynamic terms as the physical manifestation of psychological distress.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34568805'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 262, 'text': 'BACKGROUND: Functional neurological disorders (FNDs) are common but often misdiagnosed.REVIEW SUMMARY: The incidence of FNDs is between 4 and 12 per 100,000, comparable to multiple sclerosis and amyotrophic lateral sclerosis, and it is the second most common dia', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35858632'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 202, 'text': 'Functional Neurological Disorder (FND), otherwise known as Conversion Disorder, is characterized by abnormal sensory or motor symptoms that are determined to be \"incompatible\" with neurological disease.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31911360'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 228, 'text': 'Conversion disorder or functional neurological disorder is a neurological symptom complex originating from psychological factors, which manifests in voluntary motor and sensory functions or as unexplained epilepsy-like seizures.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22506326'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 141, 'text': 'Functional neurological disorder (FND) is characterized by neurological symptoms that cannot be explained by a structural neurological cause.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36075980'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 128, 'text': 'Functional neurological disorder (FND) is a constellation of common neurological symptoms without exact organic pathophysiology.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36039249'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 227, 'text': 'BACKGROUND: Functional neurological disorder (FND) is an elusive disorder characterized by unexplained neurological symptoms alongside aberrant cognitive processing and negative affect, often associated with amygdala reactivity', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28856091'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 142, 'text': 'Functional neurological disorder (FND), previously regarded as a diagnosis of exclusion, is now a rule-in diagnosis with available treatments.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35074803'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 118, 'text': 'Functional neurological disorder (FND) is a common and highly disabling disorder, but its aetiology remains enigmatic.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30455406'}]\n\n\n             'Is Functional Neurological Disorder (FND) classified as a psychosomatic disorder?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Functional neurological disorder reflects impairments in brain networks leading to distressing motor, sensory and/or cognitive symptoms that demonstrate positive clinical signs on examination incongruent with other conditions."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 173, 'offsetInEndSection': 825, 'text': 'In this review, it is argued that the relationship between the accessibility and activity of an enhancer is insufficiently described by simply considering open versus closed chromatin, or active versus inactive enhancers. Instead, recent studies focusing on the quantitative nature of accessibility signal reveal subtle differences between active enhancers and their different inactive counterparts: the closed silenced state and the accessible primed and repressed states. While the open structure as such is not a specific indicator of enhancer activity, active enhancers display a higher degree of accessibility than the primed and repressed states.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32142172'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 85, 'text': 'DNA accessibility is thought to be of major importance in regulating gene expression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31511305'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 99, 'text': 'Accessibility of promoter DNA is not the primary determinant of chromatin-mediated gene regulation.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31511305'}, {'offsetInBeginSection': 797, 'offsetInEndSection': 1020, 'text': 'Euchromatin and heterochromatin have very similar accessibilities, suggesting that transcription factors can penetrate heterochromatin. Thus, DNA accessibility is not likely to be the primary determinant of gene regulation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31511305'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 166, 'text': 'A major goal in the field of transcriptional regulation is the mapping of changes in the binding of transcription factors to the resultant changes in gene expression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36069349'}, {'offsetInBeginSection': 1692, 'offsetInEndSection': 1873, 'text': 'Together, these results show many gene expression changes can happen independently of changes in the accessibility of local chromatin in the context of a single-factor perturbation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36069349'}, {'offsetInBeginSection': 647, 'offsetInEndSection': 825, 'text': 'While the open structure as such is not a specific indicator of enhancer activity, active enhancers display a higher degree of accessibility than the primed and repressed states.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32142172'}, {'offsetInBeginSection': 349, 'offsetInEndSection': 578, 'text': 'Functional enhancers, in contrast with accessible chromatin regions that lack enhancer activity, were enriched for enhancer RNAs (eRNAs) and preferentially interacted in vivo with B cell lineage-determining transcription factors.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31873292'}, {'offsetInBeginSection': 173, 'offsetInEndSection': 394, 'text': 'In this review, it is argued that the relationship between the accessibility and activity of an enhancer is insufficiently described by simply considering open versus closed chromatin, or active versus inactive enhancers.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32142172'}, {'offsetInBeginSection': 1375, 'offsetInEndSection': 1626, 'text': 'In conclusion, loci identified as active by STARR-seq often overlap with those identified by chromatin accessibility and active epigenetic marking, yet a significant fraction is epigenetically repressed or display condition-specific enhancer activity.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32912294'}]\n\n\n             'Are accessible enhancers necessarily active?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "DNA accessibility is thought to be of major importance in regulating gene expression. However, recent studies focusing on the quantitative nature of the accessibility signal reveal subtle differences between active enhancers and their different inactive counterparts: the closed silenced state and the accessible primed and repressed states. While the open structure as such is not a specific indicator of enhancer activity, active enhancers display a higher degree of accessibility than the primed and repressed states. In addition, another study has shown that euchromatin and heterochromatin can have very similar accessibilities, suggesting that transcription factors can penetrate heterochromatin. Together, these results show that many gene expression changes can happen independently of changes in the accessibility of local chromatin."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 690, 'offsetInEndSection': 854, 'text': 'Omaveloxolone (RTA 408) is an activator of Nrf2 and an inhibitor of NF\u03baB, possessing antioxidative and anti-inflammatory activities in mitochondrial bioenergetics. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34573098'}]\n\n\n             'What is the alternative name of RTA 408?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "RTA 408 is also known as omaveloxolone."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 167, 'offsetInEndSection': 285, 'text': 'SMA is a monogenic pathology that originates from the loss of the SMN1 gene in most cases or mutations in rare cases. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36375840'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 156, 'text': 'Spinal muscular atrophy (SMA) is an autosomal recessive neurodegenerative disorder caused by defects in the survival motor neuron 1 (SMN1) gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35643151'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 152, 'text': 'Loss or deletion of survival motor neuron 1 gene (SMN1) is causative for a severe and devastating neuromuscular disease, Spinal Muscular Atrophy (SMA). ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35614235'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 243, 'text': 'Spinal muscular atrophy (SMA) is a neurodegenerative disorder caused by mutations in SMN1 (encoding survival motor neuron protein (SMN)). Reduced expression of SMN leads to loss of \u03b1-motor neurons, severe muscle weakness and often early death.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35927425'}, {'offsetInBeginSection': 114, 'offsetInEndSection': 299, 'text': 'The primary cause of most, if not all, forms of childhood-onset spinal muscular atrophy appears to be the homozygous loss of the telomeric copy of the survival motor neuron (SMNT) gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9225684'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 114, 'text': 'Spinal muscular atrophy (SMA) is caused by loss-of-function mutations in the survival of motoneuron gene 1 (SMN1).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31127156'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 166, 'text': 'Spinal muscular atrophy (SMA) is caused by the low levels of survival motor neuron (SMN) protein and is characterized by motor neuron degeneration and muscle atrophy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28811488'}, {'offsetInBeginSection': 196, 'offsetInEndSection': 424, 'text': 'Although the major cause of SMA is autosomal recessive exon deletions or loss-of-function mutations of survival motor neuron 1 (SMN1) gene, next generation sequencing technologies are increasing the genetic heterogeneity of SMA.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35126465'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 152, 'text': 'Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease caused by deletions or mutations in the survival motor neuron (SMN1) gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31371553'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 196, 'text': 'Spinal muscular atrophy (SMA) is caused by homozygous mutation or deletion of the SMN1 gene encoding survival of motor neuron (SMN) protein, resulting in the selective loss of alpha-motor neurons.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19535574'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 94, 'text': 'Chronic low levels of survival motor neuron (SMN) protein cause spinal muscular atrophy (SMA).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30010942'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 113, 'text': 'The underlying cause of spinal muscular atrophy (SMA) is a deficiency of the survival motor neuron (SMN) protein.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27299569'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 137, 'text': 'Spinal muscular atrophy (SMA) is a neurodegenerative disorder caused by mutations in SMN1 (encoding survival motor neuron protein (SMN)).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35927425'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 219, 'text': 'Spinal muscular atrophy (SMA) is an autosomal recessive genetic disorder caused by survival motor neuron (SMN) protein deficiency leading the loss of motor neurons in the anterior horns of the spinal cord and brainstem.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29799103'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 139, 'text': 'Spinal muscular atrophy (SMA) is caused by SMN1 gene deletions or mutations, and ALS is the most frequent motor neuron condition in adults.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12427909'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 161, 'text': 'Spinal Muscular Atrophy (SMA) is caused by genetic mutations in the SMN1 gene, resulting in drastically reduced levels of Survival of Motor Neuron (SMN) protein.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30368521'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 164, 'text': 'Spinal muscular atrophy (SMA) is a devastating neuromuscular disorder caused by recessive mutations in the SMN1 gene, globally affecting ~8-14 newborns per 100,000.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36142791'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 95, 'text': 'Spinal Muscular Atrophy (SMA) is a neuromuscular disorder caused by mutations in the SMN1 gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30065610'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 119, 'text': 'Spinal muscular atrophy (SMA) is a neuromuscular genetic disease caused by reduced survival motor neuron (SMN) protein.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34217376'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 91, 'text': 'Classic spinal muscular atrophy (SMA) is caused by mutations in the telomeric copy of SMN1.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11528396'}, {'offsetInBeginSection': 104, 'offsetInEndSection': 254, 'text': ' cause of infantile mortality. SMA is caused by mutation or deletion of Survival Motor Neuron-1 (SMN1). The clinical features of the disease are cause', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20392710'}]\n\n\n             'What is the cause of Spinal Muscular Atrophy (SMA)?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Spinal Muscular Atrophy (SMA) is caused by loss or deletion of survival motor neuron 1 gene (SMN) 1 or mutations in rare cases."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 2015, 'offsetInEndSection': 2208, 'text': \"CONCLUSIONS: Prasinezumab therapy had no meaningful effect on global or imaging measures of Parkinson's disease progression as compared with placebo and was associated with infusion reactions. \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35921451'}]\n\n\n             'Is Prasinezumab effective for Parkinson\u2019s Disease?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "No, Prasinezumab is not effective for Parkinson\u2019s Disease."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 127, 'text': 'Luminopsins (LMOs) are chimeric proteins consisting of a luciferase fused to an opsin that provide control of neuronal activity', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31670406'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 115, 'text': 'Previous work has demonstrated that fusion of a luciferase to an opsin, to create a luminescent opsin or luminopsin', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28862809'}, {'offsetInBeginSection': 362, 'offsetInEndSection': 540, 'text': 'luminopsins, fusion proteins of light-generating luciferase and light-sensing ion channels that could be used to increase neuronal excitability if exposed to a suitable substrate', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34281270'}, {'offsetInBeginSection': 499, 'offsetInEndSection': 583, 'text': 'BL-OG is realized through opsin-luciferase fusion proteins called luminopsins (LMOs)', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35836081'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 235, 'text': 'Luminopsins are fusion proteins of luciferase and opsin that allow interrogation of neuronal circuits at different temporal and spatial resolutions by choosing either extrinsic physical or intrinsic biological light for its activation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26733686'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 201, 'text': 'Luminopsins (LMOs) are chimeric proteins consisting of a luciferase fused to an opsin that provide control of neuronal activity, allowing for less cumbersome and less invasive optogenetic manipulation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31670406'}, {'offsetInBeginSection': 168, 'offsetInEndSection': 309, 'text': 'This is commonly achieved by utilizing a luminopsin (LMO), a fusion protein of a light-emitting luciferase tethered to a light-sensing opsin.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30152529'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 237, 'text': 'Previous work has demonstrated that fusion of a luciferase to an opsin, to create a luminescent opsin or luminopsin, provides a genetically encoded means of manipulating neuronal activity via both chemogenetic and optogenetic approaches.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28862809'}, {'offsetInBeginSection': 357, 'offsetInEndSection': 572, 'text': 'We have bypassed the challenges of external light delivery by directly coupling a bioluminescent light source (a genetically encoded luciferase) to an inhibitory opsin, which we term an inhibitory luminopsin (iLMO).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26399324'}, {'offsetInBeginSection': 299, 'offsetInEndSection': 619, 'text': 'A non-invasive and highly specific approach to neuronal stimulation is bioluminescent-optogenetics (BL-OG), where genetically expressed light emitting luciferases are tethered to light sensitive channelrhodopsins (luminopsins, LMO); neurons are activated by the addition of the luciferase substrate coelenterazine (CTZ).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35126293'}, {'offsetInBeginSection': 648, 'offsetInEndSection': 895, 'text': 'We generated a neuronal precursor cell line expressing luminopsin 3 (LMO3), a luciferase-channelrhodopsin fusion protein, which responds to the luciferase substrate coelenterazine (CTZ) with emission of blue light that in turn activates the opsin.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29577367'}, {'offsetInBeginSection': 1157, 'offsetInEndSection': 1457, 'text': 'Thus, although preserving the ability to be activated by external light sources, LMOs expand the use of optogenetics by making the same opsins accessible to noninvasive, chemogenetic control, thereby allowing the same probe to manipulate neuronal activity over a range of spatial and temporal scales.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26733686'}, {'offsetInBeginSection': 499, 'offsetInEndSection': 584, 'text': 'BL-OG is realized through opsin-luciferase fusion proteins called luminopsins (LMOs).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35836081'}, {'offsetInBeginSection': 496, 'offsetInEndSection': 709, 'text': 'We have previously addressed these challenges by employing bioluminescence and have created a new line of opto-chemogenetic probes termed luminopsins by fusing light-sensing opsins with light-emitting luciferases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30957296'}]\n\n\n             'What are Luminopsins?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Luminopsins (LMOs) are chimeric proteins consisting of a luciferase fused to an opsin."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 782, 'text': 'The hallmarks of cancer comprise six biological capabilities acquired during the multistep development of human tumors. The hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease. They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis. Underlying these hallmarks are genome instability, which generates the genetic diversity that expedites their acquisition, and inflammation, which fosters multiple hallmark functions. Conceptual progress in the last decade has added two emerging hallmarks of potential generality to this list-reprogramming of energy metabolism and evading immune destruction.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21376230'}, {'offsetInBeginSection': 364, 'offsetInEndSection': 680, 'text': 'We define seven hallmarks of cancer: selective growth and proliferative advantage, altered stress response favoring overall survival, vascularization, invasion and metastasis, metabolic rewiring, an abetting microenvironment, and immune modulation, while highlighting some considerations for the future of the field.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28560055'}, {'offsetInBeginSection': 125, 'offsetInEndSection': 557, 'text': 'These distinctive and complementary capabilities, defined as the \"hallmarks of cancer,\" include the ability of tumor cells and their microenvironment to sustain proliferative signaling, evade growth suppressors, resist cell death, promote replicative immortality, induce angiogenesis, support invasion and metastasis, reprogram energy metabolism, induce genomic instability and inflammation, and trigger evasion of immune responses.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31873723'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 164, 'text': 'Human cancers share properties referred to as hallmarks, among which sustained proliferation, escape from apoptosis, and genomic instability are the most pervasive.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25621662'}, {'offsetInBeginSection': 423, 'offsetInEndSection': 606, 'text': 'Underlying these hallmarks are genome instability, which generates the genetic diversity that expedites their acquisition, and inflammation, which fosters multiple hallmark functions.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21376230'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 134, 'text': 'The hallmarks of cancer described by Hanahan and Weinberg are properties that cancer cells must possess for successful transformation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23932019'}, {'offsetInBeginSection': 227, 'offsetInEndSection': 422, 'text': 'They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21376230'}, {'offsetInBeginSection': 1097, 'offsetInEndSection': 1459, 'text': 'The integrative concept embodied in the hallmarks of cancer is helping to distill this complexity into an increasingly logical science, and the provisional new dimensions presented in this perspective may add value to that endeavor, to more fully understand mechanisms of cancer development and malignant progression, and apply that knowledge to cancer medicine.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35022204'}, {'offsetInBeginSection': 1117, 'offsetInEndSection': 1528, 'text': 'Based on extensive study of the cancer research literature, we propose four novel hallmarks of cancer, namely, the ability of cells to regress from a specific specialized functional state, epigenetic changes that can affect gene expression, the role of microorganisms and neuronal signalling, to be included in the hallmark conceptualization along with evidence of various means to exploit them therapeutically.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33465324'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 180, 'text': 'The hallmarks of cancer conceptualization is a heuristic tool for distilling the vast complexity of cancer phenotypes and genotypes into a provisional set of underlying principles.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35022204'}, {'offsetInBeginSection': 324, 'offsetInEndSection': 561, 'text': 'The hallmarks of cancer include six biological processes, including proliferative signaling, evasion of growth suppressors, resistance to cell death, replicative immortality, inducing angiogenesis, and activating invasion and metastasis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36283507'}, {'offsetInBeginSection': 635, 'offsetInEndSection': 854, 'text': 'Attention is paid to the emerging hallmarks, deregulation of cellular energy metabolism and evasion of immune destruction, and enabling characteristics, genome instability and mutation and tumour-promoting inflammation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23263268'}, {'offsetInBeginSection': 105, 'offsetInEndSection': 434, 'text': 'This progression has been suggested to depend on six essential characteristics identified as the \"hallmarks of cancer,\" which include: self-sufficiency in growth signals, insensitivity to growth-inhibitory signals, evasion of apoptosis, limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15864800'}, {'offsetInBeginSection': 935, 'offsetInEndSection': 1364, 'text': 'The six classical hallmarks of cancer (i.e., limitless replication, self-provision of proliferative stimuli, insensitivity to antiproliferative signals, disabled apoptosis, sustained angiogenesis, invasiveness/metastatic potential), as well as other common features of tumors (i.e., avoidance of the immune response, enhanced anabolic metabolism, disabled autophagy) may directly or indirectly implicate deregulated mitochondria.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19698742'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 425, 'text': 'Hanahan and Weinberg (2000, Cell 100: 57-70) listed \"hallmarks\" of cancer that must be considered in order to understand the underlying determinants of carcinogenesis: (a) self-sufficiency in growth signals; (b) insensitivity to growth-inhibitory (antigrowth) signals; (c) evasion of programmed cell death (apoptosis); (d) limitedless replicative potential; (e) sustained angiogenesis; and (f) tissue invasion and metastasis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15650245'}, {'offsetInBeginSection': 202, 'offsetInEndSection': 385, 'text': 'These hallmarks include; unlimited proliferation, evading growth suppressors, resisting cell death, replicative immortality, inducing angiogenesis, initiating invasion and metastasis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31119147'}, {'offsetInBeginSection': 231, 'offsetInEndSection': 430, 'text': 'Cancer hallmarks include sustained proliferation, evading growth suppressors, metastasis, replicative immortality, angiogenesis, resisting cell death, altered cellular energetics, and immune evasion.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29495398'}, {'offsetInBeginSection': 14, 'offsetInEndSection': 329, 'text': 'According to Hanahan and Weinberg, cancer manifests as six essential physiologic hallmarks: (1) self-sufficiency in growth signals, (2) insensitivity to growth-inhibitory signals, (3) evasion of programmed cell death, (4) limitless replicative potential, (5) sustained angiogenesis, and (6) invasion and metastasis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27935336'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 170, 'text': 'Tumors arise through waves of genetic alterations and clonal expansion that allow tumor cells to acquire cancer hallmarks, such as genome instability and immune evasion. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32092639'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 178, 'text': 'The hallmarks of cancer provide a highly cited and well-used conceptual framework for describing the processes involved in cancer cell development and tumourigenesis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33823788'}]\n\n\n             'What are the hallmarks of cancer?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "The hallmarks of cancer comprise six biological capabilities acquired during the multistep development of human tumors. The hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease. They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis. Underlying these hallmarks are genome instability, which generates the genetic diversity that expedites their acquisition, and inflammation, which fosters multiple hallmark functions. Conceptual progress in the last decade has added two emerging hallmarks of potential generality to this list-reprogramming of energy metabolism and evading immune destruction."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 711, 'offsetInEndSection': 1109, 'text': 'Recent results from the PEACHTREE trial (ClinicalTrials.gov Identifier: NCT02595398), a phase III trial with two suprachoroidal injections of CLS-TA at 0 and 12 weeks with follow up lasting 24 weeks, showed the significant improvement in visual acuity and reduction in central subfield thickness, all without increasing the risk of elevated intraocular pressure or accelerated cataract progression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34322164'}]\n\n\n             'What was the phase of the clinical trial PEACHTREE?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "The PEACHTREE trial was a phase III clinical trial."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 316, 'text': 'Emery-Dreifuss muscular dystrophy (EDMD) is an inherited muscular disorder clinically characterized by slowly progressive weakness affecting humero-peroneal muscles, early joint contractures and cardiomyopathy with conduction defects. Autosomal dominant and recessive forms are caused by mutations in lamin A/C gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16550925'}, {'offsetInBeginSection': 516, 'offsetInEndSection': 591, 'text': 'X-linked recessive form of EDMD is caused by mutation in EMD (or STA) gene ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16550925'}, {'offsetInBeginSection': 162, 'offsetInEndSection': 353, 'text': 'The LINC components emerin, lamin A/C, SUN1, SUN2, nesprin-1 and nesprin-2 interact with each other at the NE and also with other binding partners including actin filaments and B-type lamins.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22103509'}, {'offsetInBeginSection': 473, 'offsetInEndSection': 590, 'text': 'Emerin was the first LINC component associated with a human disease, namely EDMD (Emery-Dreifuss muscular dystrophy).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22103509'}, {'offsetInBeginSection': 591, 'offsetInEndSection': 742, 'text': 'Later on, other components of the LINC complex, such as lamins A/C and small isoforms of nesprin-1 and nesprin-2, were found to be associated with EDMD', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22103509'}, {'offsetInBeginSection': 814, 'offsetInEndSection': 973, 'text': 'Only approximately 46% of the EDMD patients can be linked to genes of LINC and non-LINC components, pointing to further genes involved in the pathology of EDMD', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22103509'}, {'offsetInBeginSection': 1030, 'offsetInEndSection': 1215, 'text': ' Recently, screening of binding partners of LINC components as candidates identified LUMA (TMEM43), encoding a binding partner of emerin and lamins, as a gene involved in atypical EDMD.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22103509'}, {'offsetInBeginSection': 1303, 'offsetInEndSection': 1354, 'text': ' EDMD-causing mutations in STA/EMD (encoding emerin', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22103509'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 564, 'text': 'Emery-Dreifuss muscular dystrophy (EDMD) is a rare muscular dystrophy, but is particularly important to diagnose due to frequent life-threatening cardiac complications. EDMD classically presents with muscle weakness, early contractures, cardiac conduction abnormalities and cardiomyopathy, although the presence and severity of these manifestations vary by subtype and individual. Associated genes include EMD, LMNA, SYNE1, SYNE2, FHL1, TMEM43, SUN1, SUN2, and TTN, encoding emerin, lamin A/C, nesprin-1, nesprin-2, FHL1, LUMA, SUN1, SUN2, and titin, respectively.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31840275'}]\n\n\n             'Which genes are related to Emery-Dreifuss Muscular Dystrophy (EDMD)?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "The genes that are related to EDMD are the following: EMD (or STA),  LMNA (laminA/C gene), SUN1, SUN2, nesprin-1 (SYNE1), nesprin-2 (SYNE2), titin (TTN) and FHL1 (LUMA) genes."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 68, 'text': 'Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35857660'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 230, 'text': 'BACKGROUND: FLT180a (verbrinacogene setparvovec) is a liver-directed adeno-associated virus (AAV) gene therapy that uses a synthetic capsid and a gain-of-function protein to normalize factor IX levels in patients with hemophilia B', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35857660'}]\n\n\n             'Was AAVS3 developed for hemophilia A?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "No. AAVS3 was developed for hemophilia B."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 224, 'offsetInEndSection': 587, 'text': 'new firefly bioluminescence substrates, and further evaluated their activities in vitro and in vivo. It is worth noting that the maximum biological emission wavelength of novel luciferin analogue AL3 ((S,E)-2-(6-hydroxy-5-(3-methoxy-3-oxoprop-1-en-1-yl)benzo[d]thiazol-2-yl)-4,5-dihydrothiazole-4-carboxylic acid) is 100 nm red-shifted compared with D-luciferin, ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35551298'}, {'offsetInBeginSection': 610, 'offsetInEndSection': 711, 'text': 'AL4 ((S,E)-2-(5-(2-cyanovinyl)-6-hydroxybenzo[d]thiazol-2-yl)-4,5-dihydrothiazole-4-carboxylic acid) ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35551298'}, {'offsetInBeginSection': 733, 'offsetInEndSection': 919, 'text': 'The new substrate AL2 ((S,E)-2-(6-hydroxy-7-(3-methoxy-3-oxoprop-1-en-1-yl)benzo[d]thiazol-2-yl)-4,5-dihydrothiazole-4-carboxylic acid) showed better bioluminescence performance in vivo.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35551298'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 243, 'text': 'The interaction of luciferases from two types of luminous bacteria, Photobacterium leiognathi and Vibrio harveyi, with their substrates [the photorecovered FMNH2 and long-chain aldehydes--decanal (C10), dodecanal (C12) and tetradecanal (C14)] ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11512142'}, {'offsetInBeginSection': 593, 'offsetInEndSection': 686, 'text': 'Following coadministration of two luciferase substrates, native coelenterazine and luciferin,', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17994900'}, {'offsetInBeginSection': 377, 'offsetInEndSection': 597, 'text': 'Comparisons of experimental data with predictions based upon the three inhibitory models show that product inhibition during luciferase luminescence is noncompetitive with respect to both luciferin and ATP as substrates.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/836795'}, {'offsetInBeginSection': 140, 'offsetInEndSection': 429, 'text': 'An alternative luciferase (Luc) substrate cyclic luciferin (Cycluc) was recently advanced for BLI applications as providing a stronger, more stable signal at significantly lower doses than the classical substrate D-luciferin (D-Luc) increasing sensitivity of Luc detection 10 to 100 times.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30979501'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 43, 'text': 'ATP is one of the substrates of luciferase.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15165512'}, {'offsetInBeginSection': 286, 'offsetInEndSection': 504, 'text': 'D-luciferin, a natural substrate of firefly luciferase, has been reported to have limited brain distribution, possibly due to the efflux transporter, breast cancer resistance protein (Bcrp), at the blood-brain barrier.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34887255'}, {'offsetInBeginSection': 204, 'offsetInEndSection': 324, 'text': '4-Methyl-D-luciferin is a substrate of Photinus pyralis luciferase, and it causes light emission in luminometric assays.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/2230665'}, {'offsetInBeginSection': 1501, 'offsetInEndSection': 1659, 'text': 'This study examined the pharmacokinetics, brain distribution, and the role of active efflux transporters on the luciferase substrates D-luciferin and CycLuc1.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34887255'}, {'offsetInBeginSection': 102, 'offsetInEndSection': 337, 'text': 'Antares, a fusion of the luciferase NanoLuc to the orange fluorescent protein CyOFP, has emerged as a bright bioluminescent reporter with orthogonal substrate specificity to firefly luciferase (FLuc) and its derivatives such as AkaLuc.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32661427'}, {'offsetInBeginSection': 243, 'offsetInEndSection': 377, 'text': \"Here we report cost-effective and efficient syntheses of d-luciferin and 6'-aminoluciferin, two widely used bioluminescent substrates.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25525906'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 87, 'text': 'd-Luciferin is a popular bioluminescent substrate of luciferase in the presence of ATP.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31764924'}, {'offsetInBeginSection': 197, 'offsetInEndSection': 347, 'text': 'cusing on the tissue distribution of two luciferase substrates, D-luciferin and CycLuc1. D-luciferin, a natural substrate of firefly luciferase, has b', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34887255'}, {'offsetInBeginSection': 699, 'offsetInEndSection': 849, 'text': ' non-competitive manner with respect to the luciferase substrates D-luciferin and ATP. By contrast, the compound has no effect on Renilla and Gaussia ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22789175'}, {'offsetInBeginSection': 700, 'offsetInEndSection': 850, 'text': 'non-competitive manner with respect to the luciferase substrates D-luciferin and ATP. By contrast, the compound has no effect on Renilla and Gaussia l', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22789175'}]\n\n\n             'List the luciferase substrates'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "luciferase substrates include coelenterazine (CTZ), Luciferin, ATP, FMNH2, and luciferin analogs like AL3 ((S,E)-2-(6-hydroxy-5-(3-methoxy-3-oxoprop-1-en-1-yl)benzo[d]thiazol-2-yl)-4,5-dihydrothiazole-4-carboxylic acid), AL4 ((S,E)-2-(5-(2-cyanovinyl)-6-hydroxybenzo[d]thiazol-2-yl)-4,5-dihydrothiazole-4-carboxylic acid) and AL2 ((S,E)-2-(6-hydroxy-7-(3-methoxy-3-oxoprop-1-en-1-yl)benzo[d]thiazol-2-yl)-4,5-dihydrothiazole-4-carboxylic acid) as well as long-chain aldehydes--decanal (C10), dodecanal (C12) and tetradecanal (C14)]"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 386, 'offsetInEndSection': 734, 'text': 'Transcription factors regulating both the identity and patterning of embryonic structures and the development of individual organs are often called master regulatory genes. These genes, as well as other transcription factors, are parts of signaling networks mediating cellular communication, including inductive interactions between nearby tissues.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10066109'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 241, 'text': 'The transformation of normal precursors into cancer cells is an intricately regulated, multistep process. The master regulatory genes that play a crucial role in the process of organism development may also play a key role in carcinogenesis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26845852'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 151, 'text': 'SOX genesare master regulatory genes controlling development and are fundamental to the establishment of sex determination in a multitude of organisms.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35760052'}, {'offsetInBeginSection': 215, 'offsetInEndSection': 329, 'text': 'Because a MRG can regulate the concurrent expression of several genes, its mutation often leads to major diseases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33083114'}, {'offsetInBeginSection': 386, 'offsetInEndSection': 558, 'text': 'Transcription factors regulating both the identity and patterning of embryonic structures and the development of individual organs are often called master regulatory genes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10066109'}, {'offsetInBeginSection': 119, 'offsetInEndSection': 306, 'text': 'Such master regulators are classically seen as acting on the top of a regulatory hierarchy that determines a complete developmental program, and they usually encode transcription factors.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30043361'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 101, 'text': 'Master genes are known to induce the differentiation of a multipotent cell into a specific cell type.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27434165'}, {'offsetInBeginSection': 1054, 'offsetInEndSection': 1176, 'text': ' A poorly understood phenomenon is how developmental master regulators exert functions in different cell- and organ types.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30043361'}, {'offsetInBeginSection': 118, 'offsetInEndSection': 306, 'text': ' Such master regulators are classically seen as acting on the top of a regulatory hierarchy that determines a complete developmental program, and they usually encode transcription factors.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30043361'}]\n\n\n             'What are master regulatory genes?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Transcription factors regulating both the identity and patterning of embryonic structures and the development of individual organs are often called master regulatory genes. These genes, as well as other transcription factors, are parts of signaling networks mediating cellular communication, including inductive interactions between nearby tissues. SOX genes are an example of master regulatory genes that control development and are fundamental to the establishment of sex determination in a multitude of organisms. Because a master regulatory gene can regulate the concurrent expression of several genes, its mutation often leads to major diseases. In particular, the master regulatory genes that play a crucial role in the process of organism development may also play a key role in carcinogenesis."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 86, 'text': \"Randomized, clinical trial of RT001: Early signals of efficacy in Friedreich's ataxia.\", 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29624723'}, {'offsetInBeginSection': 352, 'offsetInEndSection': 500, 'text': \"We conducted a phase I/II double-blind, comparator-controlled trial with 2 doses of RT001 in Friedreich's ataxia patients (9 subjects each cohort). \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29624723'}]\n\n\n             'In what type of clinical trial has RT001 been evaluated against Friedreich's ataxia?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "RT001 was evaluatd in a phase I/II double-blind, randomized, comparator-controlled trial in Friedreich's ataxia patients."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 228, 'text': 'Inflammatory myopathies, including polymyositis (PM), dermatomyositis (DM), inclusion body myositis (IBM), necrotizing myopathy (NM), antisynthetase syndrome (ASS) and overlap myositis (OM), in short myositis, are rare diseases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35394612'}, {'offsetInBeginSection': 135, 'offsetInEndSection': 407, 'text': 'This review describes the clinical features, diagnosis and treatment for IIMs, namely polymyositis (PM), dermatomyositis (DM), sporadic inclusion body myositis (sIBM), immune-mediated necrotizing myopathy (IMNM), and myositis associated with antisynthetase syndrome (ASS).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34767470'}, {'offsetInBeginSection': 307, 'offsetInEndSection': 650, 'text': 'The search strategy from the 2021 Cochrane Physical Activity review in neuromuscular disease was used, and we selected articles that included people with IIM, including Dermatomyositis (DM), Inclusion Body Myositis (IBM), Immune Mediated Necrotising Myopathy (IMNM) [also known as necrotizing autoimmune myopathy (NAM)], and Polymyositis (PM).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35927155'}, {'offsetInBeginSection': 172, 'offsetInEndSection': 438, 'text': 'We present evidence based on recently emerged clinical, histologic, immunopathologic, demographic and therapeutic observations that these myopathies comprise three major and distinct groups: polymyositis (PM), dermatomyositis (DM), and inclusion-body myositis (IBM).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1423335'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 167, 'text': 'The inflammatory myopathies, including dermatomyositis, inclusion body myositis, and polymyositis, are poorly understood autoimmune diseases affecting skeletal muscle.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18351525'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 267, 'text': 'There are five major types of idiopathic inflammatory myopathies: dermatomyositis (DM), polymyositis (PM), inclusion body myositis (IBM), autoimmune necrotizing myopathy (AINM) and inflammatory myopathies associated with connective tissue diseases (overlap myositis).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19282137'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 267, 'text': 'Idiopathic inflammatory myopathy (IIM) is the umbrella term including dermatomyositis (DM), polymyositis (PM), overlap myositis (OM), sporadic inclusion body myositis (IBM) and necrotising autoimmune myopathy (NAM), also known as immune-mediated necrotising myopathy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34155760'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 307, 'text': 'Idiopathic inflammatory myopathies (IIMs), except for sporadic inclusion body myositis (sIBM), present with subacute symmetrical weakness of the limb girdle muscles, an elevated serum creatine kinase activity, and inflammatory cells in the muscle biopsy (necrotizing autoimmune myopathy being an exception).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24365315'}, {'offsetInBeginSection': 428, 'offsetInEndSection': 658, 'text': 'Five main types of inflammatory myopathies are now widely recognised: dermatomyositis, immune-mediated necrotising myopathy, sporadic inclusion-body myositis, overlap myositis (including antisynthetase syndrome), and polymyositis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30129477'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 140, 'text': 'PURPOSE OF REVIEW: The inflammatory myopathies include polymyositis, dermatomyositis, necrotizing autoimmune myopathy (NAM), and inclusion b', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21799409'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 196, 'text': 'Idiopathic inflammatory myopathies (IM), including dermatomyositis (DM) and polymyositis (PM), are a group of systemic rheumatologic diseases of unknown etiology characterized by chronic myositis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16769661'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 287, 'text': 'Idiopathic inflammatory myopathies are a group of heterogeneous striated muscle acquired autoimmune diseases, characterized by progressive symmetrical muscle weakness, elevated serum levels of muscle enzymes, electromyographic abnormalities and inflammatory infiltrates on muscle biopsy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21794659'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 270, 'text': 'Inflammatory myopathies are a group of immune-mediated muscle disorders comprising dermatomyositis; polymyositis; overlap myositis, including antisynthetase syndromes and nonspecific myositis, immune-mediated necrotizing myopathies, and sporadic inclusion body myositis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32703475'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 164, 'text': 'The idiopathic inflammatory myopathies are a group of rare disorders including polymyositis (PM), dermatomyositis (DM), and autoimmune necrotizing myopathies (NMs).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23117947'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 244, 'text': 'OBJECTIVE: The molecular basis of inflammatory myopathies such as dermatomyositis (DM), polymyositis, and inclusion body myositis, which share the characteristics of chronic muscle inflammation and skeletal muscle wasting, are poorly understood', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24757153'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 121, 'text': 'The idiopathic inflammatory myopathies include polymyositis (PM), dermatomyositis (DM) and inclusion body myositis (IBM).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22870499'}, {'offsetInBeginSection': 515, 'offsetInEndSection': 665, 'text': ' the common inflammatory myopathies, i.e. dermatomyositis, polymyositis, and sporadic inclusion body myositis, and to describe the specific spectrum o', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33554607'}]\n\n\n             'Which are the known inflammatory myopathies?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "The known inflammatory myopathies are the following: polymyositis (PM), dermatomyositis (DM), inclusion body myositis (IBM), sporadic inclusion body myositis (sIBM), necrotizing myopathy (NM), antisynthetase syndrome (ASS), overlap myositis (OM) and immune-mediated necrotizing myopathy (IMNM) also known as necrotizing autoimmune myopathy (NAM)."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 165, 'offsetInEndSection': 464, 'text': 'METHODS: We conducted a phase 1 clinical trial to assess the safety and pharmacokinetics of L9LS, a next-generation antimalarial monoclonal antibody, and its protective efficacy against controlled human malaria infection in healthy adults who had never had malaria or received a vaccine for malaria.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35921449'}, {'offsetInBeginSection': 2119, 'offsetInEndSection': 2300, 'text': 'CONCLUSIONS: In this small trial, L9LS administered intravenously or subcutaneously protected recipients against malaria after controlled infection, without evident safety concerns.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35921449'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 152, 'text': 'L9LS, a potent and safe antimalarial monoclonal antibody, demonstrated 88% protective efficacy against infection in a phase 1 trial in healthy adults.1 ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36260982'}]\n\n\n             'L9LS was developed for which disease?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "L9LS was developed for malaria."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 191, 'text': 'Developmental iron deficiency (dID) models facilitate the study of specific oligodendrocyte (OL) requirements for their progression to a mature state and subsequent contribution to myelinatio', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31162719'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 96, 'text': 'Ontogenetic oligodendrocyte maturation through gestational iron deprivation: The road not taken.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31162719'}, {'offsetInBeginSection': 1444, 'offsetInEndSection': 1564, 'text': ' the expression levels of Hes5, Sox10, and Olig1 in dID conditions correlated with an unfavorable OL maturation profile.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31162719'}, {'offsetInBeginSection': 1572, 'offsetInEndSection': 1691, 'text': ' the current results provide further evidence of dID impact on myelination, keeping OL away from the maturational path.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31162719'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 118, 'text': 'Impaired Postnatal Myelination in a Conditional Knockout Mouse for the Ferritin Heavy Chain in Oligodendroglial Cells.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32868463'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 170, 'text': 'To define the importance of iron storage in oligodendrocyte development and function, the ferritin heavy subunit (Fth) was specifically deleted in oligodendroglial cells.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32868463'}, {'offsetInBeginSection': 2314, 'offsetInEndSection': 2444, 'text': 'Fth iron storage is essential for early oligodendrocyte development as well as for OPC maturation in the demyelinated adult brain.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32868463'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 104, 'text': 'H-ferritin expression in astrocytes is necessary for proper oligodendrocyte development and myelination.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34460113'}, {'offsetInBeginSection': 1478, 'offsetInEndSection': 1629, 'text': ' These results indicate that Fth iron storage in astrocytes is vital for early oligodendrocyte development as well as for the remyelination of the CNS.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34460113'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 107, 'text': 'Iron modulates the differentiation of a distinct population of glial precursor cells into oligodendrocytes.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11518519'}, {'offsetInBeginSection': 421, 'offsetInEndSection': 692, 'text': 'Here, using an in vitro cultured differentiation model of oligodendrocytes, we found that both transferrin receptor and ferritin-H are significantly upregulated during oligodendrocyte maturation, implying the essential role of iron in the development of oligodendrocytes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25206366'}, {'offsetInBeginSection': 1060, 'offsetInEndSection': 1217, 'text': 'Our results raise the possibility that iron may affect oligodendrocyte development at stages during early embryogenesis rather than during later development.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11518519'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 114, 'text': 'When disrupted, iron homeostasis negatively impacts oligodendrocyte (OLG) differentiation and impairs myelination.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28092084'}, {'offsetInBeginSection': 355, 'offsetInEndSection': 567, 'text': 'These hypotheses are based on the observations that there is a peak in brain iron uptake in vivo that coincides with the period of greatest myelination and that a shortage of iron leads to myelination deficiency.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11518519'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 193, 'text': 'Developmental iron deficiency (dID) models facilitate the study of specific oligodendrocyte (OL) requirements for their progression to a mature state and subsequent contribution to myelination.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31162719'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 190, 'text': 'Iron is an essential trophic element that is required for cell viability and differentiation, especially in oligodendrocytes, which consume relatively high rates of energy to produce myelin.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25206366'}, {'offsetInBeginSection': 1479, 'offsetInEndSection': 1629, 'text': 'These results indicate that Fth iron storage in astrocytes is vital for early oligodendrocyte development as well as for the remyelination of the CNS.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34460113'}, {'offsetInBeginSection': 1076, 'offsetInEndSection': 1352, 'text': 'Total iron content in unperfused brain is not significantly different between Mcoln1(-/-) and wild-type littermate mice, suggesting that the observed maturation delay or loss of oligodendrocytes might be caused by impaired iron handling, rather than by global iron deficiency.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26398942'}, {'offsetInBeginSection': 1346, 'offsetInEndSection': 1534, 'text': 'These data indicate that iron delivered via transferrin and its receptor is intrinsically involved in oligodendrocyte maturation and thus plays a critical role in the onset of myelination.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7768202'}]\n\n\n             'Does iron regulate oligodendrocyte maturation?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Developmental iron deficiency has an impact on myelination and effects oligodendrocyte maturation. Iron storage in astrocytes is vital for early oligodendrocyte development as well as for the remyelination of the CNS."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 280, 'text': 'Each human, when born, has slightly different DNA sequences, which make each of us unique. The variations in DNA sequences are called genetic variants. The primary aim of genome-wide association study (GWAS) is to detect associations between genetic variants and human phenotypes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34605948'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 261, 'text': 'Genome-wide association studies (GWAS) have successfully mapped thousands of loci associated with complex traits. These associations could reveal the molecular mechanisms altered in common complex diseases and result in the identification of novel drug targets.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32477401'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 713, 'text': 'Genome-wide association studies (GWAS) provide an important avenue for undertaking an agnostic evaluation of the association between common genetic variants and risk of disease. Recent advances in our understanding of human genetic variation and the technology to measure such variation have made GWAS feasible. Over the past few years a multitude of GWAS have identified and replicated many associated variants. These findings are enriching our knowledge about the genetic basis of disease and leading some to advocate using GWA study results for genetic testing. For many of the GWA study results, however, the underlying mechanisms remain unclear and the findings explain only a limited amount of heritability.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20235850'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 321, 'text': 'Genome-wide association study (GWAS) is a powerful study design to identify genetic variants of a trait and, in particular, detect the association between common single-nucleotide polymorphisms (SNPs) and common human diseases such as heart disease, inflammatory bowel disease, type 2 diabetes, and psychiatric disorders.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29536439'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 155, 'text': 'Genome-wide association studies (GWAS) involve testing genetic variants across the genomes of many individuals to identify genotype-phenotype associations.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31068683'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 241, 'text': 'Genome-wide association (GWA) studies are best understood as an extension of candidate gene association studies, scaled up to cover hundreds of thousands of markers across the genome in samples usually of several thousand cases and controls.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21153613'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 177, 'text': 'Genome-wide association studies (GWAS) provide an important avenue for undertaking an agnostic evaluation of the association between common genetic variants and risk of disease.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20235850'}, {'offsetInBeginSection': 1710, 'offsetInEndSection': 2062, 'text': 'GWAS are an important discovery tool that require extensive follow-up to map each region, investigate the biological mechanism underpinning the association and eventually test the optimal markers for assessing risk for a disease or its outcome, such as in pharmacogenomics, the study of the effect of genetic variation on pharmacological interventions.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19906782'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 240, 'text': 'Genome-wide association studies (GWAS) are a powerful tool for investigators to examine the human genome to detect genetic risk factors, reveal the genetic architecture of diseases and open up new opportunities for treatment and prevention.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24870131'}, {'offsetInBeginSection': 156, 'offsetInEndSection': 322, 'text': 'GWAS have revolutionized the field of complex disease genetics over the past decade, providing numerous compelling associations for human complex traits and diseases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31068683'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 130, 'text': 'Genome-wide association studies (GWAS) have developed into a powerful and ubiquitous tool for the investigation of complex traits.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33442955'}, {'offsetInBeginSection': 265, 'offsetInEndSection': 385, 'text': 'Genome-wide association studies (GWAS) scan the genome to search associations of SNPs with specific traits, like cancer.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32343194'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 157, 'text': 'Genome-wide association studies (GWAS) evaluate associations between genetic variants and a trait or disease of interest free of prior biological hypotheses.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27612175'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 207, 'text': 'Genome-Wide Association studies (GWAS) offer an unbiased means to understand the genetic basis of traits by identifying single nucleotide polymorphisms (SNPs) linked to causal variants of complex phenotypes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22888763'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 219, 'text': 'Genome-wide association studies (GWAS) have provided valuable insights into the genetic basis of complex traits, discovering >6000 variants associated with >500 quantitative traits and common complex diseases in humans.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24629526'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 174, 'text': 'Genome-wide association studies (GWAS) provide a hypothesis-free approach to discover genetic variants contributing to the risk of a certain disease or disease-related trait.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29423796'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 104, 'text': 'Genome-wide association studies (GWAS) are a powerful tool for pathogenetic studies of complex diseases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26188273'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 121, 'text': 'Genome-wide association studies (GWAS) have successfully identified many genetic variants associated with complex traits.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31821614'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 169, 'text': 'Genome-wide association studies (GWAS) and sequencing studies are routinely conducted for the identification of genetic variants that are associated with complex traits.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25599666'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 185, 'text': 'Genome-wide association studies (GWAS) have been highly informative in discovering disease-associated loci but are not designed to capture all structural variations in the human genome.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35332097'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 104, 'text': 'Genome-wide association studies (GWAS) detect common genetic variants associated with complex disorders.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29727703'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 228, 'text': 'Genome-wide association studies (GWASs) have identified abundant genetic susceptibility loci, GWAS of small sample size are far less from meeting the previous expectations due to low statistical power and false positive results.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31024629'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 108, 'text': 'Genome-wide association studies (GWAS) allow the finding of genetic variants associated with several traits.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29095100'}, {'offsetInBeginSection': 193, 'offsetInEndSection': 332, 'text': 'Genome-wide association studies (GWAS) play a key role in discovering genetic variations that may contribute towards disease vulnerability.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25895066'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 154, 'text': 'Genome-wide association studies (GWAS) are a valuable approach to identify single nucleotide polymorphisms (SNPs) associated with a phenotype of interest.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31893446'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 152, 'text': 'Genome-wide association studies (GWAS) are performed to find associations between genetic variants (i.e. single-nucleotide polymorphisms) and diseases. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24754927'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 214, 'text': 'Genome-Wide Association Studies (GWAS) refer to observational studies of a genome-wide set of genetic variants across many individuals to see if any genetic variants are associated with a certain trait.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32693805'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 213, 'text': 'Genome-wide association studies (GWAS) have identified thousands of susceptibility variants, although most have been associated with small individual risk estimates that offer little predictive value. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30908599'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 257, 'text': 'Genome-Wide Association Studies (GWAS) are used to identify statistically significant genetic variants in case-control studies. The main objective is to find single nucleotide polymorphisms (SNPs) that influence a particular phenotype (i.e., disease trait).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30183645'}]\n\n\n             'What are genome-wide association studies (GWAS)?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Each human has slightly different DNA sequences, called genetic variants, which make each of us unique. Genome-wide association studies (GWAS) provide an important avenue for undertaking an agnostic evaluation of the association between common genetic variants and the risk of disease. Recent advances in our understanding of human genetic variation and the technology to measure such variation have made GWAS feasible. Over the past few years, a multitude of GWAS has identified and replicated many associated variants. These associations could reveal the molecular mechanisms altered in common complex diseases and result in the identification of novel drug targets."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 102, 'text': 'Design and synthesis of proteolysis targeting chimeras (PROTACs) as an EGFR degrader based on CO-1686.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35594654'}, {'offsetInBeginSection': 241, 'offsetInEndSection': 365, 'text': 'The emerging technology proteolysis targeting chimera (PROTAC) could be an alternative strategy to overcome these problems. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35594654'}]\n\n\n             'What does PROTACs stand for?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "PROTACs are proteolysis targeting chimeras."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 253, 'text': 'Leigh syndrome (LS), or subacute necrotizing encephalomyelopathy, is the most common childhood mitochondrial encephalopathy, accounting for more than 50% of cases in this age group. Its estimated incidence is 1:40,000 - 1:77,000 liveborn infants a year.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24299589'}, {'offsetInBeginSection': 182, 'offsetInEndSection': 253, 'text': 'Its estimated incidence is 1:40,000 - 1:77,000 liveborn infants a year.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24299589'}, {'offsetInBeginSection': 834, 'offsetInEndSection': 917, 'text': 'Leigh syndrome occurs with an estimated frequency of 1:77,000-1:34,000 live births.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18651330'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 91, 'text': 'Leigh syndrome is a neurodegenerative disorder with an incidence of 1\\u2009:\\u200940,000 live births.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34868319'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 94, 'text': 'Leigh syndrome is a progressive neurodegenerative disorder, affecting 1 in 40,000 live births.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26725255'}, {'offsetInBeginSection': 133, 'offsetInEndSection': 210, 'text': 'It has an incidence of 1 in 77,000 live births worldwide with poor prognosis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30392038'}]\n\n\n             'What is the incidence of Leigh syndrome?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "The incidence of Leigh syndrome is 1:40,000 - 1:77,000 liveborn infants a year."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 143, 'offsetInEndSection': 371, 'text': 'It is a serious threat to prehospital patients and especially injured patients, since it can induce a vicious cycle of the synergistic effects of hypothermia, acidosis and coagulopathy; referred to as the trauma triad of death. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29162267'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 67, 'text': 'The trauma triad of death: hypothermia, acidosis, and coagulopathy.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10347389'}, {'offsetInBeginSection': 665, 'offsetInEndSection': 854, 'text': 'The \"new\" golden hour may well be the time in the operating room before the patient reaches the physiologic limit, defined as the onset of the triad: hypothermia, acidosis and coagulopathy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10347389'}]\n\n\n             'What are features of the The Trauma Triad of Death?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "The trauma triad of death: hypothermia, acidosis, and coagulopathy."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 181, 'text': 'Surgeons treating advanced carcinoma of the tongue with total glossectomy face many conflicts in view of the morbidity and poor functional and survival outcomes following surgery. I', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34016519'}, {'offsetInBeginSection': 136, 'offsetInEndSection': 411, 'text': 'Ablation of a tongue tumor leaves defects that can be either surgically reconstructed or replaced by a prosthesis to help recreate normalcy and balance in the oral cavity. This clinical report describes a prosthetic design to rehabilitate a patient after a total glossectomy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33608105'}, {'offsetInBeginSection': 488, 'offsetInEndSection': 684, 'text': 'Wide variation in negotiated surgical prices was identified. Across-center ratios ranged from 6.2 (partial glossectomy without primary closure) to 22.8 (excision of tongue lesion without closure).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35671092'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 255, 'text': 'The aim of this study was to test the non-inferiority of the contralateral submental island flap (CSIF) compared with primary closure (PC) regarding local recurrence after partial glossectomy in patients with oral tongue squamous cell carcinoma (OTSCC). T', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35672195'}, {'offsetInBeginSection': 20, 'offsetInEndSection': 334, 'text': 'Locally advanced tongue or tongue base cancer is recommended to be treated by radical resection that is usually detrimental to physiological functions. This study reports the efficacy and treatment outcome of the patients who had received total glossectomy and laryngeal suspension without lip-split mandibulotomy ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35985885'}, {'offsetInBeginSection': 11, 'offsetInEndSection': 169, 'text': 'To evaluate potential interactions and compensatory mechanisms of subjectively impaired taste function with ortho- and retronasal olfaction after glossectomy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36254878'}, {'offsetInBeginSection': 182, 'offsetInEndSection': 313, 'text': ' In this cross-sectional pilot study, chemosensory functions were assessed in 25 patients with tongue carcinomas after glossectomy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36254878'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 194, 'text': 'Glossectomy, or tongue reduction, is not commonly performed in Japan even though the proportion of patients with Class III skeletal pattern is higher among Japanese people than among Caucasians.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8214788'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 158, 'text': 'UNLABELLED: Total glossectomy is the procedure for entire removal of the tongue, practice considered as one of the most mutilating possible done in head and n', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12053512'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 169, 'text': 'UNLABELLED: Total glossectomy is the procedure for entire removal of the tongue, practice considered as one of the most mutilating possible done in head and neck surgery', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12053512'}]\n\n\n             'What is a glossectomy?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Glossectomy is the removal of the tongue, usually performed as a treatment for cancer of the tongue."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 437, 'offsetInEndSection': 636, 'text': 'Epigenetic modifications may constitute changes in DNA methylation, histone modifications (methylation, acetylation etc), and changes in non-coding RNA, leading to an altered gene expression profile.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35583646'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 162, 'text': 'Epigenetic modifications viz. DNA methylation, histone modifications, and RNA-based alterations play a crucial role in the development of cardiovascular diseases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34870779'}, {'offsetInBeginSection': 275, 'offsetInEndSection': 400, 'text': 'Major epigenetic modifications are DNA methylation, histone modification, chromatin remodeling as well as the noncoding RNAs.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33605616'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 479, 'text': 'Eukaryotic gene expression is regulated not only by genomic enhancers and promoters, but also by covalent modifications added to both chromatin and RNAs. Whereas cellular gene expression may be either enhanced or inhibited by specific epigenetic modifications deposited on histones (in particular, histone H3), these epigenetic modifications can also repress viral gene expression, potentially functioning as a potent antiviral innate immune response in DNA virus-infected cells.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32533130'}, {'offsetInBeginSection': 190, 'offsetInEndSection': 286, 'text': 'Examples of epigenetic control are DNA methylation, histone deacetylation and mi-RNA expression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28259291'}, {'offsetInBeginSection': 558, 'offsetInEndSection': 701, 'text': 'These modifications are dubbed as \"epigenetic modifications\" and include, among others, histone modifications, DNA methylation, and small RNAs.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20920747'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 95, 'text': 'Epigenetic changes are defined as inherited modifications that are not present in DNA sequence.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28259291'}, {'offsetInBeginSection': 171, 'offsetInEndSection': 293, 'text': 'Examples of such modifications include DNA methylation, histone modifications, noncoding RNAs, and chromatin architecture.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23935066'}, {'offsetInBeginSection': 118, 'offsetInEndSection': 312, 'text': 'DNA methylation and histone modifications, for example, are capable of spatial and temporal regulation of expression-with several studies demonstrating that these epigenetic marks are heritable.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26074949'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 166, 'text': 'DNA methylation and histone modifications such as methylation, acetylation, and phosphorylation, are two types of epigenetic modifications that alter gene expression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30679030'}, {'offsetInBeginSection': 456, 'offsetInEndSection': 631, 'text': 'In the present review we discuss three prominent epigenetic modifications, DNA methylation, histone methylation/acetylation, and the effects of chromatin remodeling complexes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35735917'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 177, 'text': 'In the current era of epigenetics research, we have observed many examples of epigenetic modifications, like histone modification and DNA methylation, in various fatal diseases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29992310'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 157, 'text': 'Epigenetic modifications, such as DNA methylation and histone modification, result in heritable changes in gene expression without changing the DNA sequence.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30984620'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 203, 'text': 'DNA methylation has been characterized as the representative example of epigenetic modifications and implicated in numerous biological processes, such as genomic imprinting and X chromosome inactivation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31989558'}, {'offsetInBeginSection': 673, 'offsetInEndSection': 814, 'text': 'Methylation and histone acetylation are two of the most well-studied examples of the epigenetic modifications that occur on histone proteins.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34421981'}, {'offsetInBeginSection': 115, 'offsetInEndSection': 219, 'text': 'One example of epigenetic factors is DNA methylation, which prevents certain genes from being expressed.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24743128'}, {'offsetInBeginSection': 815, 'offsetInEndSection': 930, 'text': 'DNA methylation is the type of epigenetic modification that alters gene expression without modifying gene sequence.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34421981'}, {'offsetInBeginSection': 300, 'offsetInEndSection': 490, 'text': 'Epigenetic modifications are chromosome-bound, heritable changes to the genome that do not affect the DNA sequence, and can include DNA methylation, histone modification, and RNA processing.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28069135'}, {'offsetInBeginSection': 224, 'offsetInEndSection': 386, 'text': 'Epigenetic alterations such as DNA methylation and histone modification are essential for chromatin remodeling and regulation of gene expression including miRNAs.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23056006'}, {'offsetInBeginSection': 346, 'offsetInEndSection': 476, 'text': 'This review summarises the main epigenetic modifications in mammals, especially DNA methylation, histone modifications, and ncRNA.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35052371'}]\n\n\n             'What are some examples of epigenetic modifications?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Eukaryotic gene expression is regulated not only by genomic enhancers and promoters but also by covalent modifications added to both chromatin and RNAs. Epigenetic modifications may constitute changes in DNA methylation, histone modifications (methylation, acetylation, etc), chromatin remodeling, and changes in non-coding RNA, leading to an altered gene expression profile."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 543, 'offsetInEndSection': 892, 'text': 'In the United States, zanubrutinib, a next-generation BTK inhibitor, has been approved for treating adults with mantle cell lymphoma who have received at least one prior therapy, for adults with Waldenstr\u00f6m macroglobulinemia, and for adults with relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based therapy. B', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35651781'}, {'offsetInBeginSection': 2451, 'offsetInEndSection': 2587, 'text': 'To reduce these side effects, zanubrutinib, a next-generation BTK inhibitor, was designed to block BTK more specifically than ibrutinib.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35651781'}]\n\n\n             'What does Zanubrutinib inhibit?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Zanubrutinib  is a Bruton tyrosine kinase inhibitor."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 212, 'text': \"Friedreich's ataxia is classically considered a disease with onset in the first or second decade. However, late-onset (age of onset 25-39 years) and very-late-onset (age of onset >40 years) forms do occur rarely.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31467149'}, {'offsetInBeginSection': 1696, 'offsetInEndSection': 1902, 'text': \"and Friedreich's ataxia is heterogeneous. Late-onset Friedreich's ataxia and very-late-onset Friedreich's ataxia appear to belong to the same clinical and molecular continuum and should be considered togeth\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26388117'}, {'offsetInBeginSection': 57, 'offsetInEndSection': 218, 'text': \" age of 25. Rare variants have been described, such as late-onset Friedreich's ataxia and very-late-onset Friedreich's ataxia, occurring after 25 and 40 years, r\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26388117'}, {'offsetInBeginSection': 219, 'offsetInEndSection': 1021, 'text': \"spectively. We describe the clinical, functional, and molecular findings from a large series of late-onset Friedreich's ataxia and very-late-onset Friedreich's ataxia and compare them with typical-onset Friedreich's ataxia.METHODS: Phenotypic and genotypic comparison of 44 late-onset Friedreich's ataxia, 30 very late-onset Friedreich's ataxia, and 180 typical Friedreich's ataxia was undertaken.RESULTS: Delayed-onset Friedreich's ataxia (late-onset Friedreich's ataxia and very-late-onset Friedreich's ataxia) had less frequently dysarthria, abolished tendon reflexes, extensor plantar reflexes, weakness, amyotrophy, ganglionopathy, cerebellar atrophy, scoliosis, and cardiomyopathy than typical-onset Friedreich's ataxia, along with less severe functional disability and shorter GAA expansion on t\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26388117'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 137, 'text': \"Very late-onset Friedreich's ataxia (VLOFA) is characterized by symptomatic onset after 40 years of age and, usually, a benign phenotype.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16092110'}, {'offsetInBeginSection': 871, 'offsetInEndSection': 1101, 'text': \"ing Scale and EQ-5D. The Friedreich's ataxia cohort was subdivided into three groups: early disease onset (\u226414 years), intermediate onset (15-24 years), and late onset (\u226525 years), which were compared for clinical characteristics \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25566998'}, {'offsetInBeginSection': 893, 'offsetInEndSection': 1123, 'text': \"he Friedreich's ataxia cohort was subdivided into three groups: early disease onset (\u226414 years), intermediate onset (15-24 years), and late onset (\u226525 years), which were compared for clinical characteristics and outcome measures. \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25566998'}]\n\n\n             'Which are the types of Friedreich's Ataxia based on onset age?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "There are three types of Friedreich's ataxia based on onset age: Friedreich's ataxia with onset in the first or second decade, late-onset (age of onset 25-39 years) and very-late-onset (age of onset >40 years)."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 301, 'text': 'Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35671774'}, {'offsetInBeginSection': 4240, 'offsetInEndSection': 4449, 'text': 'INTERPRETATION: Updated FAKTION data showed that capivasertib addition to fulvestrant extends the survival of participants with aromatase inhibitor-resistant ER-positive, HER2-negative advanced breast cancer. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35671774'}, {'offsetInBeginSection': 866, 'offsetInEndSection': 955, 'text': 'Similarly, there was an overall survival benefit in the FAKTION study with capivasertib. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36110891'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 221, 'text': 'Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32035020'}, {'offsetInBeginSection': 130, 'offsetInEndSection': 318, 'text': 'The FAKTION trial investigated whether the addition of capivasertib to fulvestrant improved progression-free survival in patients with aromatase inhibitor-resistant advanced breast cancer.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32035020'}]\n\n\n             'Which drugs were tested in the FAKTION trial?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "The FAKTION trial investigated whether the addition of capivasertib to fulvestrant improved progression-free survival in patients with aromatase inhibitor-resistant advanced breast cancer."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 213, 'text': 'Gene knock-down technology using antisense molecules has many applications for studying gene function, disrupting undesirable genetic traits, as well as providing effective therapy for a number of viral diseases. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14961259'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 130, 'text': 'The largest gene knock-down experiments performed to date have used multiple short interfering/short hairpin (si/sh)RNAs per gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16025102'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 256, 'text': 'Short interfering RNAs (siRNAs) have been gaining popularity as the gene knock-down tool of choice by many researchers because of the clean nature of their workings as well as the technical simplicity and cost efficiency in their applications. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16443930'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 142, 'text': 'Gene knock down by RNAi is a highly effective approach to silence gene expression in experimental as well as therapeutic settings.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18577207'}, {'offsetInBeginSection': 30, 'offsetInEndSection': 209, 'text': 'gene silencing, or gene expression down-regulation is the process whereby a double-stranded RNA (dsRNA) induces the homology-dependent degradation of cognate messenger RNA (mRNA).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16509424'}]\n\n\n             'Explain gene knock-down.'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Gene knock-down technology using antisense molecules has many applications for studying gene function, disrupting undesirable genetic traits, as well as providing effective therapy for a number of viral diseases. Gene knock down by RNAi is a highly effective approach to silence gene expression in experimental as well as therapeutic settings"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 260, 'text': 'RNA splicing is a critical step in the maturation of precursor mRNA (pre-mRNA) by removing introns and exons. The combination of inclusion and exclusion of introns and exons in pre-mRNA can generate vast diversity in mature mRNA from a limited number of genes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33923658'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 285, 'text': \"Transport of messenger RNA (mRNA) from the nucleus to the cytoplasm is an essential step of eukaryotic gene expression. In the cell nucleus, a precursor mRNA undergoes a series of processing steps, including capping at the 5' ends, splicing and cleavage/polyadenylation at the 3' ends.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25836925'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 249, 'text': \"Messenger RNA precursors (pre-mRNAs) are produced as the nascent transcripts of RNA polymerase II (Pol II) in eukaryotes and must undergo extensive maturational processing, including 5'-end capping, splicing, and 3'-end cleavage and polyadenylation.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24617759'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 250, 'text': 'The cellular transformation of a precursor mRNA (pre-mRNA) into its mature or functional form proceeds by way of a splicing reaction, in which the exons are ligated to form the mature linear RNA and the introns are excised as branched or lariat RNAs.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14576302'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 156, 'text': 'In eukaryotes, pre-messenger RNA (pre-mRNA) cleavage and polyadenylation is one of the necessary processing steps that produce a mature and functional mRNA.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25487206'}, {'offsetInBeginSection': 120, 'offsetInEndSection': 285, 'text': \"In the cell nucleus, a precursor mRNA undergoes a series of processing steps, including capping at the 5' ends, splicing and cleavage/polyadenylation at the 3' ends.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25836925'}, {'offsetInBeginSection': 156, 'offsetInEndSection': 372, 'text': \"The three most prevalent processing steps are the capping reaction at the 5'-end, the removal of intervening sequences by splicing, and the formation of poly (A)-tails at the 3'-end of the message by polyadenylation.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21823231'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 220, 'text': 'Precursor mRNA (pre-mRNA) splicing is a critical step in gene expression that results in the removal of intronic sequences from immature mRNA, leading to the production of mature mRNA that can be translated into protein.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25761502'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 103, 'text': \"Spliceosome and 3'-end processing complexes are necessary for the precursor mRNA (pre-mRNA) maturation.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27350684'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 228, 'text': 'Precursor messenger RNA (pre-mRNA) splicing is a fundamental step in eukaryotic gene expression that systematically removes non-coding regions (introns) and ligates coding regions (exons) into a continuous message (mature mRNA).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34016162'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 109, 'text': 'RNA splicing is a critical step in the maturation of precursor mRNA (pre-mRNA) by removing introns and exons.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33923658'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 246, 'text': 'In trypanosomatid parasites, spliced leader (SL) trans splicing is an essential nuclear mRNA maturation step which caps mRNAs posttranscriptionally and, in conjunction with polyadenylation, resolves individual mRNAs from polycistronic precursors.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19429779'}, {'offsetInBeginSection': 289, 'offsetInEndSection': 459, 'text': 'The process of pre-mRNA cleavage and polyadenylation, and its relationship with RNA splicing and translation, have been extensively studied due to its importance in vivo.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25487206'}, {'offsetInBeginSection': 157, 'offsetInEndSection': 288, 'text': 'Regulation on pre-mRNA cleavage and polyadenylation affects other processes such as mRNA translocation, stability, and translation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25487206'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 165, 'text': \"The 3' ends of most eukaryotic messenger RNAs must undergo a maturation step that includes an endonuc-leolytic cleavage followed by addition of a polyadenylate tail.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25081038'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 106, 'text': 'mRNA polyadenylation and pre-mRNA splicing are two essential steps for the maturation of most human mRNAs.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17210931'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 157, 'text': 'Pre-mRNA (precursor mRNA) splicing is a key step in cellular gene expression where introns are excised and exons are ligated together to produce mature mRNA.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25110027'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 185, 'text': 'The process of removing intronic sequences from a precursor to messenger RNA (pre-mRNA) to yield a mature mRNA transcript via splicing is an integral step in eukaryotic gene expression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27198613'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 257, 'text': 'Eukaryotic mRNA synthesis is a complex biochemical process requiring transcription of a DNA template into a precursor RNA by the multi-subunit enzyme RNA polymerase II and co-transcriptional capping and splicing of the precursor RNA to form the mature mRNA.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31132066'}, {'offsetInBeginSection': 134, 'offsetInEndSection': 273, 'text': 'With this step, a pre-messenger RNA is processed and polyadenylated, giving rise to a mature mRNA bearing the characteristic poly(A) tract.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18630752'}]\n\n\n             'What are the necessary steps for the transition from a precursor mRNA to a mature\nmRNA?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Transport of messenger RNA (mRNA) from the nucleus to the cytoplasm is an essential step of eukaryotic gene expression. Messenger RNA precursors (pre-mRNAs) are produced as the nascent transcripts of RNA polymerase II in the cell nucleus and must undergo extensive maturational processing, including 5'-end capping, splicing, and 3'-end cleavage and polyadenylation."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 96, 'text': 'Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36255686'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 170, 'text': 'Cabotegravir extended-release (ER) injectable suspension (Apretude\u2122) is the first long-acting injectable option to be approved for HIV-1 pre-exposure prophylaxis (PrEP). ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36255686'}, {'offsetInBeginSection': 465, 'offsetInEndSection': 694, 'text': 'Cabotegravir ER injectable suspension is indicated in the USA for PrEP to reduce the risk of sexually acquired HIV-1 infection in at-risk adults and adolescents weighing \u2265\\u200935 kg who have a negative HIV-1 test prior to initiation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36255686'}, {'offsetInBeginSection': 1086, 'offsetInEndSection': 1312, 'text': 'With its convenient, less-frequent dosing schedule and its long-acting formulation enabling intramuscular administration, cabotegravir ER injectable suspension represents a novel and efficacious alternative to daily oral PrEP.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36255686'}]\n\n\n             'What is Apretude used for?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Cabotegravir extended-release (ER) injectable suspension (Apretude\u2122) is the first long-acting injectable option to be approved for HIV-1 pre-exposure prophylaxis (PrEP)."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 324, 'offsetInEndSection': 377, 'text': 'SMA with a clinical diagnosis of SMA types\\xa01, 2, or 3', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35284988'}, {'offsetInBeginSection': 591, 'offsetInEndSection': 751, 'text': ' In phase\\xa02/3 clinical trials, risdiplam significantly improved motor function in infants with SMA type\\xa01 and in patients aged 2-25\\xa0years with SMA types 2 or 3.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35284988'}, {'offsetInBeginSection': 190, 'offsetInEndSection': 265, 'text': 'Adulthood-onset SMA (SMA type 4) is rare, with few isolated cases reported.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33090613'}, {'offsetInBeginSection': 643, 'offsetInEndSection': 739, 'text': 'Twenty patients with SMA type 4 were identified in a Brazilian cohort of 227 patients with SMA. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33090613'}, {'offsetInBeginSection': 1675, 'offsetInEndSection': 1823, 'text': 'This study represents the largest cohort of patients with SMA type 4 and provides functional, genetic, radiological and neurophysiological features ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33090613'}, {'offsetInBeginSection': 295, 'offsetInEndSection': 347, 'text': 'Adolescent and adult patients with SMA types 3 and 4', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35466947'}, {'offsetInBeginSection': 1632, 'offsetInEndSection': 1900, 'text': 'We found no evidence for the contribution of motor unit and capillary recruitment capacity of the upper arm muscles in adolescent and adult patients with SMA types 3 and 4 as primary limiting factors to premature fatigue during execution of a maximal arm-cycling task.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35466947'}, {'offsetInBeginSection': 262, 'offsetInEndSection': 350, 'text': 'We report a long-term follow-up in adolescent and adult patients with SMA types 1 and 2.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36335004'}, {'offsetInBeginSection': 359, 'offsetInEndSection': 463, 'text': 'Nusinersen-treated patients with SMA types 1 and 2 between 2017 and 2022 were retrospectively reviewed. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36335004'}, {'offsetInBeginSection': 922, 'offsetInEndSection': 1068, 'text': 'Seven patients with SMA (type 1, 1; type 2, 6) with a median age of 23 (range, 12-40)years were treated with nusinersen for 3.55 (1.78-4.53)years.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36335004'}, {'offsetInBeginSection': 778, 'offsetInEndSection': 1010, 'text': 'On October 1st, 666 patients have been enrolled (357 children and 309 adults) by 44 out of 51 open centers of the national network (FILNEMUS) with: 150 type 1 (22%); 278 type 2 (42%), 232 type\\xa03 (35%) and 4 type 4 (1%) respectively.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34878390'}, {'offsetInBeginSection': 122, 'offsetInEndSection': 396, 'text': 'The identification of the underlying gene defects for familial ALS, spinal muscular atrophy (SMA), and spinal muscular atrophy with respiratory distress (SMARD) has pointed to distinct pathophysiological mechanisms that are responsible for the various forms of the disease. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14704958'}, {'offsetInBeginSection': 1046, 'offsetInEndSection': 1149, 'text': 'Interestingly, UBA1 mutations can also cause infantile-onset X-linked spinal muscular atrophy (XL-SMA).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35996994'}, {'offsetInBeginSection': 1150, 'offsetInEndSection': 1333, 'text': \"The mutation identified here and the XL-SMA causative mutations were shown to affect amino acids positioned in the vicinity of UBA1's ATP binding site and to cause structural changes.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35996994'}, {'offsetInBeginSection': 1515, 'offsetInEndSection': 1589, 'text': 'The contribution of this same gene to the etiology of XL-SMA is discussed.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35996994'}, {'offsetInBeginSection': 525, 'offsetInEndSection': 791, 'text': 'Type I spinal muscular atrophy has been subdivided into 3 groups: - type IA, the clinical signs of which set in between birth and 15 days of life with sudden severe motor impairment, sucking-swallowing disorders attesting to bulbar involvement, respiratory distress.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33357591'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 310, 'text': 'The childhood form of the spinal muscular atrophy (SMA) is classically subdivided into three groups on the basis of a combination of age of onset, milestones of development and age of survival: acute Werdning-Hoffmann (type I), intermediate Werdnig-Hoffmann (type II) and Kugelberg-Welander disease (type III).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1389561'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 225, 'text': 'Spinal muscular atrophy type 3 (SMA3), also called Kugelberg-Welander SMA, typically presents with muscle fatigue, slowly progressive weakness and atrophy of lower limbs once they have already acquired independent ambulation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33357593'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 229, 'text': 'Spinal muscular atrophy, X-linked 2 (SMAX2) is a rare type of spinal muscular atrophy characterized by muscle weakness, hypotonia, areflexia, myopathic face, tongue fibrillations, contractures, bone fractures, and cryptorchidism.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35707597'}, {'offsetInBeginSection': 185, 'offsetInEndSection': 315, 'text': 'SMA is classified in three clinical types, SMA I, SMA II, and SMA III, based on the severity of the symptoms and the age of onset.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16865356'}, {'offsetInBeginSection': 68, 'offsetInEndSection': 218, 'text': 'ring seated upper limb tasks in patients with spinal muscular atrophy types 2 and 3.DESIGN: Seventeen persons with spinal muscular atrophy and 15 heal', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31274514'}, {'offsetInBeginSection': 133, 'offsetInEndSection': 283, 'text': 'tional ability in children with non-ambulant spinal muscular atrophy types 2 and 3 in a longitudinal multi-center clinical trial. This study assessed ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16750368'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 208, 'text': 'BACKGROUND & AIMS: Different neuromuscular functional domains in types I and II Spinal Muscular Atrophy (SMAI and SMAII) could lead to differences in body composition (BC) and resting energy expenditure (REE)', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27890489'}]\n\n\n             'What are the types of Spinal Muscular Atrophy?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "The types of Spinal Muscular Atrophy are: SMA type 1, SMA type 2, SMA type 3, SMA type 4, X-linked SMA and SMA with respiratory distress."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 100, 'text': 'Outcomes of Ublituximab compared to Teriflunomide for relapsing multiple sclerosis: A meta-analysis.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35779372'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 104, 'text': 'Ublituximab is an anti-CD20 antibody that immunomodulates B-cells for relapsing multiple sclerosis (MS).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35779372'}, {'offsetInBeginSection': 826, 'offsetInEndSection': 1348, 'text': \" In the second part of the review, we summarize medications that have targeted B cells in patients with MS and their current position in the therapeutic armamentarium based on clinical trials and real-world data. Covered therapeutic strategies include the targeting of surface molecules such as CD20 (rituximab, ocrelizumab, ofatumumab, ublituximab) and CD19 (inebilizumab), and molecules necessary for B-cell activation such as B cell activating factor (BAFF) (belimumab) and Bruton's Tyrosine Kinase (BTK) (evobrutinib).\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35570581'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 65, 'text': 'Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36001711'}, {'offsetInBeginSection': 126, 'offsetInEndSection': 207, 'text': 'Ublituximab is being evaluated for the treatment of relapsing multiple sclerosis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36001711'}, {'offsetInBeginSection': 1973, 'offsetInEndSection': 2248, 'text': 'CONCLUSIONS: Among participants with relapsing multiple sclerosis, ublituximab resulted in lower annualized relapse rates and fewer brain lesions on MRI than teriflunomide over a period of 96 weeks but did not result in a significantly lower risk of worsening of disability. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36001711'}, {'offsetInBeginSection': 815, 'offsetInEndSection': 908, 'text': 'The glycoengineered antibody ublituximab is the next anti-CD20 therapy about to be approved. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35869335'}, {'offsetInBeginSection': 707, 'offsetInEndSection': 923, 'text': 'On the other hand, the anti-CD52 monoclonal antibody alemtuzumab and the anti-CD20 monoclonal antibodies rituximab, ocrelizumab, ofatumumab, and ublituximab work via eliminating selected pathogenic cell populations. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35378683'}]\n\n\n             'What disease is treated with Ublituximab?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Ublituximab is being tested for multiple sclerosis."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 186, 'text': 'Palmar erythema (\"liver palms\") was seen in 32/100 consecutive patients with classical rheumatoid arthritis and in 10/100 patients with various other internal diseases (p less than 0.001', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/3830522'}, {'offsetInBeginSection': 193, 'offsetInEndSection': 373, 'text': 'Palmar erythema commonly presents as symmetric, blanchable, slightly warm, nonscaling erythema, most frequently involving the thenar and hypothenar eminences of the palmar surface.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22474732'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 188, 'text': 'Palmar erythema (\"liver palms\") was seen in 32/100 consecutive patients with classical rheumatoid arthritis and in 10/100 patients with various other internal diseases (p less than 0.001).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/3830522'}]\n\n\n             'What is Palmar Erythema?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Palmar Erythema also known as liver palms is redness  of the palms"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 272, 'text': 'Epigenetics is defined as heritable changes in gene expression that are, unlike mutations, not attributable to alterations in the sequence of DNA. The predominant epigenetic mechanisms are DNA methylation, modifications to chromatin, loss of imprinting and non-coding RNA.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21734376'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 665, 'text': 'Genome-wide association studies of complex physiological traits and diseases consistently found that associated genetic factors, such as allelic polymorphisms or DNA mutations, only explained a minority of the expected heritable fraction. This discrepancy is known as \"missing heritability\", and its underlying factors and molecular mechanisms are not established. Epigenetic programs may account for a significant fraction of the \"missing heritability.\" Epigenetic modifications, such as DNA methylation and chromatin assembly states, reflect the high plasticity of the genome and contribute to stably alter gene expression without modifying genomic DNA sequences.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26216216'}, {'offsetInBeginSection': 1385, 'offsetInEndSection': 1493, 'text': 'Epigenetics is defined as heritable changes in gene expression that do not involve a change in DNA sequence.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17413852'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 140, 'text': 'Epigenetics is defined as mitotically and meiotically heritable changes in gene expression that do not involve a change in the DNA sequence.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17413852'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 111, 'text': 'Epigenetic changes refer to heritable changes that may modulate gene expression without affecting DNA sequence.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20620207'}, {'offsetInBeginSection': 706, 'offsetInEndSection': 954, 'text': 'Epigenetic alterations, which, by definition, comprise mitotically and meiotically heritable changes in gene expression that are not caused by changes in the primary DNA sequence, are increasingly being recognized for their roles in carcinogenesis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18042143'}, {'offsetInBeginSection': 378, 'offsetInEndSection': 597, 'text': 'Unlike heritable genetic changes, which are always associated with mutations in gene sequence, heritable epigenetic changes can be associated with physical or chemical changes in molecules or only changes in the system.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32319122'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 232, 'text': 'Epigenetic alterations are defined as heritable changes in gene expression mediated through mechanisms other than alterations in the DNA sequence itself, including DNA promoter methylation and various histone covalent modifications.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20416204'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 172, 'text': 'Epigenetics refers to heritable phenotypic alterations in the absence of DNA sequence changes, and DNA methylation is one of the extensively studied epigenetic alterations.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18331347'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 106, 'text': 'Epigenetics is defined as heritable changes that affect gene expression without altering the DNA sequence.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25191382'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 118, 'text': 'Epigenetics refers to heritable changes in patterns of gene expression that occur without alterations in DNA sequence.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25104823'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 146, 'text': 'Epigenetic modifications are classified as heritable and reversible chemical modifications of chromatin that do not cause changes in DNA sequence.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27591071'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 155, 'text': 'Epigenetics is the study of changes in gene activity that can be transmitted through cell divisions but cannot be explained by changes in the DNA sequence.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33866814'}, {'offsetInBeginSection': 624, 'offsetInEndSection': 728, 'text': 'First, some epigenetic states are transmitted intergenerationally and affect the phenotype of offspring.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33866814'}, {'offsetInBeginSection': 230, 'offsetInEndSection': 379, 'text': 'One possible but largely unexplored explanation is that exposure to sublethal doses of insecticides may alter epigenetic patterns that are heritable.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33767749'}, {'offsetInBeginSection': 112, 'offsetInEndSection': 270, 'text': 'DNA methylation is one such heritable epigenetic change, which is causally associated with the transcription regulation of many genes in the mammalian genome.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20620207'}, {'offsetInBeginSection': 837, 'offsetInEndSection': 982, 'text': 'As a result, heritable epigenetic changes can include any that can alter a wave such as changes in form, midline, frequency, amplitude, or phase.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32319122'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 230, 'text': \"Epigenetics has been defined as 'a stably heritable phenotype resulting from changes in a chromosome without alterations in the DNA sequence' and several epigenetic regulators are recurrently mutated in hematological malignancies.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31431820'}, {'offsetInBeginSection': 282, 'offsetInEndSection': 461, 'text': 'Epigenetic alterations (epimutations) could thus contribute to heritable variation within populations and be subject to evolutionary processes such as natural selection and drift.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32868918'}, {'offsetInBeginSection': 431, 'offsetInEndSection': 487, 'text': 'Some of these epigenetic changes appear to be heritable.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17684399'}, {'offsetInBeginSection': 623, 'offsetInEndSection': 728, 'text': ' First, some epigenetic states are transmitted intergenerationally and affect the phenotype of offspring.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33866814'}, {'offsetInBeginSection': 1301, 'offsetInEndSection': 1380, 'text': ' First, stress-induced methylation changes are common and are mostly heritable.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20003072'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 115, 'text': 'Epigenetic inheritance systems enable the environmentally induced phenotypes to be transmitted between generations.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10479537'}, {'offsetInBeginSection': 166, 'offsetInEndSection': 274, 'text': ' Epigenetic changes enforced by various environmental and lifestyle factors lead to heritable modifications.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33612870'}, {'offsetInBeginSection': 293, 'offsetInEndSection': 417, 'text': ' Transient epigenetic changes across the entire genome can influence metabolic outcomes and might or might not be heritable.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27312865'}, {'offsetInBeginSection': 175, 'offsetInEndSection': 279, 'text': ' More interestingly, epigenetic changes are reversible heritable changes which pass through generations.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29233676'}, {'offsetInBeginSection': 208, 'offsetInEndSection': 330, 'text': ' However, it is unclear whether the active changes mediated by variations in DNA methyltransferase activity are heritable.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29312436'}, {'offsetInBeginSection': 81, 'offsetInEndSection': 250, 'text': 'Epigenetic modification refers to heritable changes in the genetic material without any changes in the nucleic acid sequence and results in heritable phenotypic changes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35484099'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 210, 'text': 'Epigenetics refers to the heritable, but reversible, regulation of various biological functions mediated principally through changes in DNA methylation and chromatin structure derived from histone modification.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18550486'}, {'offsetInBeginSection': 760, 'offsetInEndSection': 958, 'text': 'Although epigenetic modifications may contribute substantially to average risk, they will not contribute much to recurrence risk and heritability unless they persist on average for many generations.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19416939'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 186, 'text': 'Epigenetic processes, defined as heritable changes in gene expression that occur without changes to the DNA sequence, have emerged as a promising area of cardiovascular disease research.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24768945'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 279, 'text': 'Epigenetic changes can be defined as stable molecular alterations of a cellular phenotype such as the gene expression profile of a cell that are heritable during somatic cell divisions (and sometimes germ line transmissions) but do not involve changes of the DNA sequence itself.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20627830'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 98, 'text': 'Epigenetic modifications are heritable changes in gene expression not encoded by the DNA sequence.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21941617'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 154, 'text': 'Epigenetics is defined as the study of changes in gene function that are mitotically or meiotically heritable and do not lead to a change in DNA sequence.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34058565'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'Epigenetic mechanisms are heritable traits that are mediated by changes in a genetic locus that do not involve a modification at the nucleotide level.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11597505'}, {'offsetInBeginSection': 88, 'offsetInEndSection': 238, 'text': 'ssion, notably during embryonic development. New research indicates that epigenetic factors are heritable, which is why paternal lifestyle may affect ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27649584'}]\n\n\n             'Are epigenetic changes heritable?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Epigenetics is defined as heritable changes in gene expression that are, unlike mutations, not attributable to alterations in the sequence of DNA. The predominant epigenetic mechanisms are DNA methylation, modifications to chromatin, loss of imprinting, and non-coding RNA. These epigenetic programs may account for a significant fraction of the \"missing heritability\" problem that is observed in genome-wide association studies."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 581, 'offsetInEndSection': 670, 'text': 'Trichotillomania requires a comprehensive treatment plan and interdisciplinary approach. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35118122'}, {'offsetInBeginSection': 769, 'offsetInEndSection': 1270, 'text': 'Behavioral therapy has been used with success in the treatment of trichotillomania, but not all patients are willing or able to comply with this treatment strategy. Pharmacotherapy can be necessary, especially in adolescents and adult patients. Options include tricyclic antidepressants, selective serotonin reuptake inhibitors, and glutamate-modulating agents. Glutamate-modulating agents such as N-acetylcysteine are a good first-line option due to significant benefits and low risk of side effects.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35118122'}]\n\n\n             'What is the treatment for trichotillomania?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Trichotillomania requires a comprehensive treatment plan and interdisciplinary approach. Behavioral therapy has been used with success in the treatment of trichotillomania, but not all patients are willing or able to comply with this treatment strategy. Pharmacotherapy can be necessary, especially in adolescents and adult patients. Options include tricyclic antidepressants, selective serotonin reuptake inhibitors, and glutamate-modulating agents. Glutamate-modulating agents such as N-acetylcysteine are a good first-line option due to significant benefits and low risk of side effects."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 387, 'text': 'Oculopharyngeal muscular dystrophy (OPMD) is a late-onset intractable myopathy, characterized by slowly progressive ptosis, dysphagia, and proximal limb weakness. It is caused by the abnormal expansion of the alanine-encoding (GCN)n trinucleotide repeat in the exon 1 of the polyadenosine (poly[A]) binding protein nuclear 1 gene (11-18 repeats in OPMD instead of the normal 10 repeats).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33805441'}, {'offsetInBeginSection': 179, 'offsetInEndSection': 277, 'text': 'A common cause of OPMD is the short expansion of a GCG or GCA trinucleotide repeat in PABPN1 gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34225694'}]\n\n\n             'What is the cause of Oculopharyngeal Muscular Dystrophy (OPMD)?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Oculopharyngeal Muscular Dystrophy (OPMD) is caused by the abnormal expansion of the alanine-encoding (GCN)n trinucleotide repeat in the exon 1 of the polyadenosine (poly[A]) binding protein nuclear 1 gene (PABPN1)."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 77, 'text': 'EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35172056'}, {'offsetInBeginSection': 158, 'offsetInEndSection': 252, 'text': 'EDP-938, a nonfusion replication inhibitor of RSV, acts by modulating the viral nucleoprotein.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35172056'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 111, 'text': 'EDP-938, a new antiviral with inhibitory activity against the nucleoprotein of the respiratory syncytial virus.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36401806'}, {'offsetInBeginSection': 541, 'offsetInEndSection': 586, 'text': 'EDP-938 has shown high efficacy against RSV. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36401806'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 156, 'text': 'EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate model.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33720995'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 90, 'text': 'EDP-938 is a novel non-fusion replication inhibitor of respiratory syncytial virus (RSV). ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33720995'}]\n\n\n             'Which viral disease can be treated with EDP-938?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Respiratory Syncytial Virus can be treated with EDP-938."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 12, 'offsetInEndSection': 168, 'text': 'durvalumab (Imfinzi\u2122; AstraZeneca) is a fully human monoclonal antibody that blocks programmed cell death ligand-1 binding to its receptors (PD-1 and CD80),', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28643244'}, {'offsetInBeginSection': 369, 'offsetInEndSection': 403, 'text': 'durvalumab (IMFINZI\u00ae, Astra-Zeneca', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29571563'}, {'offsetInBeginSection': 375, 'offsetInEndSection': 396, 'text': 'durvalumab (Imfinzi\u00ae)', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30917623'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 229, 'text': 'Intravenous durvalumab (Imfinzi\u2122; AstraZeneca) is a fully human monoclonal antibody that blocks programmed cell death ligand-1 binding to its receptors (PD-1 and CD80), resulting in enhanced T-cell responses against cancer cells.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28643244'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 286, 'text': 'Durvalumab (IMFINZI\u00ae), a fully human monoclonal antibody against programmed cell death-ligand 1 (PD-L1), is approved for use in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34731446'}, {'offsetInBeginSection': 211, 'offsetInEndSection': 608, 'text': 'Since 2011, the FDA-approved antibody drugs ipilimumab (Yervoy\u00ae), nivolumab (Opdivo\u00ae), pembrolizumab (Keytruda\u00ae), cemiplimab (Libtayo\u00ae), atezolizumab (Tecentriq\u00ae), durvalumab (Imfinzi\u00ae), and avelumab (Bavencio\u00ae), which block the immune checkpoint proteins, have brought about a significant breakthrough in the treatment of a wide range of cancers, as they can induce durable therapeutic responses.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30917623'}, {'offsetInBeginSection': 113, 'offsetInEndSection': 443, 'text': 'Nevertheless, new therapies have emerged recently, among which PD1 immune checkpoint inhibitors (ICI), such as nivolumab (OPDIVO\u00ae, Bristol-Myers Squibb) and pembrolizumab (KEYTRUDA\u00ae, Merck & Co), or PD-L1 ICI, such as atezolizumab (TECENTRIQ\u00ae, Genentech), durvalumab (IMFINZI\u00ae, Astra-Zeneca), and avelumab (BAVENCIO\u00ae, EMD Serono).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29571563'}, {'offsetInBeginSection': 2406, 'offsetInEndSection': 2741, 'text': 'titumor immunity. This unique mechanism of action in CD103+ DCs may contribute to clinical responses as AZD4635 is being evaluated in clinical trials with IMFINZI (durvalumab, \u03b1PD-L1) in patients with solid malignancies.CONCLUSION: We provide evidence implicating suppression of adaptive and innate immunity by adenosine as a mechanism', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32727810'}]\n\n\n             'What is the generic name for Imfinzi?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Durvalumab (Imfinzi) is used to treat locally advanced or metastatic cancer."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 474, 'text': 'The cell cycle (or cell-division cycle) is a series of events that take place in a cell, leading to its division and duplication. Cell division requires cell cycle checkpoints (CPs) that are used by the cell to both monitor and regulate the progress of the cell cycle. Tumor-suppressor genes (TSGs) or antioncogenes are genes that protect the cell from a single event or multiple events leading to cancer. When these genes mutate, the cell can progress to a cancerous state.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26110128'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 378, 'text': 'Deregulation of the cell cycle underlies the aberrant cell proliferation that characterizes cancer and loss of cell cycle checkpoint control promotes genetic instability. During the past two decades, cancer genetics has shown that hyperactivating mutations in growth signalling networks, coupled to loss of function of tumour suppressor proteins, drives oncogenic proliferation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21990031'}, {'offsetInBeginSection': 439, 'offsetInEndSection': 737, 'text': ' We now recognize that tumor suppressor genes regulate diverse cellular activities, including cell cycle checkpoint responses, detection and repair of DNA damage, protein ubiquitination and degradation, mitogenic signaling, cell specification, differentiation and migration, and tumor angiogenesis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14744434'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 133, 'text': 'p53 is a critical tumor-suppressor protein that guards the human genome against mutations by inducing cell-cycle arrest or apoptosis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32359398'}, {'offsetInBeginSection': 1238, 'offsetInEndSection': 1405, 'text': 'Tumor-suppressor gene p16 is an important negative cell-cycle regulator whose functional loss may significantly contribute to malignant transformation and progression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10854145'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 62, 'text': 'Tumor suppressor genes are negative regulators of cell growth.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1399577'}, {'offsetInBeginSection': 340, 'offsetInEndSection': 599, 'text': 'Aberrant proteolysis with oncogenic potential is elicited by two major mechanisms: defective degradation of positive cell cycle regulators (i.e., proto-oncoproteins) and enhanced degradation of negative cell cycle regulators (i.e., tumor suppressor proteins).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12665054'}, {'offsetInBeginSection': 542, 'offsetInEndSection': 738, 'text': ' Genes positively controlling cell cycle checkpoints can be targets for oncogenic activation in cancer, whereas negative regulators, such as tumour suppressor genes, are targeted for inactivation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11327114'}, {'offsetInBeginSection': 142, 'offsetInEndSection': 345, 'text': 'The p27(Kip1) protein belongs to a family of cyclin-dependent kinase-inhibitory proteins that are negative regulators of cell cycle progression and have been proposed as candidate tumor suppressor genes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9815577'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 463, 'text': 'Retinoblastoma 1 (RB1) is the first discovered tumor suppressor gene and recognized as the simple model system whose encoded defective protein can cause a pediatric cancer retinoblastoma. It functions as a negative regulator of the cell cycle through the interactions with members of the E2F transcription factors family. The protein of the RB1 gene (pRB) is engaged in various cell cycle processes including apoptosis, cell cycle arrest and chromatin remodeling.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33682629'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 171, 'text': 'The cell cycle is composed of a series of steps which can be negatively or positively regulated by various factors. Chief among the negative regulators is the p53 protein.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/2046748'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 111, 'text': 'p27Kip1 (p27) is an important negative regulator of the cell cycle and a putative tumor suppressor.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20492666'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 438, 'text': 'It is now evident that the cell cycle machinery has a variety of elements negatively regulating cell cycle progression. However, among these negative regulators in cell cycle control, only 4 have been shown to be consistently involved in the development of human cancers as tumor suppressors: Rb (Retinoblastoma susceptibility protein), p53, and two recently identified cyclin-dependent kinase inhibitors, p16INK4A/MTS1 and p15INK4B/MTS2.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8652807'}]\n\n\n             'What are negative cell-cycle regulators that can cause cancer when mutated called?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "The cell cycle is a series of events that take place in a cell, leading to its division and duplication. Cell division requires cell cycle checkpoints that are used by the cell to both monitor and regulate the progress of the cell cycle. Deregulation of the cell cycle underlies the aberrant cell proliferation that characterizes cancer and loss of cell cycle checkpoint control promotes genetic instability.\n\nTumor suppressor genes are genes that protect the cell from a single event or multiple events leading to cancer. When these genes mutate, the cell can progress to a cancerous state. We now recognize that tumor suppressor genes regulate diverse cellular activities, including cell cycle checkpoint responses, detection and repair of DNA damage, protein ubiquitination and degradation, mitogenic signaling, cell specification, differentiation and migration, and tumor angiogenesis."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 346, 'text': 'On September 4, 2014, the FDA approved pembrolizumab (KEYTRUDA; Merck Sharp & Dohme Corp.) with a recommended dose of 2 mg/kg every 3 weeks by intravenous infusion for the treatment of patients with unresectable or metastatic melanoma who have progressed following treatment with ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28235882'}]\n\n\n             'When was Keytruda approved for the treatment of melanoma?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "On September 4, 2014, the FDA approved pembrolizumab (KEYTRUDA) for the treatment of patients with unresectable or metastatic melanoma who have progressed following treatment with ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 241, 'text': 'Oculopharyngeal muscular dystrophy (OPMD) is a late-onset rare muscle disease affecting approximately 1 in 80,000 individuals worldwide. However, it can affect as much as 1:600 individuals in some populations due to a strong founder effect. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36401050'}]\n\n\n             'What is the incidence of Oculopharyngeal Muscular Dystrophy (OPMD)?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "The incidence of Oculopharyngeal Muscular Dystrophy (OPMD) is 1:600 to 1:80,000."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 175, 'offsetInEndSection': 335, 'text': 'Most commonly affecting males between 50 and 70 years of age, Clinically, the Mackler triad is vomiting, severe chest pain, and subcutaneous cervical emphysema.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34932533'}]\n\n\n             'What are features of the Mackler\u2019s Triad?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "The Mackler triad is vomiting, severe chest pain, and subcutaneous cervical emphysema."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 96, 'text': 'Human tastin, a proline-rich cytoplasmic protein, associates with the microtubular cytoskeleton.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12049630'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 194, 'text': 'Tastin was originally identified as an accessory protein for trophinin, a cell adhesion molecule that potentially mediates the initial attachment of the human embryo to the uterine epithelium. H', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12049630'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 113, 'text': 'Trophinin, tastin, and bystin have been identified as molecules potentially involved in human embryo implantation', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14633596'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 124, 'text': 'Tastin was previously characterized as an accessory protein for cell adhesion that participates in early embryo implantation', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18218922'}, {'offsetInBeginSection': 126, 'offsetInEndSection': 298, 'text': 'Here, we report that tastin is also required for spindle assembly during mitosis. Tastin protein levels peaked in the G(2)/M phase and abruptly declined after cell division', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18218922'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 192, 'text': 'Tastin was originally identified as an accessory protein for trophinin, a cell adhesion molecule that potentially mediates the initial attachment of the human embryo to the uterine epithelium.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12049630'}, {'offsetInBeginSection': 430, 'offsetInEndSection': 549, 'text': 'Another, named tastin, is a cytoplasmic protein and is necessary for trophinin to function as a cell adhesion molecule.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7758945'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 125, 'text': 'Tastin was previously characterized as an accessory protein for cell adhesion that participates in early embryo implantation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18218922'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 366, 'text': 'BACKGROUND: Bystin, Trophinin, and Tastin are component proteins of an adhesion molecule complex that plays a crucial role in the initial attachment of the embryo to the uterus.METHODS: Profiling of genes differentially expressed in the perineural invasion (PNI) in vitro model by gene microarray analysis showed overexpression of bystin in prostate cancer cells co-', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16245277'}, {'offsetInBeginSection': 619, 'offsetInEndSection': 743, 'text': 'Bystin and tastin are cytoplasmic proteins that associate with trophinin by presumably forming an active adhesion machinery.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11299965'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 111, 'text': 'Trophinin and tastin, a novel cell adhesion molecule complex with potential involvement in embryo implantation.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7758945'}, {'offsetInBeginSection': 550, 'offsetInEndSection': 641, 'text': 'Trophinin and tastin appear to be associated with the cytoskeleton in HT-H and SNG-M cells.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7758945'}, {'offsetInBeginSection': 337, 'offsetInEndSection': 429, 'text': 'One, named trophinin, is an intrinsic membrane protein and mediates homophilic self-binding.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7758945'}, {'offsetInBeginSection': 791, 'offsetInEndSection': 891, 'text': 'Tastin and bystin are cytoplasmic proteins required for trophinin to exhibit cell adhesion activity.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10797941'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 191, 'text': 'BACKGROUND: Trophinin is an intrinsic membrane protein that forms a complex in the cytoplasm with bystin and tastin, linking it microtubule-associated motor dynein (ATPase) in some cell types', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23194061'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 181, 'text': 'Trophinin and tastin form a cell adhesion molecule complex that potentially mediates an initial attachment of the blastocyst to uterine epithelial cells at the time of implantation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9560222'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 176, 'text': 'BACKGROUND: Bystin, Trophinin, and Tastin are component proteins of an adhesion molecule complex that plays a crucial role in the initial attachment of the embryo to the uterus', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16245277'}]\n\n\n             'What is Tastin?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Tastin was previously characterized as an accessory protein for cell adhesion that participates in early embryo implantation and is also required for spindle assembly during mitosis."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 455, 'offsetInEndSection': 665, 'text': 'Epigenetic modifications, such as DNA methylation and chromatin assembly states, reflect the high plasticity of the genome and contribute to stably alter gene expression without modifying genomic DNA sequences.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26216216'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 146, 'text': 'Epigenetics is defined as heritable changes in gene expression that are, unlike mutations, not attributable to alterations in the sequence of DNA.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21734376'}, {'offsetInBeginSection': 125, 'offsetInEndSection': 338, 'text': 'Epigenetic changes are inheritable modifications that can modify the gene expression without changing the DNA sequence. The most common epigenetic alternations consist of DNA methylation and histone modifications.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33781317'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 111, 'text': 'Epigenetic changes refer to heritable changes that may modulate gene expression without affecting DNA sequence.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20620207'}, {'offsetInBeginSection': 117, 'offsetInEndSection': 238, 'text': 'Epigenetic changes are reversible and do not affect the DNA sequence itself but rather control levels of gene expression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35735917'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 163, 'text': 'Epigenetic changes, or heritable alterations in gene function that do not affect DNA sequence, are rapidly gaining acceptance as co-conspirators in carcinogenesis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19183791'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 171, 'text': 'Environmentally caused changes in chromosomes that do not alter the DNA sequence but cause phenotypic changes by altering gene transcription are summarized as epigenetics.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23273101'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 98, 'text': 'Epigenetic modifications are heritable changes in gene expression not encoded by the DNA sequence.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21941617'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 356, 'text': 'Epigenetic regulation is referred to as changes in gene function that do not involve changes in the DNA sequence, it is usually accomplished by DNA methylation, histone modifications (repressive marks such as H3K9me, H3K27me, H2Aub, or active marks such as H3K4me, H3K36me, H3Ac), and chromatin remodeling (nucleosome composition, occupancy, and location).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30079076'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 113, 'text': 'Epigenetics is the study of changes in gene expression or cellular phenotype that do not change the DNA sequence.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23895656'}, {'offsetInBeginSection': 258, 'offsetInEndSection': 467, 'text': 'Epigenetic change, which does not involve alteration to the nucleotide sequence, can also cause changes in gene activity by changing the structure of chromatin through DNA methylation or histone modifications.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22949838'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 140, 'text': 'Epigenetics is defined as mitotically and meiotically heritable changes in gene expression that do not involve a change in the DNA sequence.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17413852'}, {'offsetInBeginSection': 598, 'offsetInEndSection': 730, 'text': 'These modifications, also known as epigenetic code, do not change the DNA sequence but alter the expression level of specific genes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34728591'}, {'offsetInBeginSection': 321, 'offsetInEndSection': 441, 'text': ' Epigenetic regulation refers to heritable factors of genomic modifications that do not involve changes in DNA sequence.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26579435'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 155, 'text': 'Epigenetics refers to structural modifications to genes that do not change the nucleotide sequence itself but instead control and regulate gene expression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20309920'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 108, 'text': 'Epigenetics are the heritable changes in gene expression patterns which occur without altering DNA sequence.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35664328'}, {'offsetInBeginSection': 202, 'offsetInEndSection': 302, 'text': ' Epigenetic changes appear briefly and do not involve permanent changes to the primary DNA sequence.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29541423'}, {'offsetInBeginSection': 284, 'offsetInEndSection': 429, 'text': ' Epigenetic changes responding to the environmental and intercellular signals can turn on/off specific genes, but do not modify the DNA sequence.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25512705'}, {'offsetInBeginSection': 116, 'offsetInEndSection': 238, 'text': ' Epigenetic changes are reversible and do not affect the DNA sequence itself but rather control levels of gene expression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35735917'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 124, 'text': 'Epigenetic regulation refers to heritable changes in gene expression that do not involve any alteration of the DNA sequence.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27730435'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 172, 'text': 'Epigenetic mechanisms, which include DNA methylation, histone modification, and microRNA (miRNA), can produce heritable phenotypic changes without a change in DNA sequence.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32445090'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 158, 'text': \"Epigenetic changes to the genome are biochemical alterations to the DNA that do not change an individual's genome but do change and influence gene expression.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24295192'}, {'offsetInBeginSection': 101, 'offsetInEndSection': 251, 'text': 'e next, which may alter gene expression but which do not involve changes in the primary DNA sequence. These marks include DNA methylation (methylation', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18847515'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 198, 'text': 'Epigenetics, the study of functionally relevant chemical modifications to DNA that do not involve a change in the DNA nucleotide sequence, is at the interface between research and clinical medicine.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24298130'}, {'offsetInBeginSection': 395, 'offsetInEndSection': 564, 'text': 'The accessibility of DNA is regulated by epigenetic processes, including methylation of cytosine. In these circumstances the nucleic sequence of the DNA does not change.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31609563'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 151, 'text': 'Epigenetics is comprised of the stable and heritable (or potentially heritable) changes in gene expression that do not entail a change in DNA sequence.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15485357'}]\n\n\n             'Do epigenetic changes change the DNA sequence?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Epigenetic changes are inheritable modifications that can modify gene expression without changing the DNA sequence. The most common epigenetic alternations consist of DNA methylation and histone modifications."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 1, 'offsetInEndSection': 108, 'text': 'hC1INH: a new drug for the treatment of attacks in hereditary angioedema caused by C1-inhibitor deficiency.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21426252'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 194, 'text': 'Recombinant human C1 esterase inhibitor (rhC1INH) (Ruconest(\u00ae), Pharming) is a new drug developed for the relief of symptoms occurring in patients with angioedema due to C1-inhibitor deficiency.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21426252'}, {'offsetInBeginSection': 306, 'offsetInEndSection': 545, 'text': 'Similar to the purified C1-inhibitor derived from human plasma, the therapeutic efficacy of rhC1INH results from its ability to block the actions of enzymes belonging to the overactivated bradykinin-forming pathway, at multiple locations. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21426252'}, {'offsetInBeginSection': 715, 'offsetInEndSection': 893, 'text': 'Dose-ranging efficacy studies established 50 U/kg as the recommended dose, and demonstrated the effectiveness of this agent in all localizations of hereditary angioedema attacks.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21426252'}]\n\n\n             'What is Ruconest?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Recombinant human C1 esterase inhibitor (rhC1INH) (Ruconest(\u00ae), Pharming) is a new drug developed for the relief of symptoms occurring in patients with angioedema due to C1-inhibitor deficiency. the therapeutic efficacy of rhC1INH results from its ability to block the actions of enzymes belonging to the overactivated bradykinin-forming pathway, at multiple locations. Studies have demonstrated the effectiveness of this agent in all localizations of hereditary angioedema attacks."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 264, 'text': 'Motor neurons (MNs) are specialized neurons responsible for muscle contraction that specifically degenerate in motor neuron diseases (MNDs), such as amyotrophic lateral sclerosis (ALS), spinal and bulbar muscular atrophy (SBMA), and spinal muscular atrophy (SMA). ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34603008'}, {'offsetInBeginSection': 449, 'offsetInEndSection': 612, 'text': 'Spinal muscular atrophy (SMA), spinal and bulbar muscular atrophy (SBMA), hereditary spastic paraplegia (HSP), and amyotrophic lateral sclerosis (ALS) are all MNDs', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35511862'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 229, 'text': 'Amyotrophic Lateral Sclerosis (ALS), Spinal Bulbar Muscular Atrophy (SBMA), and Spinal Muscular Atrophy (SMA) are motor neuron diseases (MNDs) characterised by progressive motor neuron degeneration, weakness and muscular atrophy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36143200'}, {'offsetInBeginSection': 136, 'offsetInEndSection': 356, 'text': 'The most common MND are amyotrophic lateral sclerosis (ALS), proximal spinal muscular atrophy (SMA) and various forms of hereditary and sporadic lower motor neuron syndromes including hereditary motor neuropathies (HMN).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21626001'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 197, 'text': 'Two motor neuron diseases, amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA), are caused by distinct genes involved in RNA metabolism, TDP-43 and FUS/TLS, and SMN, respectively.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23255347'}, {'offsetInBeginSection': 147, 'offsetInEndSection': 302, 'text': 'Similarly other motor neuron diseases such as the spinal muscular atrophies (SMA) and the motor neuropathies (MN) were grouped following clinical criteria.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12710507'}, {'offsetInBeginSection': 499, 'offsetInEndSection': 685, 'text': 'There are several types of motor neuron disease: amyotrophic lateral sclerosis (ALS), progressive bulbar palsy (PBP), progressive muscular atrophy (PMA), primary lateral sclerosis (PLS).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32671738'}, {'offsetInBeginSection': 200, 'offsetInEndSection': 431, 'text': 'The umbrella term MND refers to diseases which cause the progressive loss of upper and/or lower motor neurons and a subsequent decrease in motor ability such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31031583'}, {'offsetInBeginSection': 142, 'offsetInEndSection': 391, 'text': 'Degeneration of motor neurons results in progressive muscle weakness, which underlies several debilitating neurological disorders including amyotrophic lateral sclerosis (ALS), hereditary spastic paraplegias (HSP), and spinal muscular atrophy (SMA).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34204831'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 258, 'text': 'Motor neuron diseases (MNDs) are a group of neurodegenerative disorders with involvement of upper and/or lower motor neurons, such as amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), progressive bulbar palsy, and primary lateral sclerosis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15372378'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 401, 'text': \"Motor neuron diseases may be divided into three categories: those with lower motor neuron involvement--spinal muscular atrophy (SMA) and spinobulbar muscular atrophy (SBMA or Kennedy's disease); those with upper motor neuron involvement--primary lateral sclerosis (PLS) and the spastic paraplegias; and those with combined upper and lower motor neuron involvement--amyotrophic lateral sclerosis (ALS).\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14753656'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 220, 'text': 'Among the motor neuron diseases, three share the clinical features of prominent upper motor neuron signs--amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS) and the hereditary spastic paraplegias (HSP).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16036421'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 211, 'text': 'Motor neuron diseases, such as spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS), share several clinical similarities while differing substantially in etiology, disease onset and progression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33374658'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 218, 'text': 'Motor neuron diseases such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA) are neurodegenerative diseases, which cause progressive paralysis and premature death in affected adults and children.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15384941'}]\n\n\n             'Which are the motor neuron diseases?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Amyotrophic Lateral Sclerosis (ALS), Spinal Bulbar Muscular Atrophy (SBMA), Hereditary Spastic Paraplegia (HSP) and Spinal Muscular Atrophy (SMA) are motor neuron diseases."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 306, 'text': 'BACKGROUND: Hereditary angioedema is characterized by recurrent and unpredictable swellings that are disabling and potentially fatal. Selective inhibition of plasma prekallikrein production by antisense oligonucleotide treatment (donidalorsen) may reduce the frequency of attacks and the burden of disease.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35294812'}, {'offsetInBeginSection': 1698, 'offsetInEndSection': 1880, 'text': 'CONCLUSIONS: Among patients with hereditary angioedema, donidalorsen treatment resulted in a significantly lower rate of angioedema attacks than placebo in this small, phase 2 trial.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35294812'}, {'offsetInBeginSection': 2231, 'offsetInEndSection': 2610, 'text': 'Investigational therapies, including the activated factor XII inhibitor garadacimab and an antisense oligonucleotide targeting plasma prekallikrein messenger RNA (donidalorsen), have shown promise as long-term prophylaxis. Given the requirement of lifelong management for HAE, further research is needed to determine how best to individualize optimal treatments for each patient.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36172291'}]\n\n\n             'Donidalorsen was tested for which disease?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Donidalorsen is tested for hereditary angioedema."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 122, 'offsetInEndSection': 310, 'text': 'Therapeutic plasma exchange (TPE) is the most common modality employed with the rationale of rapid reduction of a pathogenic substance distributed primarily in the intravascular compartmen', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33991255'}, {'offsetInBeginSection': 766, 'offsetInEndSection': 1056, 'text': 'Though therapeutic apheresis modalities are employed frequently in children with kidney disease, most experiences are extrapolated from adult studies. International and national registries need to be established to elucidate the role of apheresis modalities in children with kidney disease.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33991255'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 78, 'text': 'Rescuing Cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1)', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35551087'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 79, 'text': 'Fulminant Hepatic Failure in Dengue Fever Without Plasma Leakage: A Case Report', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35547461'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 96, 'text': 'Clinical and biochemical endpoints and predictors of response to plasma exchange in septic shock', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35551628'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 196, 'text': 'Recently, a randomized controlled trial (RCT) demonstrated rapid but individually variable hemodynamic improvement with therapeutic plasma exchange (TPE) in patients with septic shock.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35551628'}, {'offsetInBeginSection': 14, 'offsetInEndSection': 145, 'text': 'Thrombotic thrombocytopenic purpura (TTP) is becoming a curable disease with the introduction of therapeutic plasma exchange (TPE).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35689538'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 85, 'text': 'Role of Therapeutic Plasmapheresis in SARS-CoV-2 Induced Cytokine Release Syndrome: A', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35585996'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 233, 'text': 'Background: Cytokine release syndrome (CRS) significantly contributes to the pathophysiology and progression of COVID-19. It is speculated that therapeutic plasma exchange (TPE) can dampen CRS via elimination of pathogenic cytokines.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35585996'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 175, 'text': 'Successful therapeutic plasma exchange in a case with extremely severe hypertriglyceridemia secondary to diabetic ketoacidosis concomitant with type IX glycogen storage diseas', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34690074'}, {'offsetInBeginSection': 9, 'offsetInEndSection': 91, 'text': 'Therapeutic plasma exchange (TPE) is a treatment option to reduce thyroid hormones', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35963982'}, {'offsetInBeginSection': 1, 'offsetInEndSection': 63, 'text': 'herapeutic plasma exchange in hyperthyroidism prior to surgery', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35963982'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 112, 'text': 'Therapeutic plasma exchange for optic neuritis attacks in patients with neuromyelitis optica spectrum disorders.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35353437'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 116, 'text': 'Optic neuritis (ON) causes several sequela. Aggressive treatment with plasma exchange (TPE) is an option', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35353437'}, {'offsetInBeginSection': 188, 'offsetInEndSection': 295, 'text': ' We recruited adults with ON in neuromyelitis optica spectrum disorders (NMOSD) patients treated with TPE. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35353437'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 58, 'text': 'Total Plasma Exchange in Neuromuscular Junction Disorders-', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35955999'}, {'offsetInBeginSection': 246, 'offsetInEndSection': 300, 'text': 'Total plasma exchange (TPE) has proven efficacy in NJD', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35955999'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 102, 'text': 'Immunoadsorption and plasma exchange-Efficient treatment options for neurological autoimmune diseases.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34904748'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 406, 'text': 'Therapeutic plasma exchange (TPE) and immunoadsorption (IA) are first or second line treatment options in patients with neurological autoimmune diseases, including multiple sclerosis, neuromyelitis optica spectrum disorders (NMSOD), chronic inflammatory demyelinating polyneuropathy, acute inflammatory demyelinating polyradiculoneuropathy (Guillain-Barr\u00e9 syndrome), and autoimmune encephalitis', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34904748'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 130, 'text': 'Therapeutic plasma exchange (TPE) has been used for the treatment of neurologic diseases in which autoimmunity plays a major role.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17224307'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 163, 'text': 'Therapeutic plasma exchange (TPE) has been used extensively for over 2 decades to treat a variety of autoimmune and congenital diseases and is now widely accepted.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10619926'}, {'offsetInBeginSection': 106, 'offsetInEndSection': 191, 'text': 'TPE is commonly used in neurological disorders where autoimmunity plays a major role.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28194064'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 130, 'text': 'Therapeutic plasma exchange (TPE) is commonly used in many neurological disorders where an immune etiology was known or suspected.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18331814'}, {'offsetInBeginSection': 1730, 'offsetInEndSection': 1837, 'text': 'In conclusion; Therapeutic plasma exchange is an effective treatment option in several neurologic diseases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23619327'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 183, 'text': 'INTRODUCTION: Therapeutic plasma exchange (TPE) is commonly used as treatment of certain autoimmune neurological diseases (ANDs), and its main objective is the removal of pathogenic a', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32802495'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 165, 'text': 'Therapeutic plasma exchange (TPE) is used in the treatment of neurological, hematological, renal and autoimmune diseases with known or suspected immune pathogenesis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29882008'}, {'offsetInBeginSection': 132, 'offsetInEndSection': 302, 'text': 'TPE has an increasing list of indications in recent years such as neurological, connective tissue, hematological, nephrological, endocrinological and metabolic disorders.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23619327'}, {'offsetInBeginSection': 303, 'offsetInEndSection': 407, 'text': 'We report our multicenter data about therapeutic plasma exchange in patients with neurological diseases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23619327'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 103, 'text': 'Therapeutic plasma exchange in patients with neurological diseases: multicenter retrospective analysis.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23619327'}, {'offsetInBeginSection': 1337, 'offsetInEndSection': 1506, 'text': 'TPE is an effective treatment in neurologic diseases in which autoimmunity plays an important role in pathogenesis, and it is safe when performed in experienced centers.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17224307'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 95, 'text': 'Therapeutic plasma exchange in the treatment of neuroimmunologic disorders: review of 50 cases.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17224307'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 95, 'text': 'Therapeutic plasma exchange (TPE) has been mainly used in the treatment of autoimmune diseases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30924130'}, {'offsetInBeginSection': 341, 'offsetInEndSection': 576, 'text': 'TPE is useful in autoimmune haematological, renal, rheumatic and neurological diseases, and is recommended for acute disorders, together with relapsed or worsened chronic diseases that are often unresponsive to conventional treatments.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30924130'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 211, 'text': 'Therapeutic plasma exchange (TPE) is a treatment administered with the aim of removing a pathogenic material or compound causing morbidity in a variety of neurologic, hematologic, renal, and autoimmune diseases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33884210'}, {'offsetInBeginSection': 253, 'offsetInEndSection': 427, 'text': 'Diseases that can be treated with TPE are classified into the following categories: (1) endocrinological, (2) neurological, (3) renal/rheumatological, and (4) haematological.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16382247'}, {'offsetInBeginSection': 571, 'offsetInEndSection': 1166, 'text': \"Moreover, TPE in kidney diseases, for instance: desensitization in renal transplantation(ABO compatible) (living donor)and desensitization in deceased donor, desensitization in renal transplantation(ABO incompatible) (living donor), thrombotic microangiopathy complement Mediated (Factor H autoantibodies), Focal segmental glomerulosclerosis(recurrent in transplanted kidney), ANCA-associated rapidly progressive glomerulonephritis(Dialysis dependence, DAH), Anti-Glomerular basement membrane disease Goodpasture's syndrome)(DAH,Dialysis-independence,) has been utilized as an initial treatment.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31029610'}, {'offsetInBeginSection': 157, 'offsetInEndSection': 265, 'text': ' For decades, therapeutic plasma exchange (TPE) is performed for the management of immune-mediated diseases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34261138'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 121, 'text': 'Therapeutic plasma-exchange (TPE) is used as primary and adjunctive therapy in treatment of several hematologic diseases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23619323'}, {'offsetInBeginSection': 222, 'offsetInEndSection': 329, 'text': ' Successful treatment of aHUS with plasma infusions and therapeutic plasma exchange (TPE) is well reported.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24277990'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 86, 'text': 'Several neurologic disorders have been treated with therapeutic plasma exchange (TPE).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22277020'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 127, 'text': 'INTRODUCTION: Therapeutic plasma exchange (TPE) is the first-line treatment for acute thrombotic thrombocytopenic purpura (TTP)', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32605805'}, {'offsetInBeginSection': 1093, 'offsetInEndSection': 1173, 'text': 'TPE is effectively and safely carried out in our center in hematologic diseases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23619323'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 192, 'text': 'BACKGROUND: Therapeutic plasma exchange (TPE) is a conventional second-line treatment for patients with multiple sclerosis (MS) or clinically isolated syndrome with steroid-refractory relapses', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35302053'}, {'offsetInBeginSection': 674, 'offsetInEndSection': 986, 'text': 'As a supportive therapy, the plasma exchange was effective in the hyperviscosity syndrome, myasthenia gravis, thrombotic thrombocytopenic syndrome, myasthenia gravis, thrombotic thrombocytopenic purpura (TTP), hypercholesterolaemia, Guillain-Barr\u00e9 Syndrome, haemolytic crisis of a homozygous sickle-cell anaemia.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1703815'}]\n\n\n             'Treatment with plasma exchange (TPE) is used for what diseases'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Therapeutic plasma exchange (TPE) is the most common modality employed with the rationale of rapid reduction of a pathogenic substance distributed primarily in the intravascular compartment This includes cancer, infectious diseases like Dengue fever and Covid-19, septic shock and cytokine storm, and others such as Thrombotic thrombocytopenic purpura (TTP), diabetic ketoacidosis concomitant with type IX glycogen storage disease (GSD) and autoimmune disease of the CNS."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 313, 'text': 'The lac operon is one of the best known gene regulatory circuits and constitutes a landmark example of how bacteria tune their metabolism to nutritional conditions. It is nearly ubiquitous in Escherichia coli strains justifying the use of its phenotype, the ability to consume lactose, for species identification.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34367115'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 489, 'text': 'Transcription of bacterial genes is controlled by the coordinated action of cis- and trans-acting regulators. The activity and mode of action of these regulators can reflect different requirements for gene products in different environments. A well-studied example is the regulatory function that integrates the environmental availability of glucose and lactose to control the Escherichia colilac operon. Most studies of lac operon regulation have focused on a few closely related strains.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31719176'}, {'offsetInBeginSection': 111, 'offsetInEndSection': 278, 'text': 'In the induced state of the lac pathway, the genes comprising the lac operon are transcribed, leading to the production of proteins that import and metabolize lactose.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34953812'}]\n\n\n             'What are the proteins that are necessary for the use of lactose in E. coli collectively called?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Transcription of bacterial genes is controlled by the coordinated action of cis- and trans-acting regulators. The activity and mode of action of these regulators can reflect different requirements for gene products in different environments. The lac operon is one of the best-known gene regulatory circuits and constitutes a landmark example of how bacteria tune their metabolism to nutritional conditions. It is nearly ubiquitous in Escherichia coli strains justifying the use of its phenotype, the ability to consume lactose, for species identification."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 102, 'text': 'Alternative microexon splicing by RBFOX2 and PTBP1 is associated with metastasis in colorectal cancer.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34346508'}, {'offsetInBeginSection': 1073, 'offsetInEndSection': 1320, 'text': 'Finally, we found that changes in the pattern of microexon splicing were associated with CRC metastasis. Our data thus suggest that altered expression of RBFOX2 and PTBP1 might influence CRC metastasis through the regulation of microexon splicing.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34346508'}]\n\n\n             'Alternative microexon splicing is associated with metastasis in which cancer?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Alternative microexon splicing by RBFOX2 and PTBP1 is associated with metastasis in colorectal cancer."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 254, 'offsetInEndSection': 376, 'text': 'LS is a rare progressive multisystem fatal disorder inherited by autosomal recessive, X-linked and maternal transmission. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24299589'}, {'offsetInBeginSection': 587, 'offsetInEndSection': 1031, 'text': 'LS is due to a deficit of various respiratory chain and Krebs cycle enzymes resulting in insufficient production of adenosine triphosphate (ATP), in particular cytochrome-c-oxidase (COX), pyruvate carboxylase, pyruvate dehydrogenase complex and complex I of the respiratory chain, which share an autosomal recessive and X-linked mode of transmission. Cases with maternal inheritance (MILS) are due to a mitochondrial DNA (mtDNA) point mutation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24299589'}]\n\n\n             'How is Leigh syndrome inherited?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Leigh syndrome is inherited by autosomal recessive, X-linked and maternal transmission."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 132, 'offsetInEndSection': 261, 'text': 'Zinner syndrome comprises triad of seminal vesicle cyst, unilateral renal agenesis and ipsilateral ejaculatory duct obstruction. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34584848'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 272, 'text': 'We present the case of a 51-year-old male with Zinner syndrome, which is a rare disease, resulting from an abnormal evolution of the mesonephric (Wolffian) duct. It consists in cystic dilations of one seminal vesicle and/or ejaculatory duct and ipsilateral renal agenesis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34527910'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 169, 'text': 'A rare triad of Wolffian duct anomaly known as Zinner syndrome includes unilateral renal agenesis with ipsilateral seminal vesicle cyst and ejaculatory duct obstruction.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34504629'}, {'offsetInBeginSection': 149, 'offsetInEndSection': 340, 'text': 'Zinner syndrome, first described in 1914, refers to a triad of features consisting of seminal vesicle cysts, ejaculatory duct obstruction, and unilateral (mostly ipsilateral) renal agenesis. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32991910'}, {'offsetInBeginSection': 220, 'offsetInEndSection': 335, 'text': 'The triad of SV cysts, ipsilateral renal agenesis and ejaculatory duct obstruction is known as the Zinner syndrome.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33462046'}]\n\n\n             'List features of the Zinner syndrome.'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Zinner syndrome comprises triad of seminal vesicle cyst, unilateral renal agenesis and ipsilateral ejaculatory duct obstruction."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 131, 'text': 'Regulons, as groups of transcriptionally co-regulated operons, are the basic units of cellular response systems in bacterial cells.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22235300'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 110, 'text': 'A group of genes controlled as a unit, usually by the same repressor or activator gene, is known as a regulon.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32421805'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 142, 'text': 'Regulons are the basic units of the response system in a bacterial cell, and each consists of a set of transcriptionally co-regulated operons.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26975728'}, {'offsetInBeginSection': 279, 'offsetInEndSection': 545, 'text': 'A regulon is conceptually defined as a set of target genes regulated by a transcription factor by physically binding to regulatory motifs to accomplish a specific biological function, such as the CO-FT regulon for flowering timing and fall growth cessation in trees.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32854400'}, {'offsetInBeginSection': 133, 'offsetInEndSection': 310, 'text': 'Most bacteria contain dozens of TCSs, each of them responsible for sensing a different range of signals and controlling the expression of a repertoire of target genes (regulon).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32817385'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 237, 'text': 'A transcriptional regulatory network encompasses sets of genes (regulons) whose expression states are directly altered in response to an activating signal, mediated by trans-acting regulatory proteins and cis-acting regulatory sequences.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15231752'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 122, 'text': 'Eukaryotic regulons are regulatory units formed by a set of genes under the control of the same transcription factor (TF).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31825805'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 118, 'text': 'Identification of groups of co-regulated genes (regulons) is an important part of studying transcriptional regulation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16813171'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 206, 'text': 'During cancer stage transition, a master regulator (MR) refers to the key gene controlling cancer initiation and progression by orchestrating the associated target genes (termed as its regulon).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30052770'}]\n\n\n             'What is a regulon?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Regulons are the basic units of the cellular response system in bacterial cells, and each consists of a set of transcriptionally co-regulated operons. While the term \"regulon\" is not used in eukaryotes, a group of genes controlled as a unit - usually by the same repressor or activator gene - can be referred to as a regulon."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 126, 'text': 'Newly Developed Skin Picking After Methylphenidate Treatment in Attention Deficit Hyperactivity Disorder: Possible Mechanisms.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29298167'}, {'offsetInBeginSection': 820, 'offsetInEndSection': 905, 'text': 'We describe a case of skin picking developing after methylphenidate therapy for ADHD.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29298167'}]\n\n\n             'Can skin picking phenotype present following methylphenidate treatment?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Newly Developed Skin Picking After Methylphenidate Treatment in Attention Deficit Hyperactivity Disorder."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 109, 'offsetInEndSection': 213, 'text': \"Kennedy's disease is nearly exclusively caused by mutations in the androgen receptor encoding gene (AR).\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35996994'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 193, 'text': 'Spinal bulbar muscular atrophy (SBMA) is caused by a CAG repeat expansion mutation in the androgen receptor (AR) gene, and mutant AR is presumed to act in motoneurons to cause SBMA.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20689246'}, {'offsetInBeginSection': 125, 'offsetInEndSection': 286, 'text': 'spinal and bulbar muscular atrophy (SBMA), an inherited neuromuscular disorder caused by a CAG trinucleotide repeat expansion in the androgen receptor (AR) gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32773451'}]\n\n\n             'What is the cause of spinal-bulbar muscular atrophy?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Spinal-bulbar muscular atrophy is caused by mutations, i.e., a CAG trinucleotide repeat expansion, in the androgen receptor encoding gene (AR)."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 449, 'offsetInEndSection': 630, 'text': 'SUMMARY: Clinical trials demonstrated that tezepelumab, an anti-TSLP monoclonal antibody, is a promising alternative treatment for asthma that is effective also in nontype 2 asthma.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34608100'}, {'offsetInBeginSection': 60, 'offsetInEndSection': 132, 'text': 'Tezepelumab in adults and adolescents with severe, uncontrolled asthma. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34606305'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 101, 'text': 'In severe, uncontrolled asthma, tezepelumab reduced exacerbations and improved asthma control at 1 y.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34606305'}, {'offsetInBeginSection': 970, 'offsetInEndSection': 1141, 'text': 'Tezepelumab and other anti-alarmins are thus likely to become, in the near future, valuable therapeutic options for the biological treatment of uncontrolled severe asthma.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34572294'}, {'offsetInBeginSection': 1010, 'offsetInEndSection': 1221, 'text': 'Omalizumab, dupilumab, and tezepelumab can directly modulate the ASM in asthma, by specifically blocking the interaction between IgE, IL-4, and TSLP, and their receptors are located on the surface of ASM cells. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34572466'}, {'offsetInBeginSection': 1409, 'offsetInEndSection': 1761, 'text': 'AHR has been suggested as the main treatable trait towards precision medicine in patients suffering from eosinophilic asthma, therefore, well-designed head-to-head trials are needed to compare the efficacy of those mAbs that directly target ASM contractility specifically against the AHR in severe asthma, namely omalizumab, dupilumab, and tezepelumab.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34572466'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 309, 'text': 'Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, an epithelial cytokine involved in asthma pathogenesis. In the phase 2b PATHWAY study (ClinicalTrials.gov identifier: NCT02054130), tezepelumab significantly reduced exacerbations in adults with severe, uncontrolled asthma. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33368307'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 124, 'text': 'Pharmacokinetic and Pharmacodynamic Modeling of Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33368307'}, {'offsetInBeginSection': 1496, 'offsetInEndSection': 1663, 'text': 'These results support the selection of 210 mg every 4 weeks subcutaneously as the dose for phase 3 studies of tezepelumab in adults and adolescents with severe asthma.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33368307'}]\n\n\n             'Which disease can be treated using Tezepelumab?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Tezepelumab can be used to treat severe asthma."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 313, 'text': 'Enhancers are cis-regulatory elements in the genome that cooperate with promoters to control target gene transcription. Unlike promoters, enhancers are not necessarily adjacent to target genes and can exert their functions regardless of enhancer orientations, positions and spatial segregations from target genes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31993419'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 153, 'text': 'Enhancers are often located many tens of kilobases away from the promoter they regulate, sometimes residing closer to the promoter of a neighboring gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19675130'}, {'offsetInBeginSection': 127, 'offsetInEndSection': 232, 'text': 'Many enhancers map quite far from their target genes, on the order of tens or even hundreds of kilobases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31285341'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 179, 'text': 'Enhancers are intergenic DNA elements that regulate the transcription of target genes in response to signaling pathways by interacting with promoters over large genomic distances.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27932455'}, {'offsetInBeginSection': 125, 'offsetInEndSection': 274, 'text': 'Enhancers have been identified at up to megabase distances from their regulated genes, and/or proximal to or within the introns of unregulated genes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32038719'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 164, 'text': 'In metazoans transcriptional enhancers and their more complex relatives, locus control regions, are often located at great linear distances from their target genes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22183586'}, {'offsetInBeginSection': 248, 'offsetInEndSection': 417, 'text': ' Given their distance from the target gene, lack of common motifs, and tissue/cell specificity, enhancer regions are thought to be difficult to predict in DNA sequences.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36071071'}, {'offsetInBeginSection': 132, 'offsetInEndSection': 339, 'text': ' Computational identification of enhancers is difficult because they do not exhibit clear location preference relative to their target gene and also because they lack clearly distinguishing genomic features.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23424115'}, {'offsetInBeginSection': 68, 'offsetInEndSection': 169, 'text': ' Enhancers function independently of their distance and orientation to the promoters of target genes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26373455'}, {'offsetInBeginSection': 360, 'offsetInEndSection': 516, 'text': \" Until recently, identifying each gene's enhancers had been challenging because enhancers do not occupy prescribed locations relative to their target genes.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26100358'}, {'offsetInBeginSection': 133, 'offsetInEndSection': 339, 'text': 'Computational identification of enhancers is difficult because they do not exhibit clear location preference relative to their target gene and also because they lack clearly distinguishing genomic features.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23424115'}, {'offsetInBeginSection': 125, 'offsetInEndSection': 275, 'text': 'cis-regulatory sequences called enhancers. Enhancers can stimulate gene activity at great genomic distances from their targets, raising questions abou', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32197056'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 269, 'text': 'Enhancer elements are essential for tissue-specific gene regulation during mammalian development. Although these regulatory elements are often distant from their target genes, they affect gene expression by recruiting transcription factors to specific promoter regions.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23525463'}, {'offsetInBeginSection': 280, 'offsetInEndSection': 473, 'text': \"Epigenetic profiling of different tissues and cell-types has identified a large number of non-coding epigenetic regulatory elements ('enhancers') that can be located far away from coding genes.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30704404'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 271, 'text': 'In metazoans, enhancers of gene transcription must often exert their effects over tens of kilobases of DNA. Over the past decade it has become clear that to do this, enhancers come into close proximity with target promoters with the looping away of intervening sequences.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22169023'}]\n\n\n             'Do enhancers have to be close to their gene targets?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Enhancers are cis-regulatory elements in the genome that cooperate with promoters to control target gene transcription. Unlike promoters, enhancers are not necessarily adjacent to target genes and can exert their functions regardless of enhancer orientations, positions, and spatial segregations from target genes."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 109, 'text': 'Spinal muscular atrophy (SMA) with respiratory distress type 1 (SMARD1) is an exceptionally rare type of SMA.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34794294'}, {'offsetInBeginSection': 902, 'offsetInEndSection': 960, 'text': 'There are no convincing reports of X-linked SMA hitherto. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8283989'}, {'offsetInBeginSection': 146, 'offsetInEndSection': 294, 'text': 'The total AChE activity was either normal or decreased in the childhood SMA (Type 1), the other SMA groups and disease controls (ALS, X-linked SMA).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/2801018'}]\n\n\n             'Are there any other types of Spinal Muscular Atrophy except for types 1-4?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Yes, there are other types of Spinal Muscular Atrophy, except for types 1-4."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 164, 'offsetInEndSection': 369, 'text': 'Zanidatamab and tislelizumab are novel monoclonal antibodies targeting HER2 and PD-1, respectively, and have shown encouraging antitumor activity in early phase studies in multiple cancers, including GEA. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36000541'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 126, 'text': 'Population pharmacokinetics of zanidatamab, an anti-HER2 biparatopic antibody, in patients with advanced or metastatic cancer.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36102999'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 184, 'text': 'Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36400106'}, {'offsetInBeginSection': 302, 'offsetInEndSection': 415, 'text': 'Zanidatamab is a humanised, bispecific monoclonal antibody directed against two non-overlapping domains of HER2. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36400106'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 100, 'text': 'Zanidatamab is safe with preliminary efficacy in multiple HER2-expressing and HER2-amplified tumors.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36459075'}, {'offsetInBeginSection': 1029, 'offsetInEndSection': 1189, 'text': 'Early phase trials of dabrafenib plus trametinib (BRAF and MEK inhibition) and zanidatamab (a bispecific HER2-antibody) have yielded encouraging response rates.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34626563'}, {'offsetInBeginSection': 1365, 'offsetInEndSection': 1649, 'text': 'Of those in late-stage development, marketing application submissions for at least 23 may occur by the end of 2023, of which 5 are bispecific (odronextamab, erfonrilimab, linvoseltamab, zanidatamab, and talquetamab) and 2 are ADCs (datopotamab deruxtecan, and tusamitamab ravtansine).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36472472'}]\n\n\n             'What is the mechanism of action of Zanidatamab?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Zanidatamab is a humanised, bispecific monoclonal antibody directed against two non-overlapping domains of HER2."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 271, 'text': 'The transcription factor SOX10 plays an important role in vertebrate neural crest development, including the establishment and maintenance of the melanocyte lineage. SOX10 is also highly expressed in melanoma tumors, and SOX10 expression increases with tumor progression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29315345'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 228, 'text': 'Transcription factors are proteins that bind to DNA sequences to regulate gene transcription. The transcription factor binding sites are short DNA sequences (5-20\\u2009bp long) specifically bound by one or more transcription factors.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26425553'}, {'offsetInBeginSection': 216, 'offsetInEndSection': 518, 'text': 'Transcription factors serve as integration centres of the different signal-transduction pathways affecting a given gene. It is obvious that the regulation of these regulators themselves is of crucial importance for differential gene expression during development and in terminally differentiated cells.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8713055'}, {'offsetInBeginSection': 1179, 'offsetInEndSection': 1315, 'text': 'We propose a role for Sox10 in conferring cell specificity to the function of other transcription factors in developing and mature glia.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9412504'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 134, 'text': 'SOX10 is a high-mobility-group transcription factor that plays a critical role in the development of neural crest-derived melanocytes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11543611'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 218, 'text': 'The high mobility group-domain containing transcription factor Sox10 is an essential regulator of developmental processes and homeostasis in the neural crest, several neural crest-derived lineages and myelinating glia.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33082503'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 153, 'text': 'Sox10 is a member of the group E Sox transcription factor family and plays key roles in neural crest development and subsequent cellular differentiation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19304657'}, {'offsetInBeginSection': 252, 'offsetInEndSection': 397, 'text': 'In most cases, Sox10 exerts its transcriptional effects in concert with other DNA-binding factors, adaptor proteins, and nuclear import proteins.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19304657'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 169, 'text': 'The SOX10 transcription factor is a characteristic marker for migratory multipotent neural crest (NC) progenitors as well as several of their differentiated derivatives.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23644063'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 235, 'text': 'The transcription factor Sox10 is an essential regulator of genes that code for structural components of the myelin sheath and for lipid metabolic enzymes in both types of myelinating glia in the central and peripheral nervous systems.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33566433'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 175, 'text': 'The transcription factor Sox10 is a key regulator of vertebrate neural crest development and serves crucial functions in the differentiation of multiple neural crest lineages.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28012818'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 158, 'text': 'SOX10 is a well-conserved and widely expressed transcription factor involved in the regulation of embryonic development and in the determination of cell fate.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22173870'}, {'offsetInBeginSection': 151, 'offsetInEndSection': 319, 'text': 'The transcription factor SOX10 is critical for Schwann cell development and maintenance, and many SOX10 target genes encode proteins required for Schwann cell function.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27466180'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 76, 'text': 'SOX10 protein is a key transcription factor during neural crest development.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20130826'}, {'offsetInBeginSection': 1178, 'offsetInEndSection': 1315, 'text': ' We propose a role for Sox10 in conferring cell specificity to the function of other transcription factors in developing and mature glia.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9412504'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 106, 'text': 'SOX10 is a transcription factor with well-known functions in neural crest and oligodendrocyte development.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26060192'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 121, 'text': 'During embryogenesis, the transcription factor, Sox10, drives the survival and differentiation of the melanocyte lineage.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23935512'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 143, 'text': 'The transcription factor Sox10 functions during multiple consecutive stages of Schwann-cell development in the peripheral nervous system (PNS).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21491499'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 137, 'text': 'The high-mobility group transcription factor Sox10 exerts many different roles during development of the neural crest and nervous system.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16214168'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 239, 'text': 'Sox10, a member of the Sry-related HMG-Box gene family, is a critical transcription factor for several important cell lineages, most notably the neural crest stem cells and the derivative peripheral glial cells and melanocytes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18786246'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 311, 'text': 'The transcription factor SOX10 is essential for all stages of Schwann cell development including myelination. SOX10 cooperates with other transcription factors to activate the expression of key myelin genes in Schwann cells and is therefore a context-dependent, pro-myelination transcription factor.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27821050'}]\n\n\n             'Describe the function of a transcription factor such as SOX10.'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Transcription factors are proteins that bind to DNA sequences to regulate gene transcription. They serve as integration centers of the different signal-transduction pathways affecting a given gene. It is obvious that the regulation of these regulators themselves is of crucial importance for differential gene expression during development and in terminally differentiated cells. In particular, the transcription factor SOX10 plays an important role in vertebrate neural crest development, including the establishment and maintenance of the melanocyte lineage."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 232, 'text': \"Friedreich's ataxia (FA) is a rare, progressive, and degenerative hereditary disorder caused by a deficiency of frataxin protein. This disease is characterised by severe neurological dysfunction and life-threatening cardiomyopathy. \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35546709'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 256, 'text': \"Friedreich's ataxia (FRDA) is a rare genetic disorder caused by mutations in the gene frataxin, encoding for a mitochondrial protein involved in iron handling and in the biogenesis of iron-sulphur clusters, and leading to progressive nervous system damage.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35682973'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 274, 'text': 'Friedreich ataxia is an autosomal recessive ataxia with onset usually before puberty whose characteristic clinical features include progressive ataxia of gait and limbs, dysarthria, loss of joint position and vibratory sense, absent knee and ankle jerks, and Babinski signs.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7614092'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 121, 'text': 'Friedreich ataxia is an autosomal recessive degenerative disease that primarily affects the nervous system and the heart.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18852343'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 294, 'text': \"Friedreich's ataxia, the most frequent progressive autosomal recessive disorder involving the central and peripheral nervous systems, is mostly associated with unstable expansion of GAA trinucleotide repeats in the first intron of the FXN gene, which encodes the mitochondrial frataxin protein.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21985033'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 168, 'text': \"Friedreich's ataxia, the most common hereditary ataxia, is caused by expansion of a GAA triplet located within the first intron of the frataxin gene on chromosome 9q13.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12878293'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 144, 'text': \"Friedreich's ataxia is a neurodegenerative disorder associated with a GAA trinucleotide repeat expansion in intron 1 of the frataxin (FXN) gene.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30159187'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 230, 'text': 'BACKGROUND: Friedreich ataxia is an autosomal recessive hereditary spinocerebellar disorder, characterized by progressive limb and gait ataxia due to proprioceptive loss, often complicated by cardiomyopathy, diabetes and skeletal ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26338206'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 125, 'text': \"Friedreich's ataxia (FRDA) is a neurodegenerative disease caused by reduced expression of the mitochondrial protein frataxin.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20413654'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 199, 'text': \"BACKGROUND: Friedreich's ataxia is an autosomal recessive mitochondrial disease caused by a triplet repeat expansion in the frataxin gene (FXN), exhibiting cerebellar sensory ataxia, diabetes and car\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34920960'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 190, 'text': \"Friedreich's ataxia is the most common inherited autosomal recessive ataxia and is characterized by progressive degeneration of the peripheral and central nervous systems and cardiomyopathy.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23936609'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 184, 'text': \"Friedreich's ataxia is an autosomal recessively inherited neurodegenerative disorder caused by expansions of an unstable GAA trinucleotide repeat in the STM7/X25 gene on chromosome 9q.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9448568'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 198, 'text': \"Friedreich's ataxia is a rare hereditary disease and although the gene defect has already been identified as a deficiency of the mitochondrial protein frataxin, the pathophysiology is still unknown.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24848865'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 177, 'text': \"Friedreich's ataxia is an autosomal recessive neurogenetic disease that is mainly associated with atrophy of the spinal cord and progressive neurodegeneration in the cerebellum.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33670433'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 235, 'text': \"Friedreich's ataxia (FRDA) is an autosomal recessive inherited disorder characterized by progressive gait and limb ataxia, dysarthria, areflexia, loss of vibratory and position sense, and a progressive motor weakness of central origin.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21550666'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 163, 'text': \"Friedreich's ataxia (FA) is a recessive, predominantly neurodegenerative disorder caused in most cases by mutations in the first intron of the frataxin (FXN) gene.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25554687'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 179, 'text': \"Friedreich's ataxia (FRDA) is a neurodegenerative disease caused by recessive mutations in the frataxin gene that lead to a deficiency of the mitochondrial frataxin (FXN) protein.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33158039'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 228, 'text': \"Friedreich's ataxia (FRDA) is a rare autosomal recessive spinocerebellar ataxia which in the majority of cases is associated with a GAA-trinucleotide repeat expansion in the first intron of Frataxin gene located on chromosome 9.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28282710'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 119, 'text': 'Friedreich ataxia is considered a neurodegenerative disorder involving both the peripheral and central nervous systems.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24860428'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 121, 'text': 'Friedreich ataxia (FRDA) is a common form of ataxia caused by decreased expression of the mitochondrial protein frataxin.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21782979'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 196, 'text': \"BACKGROUND: Friedreich's ataxia is an autosomal recessive neurodegenerative disease where impaired mitochondrial function and excessive production of free radicals play a central pathogenetic role\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18710357'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 155, 'text': \"BACKGROUND: Friedreich's ataxia is the most common hereditary ataxia and its clinical spectrum includes cardiac disease, mainly hypertrophic cardiomyopathy\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20073435'}]\n\n\n             'What is Friedreich's Ataxia?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Friedreich's ataxia (FA) is a rare, genetic, progressive, and degenerative disorder caused by mutations in the gene frataxin leading in a deficiency of frataxin protein. It is characterised by severe neurological dysfunction and life-threatening cardiomyopathy."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 2991, 'offsetInEndSection': 3363, 'text': 'INTERPRETATION: A similar safety profile was seen in all treatment groups. No beneficial treatment effects were recorded. Although this study did not provide evidence of efficacy in progressive supranuclear palsy, the findings provide potentially useful information for future investigations of passive immunisation using tau antibodies for progressive supranuclear palsy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33609476'}]\n\n\n             'Is Tilavonemab effective for progressive supranuclear palsy?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "No. Tilavonemab is not effective for progressive supranuclear palsy."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 119, 'text': 'Homeosis is classically defined as the transformation of one body part into something that resembles another body part.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26596501'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 106, 'text': 'Homeotic transformation is defined as transformation of one body part into the likeness of something else.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29227708'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 124, 'text': 'In Drosophila, the misexpression or altered activity of genes from the bithorax complex results in homeotic transformations.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7909957'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 924, 'text': 'The discovery of the broad conservation of embryonic regulatory genes across animal phyla, launched by the cloning of homeotic genes in the 1980s, was a founding event in the field of evolutionary developmental biology (evo-devo). While it had long been known that fundamental cellular processes, commonly referred to as housekeeping functions, are shared by animals and plants across the planet-processes such as the storage of information in genomic DNA, transcription, translation and the machinery for these processes, universal codon usage, and metabolic enzymes-Hox genes were different: mutations in these genes caused \"bizarre\" homeotic transformations of insect body parts that were certainly interesting but were expected to be idiosyncratic. The isolation of the genes responsible for these bizarre phenotypes turned out to be highly conserved Hox genes that play roles in embryonic patterning throughout Metazoa.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26596987'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 219, 'text': 'The study of homeotic-transformation mutants in model organisms such as Drosophila revolutionized the field of developmental biology, but how these mutants relate to human developmental defects remains to be elucidated.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23022097'}, {'offsetInBeginSection': 173, 'offsetInEndSection': 402, 'text': 'Homebox (Hox) genes are involved in this evolutionary mammalian conservation, and homeotic transformation of cervical into thoracic vertebrae (cervical ribs) is a common phenotypic abnormality when Hox gene expression is altered.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29761492'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 109, 'text': 'A human homeotic transformation resulting from mutations in PLCB4 and GNAI3 causes auriculocondylar syndrome.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22560091'}]\n\n\n             'What does the term \"homeotic transformation\" mean?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Homeotic transformation (homeosis) is defined as the transformation of one body part into something that resembles another body part. The discovery of the broad conservation of embryonic regulatory genes across animal phyla, launched by the cloning of homeotic genes in the 1980s, was a founding event in the field of evolutionary developmental biology. While it had long been known that fundamental cellular processes, commonly referred to as housekeeping functions, are shared by animals and plants, Hox genes were different: mutations in these genes caused \"bizarre\" homeotic transformations of insect body parts that were certainly interesting but were expected to be idiosyncratic. The isolation of the genes responsible for these bizarre phenotypes turned out to be highly conserved Hox genes that play roles in embryonic patterning throughout Metazoa."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 14, 'offsetInEndSection': 171, 'text': 'Spinal muscular atrophy (SMA) is a rare autosomal recessive neuromuscular disease which is characterised by muscle atrophy and early death in most patients. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35316106'}, {'offsetInBeginSection': 13, 'offsetInEndSection': 245, 'text': ' Spinal muscular atrophy (SMA), an autosomal recessive neurodegenerative disorder of alpha motor neurons of spinal cord associated with progressive muscle weakness and hypotonia, is the most common genetic cause of infant mortality.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34032944'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 84, 'text': 'Spinal muscular atrophy (SMA) is an autosomal recessive, lower motor neuron disease.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24124019'}, {'offsetInBeginSection': 203, 'offsetInEndSection': 522, 'text': 'Spinal muscular atrophy, lower extremity-predominant, is characterized by lower limb muscle weakness and wasting, associated with reduced numbers of lumbar motor neurons and is caused by mutations in DYNC1H1, which encodes a microtubule motor protein in the dynein-dynactin complex and one of its cargo adaptors, BICD2.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25497877'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 190, 'text': 'Spinal muscular atrophy is an autosomal recessive neurodegenerative disease characterised by degeneration of spinal cord motor neurons, atrophy of skeletal muscles, and generalised weakness.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18572081'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 193, 'text': 'Spinal muscular atrophy, a hereditary degenerative disorder of lower motor neurons associated with progressive muscle weakness and atrophy, is the most common genetic cause of infant mortality.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22196485'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'Autosomal recessive spinal muscular atrophy (SMA) is a neuromuscular disorder characterized by muscle atrophy combined with motor neuron degeneration.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/13129800'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 123, 'text': 'Spinal muscular atrophy is an autosomal recessive disease characterized by motor neurone loss, muscle atrophy and weakness.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10226744'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 170, 'text': 'Spinal muscular atrophy is a group of allelic autosomal recessive disorders characterized by progressive motoneuron loss, symmetric weakness, and skeletal muscle atrophy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15794183'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 175, 'text': 'Spinal muscular atrophy (SMA) is a life-threatening autosomal recessive disease that leads to progressive muscle weakness and atrophy, respiratory insufficiency and scoliosis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34560767'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 169, 'text': 'Proximal spinal muscular atrophy (SMA) is an autosomal recessive neurodegenerative disorder characterized by motor neuron loss and subsequent atrophy of skeletal muscle.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34445199'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 157, 'text': 'Spinal muscular atrophy is a genetic disorder of the motor neurons that causes profound hypotonia, severe weakness, and often fatal restrictive lung disease.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10695894'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 144, 'text': 'Spinal muscular atrophy (SMA) is an autosomal recessive disease characterized by degeneration of spinal cord motor neurons and muscular atrophy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18990310'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 149, 'text': 'Spinal muscular atrophy is an autosomal-recessive neuromuscular disorder, causing progressive proximal weakness and atrophy of the voluntary muscles.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24334346'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 158, 'text': 'Spinal muscular atrophy (SMA) is a recessive disorder caused by a mutation in the survival motor neuron 1 gene (SMN1); it affects 1 in 11\\xa0000 newborn infants.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30221755'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 165, 'text': 'Spinal muscular atrophy is a devastating neurodegenerative autosomal recessive disease that results from survival of motor neuron 1 (SMN1) gene mutation or deletion.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31371124'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 136, 'text': 'Spinal muscular atrophy (SMA) is a debilitating neurological disorder marked by degeneration of spinal motor neurons and muscle atrophy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33979606'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 191, 'text': 'Spinal muscular atrophy is an autosomal-recessive disorder characterized by degeneration of motor neurons in the spinal cord and caused by mutations in the survival motor neuron 1 gene, SMN1.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26515624'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 155, 'text': 'Spinal muscular atrophy (SMA) is a neuromuscular disease characterized by loss of lower motor neurons, which leads to proximal muscle weakness and atrophy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33353564'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 173, 'text': 'Spinal muscular atrophy (SMA) is an autosomal recessive disorder that is characterized by the degeneration of the motor neurons of the spinal cord leading to muscle atrophy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18651653'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 215, 'text': 'Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease characterized by degeneration of alpha motor neurons in the spinal cord, resulting in progressive proximal muscle weakness and paralysis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22047105'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 188, 'text': 'Spinal muscular atrophy (SMA) is a rare autosomal recessive disorder characterized by muscle atrophy and weakness resulting from motor neuron degeneration in the spinal cord and brainstem.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28229309'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 118, 'text': 'Spinal muscular atrophy (SMA) is an autosomal recessive disorder that is the leading genetic cause of infantile death.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23876144'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 197, 'text': 'Introduction: Spinal muscular atrophy is a rare genetic neurodegenerative disorder affecting the motor neurons of the anterior horn of the spinal cord, which results in muscle atrophy and weakness.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35866733'}, {'offsetInBeginSection': 105, 'offsetInEndSection': 226, 'text': 'Spinal muscular atrophy is a human motoneuron disease that is genetically linked to the survival motor neuron gene (SMN).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17761655'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 144, 'text': 'BACKGROUND: Spinal muscular atrophy is a recessively inherited autosomal neuromuscular disorder, with characteristic progressive muscle weakness', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36376972'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 198, 'text': 'Spinal muscular atrophy is a common autosomal recessive neuromuscular disorder caused by mutations in the survival motor neuron gene (SMN), which exists in 2 nearly identical copies (SMN1 and SMN2).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17761649'}]\n\n\n             'What is Spinal Muscular Atrophy?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Spinal muscular atrophy (SMA) is a rare autosomal recessive neurodegenerative disorder of alpha motor neurons of the spinal cord associated with progressive muscle weakness and hypotonia. It is the most common genetic cause of infant mortality and is characterized by muscle atrophy and early death in most patients."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 988, 'offsetInEndSection': 1755, 'text': ' There was low or moderate certainty evidence for a large (\u22652-fold) magnitude of association between hospitalisation in people with COVID-19, and: obesity class III, heart failure, diabetes, chronic kidney disease, dementia, age >45 years, male gender, black race/ethnicity (vs non-Hispanic white), homelessness and low income. Age >60\\u2009and >70 years may be associated with large increases in mechanical ventilation and severe disease, respectively. For mortality, a large magnitude of association may exist with liver disease, Bangladeshi ethnicity (vs British white), age >45 years, age >80 years (vs 65-69 years) and male gender among 20-64 years (but not older). Associations with hospitalisation and mortality may be very large (\u22655-fold) for those aged \u226560 years.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33986052'}, {'offsetInBeginSection': 1768, 'offsetInEndSection': 1864, 'text': 'Increasing age (especially >60 years) may be the most important risk factor for severe outcomes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33986052'}, {'offsetInBeginSection': 1108, 'offsetInEndSection': 1682, 'text': 'In multivariable logistic regression analyses, increasing age (adjusted odds ratio [aOR] 1.1, 95% confidence interval [CI] 1.1-1.2, p<0.001), male gender (aOR 1.8, 95% CI 1.2-2.7, p = 0.002), Hispanic ethnicity (aOR 1.9, 95% CI 1.2-3.1, p = 0.01), obesity (3.1, 95% CI 1.9-5.1, p<0.001), asthma history (aOR 2.3, 95% CI 1.3-4.0, p = 0.003), congestive heart failure (aOR 6.0, 95% CI 1.5-25.1, p = 0.01), cerebrovascular disease (aOR 4.9, 95% CI 1.7-14.7, p = 0.004), and diabetes (aOR 3.4, 95% CI 1.9-6.2, p<0.001) were predictive of severe disease diagnoses within 30 days.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34329347'}, {'offsetInBeginSection': 1417, 'offsetInEndSection': 2299, 'text': 'The strongest association with risk of severe disease after vaccination was age, which increased among patients aged 50 years or older with an adjusted odds ratio (aOR) of 1.42 (CI, 1.40-1.44) per 5-year increase in age, such that patients aged 80 years or older had an aOR of 16.58 (CI, 13.49-20.37) relative to patients aged 45 to 50 years. Immunocompromising conditions, including receipt of different classes of immunosuppressive medications (eg, leukocyte inhibitor: aOR, 2.80; 95% CI, 2.39-3.28) or cytotoxic chemotherapy (aOR, 2.71; CI, 2.27-3.24) prior to breakthrough infection, or leukemias or lymphomas (aOR, 1.87; CI, 1.61-2.17) and chronic conditions associated with end-organ disease, such as heart failure (aOR, 1.74; CI, 1.61-1.88), dementia (aOR, 2.01; CI, 1.83-2.20), and chronic kidney disease (aOR, 1.59; CI, 1.49-1.69), were also associated with increased risk.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36264571'}, {'offsetInBeginSection': 879, 'offsetInEndSection': 1332, 'text': 'Factors associated with severe COVID-19 were older age [adjusted relative risk (aRR) 1.78, 95% confidence interval (CI) 1.61-1.97; P < 0.0001], diabetes (aRR 2.00, 95% CI 1.20-3.32; P = 0.007), cardiovascular disease (aRR 2.53, 95% CI 1.53-4.17; P < 0.0001), malignancy (aRR 4.57, 95% CI 1.62-12.87; P = 0.004), surgery/trauma (aRR 23.98, 95% CI 10.35-55.57; P < 0.0001) and human immunodeficiency virus infection (aRR 4.24, 95% CI 1.55-11.61; P = 005).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33741488'}, {'offsetInBeginSection': 1302, 'offsetInEndSection': 1424, 'text': 'Cirrhosis was an independent predictor of severe COVID-19 in patients with AIH (P\\xa0<\\xa00.001; OR, 17.46; 95% CI, 4.22-72.13).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33713486'}, {'offsetInBeginSection': 21, 'offsetInEndSection': 112, 'text': 'Data regarding outcome of COVID-19 in patients with autoimmune hepatitis (AIH) are lacking.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33713486'}, {'offsetInBeginSection': 1701, 'offsetInEndSection': 1780, 'text': 'Cirrhosis was the strongest predictor for severe COVID-19 in patients with AIH.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33713486'}, {'offsetInBeginSection': 925, 'offsetInEndSection': 1090, 'text': ' Older age, male sex, non-White race, Hispanic ethnicity, obesity, and a higher number of chronic conditions were associated with increased risk of severe infection.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34538426'}, {'offsetInBeginSection': 1261, 'offsetInEndSection': 1549, 'text': 'In particular, persons 0 to 44 years of age with cancer, chronic neurologic disorders, hematologic disorders, ischemic heart disease, and other endocrine disorders had a greater than 3-fold increased risk of severe infection compared with persons of the same age without those conditions.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34538426'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 50, 'text': 'Sleep apnoea is a risk factor for severe COVID-19.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33436406'}, {'offsetInBeginSection': 148, 'offsetInEndSection': 259, 'text': 'Various risk factors for a severe course, such as higher age, male gender and pre-existing illnesses are known.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36431276'}, {'offsetInBeginSection': 1433, 'offsetInEndSection': 1515, 'text': 'Males could at higher risk of developing severe symptoms of COVID-19 than females.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33050972'}, {'offsetInBeginSection': 1028, 'offsetInEndSection': 1129, 'text': 'COVID-19 severity was associated only with older age and cardiac disease, in a multivariate analysis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34165257'}, {'offsetInBeginSection': 110, 'offsetInEndSection': 353, 'text': 'Age, gender, and comorbidities are known to be risk factors for severe COVID-19 but are generally considered independently without accurate knowledge of the magnitude of their effect on risk, potentially resulting in incorrect risk estimation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33592063'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 81, 'text': 'Immune deficiency is a risk factor for severe COVID-19 in people living with HIV.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33368966'}, {'offsetInBeginSection': 173, 'offsetInEndSection': 302, 'text': ' This study aimed to clarify the association between nervous system diseases and severity or mortality in patients with COVID-19.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33583450'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 177, 'text': 'Health factors such as diabetes, severe obesity and chronic kidney disease are all associated with a more severe outcome following coronavirus disease 2019 (COVID-19) infection.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32878679'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 154, 'text': 'BACKGROUND: Lifestyle factors including obesity and smoking are suggested to be correlated with increased risk of COVID-19 severe illness or related death', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33536004'}, {'offsetInBeginSection': 1633, 'offsetInEndSection': 1851, 'text': 'There is no evidence supporting that NAFLD is a causal risk factor for severe COVID-19. Previous observational associations between NAFLD and COVID-19 are likely attributed to the correlation between NAFLD and obesity.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35124268'}]\n\n\n             'What factors are associated with severe COVID-19?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Severe illness can occur in otherwise healthy individuals of any age, but it predominantly occurs in adults with increased age (especially older than 60 years) and/or certain underlying medical comorbidities. These include obesity, diabetes, asthma, cancer, chronic kidney disease, chronic neurologic disorders (e.g., dementia), cirrhosis, immunocompromising conditions, and cardiovascular and cerebrovascular diseases. Certain demographic features have also been associated with more severe illness, such as African-American origin or Hispanic ethnicity."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 77, 'text': 'No infectious SARS-CoV-2 in breast milk from a cohort of 110 lactating women.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35042956'}, {'offsetInBeginSection': 1169, 'offsetInEndSection': 1410, 'text': 'SARS-CoV-2 RNA can be found infrequently in the breastmilk after recent infection, but we found no evidence that breastmilk contains an infectious virus or that breastfeeding represents a risk factor for transmission of infection to infants.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35042956'}, {'offsetInBeginSection': 1418, 'offsetInEndSection': 1616, 'text': 'This article goes beyond prior small studies to provide evidence that infectious SARS-CoV-2 is not present in the milk of lactating women with recent infection, even when SARS-CoV-2 RNA is detected.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35042956'}, {'offsetInBeginSection': 1617, 'offsetInEndSection': 1726, 'text': 'Recent SARS-CoV-2 infection or detection of its RNA in human milk is not a contraindication to breastfeeding.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35042956'}, {'offsetInBeginSection': 1065, 'offsetInEndSection': 1426, 'text': 'Based on the currently available limited evidence and recognizing the benefits of breastfeeding, it may be concluded that if the health of the mother and her newborn allows, direct breastfeeding or extracted breastmilk should be encouraged by the healthcare providers after a careful discussion of the risks of vertical transmission to the mother and her family', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33394459'}, {'offsetInBeginSection': 1428, 'offsetInEndSection': 1564, 'text': 'Preventive measures should be taken by COVID-19 mothers to prevent droplet transmission of infection to the infants while breastfeeding.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33394459'}, {'offsetInBeginSection': 1147, 'offsetInEndSection': 1226, 'text': 'Currently, there is no evidence of SARS-CoV-2 transmission through breast milk.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32860259'}, {'offsetInBeginSection': 722, 'offsetInEndSection': 855, 'text': 'The authors could not find evidence for transmission of SARS-CoV-2 from mother to child through breastmilk in the population studied.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33555566'}, {'offsetInBeginSection': 174, 'offsetInEndSection': 331, 'text': 'At present, there is limited information on potential transmission of the infection from mother to child, particularly through breast milk and breastfeeding.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32860259'}, {'offsetInBeginSection': 683, 'offsetInEndSection': 849, 'text': 'However, there is limited published literature related to vertical transmission of any human coronaviruses (including SARS-CoV-2) via human milk and/or breastfeeding.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32472745'}, {'offsetInBeginSection': 656, 'offsetInEndSection': 820, 'text': 'However, there is limited published literature related to vertical transmission of any human coronavirus (including SARS-CoV-2) via human milk and/or breastfeeding.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32511431'}, {'offsetInBeginSection': 1589, 'offsetInEndSection': 2340, 'text': 'and had a benign clinical course. There was no evidence of significant clinical infection during the hospital stay or from outpatient neonatal follow-up data for all the infants included in this study.CONCLUSION: In a small cohort of SARS-CoV-2 positive lactating mothers giving birth at our institution, most of their breast milk samples (95%) contained no detectable virus, and there was no evidence of COVID-19 infection in their breast milk-fed neonates.KEY POINTS: \u00b7 Breast milk may rarely contain detectable SARS-CoV-2 RNA and was not detected in asymptomatic mothers.. \u00b7 Breast milk with detectable SARS-CoV-2 RNA from a symptomatic mother had no clinical significance for her infant.. \u00b7 Breast feeding with appropriate infection control instru', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34182576'}, {'offsetInBeginSection': 793, 'offsetInEndSection': 886, 'text': 'Taken together, our data do not support mother-to-infant transmission of SARS-CoV-2 via milk.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33563823'}, {'offsetInBeginSection': 1132, 'offsetInEndSection': 1387, 'text': 'th SARS-CoV-2 neutralization. Strong correlations between levels of IgA and IgG to SARS-CoV-2 and seasonal coronaviruses were noted.CONCLUSIONS: Our data do not support maternal-to-child transmission of SARS-CoV-2 via milk; however, risk of transmission v', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32995804'}, {'offsetInBeginSection': 1146, 'offsetInEndSection': 1226, 'text': ' Currently, there is no evidence of SARS-CoV-2 transmission through breast milk.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32860259'}, {'offsetInBeginSection': 42, 'offsetInEndSection': 109, 'text': ' Whether SARS-CoV-2 was transmitted through breast milk is unknown.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33344466'}, {'offsetInBeginSection': 774, 'offsetInEndSection': 938, 'text': 'No breast milk samples were positive for SARS-CoV-2 and, to date, there is no evidence on the presence of SARS-CoV-2 in breast milk of pregnant women with COVID-19.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32454808'}, {'offsetInBeginSection': 1409, 'offsetInEndSection': 1559, 'text': 'from 11 women tested negative.INTERPRETATION: Considering the lack of evidence for SARS-CoV-2 transmission through breast milk, breastfeeding counsell', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34013217'}]\n\n\n             'Is SARS-CoV-2 transmitted through breast milk?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Based on current evidence, SARS-Cov-2 is not transmitted through breast milk."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 345, 'text': 'Our genetic information is tightly packaged into a rather ingenious nucleoprotein complex called chromatin in a manner that enables it to be rapidly accessed during genomic processes. Formation of the nucleosome, which is the fundamental unit of chromatin, occurs via a stepwise process that is reversed to enable the disassembly of nucleosomes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20444609'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 464, 'text': 'DNA in eukaryotes is packed into chromatin. The basic component of chromatin is the nucleosome consisting of DNA wrapped around a histone octamer. Inside the cell nucleus, chromatin is folded into higher-order structures through various mechanisms, including repositioning of nucleosomes along the DNA, packing of nucleosomes into more condensed 3-dimensional configurations, looping of chromatin fibres, and tethering of chromosomal regions to nuclear structures.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15868422'}, {'offsetInBeginSection': 147, 'offsetInEndSection': 464, 'text': 'Inside the cell nucleus, chromatin is folded into higher-order structures through various mechanisms, including repositioning of nucleosomes along the DNA, packing of nucleosomes into more condensed 3-dimensional configurations, looping of chromatin fibres, and tethering of chromosomal regions to nuclear structures.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15868422'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 90, 'text': 'Chromatin is a tightly packaged structure of DNA and protein within the nucleus of a cell.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34255854'}, {'offsetInBeginSection': 138, 'offsetInEndSection': 272, 'text': 'The basic unit of chromatin is the nucleosome, which consists of a short piece of DNA wrapped around a core of eight histone proteins.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28058066'}, {'offsetInBeginSection': 273, 'offsetInEndSection': 469, 'text': 'In addition to their role in packaging DNA, nucleosomes impact the regulation of essential nuclear processes such as replication, transcription, and repair by controlling the accessibility of DNA.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28058066'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 179, 'text': 'DNA repair in eukaryotic cells takes place in the context of chromatin, where DNA, including damaged DNA, is tightly packed into nucleosomes and higher order chromatin structures.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23109894'}]\n\n\n             'Chromatin is tightly packed into what structure inside the nucleus?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "DNA in eukaryotes is packed into a nucleoprotein complex called chromatin in a manner that enables it to be rapidly accessed during genomic processes. The basic component of chromatin is the nucleosome consisting of DNA wrapped around a histone octamer. Inside the cell nucleus, chromatin is folded into higher-order structures through various mechanisms, including repositioning of nucleosomes along the DNA, packing of nucleosomes into more condensed 3-dimensional configurations, looping of chromatin fibers, and tethering of chromosomal regions to nuclear structures."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 1218, 'offsetInEndSection': 1269, 'text': 'The treatment of FSHD is currently supportive only.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31794465'}, {'offsetInBeginSection': 19, 'offsetInEndSection': 135, 'text': 'Facioscapulohumeral muscular dystrophy (FSHD) is a slowly progressive muscular dystrophy without approved therapies.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35428982'}]\n\n\n             'Is there any treatment for the Facioscapulohumeral Muscular Dystrophy?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "No, currently there are no approved therapies for the Facioscapulohumeral Muscular Dystrophy, only supportive treatment."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 355, 'offsetInEndSection': 1017, 'text': 'Recent advances in genome-wide analyses have revealed that the deregulation of distal gene regulatory elements, such as enhancers, appears in several pathophysiological conditions, including cancer. Beyond the conventional function of enhancers in recruiting transcription factors to gene promoters, enhancer elements are also transcribed into noncoding RNAs known as enhancer RNAs (eRNA). Accumulating evidence suggests that uncontrolled enhancer activity with aberrant eRNA expression promotes oncogenesis. Interestingly, tissue-specific, transcribed eRNAs from active enhancers can serve as potential therapeutic targets or biomarkers in several cancer types.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34016622'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 772, 'text': 'Enhancers are cis-regulatory sequences that fine-tune expression of their target genes in a spatiotemporal manner. They are recognized by sequence-specific transcription factors, which in turn recruit transcriptional coactivators that facilitate transcription by promoting assembly and activation of the basal transcriptional machinery. Their functional importance is underscored by the fact that they are often the target of genetic and nongenetic events in human disease that disrupt their sequence, interactome, activation potential, and/or chromatin environment. Dysregulation of transcription and addiction to transcriptional effectors that interact with and modulate enhancer activity are common features of cancer cells and are amenable to therapeutic intervention.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33934105'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 319, 'text': 'Enhancer is one kind of cis-elements regulating gene transcription, whose activity is tightly controlled by epigenetic enzymes and histone modifications. Active enhancers are classified into typical enhancers, super-enhancers and over-active enhancers, according to the enrichment and location of histone modifications.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35750313'}, {'offsetInBeginSection': 662, 'offsetInEndSection': 1000, 'text': 'Recent studies have revealed enhancer dysregulation as one of the important features for cancer. Variations in enhancer regions and mutations of enhancer regulatory genes are frequently observed in cancer cells, and altering the activity of onco-enhancers is able to repress oncogene expression, and suppress tumorigenesis and metastasis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35750313'}, {'offsetInBeginSection': 540, 'offsetInEndSection': 984, 'text': \"The disruption of enhancer activity, through genetic or epigenetic alterations, can impact cell-type-specific functions, resulting in a wide range of pathologies. In cancer, these alterations can promote a 'cell identity crisis', in which enhancers associated with oncogenes and multipotentiality are activated, while those promoting cell fate commitment are inactivated. Overall, these alterations favor an undifferentiated cellular phenotype.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25473436'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 207, 'text': 'Enhancers are selectively utilized to orchestrate gene expression programs that first govern pluripotency and then proceed to highly specialized programs required for the process of cellular differentiation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25473436'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 854, 'text': \"Enhancer elements function as the logic gates of the genetic regulatory circuitry. One of their most important functions is the integration of extracellular signals with intracellular cell fate information to generate cell type-specific transcriptional responses. Mutations occurring in cancer often misregulate enhancers that normally control the signal-dependent expression of growth-related genes. This misregulation can result from trans-acting mechanisms, such as activation of the transcription factors or epigenetic regulators that control enhancer activity, or can be caused in cis by direct mutations that alter the activity of the enhancer or its target gene specificity. These processes can generate tumour type-specific super-enhancers and establish a 'locked' gene regulatory state that drives the uncontrolled proliferation of cancer cells.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27364481'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 679, 'text': 'Transcription factors, cofactors, chromatin regulators, and transcription apparatuses interact with transcriptional regulatory elements, including promoters, enhancers, and super-enhancers (SEs), to coordinately regulate the transcription of target genes and thereby control cell behaviors. Among these transcriptional regulatory components and related elements, SEs often play a central role in determining cell identity and tumor initiation and progression. Therefore, oncogenic SEs, which are generated within cancer cells in oncogenes and other genes important in tumor pathogenesis, have emerged as attractive targets for novel cancer therapeutic strategies in recent years.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35277481'}, {'offsetInBeginSection': 120, 'offsetInEndSection': 937, 'text': 'Transcriptional dysregulation of these pathways is commonly associated with tumorigenesis and the development of cancer. Genetic and epigenetic alterations may mediate dysregulated transcriptional activity. One of the most important epigenetic alternations is the non-coding regulatory element, which includes both enhancers and super-enhancers (SEs). SEs, characterized as large clusters of enhancers with aberrant high levels of transcription factor binding, have been considered as key drivers of gene expression in controlling and maintaining cancer cell identity. In cancer cells, oncogenes acquire SEs and the cancer phenotype relies on these abnormal transcription programs driven by SEs, which leads to cancer cells often becoming addicted to the SEs-related transcription programs, including prostate cancer.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33299103'}, {'offsetInBeginSection': 116, 'offsetInEndSection': 206, 'text': 'In fact, many human cancers and diseases are associated with the malfunction of enhancers.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35170113'}, {'offsetInBeginSection': 820, 'offsetInEndSection': 1073, 'text': 'We discuss how enhancer dysregulation is a common theme in SWI/SNF mutant cancers and describe how resultant alterations in enhancer and super-enhancer activity conspire to block development and differentiation while promoting stemness and self-renewal.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35911061'}, {'offsetInBeginSection': 264, 'offsetInEndSection': 400, 'text': 'Mutations occurring in cancer often misregulate enhancers that normally control the signal-dependent expression of growth-related genes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27364481'}, {'offsetInBeginSection': 126, 'offsetInEndSection': 288, 'text': 'Many human cancers were found to associate with enhancer malfunction, due to genetic and epigenetic alterations, which in some cases directly drive tumour growth.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31916476'}, {'offsetInBeginSection': 682, 'offsetInEndSection': 854, 'text': \"These processes can generate tumour type-specific super-enhancers and establish a 'locked' gene regulatory state that drives the uncontrolled proliferation of cancer cells.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27364481'}, {'offsetInBeginSection': 681, 'offsetInEndSection': 863, 'text': 'In cancer, super-enhancers have multifaceted roles by activating various oncogenes and other cancer-related genes and shaping characteristic gene expression patterns in cancer cells.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35967935'}, {'offsetInBeginSection': 661, 'offsetInEndSection': 951, 'text': 'In this review we discuss different mechanisms through which enhancers are exploited in malignant B cells, from the well-studied translocations juxtaposing oncogenes to immunoglobulin loci, through enhancer dysregulation by sequence variants and mutations, to enhancer hijacking by viruses.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34210001'}, {'offsetInBeginSection': 703, 'offsetInEndSection': 911, 'text': \"In cancer, these alterations can promote a 'cell identity crisis', in which enhancers associated with oncogenes and multipotentiality are activated, while those promoting cell fate commitment are inactivated.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25473436'}, {'offsetInBeginSection': 403, 'offsetInEndSection': 590, 'text': 'Super-enhancers, characterized as large clusters of enhancers in close proximity, have been identified as essential oncogenic drivers required for the maintenance of cancer cell identity.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30885876'}]\n\n\n             'What is the role of enhancers in cancer?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Recent studies have revealed that the deregulation of distal gene regulatory elements, such as enhancers, appears in several pathophysiological conditions, including cancer. In cancer, mutations often misregulate enhancers that normally control the signal-dependent expression of growth-related genes. This misregulation can result from trans-acting mechanisms, such as activation of the transcription factors or epigenetic regulators that control enhancer activity or can be caused in cis by direct mutations that alter the activity of the enhancer or its target gene specificity. These processes can generate tumor-type-specific super-enhancers and establish a 'locked' gene regulatory state that drives the uncontrolled proliferation of cancer cells."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 358, 'offsetInEndSection': 582, 'text': ' Non-pharmacological comfort measures such as breastfeeding, swaddling and sweet solutions are inconsistently implemented and are not always practical or effective in reducing the transmission of noxious input to the brain. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36250332'}, {'offsetInBeginSection': 137, 'offsetInEndSection': 400, 'text': \"In this comparative effectiveness research 195 neonates >36 weeks' gestation were randomised to three groups, receiving during heel stick: (i) breastfeeding, (ii) sucrose 24% liquid with non-nutritive sucking and (iii) sucrose 24% gel with non-nutritive sucking. \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33664472'}, {'offsetInBeginSection': 470, 'offsetInEndSection': 537, 'text': 'All the methods analysed has shown to be effective in reducing pain', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33664472'}, {'offsetInBeginSection': 539, 'offsetInEndSection': 668, 'text': 'There was an increase in odds of pain following liquid sucrose compared to breastfeeding (OR\\u2009=\\u20091.60; 95% CI: 0.82-3.3; p\\u2009=\\u20090.17).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33664472'}, {'offsetInBeginSection': 861, 'offsetInEndSection': 999, 'text': 'Sucrose 24% gel with non-nutritive sucking seems to be a valid alternative when breastfeeding is not possible. Further research is needed.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33664472'}, {'offsetInBeginSection': 195, 'offsetInEndSection': 264, 'text': 'Oral sucrose is commonly given to children to reduce procedural pain.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31317627'}, {'offsetInBeginSection': 1508, 'offsetInEndSection': 1849, 'text': 'he present systematic review and meta-analyses demonstrate that glucose reduces pain scores and crying during single heel lances and venipunctures. Results indicate that 20% to 30% glucose solutions have analgesic effects and can be recommended as an alternative to sucrose for procedural pain reduction in healthy term and preterm neonates.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23748256'}]\n\n\n             'What are the currently used non-pharmacological measures for the management of procedural pain in neonates?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "The currently used measures for the management of procedural pain in neonates are the following: breastfeeding, swaddling and sweet solutions such as sucrose and glucose."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 501, 'text': 'The use of several translation initiation codons in a single mRNA, by expressing several proteins from a single gene, contributes to the generation of protein diversity. A small, yet growing, number of mammalian mRNAs initiate translation from a non-AUG codon, in addition to initiating at a downstream in-frame AUG codon. Translation initiation on such mRNAs results in the synthesis of proteins harbouring different amino terminal domains potentially conferring on these isoforms distinct functions.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12867081'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 531, 'text': \"In eukaryotes, it is generally assumed that translation initiation occurs at the AUG codon closest to the messenger RNA 5' cap. However, in certain cases, initiation can occur at codons differing from AUG by a single nucleotide, especially the codons CUG, UUG, GUG, ACG, AUA and AUU. While non-AUG initiation has been experimentally verified for a handful of human genes, the full extent to which this phenomenon is utilized--both for increased coding capacity and potentially also for novel regulatory mechanisms--remains unclear.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21266472'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 149, 'text': 'The removal of N-terminal translation initiator Met by methionine aminopeptidase (MetAP) is often crucial for the function and stability of proteins.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15215523'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 201, 'text': 'Protein synthesis is initiated by methionine in eukaryotes and by formylmethionine in prokaryotes. N-terminal methionine can be co-translationally cleaved by the enzyme methionine aminopeptidase (MAP).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28369664'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 235, 'text': \"Our understanding of translation underpins our capacity to engineer living systems. The canonical start codon (AUG) and a few near-cognates (GUG, UUG) are considered as the 'start codons' for translation initiation in Escherichia coli.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28334756'}, {'offsetInBeginSection': 571, 'offsetInEndSection': 672, 'text': 'Translation from non-canonical start codons ranged from 0.007 to 3% relative to translation from AUG.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28334756'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 403, 'text': 'Protein synthesis is initiated universally with the amino acid methionine. In Escherichia coli, studies with anticodon sequence mutants of the initiator methionine tRNA have shown that protein synthesis can be initiated with several other amino acids. In eukaryotic systems, however, a yeast initiator tRNA aminoacylated with isoleucine was found to be inactive in initiation in mammalian cell extracts.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9710598'}, {'offsetInBeginSection': 881, 'offsetInEndSection': 1207, 'text': 'Our results show that in the presence of the corresponding mutant initiator tRNAs, AGG and GUC can initiate protein synthesis in COS1 cells with methionine and valine, respectively. CAG initiates protein synthesis with glutamine but extremely poorly, whereas UAG could not be used to initiate protein synthesis with glutamine.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9710598'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 108, 'text': 'Methionine is the universal translation start but the first methionine is removed from most mature proteins.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8199241'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 88, 'text': 'Protein synthesis generally starts with a methionine that is removed during translation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36173861'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 141, 'text': 'Most mature proteins do not retain their initial N-terminal amino acid (methionine in the cytosol and N-formyl methionine in the organelles).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11738381'}]\n\n\n             'Do all proteins start with methionine?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "In eukaryotes, it is generally assumed that translation initiation occurs at the AUG codon closest to the messenger RNA 5' cap, which codes for methionine; hence, an initial assumption would be that all proteins should contain a methionine at their N-terminus (i.e., start site). However, this is not the case mostly for two reasons. First, in certain cases, initiation can occur at codons differing from AUG, which may still code for methionine (e.g., AGG) or less commonly another amino acid (e.g., GUC coding for valine). Moreover, N-terminal methionine can be cleaved after translation by the enzyme methionine aminopeptidase and this removal can be crucial for the function and stability of the final protein. For these reasons, not all proteins start with methionine at their N-terminus."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 447, 'offsetInEndSection': 727, 'text': ' The molecular genetics of FSHD are complex, with current understanding focusing on epigenetic effects related to contraction-dependent (FSHD1) and contraction-independent (FSHD2) effects of a hypomethylated repeat sequence (D4Z4), in the presence of a specific 4qA161 phenotype. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21496633'}]\n\n\n             'Which are the types of Facioscapulohumeral Muscular Dystrophy?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "The types of Facioscapulohumeral Muscular Dystrophy (FSHD) are FSHD1 and FSHD2."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 104, 'text': 'Microphthalmia-associated transcription factor (MITF) is the master regulator of the melanocyte lineage.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25803486'}, {'offsetInBeginSection': 568, 'offsetInEndSection': 940, 'text': 'MITF and SOX10 actively recruit BRG1 to a set of MITF-associated regulatory elements (MAREs) at active enhancers. Combinations of MITF, SOX10, TFAP2A, and YY1 bind between two BRG1-occupied nucleosomes thus defining both a signature of transcription factors essential for the melanocyte lineage and a specific chromatin organisation of the regulatory elements they occupy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25803486'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 153, 'text': 'MITF governs multiple steps in the development of melanocytes, including specification from neural crest, growth, survival, and terminal differentiation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28649789'}, {'offsetInBeginSection': 298, 'offsetInEndSection': 331, 'text': 'However, MITF does not act alone.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28649789'}, {'offsetInBeginSection': 427, 'offsetInEndSection': 982, 'text': 'ChIP-seq studies have indicated that the transcription factors SOX10, YY1, and TFAP2A co-occupy subsets of regulatory elements bound by MITF in melanocytes. Analyses at single loci also support roles for LEF1, RB1, IRF4, and PAX3 acting in combination with MITF, while sequence motif analyses suggest that additional transcription factors colocalize with MITF at many melanocyte-specific regulatory elements. However, the precise biochemical functions of each of these MITF collaborators and their contributions to gene expression remain to be elucidated.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28649789'}, {'offsetInBeginSection': 682, 'offsetInEndSection': 940, 'text': 'Combinations of MITF, SOX10, TFAP2A, and YY1 bind between two BRG1-occupied nucleosomes thus defining both a signature of transcription factors essential for the melanocyte lineage and a specific chromatin organisation of the regulatory elements they occupy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25803486'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 169, 'text': 'The microphthalmia-associated transcription factor (Mitf) is essential for melanocytic lineage development and for expression of melanogenic enzymes, such as tyrosinase.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11830592'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 190, 'text': 'Mitf encodes a basic helix-loop-helix transcription factor that plays an essential role in the differentiation of the retinal pigmented epithelium (RPE) and neural crest-derived melanocytes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15277526'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 142, 'text': 'Commitment to the melanocyte lineage is characterized by the onset of expression of the microphthalmia-associated transcription factor (Mitf).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17000761'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 163, 'text': 'The microphthalamia-associated transcription factor (MITF) is an integral transcriptional regulator in melanocyte, the lineage from which melanoma cells originate.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12789278'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 135, 'text': 'Commitment to the melanocyte lineage is characterized by the onset of microphthalmia-associated transcription factor (Mitf) expression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10770922'}, {'offsetInBeginSection': 462, 'offsetInEndSection': 567, 'text': 'BRG1 is essential for melanoma cell proliferation in vitro and for normal melanocyte development in vivo.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25803486'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 117, 'text': 'Transcription factor MITF and remodeller BRG1 define chromatin organisation at regulatory elements in melanoma cells.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25803486'}, {'offsetInBeginSection': 1001, 'offsetInEndSection': 1090, 'text': 'MITF-BRG1 interplay thus plays an essential role in transcription regulation in melanoma.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25803486'}, {'offsetInBeginSection': 105, 'offsetInEndSection': 372, 'text': \"The basic helix-loop-helix microphthalmia transcription factor (MITF) is the master regulator determining the identity and properties of the melanocyte lineage, and is regarded as a lineage-specific 'oncogene' that has a critical role in the pathogenesis of melanoma.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21258399'}, {'offsetInBeginSection': 273, 'offsetInEndSection': 529, 'text': 'MITF regulates expression of numerous pigmentation genes to promote melanocyte differentiation, as well as fundamental genes for maintaining cell homeostasis, including genes encoding proteins involved in apoptosis (eg, BCL2) and the cell cycle (eg, CDK2).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28263292'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 121, 'text': 'During embryogenesis, the transcription factor, Sox10, drives the survival and differentiation of the melanocyte lineage.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23935512'}, {'offsetInBeginSection': 199, 'offsetInEndSection': 352, 'text': 'MITF encodes a transcription factor that is essential for normal melanocyte development and appears to regulate expression of several pigmentation genes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12819038'}, {'offsetInBeginSection': 324, 'offsetInEndSection': 547, 'text': 'Mitf is a basic helix-loop-helix-leucine zipper transcription factor whose M isoform is restricted to neural crest derived melanocytes and is essential for the development of these cells in vertebrates from mammals to fish.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14660543'}, {'offsetInBeginSection': 826, 'offsetInEndSection': 990, 'text': ' In melanocytes, studies have so far focused on the Sox10 protein which functions both during melanocyte specification and at later times in the melanocyte lineage.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15760336'}, {'offsetInBeginSection': 121, 'offsetInEndSection': 288, 'text': ' However, the molecular mechanisms by which SOX10 guides the appropriate gene expression programs necessary to promote the melanocyte lineage are not fully understood.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26206884'}, {'offsetInBeginSection': 475, 'offsetInEndSection': 630, 'text': ' SMARCA4 is also required for development of multipotent neural crest precursors into melanoblasts, which differentiate into pigment-producing melanocytes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36112085'}, {'offsetInBeginSection': 990, 'offsetInEndSection': 1090, 'text': ' During specification, Sox10 activates the Mitf gene as the key regulator of melanocyte development.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15760336'}, {'offsetInBeginSection': 953, 'offsetInEndSection': 1084, 'text': ' MITF directs the terminal differentiation of melanocytes, and PAX3 helps to establish the properties of the melanocyte stem cells.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22999738'}, {'offsetInBeginSection': 473, 'offsetInEndSection': 616, 'text': ' Functionally, Tfap2b is required for only a few late-stage embryonic melanocytes, and is essential for McSC-dependent melanocyte regeneration.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35021087'}, {'offsetInBeginSection': 105, 'offsetInEndSection': 314, 'text': 'Here, by screening a pool of candidate transcription factors, we identify that a combination of the three factors, MITF, SOX10 and PAX3, directly converts mouse and human fibroblasts to functional melanocytes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25510211'}]\n\n\n             'Which transcription factors are essential for the melanocyte lineage?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Microphthalmia-associated transcription factor (MITF) is the master regulator of the melanocyte lineage. It governs multiple steps in the development of melanocytes, including specification from the neural crest, growth, survival, and terminal differentiation. However, MITF does not act alone. ChIP-seq studies have indicated that the transcription factors SOX10, YY1, and TFAP2A co-occupy subsets of regulatory elements bound by MITF in melanocytes. Analyses at single loci also support roles for LEF1, RB1, IRF4, and PAX3 acting in combination with MITF, while sequence motif analyses suggest that additional transcription factors co-localize with MITF at many melanocyte-specific regulatory elements. Nonetheless, the precise biochemical functions of each of these MITF collaborators and their contributions to gene expression remain to be elucidated."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 12, 'offsetInEndSection': 212, 'text': 'Facial-scapular-humeral myodystrophy Landouzy-Dejerine (FSHD) is an autosomal dominant disease, the basis of its pathogenesis is ectopic expression of the transcription factor DUX4 in skeletal muscle.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30871534'}, {'offsetInBeginSection': 480, 'offsetInEndSection': 584, 'text': 'FSHD2 is caused by the mutations in the protein regulating the methylation status of chromatin - SMCHD1.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30871534'}, {'offsetInBeginSection': 1116, 'offsetInEndSection': 1325, 'text': 'Given the previous report of SMCHD1 mutations in FSHD2 and the clinical presentations consistent with the FSHD phenotype, we conclude that the SMCHD1 mutation is the likely cause of the disease in this family.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24128691'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 96, 'text': 'Exome sequencing identifies a novel SMCHD1 mutation in facioscapulohumeral muscular dystrophy 2.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24128691'}, {'offsetInBeginSection': 275, 'offsetInEndSection': 373, 'text': 'Recently, mutations in SMCHD1 combined with a permissive 4q35 allele were reported to cause FSHD2.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24128691'}, {'offsetInBeginSection': 140, 'offsetInEndSection': 318, 'text': 'Facioscapulohumeral muscular dystrophy type 2 (FSHD2) accounts for approximately 5% of all cases of FSHD and describes patients without a D4Z4 repeat contraction on chromosome 4.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34711481'}, {'offsetInBeginSection': 256, 'offsetInEndSection': 491, 'text': 'Type 1 facioscapulohumeral muscular dystrophy (FSHD) is caused by contraction of D4Z4 repeats on 4q35, whereas type 2 FSHD is associated with mutations of the SMCHD1 or DNMT3B gene in the presence of a disease-permissive 4qA haplotype.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30923442'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 215, 'text': 'Facioscapulohumeral muscular dystrophy (FSHD) 2 is caused by a combination of heterozygous structural maintenance of chromosomes flexible hinge domain containing 1 (SMCHD1) mutation plus DNA hypomethylation on D4Z4.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30327220'}, {'offsetInBeginSection': 808, 'offsetInEndSection': 1037, 'text': 'The less common form of the disease, FSHD2, results from haploinsufficiency of the SMCHD1 gene in individuals carrying a permissive 4qA allele, also leading to the derepression of DUX4, further supporting a central role for DUX4.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28915324'}, {'offsetInBeginSection': 463, 'offsetInEndSection': 613, 'text': 'iduals and 1-10 repeats in patients), and FSHD2 is caused by mutations in SMCHD1 or DNMT3B. Here, we present clinical features and results of genetic ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29402602'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 367, 'text': 'OBJECTIVE: To determine whether congenital arhinia/Bosma arhinia microphthalmia syndrome (BAMS) and facioscapulohumeral muscular dystrophy type 2 (FSHD2), 2 seemingly unrelated disorders both caused by heterozygous pathogenic missense variants in the SMCHD1 gene, might represent different ends of a broad single phenotypic spectrum associated with SMCHD1 dysfunction', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29980640'}]\n\n\n             'What is the cause of Facioscapulohumeral Muscular Dystrophy type 2 (FSHD2)?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Facioscapulohumeral Muscular Dystrophy type 2 (FSHD2) is an autosomal dominant disease that is caused by the mutations in the protein regulating the methylation status of chromatin - SMCHD1tha leads in the ectopic expression of the transcription factor DUX4 in skeletal muscle."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 154, 'offsetInEndSection': 395, 'text': 'Spinal and bulbar muscular atrophy (SBMA) is an X-linked and adult-onset neurodegenerative disorder caused by the expansion of trinucleotide cytosine-adenine-guanine repeats, which encodes a polyglutamine tract in the androgen receptor gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35052449'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 228, 'text': \"Kennedy's disease (KD), also known as spinal and bulbar muscular atrophy (SBMA), is a rare, adult-onset, X-linked recessive neuromuscular disease caused by CAG expansions in exon 1 of the androgen receptor gene (AR).\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32276665'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 177, 'text': 'Spinal and bulbar muscular atrophy (SBMA) is an X-linked adult motor neuron disorder caused by an abnormal CAG-repeat expansion in the first exon of the androgen receptor gene. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17852020'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 182, 'text': 'Spinal and bulbar muscular atrophy (SBMA) is a late-onset motor neuron disease characterized by proximal muscle atrophy, weakness, contraction fasciculations, and bulbar involvement.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15133611'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 203, 'text': 'Spinal and bulbar muscular atrophy (SBMA) is an adult-onset degenerative disorder of the neuromuscular system resulting in slowly progressive weakness and atrophy of the proximal limb and bulbar muscles.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29478604'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 179, 'text': 'Spinal and bulbar muscular atrophy (SBMA) is an X-linked, adult-onset motor neuronopathy that is caused by expansion of a trinucleotide (CAG) repeat in the androgen-receptor gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8545913'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 219, 'text': \"Spinal and bulbar muscular atrophy (SBMA), also known as Kennedy's disease, is an adult-onset, X-linked motor neuron disease characterized by muscle atrophy, weakness, contraction fasciculations, and bulbar involvement.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22476656'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 218, 'text': 'Spinal and bulbar muscular atrophy (SBMA) is a neurodegenerative disorder of lower motor neurons characterized by proximal limb muscular atrophy, bulbar involvement, marked fasciculation, hand tremor and gynaecomastia.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24785145'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 183, 'text': 'Spinal and bulbar muscular atrophy (SBMA) is an adult-onset motor neuron disease, caused by the expansion of a trinucleotide repeat (TNR) in exon 1 of the androgen receptor (AR) gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12189162'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'Spinal and bulbar muscular atrophy (SBMA) is an adult-onset neurodegenerative disease characterized by slowly progressive muscle weakness and atrophy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20687495'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 172, 'text': 'Spinal and bulbar muscular atrophy (SBMA), or Kennedy disease, is an adult-onset lower motor neuron disease characterized by slowly progressive muscle weakness and atrophy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22158719'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 184, 'text': 'Spinal and bulbar muscular atrophy (SBMA) is a hereditary neurodegenerative disease characterized by slowly progressive muscle weakness and atrophy of bulbar, facial, and limb muscles.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16513111'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 191, 'text': 'Spinal and bulbar muscular atrophy (SBMA) is a rare, X-linked neuromuscular disease characterised by lower motor neurons degeneration, slowly progressive myopathy and multisystem involvement.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32631678'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 95, 'text': 'Spinal and bulbar muscular atrophy: a trinucleotide-repeat expansion neurodegenerative disease.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8545913'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 269, 'text': \"X-linked spinal and bulbar muscular atrophy (SBMA; Kennedy's disease) is a polyglutamine (polyQ) disease in which the affected males suffer progressive motor neuron degeneration accompanied by signs of androgen insensitivity, such as gynecomastia and reduced fertility.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16772330'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 221, 'text': 'SBMA (spinal and bulbar muscular atrophy), also called Kennedy disease, is an X-chromosomal recessive adult-onset neurodegenerative disorder caused by death of the spinal and bulbar motor neurones and dorsal root ganglia.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11436124'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 170, 'text': \"Spinal and bulbar muscular atrophy (SBMA), also known as Kennedy's Disease, is a late-onset X-linked progressive neuromuscular disease, which predominantly affects males.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32152060'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 173, 'text': 'Spinal and Bulbar Muscular Atrophy (SBMA) is an X-linked adult-onset progressive neuromuscular disease that affects the spinal and bulbar motor neurons and skeletal muscles.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35726299'}, {'offsetInBeginSection': 182, 'offsetInEndSection': 375, 'text': \"SBMA, also known as Kennedy's disease, is a neurodegenerative disease caused by an expansion of a repeat of the trinucleotide CAG encoding glutamine in the gene encoding androgen receptor (AR).\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26875173'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 88, 'text': 'Spinal bulbar muscular atrophy (SBMA) is a classic CAG-repeat neurodegenerative disease.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15111251'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 182, 'text': \"Spinal and bulbar muscular atrophy (SBMA), also known as Kennedy's disease, is a rare, X-linked hereditary lower motor neuron disease, characterized by progressive muscular weakness.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30006721'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 157, 'text': 'Spinal and bulbar muscular atrophy (SBMA) is an adult-onset, X-linked motor neuron disease characterized by muscle atrophy, weakness, and bulbar involvement.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21952871'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 183, 'text': \"Spinal and bulbar muscular atrophy (SBMA) or Kennedy's disease is a motor neurone disease characterized by muscle atrophy, weakness, contraction fasciculations and bulbar involvement.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17359355'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': \"Kennedy's disease, or spinal and bulbar muscular atrophy (SBMA), is a rare X-linked motoneuron disorder with variable signs of androgen insensitivity.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8749704'}, {'offsetInBeginSection': 549, 'offsetInEndSection': 674, 'text': \" Moderate meiotic instability has been demonstrated in X-linked spinal and bulbar muscular atrophy (SBMA, Kennedy's disease).\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8807333'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 187, 'text': 'Spinal and bulbar muscular atrophy (SBMA) is a hereditary neuromuscular disease affecting only males characterized by progressive muscular atrophy and weakness in bulbar and limb muscles.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31669728'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 193, 'text': 'Spinal and bulbar muscular atrophy (SBMA) is an adult form of X-linked motor neuron disease caused by an expansion of a CAG repeat sequence in the first exon of the androgen receptor (AR) gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17854832'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 167, 'text': 'Spinal and bulbar muscular atrophy (SBMA) is an X-linked, late-onset neuroendocrine disorder resulting from an expansion of a CAG repeat in the androgen receptor gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15851746'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 176, 'text': 'Spinal and bulbar muscular atrophy (SBMA) is an X-linked adult motor neuron disorder caused by an abnormal CAG-repeat expansion in the first exon of the androgen receptor gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17852020'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 120, 'text': 'Spinal and bulbar muscular atrophy (SBMA) is a rare X-linked motor neuron disease with significant phenotypic viability.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27807335'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 172, 'text': 'Spinal and bulbar muscular atrophy (SBMA) is an adult-onset hereditary neurodegenerative disease caused by the expansions of CAG repeats in the androgen receptor (AR) gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35821212'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 181, 'text': 'INTRODUCTION: Spinal and bulbar muscular atrophy (SBMA) is an X-linked, late-onset neuro-endocrine disorder resulting from an expansion of a CAG repeat in the androgen receptor gene', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15924079'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 158, 'text': 'Spinal and bulbar muscular atrophy (SBMA) is a hereditary motor neuron disease caused by the expansion of a polyglutamine tract in the androgen receptor (AR).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19399234'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 182, 'text': 'Spinal and bulbar muscular atrophy (SBMA) is an X-linked recessive motor neuron disease characterized by slowly progressive weakness and atrophy of proximal limbs and bulbar muscles.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25811990'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 231, 'text': \"Spinal and bulbar muscular atrophy (SBMA, or Kennedy's disease) is an X-linked, late-onset neuro-endocrine disorder characterized by degeneration of motor neurons in the spinal cord and brainstem and partial androgen insensitivity.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19078709'}]\n\n\n             'What is Spinal-bulbar muscular atrophy (SBMA)?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Spinal and bulbar muscular atrophy (SBMA), also known as Kennedy's disease (KD), is a recessive X-linked and adult-onset neurodegenerative disorder caused by the expansion of trinucleotide cytosine-adenine-guanine (CAG) repeats in exon 1, which encodes a polyglutamine tract in the androgen receptor (AR) gene."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 121, 'offsetInEndSection': 188, 'text': '8% of female DMD carriers have muscle weakness and cardiomyopathy. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32022138'}, {'offsetInBeginSection': 820, 'offsetInEndSection': 982, 'text': 'Pseudohypertrophy of calf muscles, muscular weakness, compensatory movements and longer timed performance on functional tasks were observed in most of the cases. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32022138'}, {'offsetInBeginSection': 1465, 'offsetInEndSection': 1686, 'text': 'Clinical manifestation of asymmetrical muscle weakness and compensatory movements, or both can be found in female carriers of DMD mutations, which can adversely affect posture and functional performance of these patients.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32022138'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 198, 'text': 'BACKGROUND: Female carriers of Duchenne muscular dystrophy (DMD), although usually asymptomatic, develop muscle weakness up to 17% of the time, and a third present cardiac abnormalities or cognitive', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26718981'}, {'offsetInBeginSection': 672, 'offsetInEndSection': 789, 'text': 'The symptomatic females shared mild but progressive muscular weakness and increased serum creatin kinase (CK) levels.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24135430'}, {'offsetInBeginSection': 105, 'offsetInEndSection': 240, 'text': 'Approximately 8% of female Duchenne muscular dystrophy (DMD) carriers are manifesting carriers and have muscle weakness to some extent.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21155054'}, {'offsetInBeginSection': 499, 'offsetInEndSection': 688, 'text': 'Two to 20% of female heterozygotes with a P/LP variant develop symptoms of dystrophinopathy ranging from mild muscle weakness to significant disability similar to Becker muscular dystrophy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36152336'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 198, 'text': 'Female carriers of Duchenne muscular dystrophy (DMD) presenting with DMD symptomology similar to males with DMD, such as skeletal muscle weakness and cardiomyopathy, are termed manifesting carriers.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33788896'}, {'offsetInBeginSection': 166, 'offsetInEndSection': 289, 'text': 'ales. Female DMD/BMD carriers (DMDc/BMDc) are mostly free of skeletal muscle symptoms, but they are also prone to cardiomyo', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26113120'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 134, 'text': 'Female carriers of mutations in the dystrophin gene (DMD-carriers) may manifest clinically in the skeletal muscle, the heart, or both.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29862154'}, {'offsetInBeginSection': 520, 'offsetInEndSection': 600, 'text': 'Cardiomyopathy is sometimes the only clinical symptom in female carriers of DMD.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10674846'}, {'offsetInBeginSection': 137, 'offsetInEndSection': 289, 'text': ' Cardiomyopathy is common and often prevalent at similar frequency in female DMD carriers irrespective of whether they manifest skeletal muscle disease.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32762558'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 119, 'text': 'Female carriers of DMD gene mutations may be symptomatic and show variable skeletal as well as cardiac muscle symptoms.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31326192'}, {'offsetInBeginSection': 519, 'offsetInEndSection': 600, 'text': ' Cardiomyopathy is sometimes the only clinical symptom in female carriers of DMD.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10674846'}, {'offsetInBeginSection': 553, 'offsetInEndSection': 633, 'text': ' Our findings show abnormal muscle energy metabolism in DMD/BMD female carriers.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1557082'}, {'offsetInBeginSection': 220, 'offsetInEndSection': 329, 'text': ' DMD/BMD female carriers are usually asymptomatic, although about 8\\xa0% may exhibit muscle or cardiac symptoms.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27098336'}, {'offsetInBeginSection': 973, 'offsetInEndSection': 1123, 'text': ' mutations were found. 28 (22%) women had symptoms. 22 (17%) had muscle weakness, varying from mild to moderately severe. Muscle weakness was found in', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10382696'}]\n\n\n             'What are common symptoms in female carriers of DMD?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Some common symptoms in female carriers of DMD are the following: asymmetrical muscle weakness, compensatory movements, pseudohypertrophy of calf muscles, longer timed performance on functional tasks and cardiomyopathy."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 467, 'offsetInEndSection': 699, 'text': 'There are four types: CMT1, CMT2, CMT3 and CMT4, depending upon the involvement of specific gene deficit, inheritance pattern, age of onset and whether the primary defect results in an abnormality of the myelin or axon of the nerve.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34540429'}, {'offsetInBeginSection': 141, 'offsetInEndSection': 268, 'text': 'Clinically, CMT can be divided into two main types: a demyelinating type (CMT1, CMT3, CMT4 and CMTX1) and an axonal type (CMT2)', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24846915'}, {'offsetInBeginSection': 467, 'offsetInEndSection': 740, 'text': ' CMT1, or hypertrophic form in which mutations or a duplication were found on chromosome 17 is the most frequent (CMT1A), CMT2 is the neuronal form, CMT3 is termed the Dejerine-Sottas disease, CMT4 recessive forms, CMT5 a form with associated pyramidal features, and CMTX. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9686263'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 375, 'text': 'Charcot-Marie-Tooth (CMT) is a group of inherited diseases clinically and genetically heterogenous, characterised by length dependent degeneration of axons of the peripheral nervous system. A missense mutation (p.R158H) in the pyruvate dehydrogenase kinase 3 gene (PDK3) has been identified as the genetic cause for an X-linked form of CMT (CMTX6) in two unrelated families. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32504000'}, {'offsetInBeginSection': 571, 'offsetInEndSection': 697, 'text': 'The subdivision into demyelinating CMT1 and axonal CMT2 types was a milestone and is still valid for the majority of patients.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16775364'}, {'offsetInBeginSection': 752, 'offsetInEndSection': 895, 'text': 'Intermediate conduction velocities are often found in males with X-linked CMT (CMTX), and different intermediate CMT types have been identified', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16775364'}, {'offsetInBeginSection': 246, 'offsetInEndSection': 408, 'text': 'The association of neuropathy and optic atrophy (also known as CMT type 6) has been described with autosomaldominant, recessive and X-linked modes of inheritance.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24198383'}, {'offsetInBeginSection': 409, 'offsetInEndSection': 482, 'text': 'Mutations in Mitofusin 2 have been found to cause dominant forms of CMT6.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24198383'}, {'offsetInBeginSection': 189, 'offsetInEndSection': 439, 'text': 'Mutations of the gene encoding mitofusin 2 (MFN2) have recently been identified as the cause of approximately one-third of dominantly inherited cases of the axonal degenerative forms of Charcot-Marie-Tooth disease (CMT type 2A) and of rarer variants.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20163430'}, {'offsetInBeginSection': 440, 'offsetInEndSection': 641, 'text': 'The latter include a severe, early-onset axonal neuropathy, which may occur in autosomal dominant or recessive forms, as well as some instances associated with pyramidal tract involvement (CMT type 5),', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20163430'}, {'offsetInBeginSection': 642, 'offsetInEndSection': 674, 'text': 'with optic atrophy (CMT type 6),', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20163430'}, {'offsetInBeginSection': 310, 'offsetInEndSection': 481, 'text': 'Two principal forms of Charcot-Marie-Tooth (CMT) disease have been distinguished: CMT 1, corresponding to a demyelinating type, and CMT 2, corresponding to an axonal type.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12901697'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 214, 'text': 'Charcot-Marie-Tooth disease (CMT), the most common inherited peripheral neuropathy, is a progressive sensorimotor neuropathy divided into types 1 and 2 based upon electrophysiologic and neuropathologic differences.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1549221'}, {'offsetInBeginSection': 435, 'offsetInEndSection': 583, 'text': 'Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common form, exhibiting autosomal dominant inheritance and linkage to chromosome 17p11.2p12.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8128981'}, {'offsetInBeginSection': 517, 'offsetInEndSection': 674, 'text': 'Recent work has identified the gene products corresponding to CMT1A, CMT1B and CMTX as peripheral myelin protein-22(PMP22), Po and connexin 32, respectively.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8810804'}, {'offsetInBeginSection': 581, 'offsetInEndSection': 822, 'text': 'A systematic computer-based literature search was conducted on PubMed, using the following MeSH: (1) intermediate Charcot-Marie-Tooth; (2) X-linked intermediate Charcot-Marie-Tooth; and (3) X-linked Charcot-Marie-Tooth and electrophysiology.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28364294'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 130, 'text': 'Charcot-Marie-Tooth disease (CMT) has been classified into two types, CMT1 and CMT2, demyelinating and axonal forms, respectively.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15549395'}, {'offsetInBeginSection': 114, 'offsetInEndSection': 434, 'text': 'Two major types can be distinguished based on electrophysiologic phenotypes: CMT type 1 (CMT1) displays uniformly decreased nerve conduction velocity associated with a demyelinating hypertrophic neuropathy, and CMT type 2 (CMT2) displays normal or near-normal nerve conduction velocity associated with a neuronal defect.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8128981'}, {'offsetInBeginSection': 141, 'offsetInEndSection': 269, 'text': 'Clinically, CMT can be divided into two main types: a demyelinating type (CMT1, CMT3, CMT4 and CMTX1) and an axonal type (CMT2).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24846915'}, {'offsetInBeginSection': 142, 'offsetInEndSection': 341, 'text': 'Common clinical manifestations of CMTX, as in other forms of Charcot-Marie-Tooth disease (CMT), are distal muscle wasting and weakness, hyporeflexia, distal sensory disturbance, and foot deformities.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12185164'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 121, 'text': 'Charcot-Marie-Tooth disease (CMT) has been classified into two types: demyelinating forms (CMT1) and axonal forms (CMT2).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17437620'}, {'offsetInBeginSection': 426, 'offsetInEndSection': 576, 'text': 'y known to affect 1 in 2500 individuals. There are four types: CMT1, CMT2, CMT3 and CMT4, depending upon the involvement of specific gene deficit, inh', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34540429'}]\n\n\n             'Which are the types of Charcot-Marie-Tooth Disease (CMT)?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "The types of Charcot-Marie-Tooth Disease (CMT) are the following: CMT1, CMT2, CMT3, CMT4, CMT5, CMT6 and CMTX."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 213, 'offsetInEndSection': 470, 'text': 'There are two types of the disease: FSHD1 (MIM:158900) and FSHD2 (MIM: 158901), which have different genetic causes but are phenotypically indistinguishable. In FSHD1, partial deletion of the D4Z4 repeats on the 4th chromosome affects the expression of DUX4', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30871534'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 212, 'text': 'Facial-scapular-humeral myodystrophy Landouzy-Dejerine (FSHD) is an autosomal dominant disease, the basis of its pathogenesis is ectopic expression of the transcription factor DUX4 in skeletal muscle.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30871534'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 206, 'text': 'FSHD2 is a rare form of facioscapulohumeral muscular dystrophy (FSHD) characterized by the absence of a contraction in the D4Z4 macrosatellite repeat region on chromosome 4q35 that is the hallmark of FSHD1.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24128691'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 152, 'text': 'The myopathy facioscapulohumeral muscular dystrophy type 1 (FSHD1) is caused by copy number variation of the D4Z4 macrosatellite repeat on chromosome 4.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27822859'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 151, 'text': 'The autosomal dominant myopathy facioscapulohumeral muscular dystrophy (FSHD1, OMIM 158900) is caused by contraction of the D4Z4 repeat array on 4qter.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14634647'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 144, 'text': 'Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is caused by contraction of the D4Z4 repeat array on chromosome 4 to a size of 1-10 units.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24075187'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 225, 'text': 'Facioscapulohumeral muscular dystrophy 1 (FSHD1) is caused by a contraction in the number of D4Z4 repeats on chromosome 4, resulting in relaxation of D4Z4 chromatin causing inappropriate expression of DUX4 in skeletal muscle.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24755953'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 207, 'text': 'Facioscapulohumeral dystrophy type 1 (FSHD1) is caused by contraction of the D4Z4 repeat array on chromosome 4q resulting in sporadic misexpression of the transcription factor DUX4 in skeletal muscle tissue.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31518905'}, {'offsetInBeginSection': 287, 'offsetInEndSection': 526, 'text': 'Autosomal dominant FSHD1 (95% of patients) is characterized by chromatin relaxation induced by pathogenic contraction of a macrosatellite repeat called D4Z4 located on the 4q subtelomere (FSHD1 patients harbor 1 to 10 D4Z4 repeated units).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24882751'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 258, 'text': 'Facioscapulohumeral dystrophy (FSHD) is a progressive muscular dystrophy caused by decreased epigenetic repression of the D4Z4 macrosatellite repeats and ectopic expression of DUX4, a retrogene encoding a germline transcription factor encoded in each repeat.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23593020'}, {'offsetInBeginSection': 137, 'offsetInEndSection': 331, 'text': 'tal muscle. The genetic cause of FSHD1 is contraction of the D4Z4 macrosatellite array on chromosome 4 alleles associated with a permissive haplotype causing infrequent sporadic expression of th', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30122154'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 162, 'text': 'Sporadic DUX4 expression in FSHD myocytes is associated with incomplete repression by the PRC2 complex and gain of H3K9 acetylation on the contracted D4Z4 allele.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30122154'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 104, 'text': 'Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is caused by contraction of the D4Z4 repeat array.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29436205'}, {'offsetInBeginSection': 41, 'offsetInEndSection': 191, 'text': ' dystrophy type 1 (FSHD1) is caused by copy number variation of the D4Z4 macrosatellite repeat on chromosome 4. In unaffected individuals the number o', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27822859'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 175, 'text': 'Facioscapulohumeral muscular dystrophy (FSHD) is caused by the loss of repression at the D4Z4 locus leading to aberrant double homeobox 4 (DUX4) expression in skeletal muscle.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32576599'}]\n\n\n             'What is the cause of Facioscapulohumeral Muscular Dystrophy type 1 (FSHD1)?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "FSHD1 is an autosomal dominant disease that is caused by partial deletion of the D4Z4 repeats on the 4th chromosome, affecting the expression of DUX4."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 139, 'text': 'Kearns Sayre Syndrome (KSS) is a rare mitochondrial disease characterized by a primary dysfunction of the mitochondrial respiratory chain. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35795638'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 196, 'text': 'Kearns-Sayre syndrome is a rare mitochondrial disorder. It had a triad of features, including progressive external ophthalmoplegia, pigmentary retinopathy, and an alteration of cardiac conduction.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35721635'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 95, 'text': 'Kearns-Sayre syndrome (KSS) is a rare, multisystem mitochondrial encephalomyopathy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35073857'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 204, 'text': 'Kearns-Sayre syndrome (KSS), first described in 1958, is a multisystem disease defined by a characteristic triad of progressive external ophthalmoplegia, pigmentary retinopathy and atrioventricular block.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22981519'}, {'offsetInBeginSection': 487, 'offsetInEndSection': 571, 'text': 'KSS is a mitochondrial disorder that occurs rarely; the actual incidence is unknown.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1638160'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 252, 'text': 'The Kearns-Sayre syndrome (KSS) is a distinctive type of progressive external ophthalmoplegia, characterized by pigmentary degeneration of the retina, heart block, elevated concentration of cerebrospinal fluid protein, and abnormal muscle mitochondria.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/572507'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 216, 'text': 'Kearns-Sayre syndrome (KSS) is a form of mitochondrial myopathy in which specific clinical features, namely progressive external ophthalmoplegia, pigmentary retinal degeneration and cardiac conduction defects, occur.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1424198'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 294, 'text': 'UNLABELLED: Kearns-Sayre syndrome (KSS) is a rare mitochondrial DNA deletion syndrome defined as the presence of ophthalmoplegia, pigmentary retinopathy, onset less than age 20 years, and one of the following: cardiac conduction defects, cerebellar syndrome, or cerebrospinal fluid protein abov', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22875312'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 306, 'text': 'Kearns-Sayre Syndrome is form of rare mitochondrial cytopathy, first described by Thomas P. Kearns and George Pomeroy Sayre in 1958 and is characterized by progressive external opthalmoplegia, cardiac conduction block, pigmentary retinal degeneration, variable number of red ragged fibers on muscle biopsy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22231766'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 186, 'text': 'Kearns-Sayre syndrome (KSS) is a mitochondrial encephalomyopathy characterized by progressive external ophthalmoplegia (PEO), pigmentary retinopathy and onset before the age of 20 years.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16735000'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 305, 'text': 'Kearns Sayre syndrome (KSS) is a mitochondrial disorder characterized by the emergence before age 20 of progressive external ophthalmoplegia, pigmentary retinopathy, together with other heterogeneous clinical manifestations, including cardiac conduction defects, muscle abnormalities and endocrinopathies.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16735969'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 56, 'text': 'Kearns-Sayre syndrome (KSS) is a mitochondrial disorder.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9677732'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 248, 'text': 'Kearns-Sayre syndrome (KSS) is a sporadic multisystem disorder due to a defect of oxidative phosphorylation and associated with clonally-expanded rearrangements of mitochondrial DNA (mtDNA) deletions (Delta-mtDNAs) and/or duplications (dup-mtDNAs).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11018246'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 197, 'text': 'INTRODUCTION: Kearns-Sayre syndrome (KSS) is a mitochondrial disorder characterized by progressive external ophthalmoplegia, pigmentary retinopathy, onset before 20 years, and ragged-red fibers on ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16977556'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 216, 'text': 'Kearns-Sayre syndrome (KSS) is a progressive neuromuscular disease characterized by ophthalmoplegia, cardiac conduction block, and pigmentary retinopathy associated with abnormal mitochondrial structure and function.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9832255'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 291, 'text': 'Kearns-Sayre syndrome (KSS) is a rare syndrome characterized by the triad of progressive external ophthalmoplegia, pigmentary retinopathy and cardiac conduction system disturbances; it is a mitochondrial encephalomyopathy with which usually presents before the patient reaches the age of 20.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23102393'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 96, 'text': 'Kearns-Sayre Syndrome (KSS) is a subtype of chronic progressive external ophthalmoplegia (CPEO).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35477912'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 235, 'text': \"Kearns-Sayre syndrome (KSS) was first described in 1958 as 'a rare neuromuscular disorder defined by a characteristic triad of progressive external ophthalmoplegia, pigmentary retinopathy, atrioventricular block and cerebellar ataxia'.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26949540'}, {'offsetInBeginSection': 66, 'offsetInEndSection': 203, 'text': 'scribed. Kearns-Sayre syndrome (KSS) is a mitochondrial disorder characterized by retinitis pigmentosa, external ophthalmoplegia, and hea', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27442316'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 318, 'text': 'Kearns-Sayre syndrome (KSS) is a multisystem mitochondrial disorder characterized by the invariant triad: onset before 20, progressive external ophthalmoplegia and pigmentary retinal degeneration, plus at least one of the following: complete (or not) heart block, cereberal dysfunction and CSF protein above 100 mg/dl.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12007693'}, {'offsetInBeginSection': 367, 'offsetInEndSection': 503, 'text': ' This has lead to increasing interest in the contribution which mtDNA deletions make to Kearns-Sayre Syndrome (KSS) and other disorders.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17342029'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 128, 'text': 'Kearns-Sayre syndrome (KSS) is the most commonly diagnosed mitochondrial myopathy and it produces severe neuromuscular symptoms.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9509412'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 134, 'text': 'Kearns-Sayre syndrome (KSS) is a disease with severe clinical symptoms that often arises from a mitochondrial DNA deletion of 4977 bp.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7946321'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 83, 'text': 'Kearns-Sayre syndrome (KSS) is a disorder caused by mutations in mitochondrial DNA.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27709644'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 58, 'text': 'Kearns-Sayre syndrome (KSS) is a rare genetic abnormality.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15869681'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 106, 'text': 'Kearns-Sayre syndrome (KSS) is a rare mitochondrial myopathy that usually develops before 20 years of age.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25368789'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 339, 'text': 'Kearns-Sayre syndrome (KSS) is a rare mitochondrial DNA (mtDNA) deletion syndrome that typically presents before 20\\xa0years of age and is characterized by chronic progressive external ophthalmoplegia, pigmentary retinopathy, and a combination of cardiac conduction defects, cerebellar ataxia, and elevated cerebrospinal fluid protein levels.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31158487'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 199, 'text': 'Kearns-Sayre syndrome (KSS), a rare form of mitochondrial myopathy, is a triad of chronic progressive external ophthalmoplegia, bilateral pigmentary retinopathy, and cardiac conduction abnormalities.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29416473'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 114, 'text': 'Kearns-Sayre syndrome (KSS) is a sporadic multisystem disorder due to rearrangements in mitochondrial DNA (mtDNA).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10465502'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 138, 'text': 'Kearns Sayre Syndrome (KSS) is a rare mitochondrial disease characterized by a primary dysfunction of the mitochondrial respiratory chain.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35795638'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 194, 'text': 'UNLABELLED: Kearns Sayre syndrome (KSS) is a multisystem disorder with a confounding variety of clinical manifestations, including ocular myopathy, pigmentary retinopathy, heart block and ataxia', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9727847'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 305, 'text': 'UNLABELLED: Kearns-Sayre syndrome (KSS) is a rare mitochondrial DNA deletion syndrome defined as the presence of ophthalmoplegia, pigmentary retinopathy, onset less than age 20 years, and one of the following: cardiac conduction defects, cerebellar syndrome, or cerebrospinal fluid protein above 100 mg/dl', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22875312'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 254, 'text': 'BACKGROUND: Kearns-Sayre syndrome (KSS) is a rare multisystem mitochondrial disorder characterized by onset before 20\\u2009years of age and a typical clinical triad: progressive external ophthalmoplegia, pigmentary retinopathy and cardiac conduction anomalies', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36181358'}]\n\n\n             'What is Kearns-Sayre syndrome (KSS)?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Kearns Sayre Syndrome (KSS) is a rare multisystem mitochondrial encephalomyopathy characterized by a primary dysfunction of the mitochondrial respiratory chain. It has a triad of features, including progressive external ophthalmoplegia, pigmentary retinopathy, and an alteration of cardiac conduction."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'Golodirsen (Vyondys 53\u2122), an antisense oligonucleotide of the phophorodiamidate morpholino oligomer (PMO) subclass designed to induce exon 53 skipping', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32026421'}, {'offsetInBeginSection': 452, 'offsetInEndSection': 782, 'text': 'Antisense oligonucleotides, e.g., phosphorodiamidate morpholino oligomers (PMOs), can induce therapeutic exon skipping during pre-mRNA processing to restore the reading frame of the primary transcript of DMD. As a result, truncated but partially functional dystrophin is produced, potentially slowing down the disease progression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33025945'}, {'offsetInBeginSection': 783, 'offsetInEndSection': 901, 'text': 'Golodirsen is a provisionally approved PMO-based drug for approx. 8% of all DMD patients amenable to exon 53 skipping.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33025945'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 250, 'text': 'Golodirsen (Vyondys 53\u2122), an antisense oligonucleotide of the phophorodiamidate morpholino oligomer (PMO) subclass designed to induce exon 53 skipping, has been developed by Sarepta Therapeutics for the treatment of Duchenne muscular dystrophy (DMD).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32026421'}, {'offsetInBeginSection': 251, 'offsetInEndSection': 514, 'text': 'In December 2019, intravenous golodirsen received its first global approval in the USA for the treatment of DMD in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping, based on positive results from a phase I/II clinical trial.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32026421'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 247, 'text': 'Several exon skipping antisense oligonucleotides (eteplirsen, golodirsen, viltolarsen, and casimersen) have been approved for the treatment of Duchenne muscular dystrophy, but many more are in development targeting an array of different DMD exons.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35213020'}, {'offsetInBeginSection': 332, 'offsetInEndSection': 506, 'text': 'Two exon 53 skipping PMOs, golodirsen and viltolarsen, have received conditional approval for treating patients due to their ability to restore dystrophin protein expression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36401027'}]\n\n\n             'What is golodirsen's mechanism of action?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Golodirsen (Vyondys 53\u2122) is an antisense oligonucleotide of the phophorodiamidate morpholino oligomer (PMO) subclass that induces exon 53 skipping during pre-mRNA processing to restore the reading frame of the primary transcript of DMD, resulting in a truncated but partially functional dystrophin and slowing down the disease progression."}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 179, 'text': '\\xa0Emery-Dreifuss Muscular Dystrophy (EDMD) is an early-onset, slowly-progressive group of myopathies, presenting with joint contractures, muscle weakness and cardiac abnormalities.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36031908'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 157, 'text': 'Emery-Dreifuss muscular dystrophy (EDMD) is an uncommon, gradually progressive X-linked myopathy, and it could result in rigid spinal deformity. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36250567'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 94, 'text': 'X-Linked Emery-Dreifuss muscular dystrophy is caused by mutations in the gene encoding emerin.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36274837'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 154, 'text': 'Emery-Dreifuss muscular dystrophy (EDMD) is a progressive muscle-wasting disorder defined by early contractures of the Achilles tendon, spine, and elbows.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21496632'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 259, 'text': 'Emery-Dreifuss muscular dystrophy (EDMD) is an inherited muscular disorder characterized by the triad of progressive weakness in humero-peroneal muscles, early onset contractures and cardiomyopathy with conduction block that shows a high risk of sudden death.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9436433'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 171, 'text': 'Emery-Dreifuss muscular dystrophy (EDMD) is an X-linked recessive disorder characterized by slowly progressing contractures, wasting of skeletal muscle and cardiomyopathy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7894480'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 168, 'text': 'Emery-Dreifuss muscular dystrophy (EDMD) is a rare muscular dystrophy, but is particularly important to diagnose due to frequent life-threatening cardiac complications.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31840275'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 94, 'text': 'Emery-Dreifuss muscular dystrophy (EDMD) is the third most common X-linked muscular dystrophy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10711990'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 195, 'text': 'Emery-Dreifuss muscular dystrophy (EDMD) is an X-linked humeroperoneal dystrophy associated with cardiomyopathy that is distinct from the Duchenne and Becker forms of X-linked muscular dystrophy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1998333'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 234, 'text': 'Emery-Dreifuss muscular dystrophy (EDMD) is an inherited muscular disorder clinically characterized by slowly progressive weakness affecting humero-peroneal muscles, early joint contractures and cardiomyopathy with conduction defects.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16550925'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 230, 'text': 'Emery-Dreifuss muscular dystrophy (EDMD) is characterized by early contractures of elbows and Achilles tendons, slowly progressive muscle wasting and weakness, and a cardiomyopathy with conduction blocks which is life-threatening.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10080180'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 241, 'text': 'Emery-Dreifuss muscular dystrophy (EDMD) is characterised by early contractures, slowly progressive muscle wasting and weakness with a distinctive humero-peroneal distribution and cardiac conduction defects leading to dilated cardiomyopathy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11973618'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 234, 'text': 'Emery-Dreifuss muscular dystrophy (EDMD), a rare inherited disease, is characterized clinically by humero-peroneal muscle atrophy and weakness, multijoint contractures, spine rigidity and cardiac insufficiency with conduction defects.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27179216'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 244, 'text': 'Emery-Dreifuss muscular dystrophy (EDMD) was delineated as a separate form of muscular dystrophy nearly 40 years ago, based on the distinctive clinical features of early contractures and humero-peroneal weakness, and cardiac conduction defects.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10838246'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 329, 'text': 'Emery-Dreifuss muscular dystrophy (EDMD) is an X-linked inherited disease characterized by early contracture of the elbows, Achilles tendons and post-cervical muscles, slow progressive muscle wasting and weakness and cardiomyopathy presenting with arrhythmia and atrial paralysis: heart block can eventually lead to sudden death.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9361031'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 240, 'text': 'Emery-Dreifuss muscular dystrophy (EDMD) is a rare X-linked recessive disease characterized by the clinical triad of early childhood joint contractures, progressive weakness in muscles and cardiac involvement and can result in sudden death.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31645980'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 278, 'text': 'Emery-Dreifuss muscular dystrophy (EDMD) is an X-linked recessive or autosomal dominant progressive muscular dystrophy characterized by progressive muscle wasting and weakness with scapulo-humero-peroneal distribution, early contracture and cardiomyopathy with conduction block.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10689937'}, {'offsetInBeginSection': 200, 'offsetInEndSection': 391, 'text': 'The most frequent and best known form is Emery-Dreifuss muscular dystrophy (EDMD), a skeletal myopathy characterized by progressive muscular weakness, joint contractures, and cardiac disease.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23622360'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 318, 'text': 'X-linked recessive Emery-Dreifuss muscular dystrophy (EDMD) is an inherited muscle disorder characterized by the clinical triad of progressive wasting of humero-peroneal muscles, early contractures of the elbows, Achilles tendons and postcervical muscles, and cardiac conduction block with a high risk of sudden death.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10732816'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 154, 'text': 'INTRODUCTION: Emery-Dreifuss muscular dystrophy (EDMD) is a disease characterized by skeletal muscle wasting, major tendon contractures, and cardiac condu', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32304242'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 281, 'text': 'Emery-Dreifuss muscular dystrophy (EDMD) is an inherited disorder characterized by the clinical triad of life-threatening progressive cardiomyopathy with conduction defect, early onset joint contractures and slow progressive muscle weakness in scapulo-humero-peroneal distribution.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10220866'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 206, 'text': 'Emery-Dreifuss Muscular Dystrophy (EMD or EDMD) is a rare X-linked recessive disorder, characterized by progressive muscle wasting and weakness, contractures, and cardiomyopathy, manifesting as heart block.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11385714'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 138, 'text': 'Emery-Dreifuss muscular dystrophy (EDMD) is a distinctive form of muscular dystrophy which is often associated with cardiac abnormalities.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21372459'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 119, 'text': 'Emery-Dreifuss muscular dystrophy (EDMD) is an X-linked muscular dystrophy in which cardiac involvement can be serious.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20139205'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 124, 'text': 'Emery Dreifuss Muscular Dystrophy (EDMD) is an inherited disorder which leads to progressive worsening of muscular function.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33409349'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 79, 'text': 'Emery-Dreifuss muscular dystrophy (EDMD) is a rare X-linked muscular dystrophy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/2311208'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 90, 'text': 'Emery-Dreifuss muscular dystrophy (EDMD) is a rare and genetically heterogeneous disorder.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16804269'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 171, 'text': 'Emery-Dreifuss muscular dystrophy is a rare form of muscular dystrophy associated with cardiac implications such as cardiomyopathy and arrhythmias leading to sudden death.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12075650'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 160, 'text': 'Emery Dreifuss muscular dystrophy (EDMD) is a hereditary muscular disorder, characterized by contractures, progressive muscular wasting and cardiac involvement.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23500067'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 205, 'text': 'Emery Dreifuss muscular dystrophy (EDMD) is an uncommon hereditary myopathy characterized by 3 symptoms: slow progressive muscular atrophy, muscular contractures and cardiac disease which affect prognosis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17042210'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 372, 'text': 'Emery-Dreifuss muscular dystrophy (EDMD), clinically characterized by scapulo-humero-peroneal muscle atrophy and weakness, multi-joint contractures with spine rigidity and cardiomyopathy with conduction defects, is associated with structural/functional defect of genes that encode the proteins of nuclear envelope, including lamin A and several lamin-interacting proteins.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29633897'}]\n\n\n             'What is Emery-Dreifuss Muscular Dystrophy (EDMD)?'.\n             You are a biomedical expert, write a concise and clear answer to the above question.\n             It is very important that the answer is correct.\n             The maximum allowed length of the answer is 200 words, but try to keep it short and concise."}, {"role": "assistant", "content": "Emery-Dreifuss Muscular Dystrophy (EDMD) is an early-onset, slowly-progressive X-linked myopathy. It is caused by mutations in the gene encoding emerin.  It presents with joint contractures, muscle weakness and cardiac abnormalities and could result in rigid spinal deformity."}]}
